WorldWideScience

Sample records for injectable risperidone efficacy

  1. Risperidone Injection

    Science.gov (United States)

    ... depressive disorder; a disease that causes episodes of depression, episodes of severe mania, and other abnormal moods). Risperidone is in a class of medications called atypical antipsychotics. It works by ...

  2. Risperidone long-acting injection: a review of its long term safety and efficacy

    Directory of Open Access Journals (Sweden)

    Michael K Rainer

    2008-08-01

    Full Text Available Michael K RainerMemory-Clinic and Psychiatric Department, Donauspital, Vienna, AustriaAbstract: A long-acting form of the second-generation antipsychotic drug risperidone is now broadly available for the treatment of schizophrenia and closely related psychiatric conditions. It combines the advantage of previously available depot formulations for first-generation drugs with the favorable characteristics of the modern “atypical” antipsychotics, namely higher efficacy in the treatment of the negative symptoms of schizophrenia and reduced motor disturbances. Published clinical studies show an objective clinical efficacy (as per psychiatric symptom scores and relapse data that exceeds that of oral atypical antipsychotics when patients are switched to the long-acting injectable form, a low incidence of treatment-emergent extrapyramidal side effects, and very good acceptance by patients. Available data for maintenance treatment of bipolar disorder show equivalence with the oral form instead of superiority, but are still limited. As it seems likely that efficacy benefits are mostly due to the fact that the injectable form reduces the demand for patient compliance to one physician visit every 2 weeks instead of self-administration on a daily or twice-daily basis, additional potential could exist in other psychiatric disorders where atypical antipsychotic drugs are of benefit but where patient adherence to treatment schedules is typically low.Keywords: risperidone, schizophrenia, psychotic disorders, patient compliance; delayed-action preparations, injections, intramuscular

  3. Risperidone long-acting injection: a review of its long term safety and efficacy

    OpenAIRE

    Rainer, Michael K

    2008-01-01

    Michael K RainerMemory-Clinic and Psychiatric Department, Donauspital, Vienna, AustriaAbstract: A long-acting form of the second-generation antipsychotic drug risperidone is now broadly available for the treatment of schizophrenia and closely related psychiatric conditions. It combines the advantage of previously available depot formulations for first-generation drugs with the favorable characteristics of the modern “atypical” antipsychotics, namely higher efficacy in the ...

  4. Combination treatment with risperidone long-acting injection and psychoeducational approaches for preventing relapse in schizophrenia

    Directory of Open Access Journals (Sweden)

    Zhao Y

    2013-10-01

    Full Text Available Yueren Zhao,1–3 Taro Kishi,1 Nakao Iwata,1 Manabu Ikeda3,4 1Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan; 2Department of Psychiatry, Okehazama Hospital Fujita Kokoro Care Center, Toyoake, Aichi, Japan; 3Department of Neuropsychiatry, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Kumamoto, Japan; 4Department of Neuropsychiatry, Faculty of Life Sciences, Kumamoto University, Kumamoto, Kumamoto, Japan Abstract: A recent meta-analysis showed that long-acting injectable (LAI antipsychotics were not superior to oral antipsychotics for preventing relapse in patients with schizophrenia. We therefore designed a treatment strategy combining risperidone LAI and COMPASS (COMprehensive Psycho-educational Approach and Scheme Set, an original psychoeducational program supporting treatment with risperidone LAI and evaluating subjective treatment satisfaction, transition of symptoms, and effectiveness in preventing symptomatic relapse. The aim of this study was to examine whether addition of COMPASS to risperidone LAI was more effective in preventing relapse in schizophrenia patients than risperidone LAI alone, with the latter group consisting of patients enrolled in a Phase III trial of risperidone LAI in Japan. Patients were followed up for 6 months, with COMPASS continuously implemented from the transition to the observation phase. The primary efficacy measurements were relapse rate (rates of rehospitalization and discontinuation due to inefficacy. Secondary efficacy measurements were the Brief Psychiatric Rating Scale (BPRS and Global Assessment of Functioning (GAF scores. Of the 96 patients originally enrolled, 19 (19.8% were discontinued from all causes. During the 6-month study period, ten of the 96 patients (10.4% relapsed, compared with a 12.2% relapse rate in patients enrolled in a Phase III trial of risperidone LAI in Japan. Patients showed significant improvements in BPRS total

  5. A comparison of continuous subcutaneous paliperidone infusion and repeated subcutaneous injection of risperidone free-base in rats.

    Science.gov (United States)

    Marchese, G; Pittau, B; Casu, G; Peddio, G; Spada, G P; Pira, M; Deriu, A; Portesani, F; Pisu, C; Lazzari, P; Pani, L

    2010-03-01

    It is proposed that to achieve a therapeutic effect in schizophrenia patients, dopamine D(2)-receptor occupancy by antipsychotics within the striatum must exceed 60-65%. However, at high levels of D(2)-receptor occupancy, the risk of extrapyramidal symptoms (EPS) is increased. Following oral dosing of antipsychotics, peaks and troughs in plasma drug concentrations may be mirrored by fluctuations in D(2)-receptor occupancy. Paliperidone, a novel antipsychotic available as extended-release tablets (paliperidone ER), is the major active metabolite of risperidone and exhibits a plasma pharmacokinetic profile with reduced peak-trough fluctuations and consistent D(2)-receptor occupancy compared with conventional oral antipsychotic formulations. Using formulations that resemble those in clinical practice, this study provides a preclinical evaluation of the pharmacological properties of paliperidone ER and risperidone immediate-release formulation in terms of consistent antipsychotic efficacy over time and extrapyramidal symptom liability. Significant fluctuations in inhibition of d-amphetamine-induced hyperlocomotion were observed for repeated subcutaneous (SC) risperidone injections, whereas stable inhibitory efficacy was demonstrated during continuous SC paliperidone infusion. Similarly, significant fluctuations in latency on-bar were observed with repeated SC risperidone injections, whereas significantly lower latency on-bar was demonstrated following continuous SC paliperidone infusion. These results in an animal model suggest that although risperidone and paliperidone demonstrate similar pharmacologic effects, continuous administration of paliperidone achieves more stable antipsychotic efficacy with reduced motor impairment, akin to the effects observed with paliperidone ER in clinical studies. PMID:19640686

  6. Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing interval

    Directory of Open Access Journals (Sweden)

    Naessens Ineke

    2007-01-01

    Full Text Available Abstract Background Several clinical studies have established the efficacy, safety, and tolerability of long-acting risperidone administered once every 2 weeks in patients with schizophrenia or schizoaffective disorder. This report evaluates preliminary efficacy, safety, tolerability, and pharmacokinetic data for a novel (once-monthly administration of long-acting injectable risperidone 50 mg in patients with schizophrenia or schizoaffective disorder. Methods Clinically stable patients participated in a 1-year, open-label, single-arm, multicenter pilot study. During the 4-week lead-in phase, patients received long-acting risperidone 50 mg injections every 2 weeks, with 2 weeks of oral risperidone supplementation. Injections of long-acting risperidone 50 mg every 4 weeks followed for up to 48 weeks, without oral supplementation. The primary endpoint was relapse; other assessments included PANSS, CGI-S, adverse event reports, and determination of risperidone and 9-hydroxyrisperidone plasma concentrations. Results Twelve patients in the intent-to-treat population (n = 67 met relapse criteria (17.9%. Relapse risk at 1 year was estimated as 22.4%. Non-statistically significant improvements in symptoms (PANSS and clinical status (CGI-S at endpoint were observed. The most common adverse events included schizophrenia aggravated not otherwise specified (19.5%, anxiety (16.1%, insomnia (16.1%, and headache (11.5%. There were no unexpected safety and tolerability findings. Mean plasma concentrations for risperidone and 9-hydroxyrisperidone were generally stable during the study. Conclusion Once-monthly dosing of long-acting risperidone was well tolerated, associated with a relatively low relapse rate (similar to that reported with other antipsychotics, and maintained the clinically stable baseline status of most patients. Although the results suggest that some symptomatically stable patients with schizophrenia or schizoaffective disorder might be safely

  7. Emerging treatments in the management of bipolar disorder – focus on risperidone long acting injection

    Directory of Open Access Journals (Sweden)

    Wissam El-Hage

    2010-07-01

    Full Text Available Wissam El-Hage1, Simon A Surguladze21Inserm U930 ERL CNRS 3106, Université François Rabelais and Clinique Psychiatrique Universitaire, CHRU de Tours, Tours, France; 2Institute of Psychiatry, King’s College London, UKAbstract: Bipolar disorder is a life-long psychiatric illness characterized by a high frequency of relapses and substantial societal costs. Almost half of the patients are prescribed second generation antipsychotics for treatment of manic states, or as the maintenance therapy. ­Risperidone long acting injection (RLAI as a monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder was approved by Food and Drug Administration (FDA in United States in May 2009. In this review we will consider the aspects of pharmacology, pharmacokinetics, metabolism, safety and tolerability, and clinical trials focusing on the efficacy of RLAI in bipolar disorder. The patients’ perspective and attitudes to long-acting injections will also be discussed.Keywords: second generation, antipsychotics, patient attitudes, lithium, valproate, monotherapy

  8. Costs and efficacy ofolanzapine and risperidone in schizophrenia

    Directory of Open Access Journals (Sweden)

    Vittorio Mapelli

    2007-06-01

    Full Text Available Introduction: schizophrenia is a serious and long lasting psychiatric disease. The new “atypical” antipsychotic drugs, introduced in the 90s, have substantially improved the effectiveness of medical treatments, compared to previous neuroleptic drugs. Nowadays they tend to be used as first choice drugs. The ddd cost of atypicals may differ by 20% and health authorities may have an incentive to deliver the less costly drug, especially if they are generic. However the various drugs show differential effectiveness rates and a rational choice should consider both cost and effectiveness.
Objective: the purpose of this analysis is to review the existing evidence on cost-effectiveness studies of olanzapine and risperidone, the two most prescribed drugs in Italy. Six published studies were identified, but attention was focused on two articles that reported consistent and methodologically sound results.
Results: most reviewed studies are cost-minimization analyses, since effectiveness indicators show no significant statistical difference between the two drugs, and are inconclusive since the results depend on the evaluation setting. However one observational retrospective study showed a significant severity reduction over 12 months for patients treated with olanzapine (-2.46 on HoNOS scale; p<0.05, compared to a smaller non significant reduction of the risperidone group (-0.57. Despite the higher drug cost, the average total cost per reduced severity score was lower for olanzapine than for risperidone patients (€ 4,554 vs. € 10,897. The only medical and related health care costs for risperidone patients were higher than total costs for olanzapine patients. Another study comparing cohorts of patients with similar starting severity showed a significant severity reduction and global functioning increase over 12 months for olanzapine but no significant increase for risperidone patients (-0.35, p<0.01 on CGI scale; +3.66, p <0.05 on GAF scale

  9. Efficacy and safety of risperidone oral solution combination clonazepam oral versus haloperidol intramuscular injection for treatment of acute psychotic agitation in schizophrenia%利培酮口服液合用氯硝西泮与氟哌啶醇针剂肌内注射治疗精神分裂症急性激越症状疗效和安全性的研究

    Institute of Scientific and Technical Information of China (English)

    房茂胜; 王刚; 张庆娥; 郑洪波; 张璐璐; 汪波; 周建初; 赵靖平; 李乐华; 陈红辉; 李毅; 刘连忠; 叶萌; 黄继忠; 诸索宇

    2010-01-01

    Objective To compare the efficacy and safety between risperidone oral solution combination clonazepam oral and haloperidol IM injection on controlling psychotic agitation in patients of acute schizophrenia or schizophrenic-affective disorder and to explore the possibility of decreasing efficacy of 6 week acute treatment from switching IM injection to oral.Method Altogether 205 patients exhibiting agitation were randomly assigned to receive either oral treatment with risperidone oral solution puls clonazepam ( n = 104) or intramuscular injection treatment with haloperidol ( n = 101 ).The primary efficacy outcome measure was the change in scores based on PANSS-EC in session Ⅰ ( the first five days), and the response rate based on the PANSS score in session Ⅱ ( the following 6 weeks).Safety was evaluated using the Simpson-Angus Scale (ASA), Barnes Akathisia Scale (BAS), adverse events and lab test.Result Mean acute-agitation score improvement was significant after 5 day treatment in both groups (P <0.01 ) and were similar in both groups ( P > 0.05).While the cooperation was better and the advert events, especially extrapyramidal symptoms was lower in risperidone oral solution groups than that in haloperidol IM injection group(P <0.05).The mean PANSS-EC and PANSS scores remained stable after switching from IM injection to oral.The efficacy was not differenct in both groups after 6 week treatment (P > 0.05).There was no significant difference at the rate of total advert events ( P > 0.05 ) while there were yet significantly higher rates of extrapyramidal symptoms in switching drug group than that in oral group ( P < 0.05 ).Conclusion Risperidone oral solution plus oral clonazepam has similar therapeutic effect to haloperidol IM injection in the treatment of acute agitation, but risperidone oral solution plus clonazepam has better compliance and tolerability.The illness is stable after switching from haloperidol IM injection to risperidone oral solution

  10. Efficacy and safety of risperidone oral solution in agitation associated with dementia in the elderly

    Directory of Open Access Journals (Sweden)

    Laks Jerson

    2001-01-01

    Full Text Available BACKGROUND: Behavioral and psychological symptoms in dementia (BPSD contribute to caregiver burden and institutionalization of elderly. Neuroleptics are prescribed to control agitation. Side effects of typical neuroleptics are harmful, making atypical neuroleptics an indication. OBJECTIVES: To evaluate efficacy and tolerability of risperidone oral solution (ROS given once daily to demented elderly outpatients with BPSD (agitation. METHOD: Patients (n=26, 76.35±8.63 years, Diagnostic and Statistical Manual of Mental Disorders 4th ed. (DSM-IV criteria for dementia. RSO was given, starting dose of 0.25 mg and increments of 0.25 mg every week. Mini-Mental State Examination (MMSE assessed cognitive status, Behavioral and Emotional Activities Manifested in Dementia (BEAM-D and Clinical Global Impression (CGI measured BPSD, Extrapiramidal Symptom Rating Scale (ESRS evaluated extrapyramidal symptoms. Cardiovascular side effects were evaluated clinically. RESULTS: There was a 26% reduction in agitation and no cardiovascular side effects in the range from 1.0 to 1.25 mg. Side effects were more prevalent above 2.5 mg. CONCLUSION: Risperidone oral solution improved agitation with good tolerability from 0.5 to 1.25 mg. A single dose with increments of 0.25 mg may be more acceptable to patients and caregivers.

  11. Efficacy and Safety of Risperidone and Quetiapine in Adolescents With Bipolar II Disorder Comorbid With Conduct Disorder.

    Science.gov (United States)

    Masi, Gabriele; Milone, Annarita; Stawinoga, Agnieszka; Veltri, Stefania; Pisano, Simone

    2015-10-01

    Although a frequent co-occurrence between bipolar disorder (BD) and conduct disorder (CD) in youth has been frequently reported, data about pharmacological management are scarce and focused on BD type I. Second generation antipsychotics are frequently used in clinical practice, but no comparative studies are available. The aim of this exploratory study was to compare efficacy and safety of risperidone and quetiapine in a sample of adolescents presenting a BD type II comorbid with CD. Twenty-two patients diagnosed with a structured interview according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, (male/female ratio, 12/10; mean (SD) age 15.0 (1.4) years) were randomized in 2 treatment groups (quetiapine [n = 12] vs risperidone [n = 10]), treated with flexible doses, and followed up for 12 weeks. Efficacy measures assessed manic symptoms, aggression, anxiety, depression, global clinical severity, and impairment. Safety measures included body mass index, serum prolactin, extrapyramidal adverse effects, and electrocardiogram. At the end of the study, all patients improved in all efficacy measures. Both treatments showed similar efficacy in reducing manic symptoms and aggression. Quetiapine was more effective in improving anxiety and depressive symptoms. A change in body mass index was found, and in a post hoc analysis, it was significant only in the risperidone group. Prolactin significantly increased only in the risperidone group. In BD type II, CD comorbidity, quetiapine, or risperidone monotherapy may be effective and relatively safe, although the small sample size, the limited duration of the study, and the design (lack of a blind assessments and of a placebo group) make it difficult to draw definitive conclusions. PMID:26226481

  12. Minocycline and risperidone prevent microglia activation and rescue behavioral deficits induced by neonatal intrahippocampal injection of lipopolysaccharide in rats.

    Directory of Open Access Journals (Sweden)

    Furong Zhu

    Full Text Available BACKGROUND: Various signs of activation of microglia have been reported in schizophrenia, and it is hypothesized that microglia activation is closely associated with the neuropathology of schizophrenia. METHODS: Neonatal intrahippocampal injection of lipopolysaccharide (LPS, an activator of microglia, was performed in rats at postnatal day 7 (P7, and they were separately given saline, risperidone (0.5 mg/kg, minocycline (40 mg/kg or a combination of both of them at P42 for consecutive 14 days. Behavioral changes (locomotion activity, social interaction, novel object recognition and prepulse inhibition were examined and the number of microglia was assessed by using immunohistochemistry in adulthood. RESULTS: The adult rats in LPS-injected group showed obvious behavioral alteration (e. g. deficits in social interaction, novel object recognition and prepulse inhibition and a dramatic increase of number of activated microglial cells in the hippocampus and other brain regions such as cerebral cortex and thalamus compared to those in saline-injected group. Interestingly, application of either minocycline, risperidone or both of them significantly rescued behavioral deficits and attenuated microglia activation. CONCLUSION: Our results suggest that inhibition of microglia activation may be one of mechanisms underlying the antipsychotic effect of minocycline and risperidone.

  13. Minocycline and Risperidone Prevent Microglia Activation and Rescue Behavioral Deficits Induced by Neonatal Intrahippocampal Injection of Lipopolysaccharide in Rats

    Science.gov (United States)

    Ding, Yu-qiang; Liu, Yong; Zhang, Xianghui; Wu, Renrong; Guo, Xiaofeng; Zhao, Jingping

    2014-01-01

    Background Various signs of activation of microglia have been reported in schizophrenia, and it is hypothesized that microglia activation is closely associated with the neuropathology of schizophrenia. Methods Neonatal intrahippocampal injection of lipopolysaccharide (LPS), an activator of microglia, was performed in rats at postnatal day 7 (P7), and they were separately given saline, risperidone (0.5 mg/kg), minocycline (40 mg/kg) or a combination of both of them at P42 for consecutive 14 days. Behavioral changes (locomotion activity, social interaction, novel object recognition and prepulse inhibition) were examined and the number of microglia was assessed by using immunohistochemistry in adulthood. Results The adult rats in LPS-injected group showed obvious behavioral alteration (e. g. deficits in social interaction, novel object recognition and prepulse inhibition) and a dramatic increase of number of activated microglial cells in the hippocampus and other brain regions such as cerebral cortex and thalamus compared to those in saline-injected group. Interestingly, application of either minocycline, risperidone or both of them significantly rescued behavioral deficits and attenuated microglia activation. Conclusion Our results suggest that inhibition of microglia activation may be one of mechanisms underlying the antipsychotic effect of minocycline and risperidone. PMID:24705495

  14. A six month randomized controlled trial of long acting injectable risperidone 50 and 100mg in treatment resistant schizophrenia.

    Science.gov (United States)

    Meltzer, H Y; Lindenmayer, J-P; Kwentus, J; Share, D B; Johnson, R; Jayathilake, K

    2014-04-01

    It has been suggested that atypical antipsychotic drugs (A-APDs) other than clozapine may be effective to improve positive symptoms in some patients with treatment resistant schizophrenia (TRS), if both the dose is higher, and the duration of the trial longer, than those which have been ineffective in non-TRS (NTRS) patients. This hypothesis was tested with long acting injectable risperidone (Risperdal Consta®, RLAI). One hundred sixty TRS patients selected for persistent moderate-severe delusions or hallucinations, or both, were randomized to RLAI, 50 or 100mg biweekly, in a six month, outpatient, double-blind, multicenter trial. We hypothesized that RLAI, 100mg, would be more effective than RLAI, 50mg. However, both doses produced clinically significant and equivalent improvement in PANSS Total, Positive, and Negative subscale scores, as well as key cognitive, global and functional measures, with increasing response during the course of the study, confirming the value of longer clinical trial duration for patients with TRS, but not superiority of the higher dose. The overall response rate was comparable to that previously reported for clozapine and high dose olanzapine, another A-APD, in TRS. Both doses of RLAI were equally well tolerated, producing minimal extrapyramidal side effects and few drop outs. Plasma levels of the active moiety, risperidone+9-hydroxyrisperidone, during treatment with RLAI 100mg, were comparable to those for 6-8 mg/day oral risperidone, which have not been effective in TRS. Further study of RLAI, ≥ 50-100mg biweekly, should compare it with clozapine and oral risperidone in TRS, with duration of treatment ≥ six months. PMID:24630262

  15. Clinical utility of the risperidone formulations in the management of schizophrenia

    Directory of Open Access Journals (Sweden)

    Madaan V

    2011-10-01

    Full Text Available Vishal Madaan1, Durga P Bestha2, Venkata Kolli2, Saurabh Jauhari2, Roger C Burket1 1University of Virginia Health System, Charlottesville, VA, USA; 2Creighton University Medical Center, Omaha, NE, USA Abstract: Risperidone is one of the early second-generation antipsychotics that came into the limelight in the early 1990s. Both the oral and long-acting injectable formulations have been subject to numerous studies to assess their safety, efficacy, and tolerability. Risperidone is currently one of the most widely prescribed antipsychotic medications, used for both acute and long-term maintenance in schizophrenia. Risperidone has better efficacy in the treatment of psychotic symptoms than placebo and possibly many first-generation antipsychotics. Risperidone fares better than placebo and first-generation antipsychotics in the treatment of negative symptoms. Risperidone's long acting injectable preparation has been well tolerated and is often useful in patients with medication nonadherence. Risperidone has a higher risk of hyperprolactinemia comparable to first-generation antipsychotics (FGAs but fares better than many second-generation antipsychotics with regards to metabolic side effects. In this article, we briefly review the recent literature exploring the role of risperidone formulations in schizophrenia, discuss clinical usage, and highlight the controversies and challenges associated with its use. Keywords: risperidone, schizophrenia, formulation, antipsychotic, side effects

  16. Comparison of Subjective Experiences and Effectiveness of First-Generation Long-Acting Injectable Antipsychotics and Risperidone Long-Acting Injectables in Patients With Schizophrenia.

    Science.gov (United States)

    Chen, Wen-Yin; Lin, Shih-Ku

    2016-10-01

    We conducted a cross-sectional study to compare the subjective experiences and clinical effects of first-generation long-acting injectable (FGA-LAI) antipsychotics with those of risperidone long-acting injectables (RIS-LAIs) in 434 schizophrenia patients. Compared with the RIS-LAI group, the patients treated with FGA-LAIs had a significantly longer duration of illness and LAI treatment and were older. Our results suggest that patients treated with FGA-LAI have more satisfactory subjective experiences compared with patients treated with RIS-LAI and that both FGA-LAI and RIS-LAI treatments can prevent relapses and hospitalization. Additional longitudinal studies determining the long-term benefits of RIS-LAI are warranted. PMID:27580495

  17. Preparation and in-vitro characterization of Risperidone-cyclodextrin inclusion complexes as a potential injectable product

    Directory of Open Access Journals (Sweden)

    D Shukla

    2009-12-01

    Full Text Available "n  "n Background and the purpose of the study: This investigation deals with risperidone cyclodextrin (CD complexation for parenteral administration to improve its aqueous solubility which would be beneficial over immediate and sustained release formulations available in market especially for agitated and non-cooperative psychotic patients. "nMethods: The phase solubility study of the drug with β-CD, hydroxypropyl (HP-β-CD and γ-CD was conducted and CDs with higher stability constants were selected for complexation. The complexes of Risperidone with β-CD and HP-β-CD were prepared by precipitation and vacuum drying methods, respectively. Fourier transform-infrared, X-ray diffraction and differential scanning calorimetry techniques were used for characterization of complexes. Drug precipitation study of complex's solution in water for injection and 100 ml of 0.1 M pH 7.4 phosphate buffer saline and stability study in accelerated condition were also carried out. "nResults: The stability constants of the CD were in the following order: β-CD (341.953±11.87 M-1 > HP-β-CD (170.817± 5.93 M-1 > γ-CD (93.716 ± 3.25 M-1. CDs with high stability constants were selected to prepare the drug CD complex. The complexation efficiencies of β-CD and HP-β-CD were 95.23 ± 2.27% and 97.59 ±1.97%, respectively. Both types of CDs exhibited complexation at 1:2 molar stoichiometric ratio. The drug precipitation study indicated complete solubility (100% drug dissolution without a trace of precipitate within 5 mins. The complexes were found to be stable for a period of 3 months under accelerated stability conditions. Major conclusion:Stable complexes of risperidone were successfully formulated using both β-CD and HP-β-CD by simple and highly efficient methods of complexation for parenteral administration.

  18. Comparison between the efficacies of Risperidone with Haloperidol in the treatment of attention-deficit hyperactivity disorder (ADHD) among preschoolers: a randomized double-blind clinical trial

    Science.gov (United States)

    Riahi, Forough; Tashakori, Ashraf; Abdi, Leila

    2016-01-01

    Background Attention-deficit hyperactivity disorder (ADHD) is a common psychiatric disease with a worldwide pooled prevalence of 5.29%. Objective To compare the efficacy of Risperidone with Haloperidol in the treatment of attention-deficit hyperactivity disorder (ADHD) among 3- to 6-year-old children. Methods In a 6-week double-blind clinical trial, the efficacy of Risperidone 0.5–2 mg with a dose of maximum Haloperidol 0.075 mg/kg was assessed in 39 children aged 3–6 years. This study was conducted at the Golestan Psychiatric Clinic (Ahvaz, Iran). Measurement tools included the Conners’ Parent Rating Scale (CPRS-48), Children’s Global Assessment Scale (CGAS), and the Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS). Data were analyzed using the Wilcoxon, Mann-Whitney, and Fisher’s exact tests in the SPSS 19. Results During the 6 weeks, the decline in points was seen in Conner’s rating scale and in ADHD-RS score in Risperidone and Haloperidol groups (p0.05). Conclusions Haloperidol and Risperidone possibly can be an acceptable treatment choice in the ADHD treatment of 3- to 6-year-old children. Trial registration The trial was registered at the Iranian Registry of Clinical Trials (http://www.irct.ir) with the Irct ID: IRCT2015082623766N1. Funding This work was financially supported by grant (ref. no.: U-93130) from the vice chancellor for Research Affairs of Ahvaz Jundishapur University of Medical Sciences. PMID:27790334

  19. [The study of therapeutic efficacy of two forms of risperidone--rileptid and rispolept in patients with schizophrenia].

    Science.gov (United States)

    Akhapkin, R V

    2008-01-01

    Generic drugs represent a big part of the Russian pharmaceutical market, a number of registered copies of the same drug manufactured by different pharmaceutical companies being estimated as several tens of drugs that does not mean their equally high quality and complete interchangeability. A choice of optimal price-to-quality ratio of a drug among a great number of analogues is possible only with taking into account a number of factors related to a manufacturer, a drug and a patient. The most important index of interchangeability of generic drugs is their therapeutic equivalence to the original one. A study aimed to compare the therapeutic equivalence of two preparations of risperidone--original rispolept and generic rileptid--has been carried out. The comparison of efficacy and tolerability of the therapy has not revealed differences both in any of the parameters and in any stages of the study. In conclusion, the full therapeutic equivalence of generic drug rileptid to original rispolept is revealed. PMID:18833105

  20. Optimizing limbic selective D2/D3 receptor occupancy by risperidone: a [123I]-epidepride SPET study.

    Science.gov (United States)

    Bressan, Rodrigo A; Erlandsson, Kjell; Jones, Hugh M; Mulligan, Rachel S; Ell, Peter J; Pilowsky, Lyn S

    2003-02-01

    Selective action at limbic cortical dopamine D2-like receptors is a putative mechanism of atypical antipsychotic efficacy with few extrapyramidal side effects. Although risperidone is an atypical antipsychotic with high affinity for D2 receptors, low-dose risperidone treatment is effective without inducing extrapyramidal symptoms. The objective was to test the hypothesis that treatment with low-dose risperidone results in 'limbic selective' D2/D3 receptor blockade in vivo. Dynamic single photon emission tomography (SPET) sequences were obtained over 5 hours after injection of [123I]-epidepride (approximately 150 MBq), using a high-resolution triple-headed brain scanner (Marconi Prism 3000XP). Kinetic modelling was performed using the simplified reference region model to obtain binding potential values. Estimates of receptor occupancy were made relative to a normal volunteer control group (n = 5). Six patients treated with low-dose risperidone (mean = 2.6 mg) showed moderate levels of D2/D3 occupancy in striatum (49.9%), but higher levels of D2/D3 occupancy in thalamus (70.8%) and temporal cortex (75.2%). Occupancy values in striatum were significantly different from thalamus (F (1,4) = 26.3, p < 0.01) and from temporal cortex (F (1,4) = 53.4, p < 0.01). This is the first study to evaluate striatal and extrastriatal occupancy of risperidone. Low dose treatment with risperidone achieves a similar selectivity of limbic cortical over striatal D2/D3 receptor blockade to that of atypical antipsychotics with lower D2/D3 affinity such as clozapine, olanzapine and quetiapine. This finding is consistent with the relevance of 'limbic selective' D2/D3 receptor occupancy to the therapeutic efficacy of atypical antipsychotic drugs. PMID:12544369

  1. Adjunctive long-acting risperidone in patients with bipolar disorder who relapse frequently and have active mood symptoms

    OpenAIRE

    Haskins John T; Turkoz Ibrahim; Adler Caleb M; Macfadden Wayne; Turner Norris; Alphs Larry

    2011-01-01

    Abstract Background The objective of this exploratory analysis was to characterize efficacy and onset of action of a 3-month treatment period with risperidone long-acting injection (RLAI), adjunctive to an individual's treatment regimen, in subjects with symptomatic bipolar disorder who relapsed frequently and had significant symptoms of mania and/or depression. Methods Subjects with bipolar disorder with ≥4 mood episodes in the past 12 months entered the open-label stabilization phase preced...

  2. Risperidone in idiopathic and symptomatic dystonia: preliminary experience.

    Science.gov (United States)

    Grassi, E; Latorraca, S; Piacentini, S; Marini, P; Sorbi, S

    2000-04-01

    Risperidone is a heterocyclic neuroleptic with prominent antiserotoninergic (5HT2) as well as antidopaminergic (D2) activity. We studied the efficacy of risperidone in the treatment of idiopathic and symptomatic dystonias in seven patients using the Fahn and Marsden rating scale for torsion dystonia before and after four weeks of treatment (2-6 mg/day). The twisting and involuntary movements with abnormal postures decreased in all the patients treated, with a statistically significant mean improvement (41%; p = 0.009, CI 95%). Our results suggest that risperidone is useful in idiopathic and symptomatic dystonia. PMID:10938193

  3. Medication adherence in patients with psychotic disorders: an observational survey involving patients before they switch to long-acting injectable risperidone

    Directory of Open Access Journals (Sweden)

    Baylé FJ

    2015-09-01

    Full Text Available Franck Jean Baylé,1 Arnaud Tessier,2,3 Sophie Bouju,4 David Misdrahi2,3 1Sainte-Anne Hospital (SHU, Paris V-Descartes University, Paris, 2Hôpital Charles Perrens, Pôle de Psychiatrie Adulte, 3CNRS UMR 5287-INCIA, Bordeaux University, Bordeaux, 4Janssen-Cilag France, Issy Les Moulineaux, Paris, France Background: Maintaining antipsychotic therapy in psychosis is important in preventing relapse. Long-acting depot preparations can prevent covert non-adherence and thus potentially contribute to better patient outcomes. In this observational survey the main objective is to evaluate medication adherence and its determinants for oral treatment in a large sample of patients with psychosis.Methods: In this cross-sectional survey medication adherence for oral treatment was assessed by patients using the patient-rated Medication Adherence Questionnaire (MAQ. Data were collected by physicians on patients with a recent acute psychotic episode before switching to long-acting injectable risperidone. Other evaluations included disease severity (Clinical Global Impression – Severity, patients’ insight (Positive and Negative Syndrome Scale item G12, treatment acceptance (clinician-rated Compliance Rating Scale, and therapeutic alliance (patient-rated 4-Point ordinal Alliance Scale.Results: A total of 399 psychiatrists enrolled 1,887 patients (mean age 36.8±11.9 years; 61.6% had schizophrenia. Adherence to oral medication was “low” in 53.2% of patients, “medium” in 29.5%, and “high” in 17.3%. Of patients with psychiatrist-rated active acceptance of treatment, 70% had “medium” or “high” MAQ scores (P<0.0001. Medication adherence was significantly associated with therapeutic alliance (4-Point ordinal Alliance Scale score; P<0.0001. Patient age was significantly associated with adherence: mean age increased with greater adherence (35.6, 36.7, and 38.6 years for patients with “low”, “medium”, and “high” levels of adherence

  4. Formulation, in vitro and in vivo evaluation of transdermal patches containing risperidone.

    Science.gov (United States)

    Aggarwal, Geeta; Dhawan, Sanju; Hari Kumar, S L

    2013-01-01

    The efficacy of oral risperidone treatment in prevention of schizophrenia is well known. However, oral side effects and patient compliance is always a problem for schizophrenics. In this study, risperidone was formulated into matrix transdermal patches to overcome these problems. The formulation factors for such patches, including eudragit RL 100 and eudragit RS 100 as matrix forming polymers, olive oil, groundnut oil and jojoba oil in different concentrations as enhancers and amount of drug loaded were investigated. The transdermal patches containing risperidone were prepared by solvent casting method and characterized for physicochemical and in vitro permeation studies through excised rat skin. Among the tested preparations, formulations with 20% risperidone, 3:2 ERL 100 and ERS 100 as polymers, mixture of olive oil and jojoba oil as enhancer, exhibited greatest cumulative amount of drug permeated (1.87 ± 0.09 mg/cm(2)) in 72 h, so batch ROJ was concluded as optimized formulation and assessed for pharmacokinetic, pharmacodynamic and skin irritation potential. The pharmacokinetic characteristics of the optimized risperidone patch were determined using rabbits, while orally administered risperidone in solution was used for comparison. The calculated relative bioavailability of risperidone transdermal patch was 115.20% with prolonged release of drug. Neuroleptic efficacy of transdermal formulation was assessed by rota-rod and grip test in comparison with control and marketed oral formulations with no skin irritation. This suggests the transdermal application of risperidone holds promise for improved bioavailability and better management of schizophrenia in long-term basis.

  5. Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trial

    DEFF Research Database (Denmark)

    Lublin, Henrik; Haug, Hans-Joachim; Koponen, Hannu;

    2009-01-01

    The efficacy, safety and tolerability of ziprasidone versus the comparators olanzapine, risperidone or quetiapine were investigated in adult patients with chronic schizophrenia, schizoaffective and schizophreniform disorders, with lack of efficacy or intolerance to their previous antipsychotic...

  6. 齐拉西酮和利培酮治疗精神分裂症的临床疗效及安全性评价%Clinical efficacy and safety of ziprasidone and risperidone in the treatment of schizophrenia

    Institute of Scientific and Technical Information of China (English)

    陈统献; 闫耀宇; 鲍佑元

    2015-01-01

    Objective To evaluate the efficacy and safety of ziprasidone versus risperidone in the treatment of schizophrenia .Methods A total of 120 patients with schizophrenia were randomly divided into treatment group (n=62) and control group(n=58).Patients in the control group were administered risperidone 0.25 mg・ d-1 initially with maximum of 4.0 mg・ d-1 orally, qd. And patients in the treatment group were administered of ziprasidone 40 mg・ d -1 initially with maximum of 160 mg・ d-1 orally, bid.All the patients received 8 weeks treatment.After treatment, the clinical efficacy ,quality of life score and side effects were compared between the two groups.Results After treatment, the clinical efficacy were 89.66% and 91.94% in control and treatment group respectively, with no statistical difference(P>0.05).The score evalua-ted by the short from health survey ( SF-36 ) was significant higher in treatment group compared with control group ( P <0.05 ) . The side effects incidence rate were 20.69% in control group and 8.06% in treatment group, which was significantly difference ( P <0.05 ) . Conclusion The clinical efficacy was not different between ziprasidone and risperidone.But ziprasidone can improve patients′quality of life much more significantly with and less adverse events .%目的:评价齐拉西酮和利培酮治疗精神分裂症的临床疗效及安全性。方法将120例精神分裂症患者随机分为对照组58例和试验组62例。对照组予以利培酮起始给药剂量为0.25 mg・ d-1,最大给药剂量4.0 mg・ d-1,每日1次;试验组予以齐拉西酮初始剂量为40 mg・ d-1开始,分2次服用,按照控制情况逐渐加量,根据患者病情和耐受情况,1周之内达到最大剂量160 mg・ d-1,2组均治疗8周。比较2组的临床疗效、生活质量评分及不良反应发生率有无差别。结果对照组临床总有效率为89.66%,试验组临床总有效率为91.94%,2组比

  7. Comparison of efficacy and safety of amisulpride ang risperidone in treating patients with schizophrenia%氨黄必利与利培酮治疗患者精神分裂症患者的对照研究

    Institute of Scientific and Technical Information of China (English)

    杨奎娟; 刘超

    2013-01-01

    目的比较氨黄必利与利培酮治疗精神分裂症患者的疗效与不良反应。方法 120例符合中国精神障碍分类与诊断标准第3版精神分裂症诊断标准的患者随机分为两组,每组60例,分别给予氨黄必利和利培酮治疗8周,采用阳性与阴性症状量表(PANSS)评定疗效,治疗中出现的症状量表(TESS)评定不良反应,用世界卫生组织编制的生活质量量表(WHOQOL-100)评定生活质量。结果 治疗8周后,氨黄必利组显效率73.3%,有效率90%,利培酮组显效率66.7%,总有效率86.7%,两组疗效比较差异无统计学意义(P>0.05);两组WHOQOL-100各领域评分较治疗前均明显差异(P>0.01);氨黄必利组不良反应发生率16.7%,利培酮组为13.3%两组差异无统计学意义(P>0.05)。结论 氨黄必利与利培酮治疗精神分裂症患者的疗效相当,不良反应小,明显改善患者生活质量。%Objective: To compare the efficacy and safety between amisulpride and rispeeidone in treatment of schizophrenia. Method: one hundred and twenty Patients with schizophrenia who met the schizophrenia critetion of Chinese classification of mental disorders were devided into two groups ramdomly and treated with amisulpride or riseridone for 8weeks respectively .The positive and negative scale (PANSS) and treatment Emergent side effect scale (TESS) were used to evaluate the efficacy and adverse effect respectively, the quality of life was measured by World Health Organization quality of life questionnaire (WHOQOL-100). Results:The significant efficacy rate of amisulpride group Was 73.3%and the efficacy rate was 90.0% after 8 weeks, while 66.7% and 86.7% in risperidone group . There were no statistical difference between two groups (P>0.05).The two groups showed similar improvement on quality of life. The incidence rate of adverse effect was 16.7% in amisulpride group and that was 13.3% in risperidone group, without

  8. Risperidone Improves Behavioral Symptoms in Children with Autism in a Randomized, Double-Blind, Placebo-Controlled Trial

    Science.gov (United States)

    Pandina, Gahan J.; Bossie, Cynthia A.; Youssef, Eriene; Zhu, Young; Dunbar, Fiona

    2007-01-01

    Subgroup analysis of children (5-12 years) with autism enrolled in an 8-week, double-blind, placebo-controlled trial of risperidone for pervasive developmental disorders. The primary efficacy measure was the Aberrant Behavior Checklist-Irritability (ABC-I) subscale. Data were available for 55 children given risperidone (n = 27) or placebo (n =…

  9. Risperidone Dosing in Children and Adolescents with Autistic Disorder: A Double-Blind, Placebo-Controlled Study

    Science.gov (United States)

    Kent, Justine M.; Kushner, Stuart; Ning, Xiaoping; Karcher, Keith; Ness, Seth; Aman, Michael; Singh, Jaskaran; Hough, David

    2013-01-01

    Efficacy and safety of 2 risperidone doses were evaluated in children and adolescents with autism. Patients (N = 96; 5-17 years), received risperidone (low-dose: 0.125 mg/day [20 to 45 kg] or high-dose: 1.25 mg/day [20 to 45 kg]) or placebo. Mean baseline (range 27-29) to endpoint change…

  10. Efficacy of Clozapine Combined with Risperidone in Refractory Schizophrenia%氯氮平联合利培酮治疗难治性精神分裂症的疗效

    Institute of Scientific and Technical Information of China (English)

    李晓波; 韦伟香

    2014-01-01

    Objective To explore the efficacy and safety of clozapine combined with risperidone in the treatment of refractory schizophrenia.Methods A total of 118 patients with refractory schizophrenia were randomly treated with clozapine tablets alone(control group,n = 59)or in combination with risperidone tablets(observation group,n=59).Clinical efficacy and adverse re-actions were observed in both groups.Patients were scored using the Positive and Negative Syn-drome Scale(PANSS)before and after treatment for 2,4,8 and 12 weeks.Results PANSS scores significantly decreased in both groups after treatment for 8 and 12 weeks(P <0.05),and the de-crease in observation group was more obvious than that in control group(P <0.05).In addition, the total effective rate in observation group was significantly higher than that in control group (96.6% vs 81.4%,P < 0.05),and the incidence of adverse reactions in observation group was significantly lower than that in control group(15.3% vs 27.1%,P < 0.05).Conclusion The combination of clozapine and risperidone is an effective,safe and reliable treatment and can reduce adverse reactions in the treatment of refractory schizophrenia.%目的:探讨氯氮平联合利培酮治疗难治性精神分裂症的临床疗效和安全性。方法将118例难治性精神分裂症患者按入院的先后顺序分为2组:观察组和对照组,每组59例。2组均采用氯氮平片治疗。在此基础上,观察组加用利培酮片治疗。观察2组临床疗效以及不良反应发生的情况,并对2组治疗前及治疗2、4、8和12周后采用阳性与阴性症状量表(PANSS)进行评分。结果2组治疗8、12周后 PANSS 得分均较治疗前明显降低(均 P <0.05),观察组治疗8、12周后 PANSS 得分均较对照组下降更明显(均 P <0.05)。观察组总有效率明显高于对照组(96.6%比81.4%,P <0.05),不良反应发生率明显低于对照组(15.3%比27.1%,P <0.05

  11. Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis

    Directory of Open Access Journals (Sweden)

    Schooler Nina

    2011-02-01

    Full Text Available Abstract Background To compare the efficacy and tolerability of paliperidone extended-release (ER with risperidone immediate-release using propensity score methodology. Methods Six double-blind, randomized, placebo-controlled, short-term clinical trials for acute schizophrenia with availability of individual patient-level data were identified (3 per compound. Propensity score pairwise matching was used to balance observed covariates between the paliperidone ER and risperidone patient populations. Scores were generated using logistic regression models, with age, body mass index, race, sex, baseline Positive and Negative Syndrome Scale (PANSS total score and baseline Clinical Global Impressions–Severity (CGI-S score as factors. The dosage range of paliperidone ER (6-12 mg/day was compared with 2 risperidone dosage ranges: 2-4 and 4-6 mg/day. The primary efficacy measure was change in PANSS total score at week 6 end point. Tolerability end points included adverse event (AE reports and weight. AEs with rates ≥5% and with a ≥2% difference between paliperidone ER and risperidone were identified. Results Completion rates for placebo-treated subjects in paliperidone ER trials (n = 95 and risperidone trials (n = 122 groups were 36.8% and 51.6%, respectively; end point changes on PANSS total scores were similar (p = 0.768. Completion rates for subjects receiving paliperidone ER 6-12 mg/day (n = 179, risperidone 2-4 mg/day (n = 113 or risperidone 4-6 mg/day (n = 129 were 64.8%, 54.0% and 66.7%, respectively (placebo-adjusted rates: paliperidone ER vs risperidone 2-4 mg/day, p = 0.005; paliperidone ER vs risperidone 4-6 mg/day, p = 0.159. PANSS total score improvement with paliperidone ER was greater than with risperidone 2-4 mg/day (difference in mean change score, -6.7; p Conclusions This indirect database analysis suggested that paliperidone ER 6-12 mg/day may be more efficacious than risperidone 2-4 mg/day and as efficacious as risperidone 4-6 mg

  12. 二甲双胍联合行为干预治疗利培酮所致的代谢紊乱%Efficacy of metformin combined behavior intervention in the treatment of metabolic disorders caused by risperidone

    Institute of Scientific and Technical Information of China (English)

    夏金校; 王一冰; 甘建光; 曹世林; 段迪; 钱佩华; 沈妃

    2011-01-01

    目的 观察二甲双胍(降血糖药)联合行为干预治疗利培酮(抗精神分裂症药)所致体质量增加及糖、脂代谢紊乱的临床疗效.方法 对口服利培酮所致肥胖的150例精神分裂症患者,随机分为A组(75例)和B组(75例),2组均给予行为干预;但A组加服二甲双胍,治疗6个月,测相关生化指标并进行比较.结果 除DBP、HDL-C和PRL外,A组余各指标,6个月末与入组时比较有极显著性差异;除DBP、TC、PRL、HDL-C外,B组余各指标,做相应地比较也有显著性差异.6个月末,除血压、脂蛋白、AST、PRL外,余各指标,A组与同期B 组比较有显著性差异;不良反应(主要为轻度恶心)发生率,A、B 2组分别为8%,7%,2组比较无显著性差异.结论 二甲双胍与行为干预单一或联合治疗利培酮所致体质量增加及代谢紊乱均有较好效果,尤以二甲双胍联合行为干预效果更好.%Objective To explore the clinical efficacy of metformin combined behavior intervention in treating metabolic disorders caused by risperidone, such as weight gain, glucose and lipid metabolism disorders.Methods A total of 150 schizophrenia patients who become obese after treated with risperidone were randomly divided into groups A (n =75) and B (n = 75).Both groups were given the same behavioral intervention for 6 months, but patients in group A also received treatment with metformin.At the point of baseline and the 6th month end, patients in both two groups received physical examination as well as a series of serological tests followed by statistic analysis.Results All the examine indexes except diastolic blood pressure, HDL -C and PRL were different between the point of baseline and the 6th month end in group A.All the examine indexes in addition to diastolic blood pressure, TC, PRL and HDL - C were different between the point of baseline and the 6th month end in group B.A lot of exam indexes were definitely different between two groups at the 6th month end

  13. Efficacy of abamectin injection against Dermatobia hominis in cattle.

    Science.gov (United States)

    Cruz, J B; Benitez-Usher, C; Cramer, L G; Gross, S J; Kohn, A B

    1993-01-01

    The efficacy of abamectin 1%, when injected subcutaneously in cattle at a dose of 200 micrograms/kg body weight, against the larval stages (grubs) of the fly Dermatobia hominis was evaluated in two trials in endemic areas of Brazil and Argentina. Eighteen Holstein x Brahman castrated males and 16 Brahman-cross with natural infestations were used. Larvae were counted by instar in situ on both sides of each animal before treatment, and were expressed, identified as to stage and classified as live or dead 10 days after treatment. Further larval counts were made periodically until day 79 to evaluate the degree of reinfestation and the stage of larval development. Reinfestation was first detected in the abamectin-treated cattle on day 44. Live larvae were found on 6-8 (Argentina) and on all (Brazil) controls at each post-treatment examination. The difference in numbers of live larvae between treatment groups was statistically significant (P < 0.05) at all post-treatment examinations. These data show that abamectin at a dose of 200 micrograms/kg body weight is highly effective in the treatment and control of established parasitic stages of D. hominis in cattle. No adverse reactions were observed in any of the treated animals. PMID:8493240

  14. Evidence based administration of risperidone and paliperidone for the treating conduct disorder

    OpenAIRE

    Ahmad Ghanizadeh

    2013-01-01

    Background: This study evaluates the evidence-based administration of risperidone and paliperidone for the treating children and adolescents with conduct disorder (CD). Materials and Methods: A review of the current literature from clinical trials that investigated the efficacy of risperidone and paliperidone on CD considering the inclusion criteria and search strategies was performed by a search of PubMed and Google Scholar databases. Results: Out of 53 titles, 31 were irrelevant. The abstra...

  15. Efficacy and executive function of olanzapine and risperidone in the treatment of elderly patients with schizophrenia%奥氮平与利培酮治疗老年精神分裂症患者疗效及执行功能比较

    Institute of Scientific and Technical Information of China (English)

    杭荣华; 程万良; 王瑞权; 吴明飞

    2012-01-01

    AIM: To explore the difference on efficacy and executive function between olanzapine and risperidone in treatment of elderly patients with schizophrenia. METHODS: 84 eider-ly patients with schizophrenia were randomly divided into olanzapine group (43 cases) and ris-peridon group (41 cases) treated for 8 weeks. The efficacy was assessed with the positive and negative symptoms scale (PANSS) and the executive function was evaluated with Wisconsin Card Sorting Test (WCST) in baseline and after 8 weeks of treatment. RESULTS: After 8 weeks of treatment, the efficacy rate of olanzapine was 90. 6 % . in which 67. 4% was improved markedly. The efficacy rate of risperidon was 92. 6%, in which 68.3% were improved markedly. There were no differences between two groups (P>0. 01). The score of negative symptom of olanzapine group was significantly lower than that of risperidon group(P<0. 05). The score of categories control in risperidon group was significantly lower than that in olanzapine group, persistent errors and response error were higher than that in olanzapine group(P<0. 01). CONCLUSION; Both olanzapine and risperidon can improve the symptom and executive function of elderly patients with schizophrenia. Olanzapine is better than risperidon in improving negative symptom and executive function.%目的:比较奥氮平与利培酮治疗老年精神分裂症的疗效及对执行功能的影响.方法:84例老年精神分裂症患者随机分为奥氮平组(43例)和利培酮组(41例),于治疗前及治疗后第8周末采用阳性与阴性症状量表(PANSS)和威斯康星卡片分类测验( WCST)评定疗效和执行功能,分别比较每组治疗前后及两组间的结果.结果:治疗后奥氮平组的有效率及显效率分别为90.6%和67.4%,利培酮组的有效率及显效率分别为92.6%和68.3%,两者差异无统计学意义(P>0.05).治疗后奥氮平组的阴性症状分低于利培酮组(P<0.01).利培酮组WCST的完成分类数低于奥氮平组,

  16. 认知行为与利培酮联合治疗精神分裂症残留型的临床疗效分析%Analysis of the Clinical Efficacy of Cognitive Behavior Combined With Risperidone in the Treatment of Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    王永良

    2015-01-01

    目的:分析认知行为配合利培酮治疗残留型精神分裂症的疗效。方法将72名残留型精神分裂症患者分成Og(观察)组和Cg(对照)组。Cg组单纯用利培酮治疗,Og组用利培酮时配合认知行为治疗。结果 Og组治疗后阴性症状、语言记忆、表达流畅、HAMD、HAMA等得分比治疗前降低,同时也比Cg组治疗后降低,而PSP得分增加。病理状态、阳性症状、SES得分及总分治疗前后无明显差别。结论认知行为疗法配合利培酮对于治疗残留型精神分裂患者获得的疗效比单纯服用药物好。%Objective To analyze the effect of cognitive behavior combined with risperidone in the treatment of residual type of schizophrenia.Methods 72 patients with schizophrenia were divided into Og (observation) group and Cg(control) group. Cg group was treated with risperidone alone, while the Og group was treated with the cognitive behavioral therapy and risperidone. ResultsThe negative symptoms,language memory, expression, HAMA and HAMD in the Og group were significantly less than those in Cg group,while the PSP score increased after treatment. There was no obvious difference in the pathological status, positive symptoms,SES score and total score.Conclusion Cognitive behavior therapy combined with risperidone in the treatment of residual type of schizophrenia patients has good efficacy.

  17. Development of risperidone liposomes for brain targeting through intranasal route.

    Science.gov (United States)

    Narayan, Reema; Singh, Mohan; Ranjan, OmPrakash; Nayak, Yogendra; Garg, Sanjay; Shavi, Gopal V; Nayak, Usha Y

    2016-10-15

    The present paper is aimed at development of functionalized risperidone liposomes for brain targeting through nasal route for effective therapeutic management of schizophrenia. The risperidone liposomes were prepared by thin film hydration method. Various parameters such as lipid ratio and lipid to drug ratio were optimized by using Design-Expert(®) Software to obtain high entrapment with minimum vesicle size. The surface of the optimized liposomes was modified by coating stearylamine and MPEG-DSPE for enhanced penetration to the brain. The formulations were evaluated for vesicle size, zeta potential, and entrapment efficiency. The morphology was studied by Transmission Electron Microscopy (TEM). In vivo efficacy was assessed by performing pharmacokinetic study in Wistar albino rats following intranasal administration of the formulations in comparison to intravenous bolus administration of pure drug. The mean vesicle size of optimized liposomes ranged from 90 to 100nm with low polydispersity index (smooth bilayered surface. All formulations showed prolonged diffusion controlled drug release. The in vivo results showed that liposomal formulations provided enhanced brain exposure. Among the formulations studied, PEGylated liposomes (LP-16) had shown greater uptake of risperidone into the brain than plasma. High brain targeting efficiency index for LP-16 indicating preferential transport of the drug to brain. The study demonstrated successful formulation of surface modified risperidone liposomes for nasal delivery with brain targeting potential. PMID:27593571

  18. A Comparative Study between Olanzapine and Risperidone in the Management of Schizophrenia

    Directory of Open Access Journals (Sweden)

    Saeed Shoja Shafti

    2014-01-01

    Full Text Available Introduction. Since a variety of comparisons between risperidone and olanzapine have resulted in diverse outcomes, so safety and efficacy of them were compared again in a new trial. Method. Sixty female schizophrenic patients entered into one of the assigned groups for random allocation to olanzapine or risperidone (n=30 in each group in a double-blind, 12-week clinical trial. Scale for Assessment of Positive Symptoms (SAPS and Scale for Assessment of Negative Symptoms (SANS were used as the primary outcome measures. Clinical Global Impressions-Severity Scale (CGI-S, Schedule for Assessment of Insight (SAI, and finally Simpson Angus Scale (SAS as well were employed as secondary scales. Results. While both of olanzapine and risperidone were significantly effective for improvement of positive symptoms (P<0.0001, as regards negative symptoms, it was so only by means of olanzapine (P<0.0003. CGI-S and SAI, as well, were significantly improved in both of the groups. SAS increment was significant only in the risperidone group (P<0.02. Conclusion. While both of olanzapine and risperidone were equally effective for improvement of positive symptoms and insight, olanzapine showed superior efficacy with respect to negative symptoms, along with lesser extrapyramidal side effects, in comparison with risperidone.

  19. Profile of paliperidone palmitate once-monthly long-acting injectable in the management of schizophrenia: long-term safety, efficacy, and patient acceptability – a review

    Directory of Open Access Journals (Sweden)

    González-Rodríguez A

    2015-05-01

    Full Text Available Alexandre González-Rodríguez,1 Rosa Catalán,1–4 Rafael Penadés,1–4 Clemente Garcia-Rizo,1,3,4 Miquel Bioque,1,4 Eduard Parellada,1,3–5 Miquel Bernardo1–4 1Barcelona Clinic Schizophrenia Unit (BCSU, Neuroscience Institute, Hospital Clinic of Barcelona, 2Department of Psychiatry and Clinical Psychobiology, University of Barcelona, 3Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS, Barcelona, Spain; 4Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM, Madrid, Spain; 5Department of Pharmacology, University of Barcelona, Barcelona, Spain Background and objectives: Short-term studies focused on once-monthly paliperidone palmitate (PP at doses of 25 mg eq, 50 mg eq, 75 mg eq, 100 mg eq, or 150 mg eq have shown its efficacy and tolerability in the treatment of schizophrenia patients. However, few open-label and long-term studies are available regarding this new pharmacological formulation. Thus, our main aim was to review the scientific evidence on efficacy, safety, tolerability, and preference of PP in these populations. Method: Electronic searches were conducted by using PubMed and ISI Web of Knowledge databases. All relevant studies published from 2009 until January 2015 were included without any language restriction if patients met diagnostic criteria for schizophrenia, and adequate information on efficacy, safety, and tolerability of once-monthly PP was available. Results: Nineteen studies were identified irrespective of the study design and duration of the follow-up period. Randomized, double-blind, placebo-controlled trials found that schizophrenia patients receiving PP showed a significant improvement in psychotic symptoms and similar adverse events compared to placebo and suggested that all doses of PP were efficacious and well tolerated. Other studies demonstrated noninferiority of PP compared to risperidone long-acting injectable in recently diagnosed schizophrenia patients, chronically

  20. Clinical efficacy of Risperidone combined with Paroxetine in treatment of methamphetamine-induced mental disorder patients%利培酮合并帕罗西汀治疗甲基苯丙胺所致精神障碍患者的临床疗效

    Institute of Scientific and Technical Information of China (English)

    文卫

    2015-01-01

    目的::对比分析利培酮单用与利培酮合并帕罗西汀治疗甲基苯丙胺所致精神障碍患者的治疗效果。方法:将68例甲基苯丙胺所致精神障碍患者的临床资料,采用数字单双号的模式随机分为对照组(利培酮)与治疗组(利培酮合并帕罗西汀),每组各34例。结果:对照组患者的总有效率为82.35%,治疗组患者的总有效率为94.12%,治疗组明显高于对照组,(P0.05)。结论:针对甲基苯丙胺所致精神障碍患者,采用利培酮合并帕罗西汀进行治疗能够显著改善患者的精神病性状态和抑郁、焦虑情绪,临床疗效明显,值得临床推广应用。%Objective: To comparatively analyze effects of Risperidone alone and Risperidone combined with Paroxetine in treatment of methamphetamine-induced mental disorder patients. Methods: A retrospective analysis of clinical data of 68 cases with methamphetamine-induced mental disorder was done by using digital odd and even numbers modes, and these cases were randomly di-vided into control group ( Risperidone) and treatment group ( Risperidone merger Paroxetine) , 34 cases in each group. Results:The total effective rates of control group and treatment group were 82. 35% and 94. 12%, and the difference was statistically significant (P0. 05). Conclusions:For the methamphetamine-induced mental disorder patients, Paroxetine combined with Risperidone can significantly improve the patient's mental state and de-pression and anxiety emotions with a significant clinical efficacy, and is worthy of clinical application and promotion.

  1. Valproate-Risperidone versus Valproate-Lithium combination in acute mania

    Directory of Open Access Journals (Sweden)

    M Barekatain

    2005-09-01

    Full Text Available Background: We evaluated the efficacy of valproate plus risperidone versus valproate plus lithium combination in the treatment of acute mania. Methods: In 2-week, randomized, double-blind, parallel group study, 46 acute manic patients according to DSM-IV criteria were randomly assigned to receive combination of valproate 20 mg/ kg/day plus risperidone 2-4 mg/day (n=23 or lithium600-1200 mg/day (n=23. The assessment of efficacy measures were according to Young Mania Rating Scale (YMRS and Clinical Global Impressions-Severity (CGI-S and Improvement (CGI-I scale. Other effectiveness measures included YMRS response (YMRS reduction >50 % and YMRS remission (YMRS total scores <12. Results: In each group, 16 of 23 patients (70 % completed the study. YMRS response, CGI-Improvement, and reduction in the total scores of YMRS and CGI-S observed in both groups, significantly greater for valproate-risperidone than valproate-lithium combination group (P=0.006, P=0.015, P=0.004, and P=0.007, respectively.YMRS remission were shown in both groups without statistical significance (P=0.073. The total scores of YMRS at 4th, 8th, and 14th days of trial were lower in valproate-risperidone than valproate-lithium combination group (P=0.017, P=0.005, and P=0.004, respectively. The rate of adverse events and mean weight gain in both groups were not statistically different. Conclusion: In acute manic patients, both combinations of valproate with lithium or with risperidone had efficacy in acutely manic patients, but valproate-risperidone combination was more effective. Both treatments were safe and well tolerated. Considering the small sample size and limited period of observation, further studies need to be conducted to find out the best combination in the treatment of acute mania. Key words: Acute mania, Valproate, Risperidone, Lithium, Combination Therapy

  2. EFFICACY OF TRANSFORAMINAL EPIDURAL STEROID INJECTION IN LUMBOSACRAL RADICULOPATHY

    Directory of Open Access Journals (Sweden)

    Saheel

    2016-02-01

    Full Text Available BACKGROUND Lumbosacral radiculopathy is a common medical and socioeconomic problem with a lifetime prevalence estimated to be around 40%-60%. In 1930, Evans reported that sciatica could be treated by epidural injection. The use of epidural corticosteroid injection for the treatment of axial and radicular back pain was first reported in 1953. Lumbar Transforminal Epidural Steroid Injections (TFESIs are performed to provide symptomatic relief in patients with radicular pain. A transforaminal epidural steroid injection (TFESI using a small volume of local anaesthetic will anaesthetize the spinal nerve and also partially anaesthetize the dura, the posterior longitudinal ligament, the intervertebral disc and facet joint. For these reasons, fluoroscopy-guided TFESI has become the preferred approach to epidural space. AIMS AND OBJECTIVES To study the role of transforaminal epidural steroid injection in management of radiculopathy. SETTINGS AND DESIGN This prospective study was conducted in the Department of Orthopaedics, SKIMS Medical College and Hospital, Bemina, Srinagar, J and K, India, for a 2-year period from November 2012 to October 2014; 110 cases, both male and female in the age group of 20-60 years having back pain with radiculopathy of varied types and duration without neurodeficit were enrolled in the study. MATERIALS AND METHODS After selecting a patient for giving transforaminal block, we used a local anaesthetic (2% Xylocaine. Contrast media, e.g. Iohexol was used to demarcate the correct positioning of the needle. A spinal needle (20-25 gauge and 5mL syringe were used to deliver the drug. CONCLUSION Transforaminal epidural steroid injections with long acting anaesthetic is an excellent form of conservative treatment in management of low back ache with radicular pain. It is relatively safe, simple, economical and shortens the time of recovery from severe pain, avoids risks and complications of surgery and also avoids long periods of bed

  3. Valproate-Risperidone versus Valproate-Lithium combination in acute mania

    OpenAIRE

    M Barekatain; A. Fatemi; N BASHARDOOST; A Darougheh; M Salehi; GH Asadollahi

    2005-01-01

    Background: We evaluated the efficacy of valproate plus risperidone versus valproate plus lithium combination in the treatment of acute mania. Methods: In 2-week, randomized, double-blind, parallel group study, 46 acute manic patients according to DSM-IV criteria were randomly assigned to receive combination of valproate 20 mg/ kg/day plus risperidone 2-4 mg/day (n=23) or lithium600-1200 mg/day (n=23). The assessment of efficacy measures were according to Young Mania Rating Scale (YMRS) ...

  4. Adjunctive Aripiprazole Treatment for Risperidone-Induced Hyperprolactinemia: An 8-Week Randomized, Open-Label, Comparative Clinical Trial

    OpenAIRE

    Jingyuan Zhao; Xueqin Song; Xiaoqing Ai; Xiaojing Gu; Guangbiao Huang; Xue Li; Lijuan Pang; Minli Ding; Shuang Ding; Luxian Lv

    2015-01-01

    Objective The present study aimed to evaluate the efficacy and safety of adjunctive aripiprazole treatment in schizophrenia patients with risperidone-induced hyperprolactinemia. Methods One hundred and thirteen patients who were receiving a stable dose of risperidone were randomly assigned to either adjunctive aripiprazole treatment (10 mg/day) (aripiprazole group) or no additional treatment (control group) at a 1:1 ratio for 8 weeks. Schizophrenia symptoms were measured using the Positive an...

  5. 氨磺必利与利培酮治疗精神分裂症疗效和安全性的Meta分析%Meta-analysis on the Efficacy and Safety of Amisulpride and Risperidone in the Treatment of Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    陈志强; 周峰; 陈惠萍

    2015-01-01

    Objective:To evaluate the efficacy and safety of amisulpride and risperidone in the treatment of schizophrenia. Meth-ods:The RCTs literatures on amisulpride and risperidone in the treatment of schizophrenia were retrieved and screened, and the quali-fied ones were analyzed by meta-analysis. Results:A total of 10 literatures were included involving 802 patients. Meta-analysis results showed that the difference between the two groups after the treatment was not statistically significant by comparing the clinical efficien-cy, PANSS score and TESS score. About the incidence of adverse reactions, amisulpride was better than risperidone in the endocrine function, extrapyramidal symptoms, weight gain and cardiovascular system. The incidence of nausea and vomiting of amisulpride was more than that of risperidone. There was no statistical significance in insomnia, headache, dizziness and the others. Conclusion:Ex-isting literature analysis shows that amisulpride is safe and effective in the treatment of schizophrenia.%目的::评价氨磺必利与利培酮治疗精神分裂症的疗效和安全性。方法:检索氨磺必利与利培酮治疗精神分裂症相关的随机对照研究文献,纳入合格文献进行Meta分析。结果:共纳入10篇文献,802例患者纳入分析。 Meta分析结果显示:两组治疗后临床有效率、阳性和阴性症状量表( PANSS)评分及治疗中出现的症状量表( TESS)评分比较,差异无统计学意义(P>0.05);药品不良反应发生率:内分泌功能、锥体外系症状、体重增加及心血管系统不良反应比较,氨磺必利少于利培酮(P0.05)。讨论:现有文献分析结果表明,氨磺必利治疗精神分裂症安全、有效。

  6. Efficacy of tramadol and butorphanol pretreatment in reducing pain on propofol injection: A placebo-controlled randomized study

    Directory of Open Access Journals (Sweden)

    Arvinderpal Singh

    2016-01-01

    Conclusion: Pretreatment with both butorphanol and tramadol significantly reduced pain on propofol injection; however, they exhibited comparable efficacy among each other. Thus, either of these two drugs can be considered for pretreatment to reduce propofol injection pain.

  7. SAFETY AND EFFICACY OF PHARMACOLOGICAL VITREOLYSIS BY INTRAVITREAL INJECTION OF HYALURONIDASE

    OpenAIRE

    Rajalingam; Karunakar; Sabiha; Rao; Lokabhi Reddy

    2015-01-01

    AIM: To study the safety and efficacy of pharmacological vitreolysis by intravitreal injection by hyaluronidase . METHODS: a prospective comparative interventional case series of 20 eyes of 20 patients who underwent intravitreal injection of Hyaluronidase 100 IU in one eye in a tertiary eye care centre by a single surgeon between June 2012 to June 2014 at Sarojini Devi Eye Hos pital.20 eyes of 20 patients were taken with other eye being taken as control RESULTS: ...

  8. 利培酮和氯氮平治疗精神分裂症疗效评价及其对糖、脂代谢的影响分析%Clinical efficacy of risperidone and clozapine treatment for schizophrenia and the impact on glucose and lipid metabolism

    Institute of Scientific and Technical Information of China (English)

    刘洪光; 曾志强; 王元彬; 叶昌斌

    2013-01-01

    目的 探讨利培酮和氯氮平治疗精神分裂症初诊患者的临床疗效及其对糖脂代谢的影响.方法 94例精神分裂症初诊患者分为利培酮组和氯氮平组,治疗8周后评价临床疗效,测定并比较治疗前后患者总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白(LDL)、高密度脂蛋白(HDL)、空腹血糖(FBG)、空腹胰岛素(Fins)、胰岛素抵抗指数(IRI)及胰岛素敏感指数(ISI)水平.结果 两组患者治疗总有效率无统计学差异(P>0.05).两组患者治疗后血浆TC、TG、LDL、FBG、Fins、IRI水平升高,HDL、ISI水平降低(P<0.05),氯氮平组TC、TG、LDL水平升高幅度、HDL降低幅度大于利培酮组(P<0.05).结论 氯氮平和利培酮对精神分裂症初诊患者临床疗效确切,二者均对患者糖、脂代谢有影响;利培酮对患者脂代谢的影响相对较小,可作为患者临床治疗的首选用药.%Objective To investigate the clinical efficacy of risperidone and clozapine for treating patients with first-case schizophrenia and the impact on glucose and lipid metabolism.Methods 94 patients with first-case schizophrenia were randomly divided into risperidone group and clozapine group.After treatment of 8 weeks, clinical efficacy was evaluated.The pre-treatment and pro-treatment total cholesterol(TC),triacylglycerol(TG),low density lipoprotein(LDL) ,high density lipoprotein(HDL),fasting blood glucose(FBG) and fasting insulin(Fins), insulin resistance index(IRI) .insulin sensitivity index(ISI) levels of the two groups were detected and compared.Results The total effective rate of the two groups was with no statistical difference(PX).05).After treatment, the plasma TC,TG,LDL,FBG,Fins and IRI levels of two groups significantly increased,the HDL,ISI levels significantly de-creased(P<0.05),and the increase extent of TC,TG and LDL level and the decrease extent of HDL level of the clozapine group was more obvious than the risperidone group(P<0.05).Conclusion The

  9. Review of risperidone for the treatment of pediatric and adolescent bipolar disorder and schizophrenia

    Directory of Open Access Journals (Sweden)

    Jeffrey R Bishop

    2008-03-01

    Full Text Available Jeffrey R Bishop1,2, Mani N Pavuluri21Department of Pharmacy Practice, University of Illinois at Chicago College of Pharmacy, Chicago, IL, USA; 2Department of Psychiatry, Pediatric Mood Disorders Program and Center for Cognitive Medicine, University of Illinois at Chicago College of Medicine, Chicago, IL, USAAbstract: Risperidone is a commonly used medication for the treatment of bipolar disorder and schizophrenia in children and adolescents. It has been studied as a monotherapy treatment in early onset schizophrenia and as both monotherapy and combination therapy for pediatric bipolar disorder. Studies to date indicate that risperidone is an effective treatment for positive and negative symptoms of schizophrenia and mania symptoms of bipolar disorder. In young patient populations, side effects such as weight gain, extrapyramidal side effects, and prolactin elevation require consideration when evaluating the risk benefit ratio for individual patients. Here we review published studies of risperidone for the treatment of bipolar disorder and schizophrenia in children and adolescents to provide practitioners with an overview of published data on the efficacy and safety of risperidone in these patient populations.Keywords: risperidone, bipolar disorder, schizophrenia, children, adolescents

  10. Ethanol injection of ornamental trees facilitates testing insecticide efficacy against ambrosia beetles (Coleoptera: Curculionidae: Scolytinae).

    Science.gov (United States)

    Reding, Michael E; Oliver, Jason B; Schultz, Peter B; Ranger, Christopher M; Youssef, Nadeer N

    2013-02-01

    Exotic ambrosia beetles are damaging pests in ornamental tree nurseries in North America. The species Xylosandrus crassiusculus (Motshulsky) and Xylosandrus germanus (Blandford) are especially problematic. Management of these pests relies on preventive treatments of insecticides. However, field tests of recommended materials on nursery trees have been limited because of unreliable attacks by ambrosia beetles on experimental trees. Ethanol-injection of trees was used to induce colonization by ambrosia beetles to evaluate insecticides and botanical formulations for preventing attacks by ambrosia beetles. Experiments were conducted in Ohio, Tennessee, and Virginia. Experimental trees injected with ethanol had more attacks by ambrosia beetles than uninjected control trees in all but one experiment. Xylosandrus crassiusculus and X. germanus colonized trees injected with ethanol. In most experiments, attack rates declined 8 d after ethanol-injection. Ethanol-injection induced sufficient pressure from ambrosia beetles to evaluate the efficacy of insecticides for preventing attacks. Trunk sprays of permethrin suppressed cumulative total attacks by ambrosia beetles in most tests. Trunk sprays of the botanical formulations Armorex and Veggie Pharm suppressed cumulative total attacks in Ohio. Armorex, Armorex + Permethrin, and Veggie Pharm + Permethrin suppressed attacks in Tennessee. The bifenthrin product Onyx suppressed establishment of X. germanus in one Ohio experiment, and cumulative total ambrosia beetle attacks in Virginia. Substrate drenches and trunk sprays of neonicotinoids, or trunk sprays of anthranilic diamides or tolfenpyrad were not effective. Ethanol-injection is effective for inducing attacks and ensuring pressure by ambrosia beetles for testing insecticide efficacy on ornamental trees.

  11. POST MARKETING SURVEILLANCE STUDY ON RISPERIDONE IN PATIENTS SUFFERING FROM SCHIZOPHRENIA

    Directory of Open Access Journals (Sweden)

    J R Zaveri

    2011-04-01

    Full Text Available Schizophrenia is one of the commonest psychiatric ailments. It has been estimated that approximately 1% of the population and 15% of the adults suffers from this disease. Risperidone, atypical antipsychotic, acts mainly by 5HT2 blockade action. Produce virtually no extra pyramidal side effects at low dose, has a broad efficacy. But extra pyramidal dysfunction can appear at higher doses. We conducted a post marketing surveillance study on risperidone in 40 patients suffering from schizophrenia at Psychiatric department of Civil Hospital, Ahmedabad. In this study we specially studied its efficacy and safety. The results of this study are consistent with phase III clinical studies on risperidone carried out in Indian patients except its effects on food intake. As far as the efficacy of risperidone in patient with schizophrenia is concerned, it provided good symptomatic relief In term of safety, 7 patients out of 40, experience adverse effects like decrease appetite, constipation, insomnia, EPS and NMS. Patient with NMS was admitted in hospital and was died later on. [National J of Med Res 2011; 1(2.000: 34-36

  12. Development of Risperidone PLGA Microspheres

    Directory of Open Access Journals (Sweden)

    Susan D’Souza

    2014-01-01

    Full Text Available The aim of this study was to design and evaluate biodegradable PLGA microspheres for sustained delivery of Risperidone, with an eventual goal of avoiding combination therapy for the treatment of schizophrenia. Two PLGA copolymers (50 : 50 and 75 : 25 were used to prepare four microsphere formulations of Risperidone. The microspheres were characterized by several in vitro techniques. In vivo studies in male Sprague-Dawley rats at 20 and 40 mg/kg doses revealed that all formulations exhibited an initial burst followed by sustained release of the active moiety. Additionally, formulations prepared with 50 : 50 PLGA had a shorter duration of action and lower cumulative AUC levels than the 75 : 25 PLGA microspheres. A simulation of multiple dosing at weekly or 15-day regimen revealed pulsatile behavior for all formulations with steady state being achieved by the second dose. Overall, the clinical use of Formulations A, B, C, or D will eliminate the need for combination oral therapy and reduce time to achieve steady state, with a smaller washout period upon cessation of therapy. Results of this study prove the suitability of using PLGA copolymers of varying composition and molecular weight to develop sustained release formulations that can tailor in vivo behavior and enhance pharmacological effectiveness of the drug.

  13. 阿立哌唑与利培酮治疗痴呆精神行为症状的疗效及安全性比较%Comparison of efficacy and safety of aripiprazole and risperidone treating behavioral and psychological symptoms of dementia

    Institute of Scientific and Technical Information of China (English)

    罗克勇; 刘克祥; 王瑞超; 付华斌

    2013-01-01

    by patients in risperidone group with a starting dose of 0.5 mg/d and less than the maximum dose 3 mg/d.Two groups were treated for 8 weeks.BEHAVE-AD and treatment emergent symptom scale (TESS) were used to evaluate the efficacy and adverse effect respectively before and at the ends of 8 weeks treatment.The levels of blood glucose,total cholesterol(TC),triglyceride(TG),high density lipoproteincholesterol (HDL-C),low density lipoprotein-cholesterol (LDL-C) and weight were measured at baseline and after 8 weeks.Results After 8 weeks treatment,the scores of BEHAVE-AD in both groups significantly reduced [aripiprazole group:(14.8 ± 4.2),(10.2 ± 3.6),(6.8 ± 2.6) scores vs (16.4 ± 4.6) scores ; risperidone group:(15.2 ±3.9),(11.8 ±3.8),(7.2 ±3.0)scores vs (17.2 ±5.0)scores,P<0.05 or P<0.01],but there were no significantly differences between the two groups (P > 0.05) ; there were few side effects in both groups [both 8.8% (3/34)],but the weight gaining,TC and LDL-C in risperidone group were higher than those before treatment [(71-±6)kg vs (66 ±6)kg,(1.62 ± 0.46) mmol/L vs (0.96 ± 0.29) mmol/L,(3.82±0.86)mmol/L vs (3.08 ± 0.74)mmol/L,all P < 0.05].Conclusion The results suggest that aripiprazole is as effective and safe as risperidone for the treatment of BPSD,but aripiprazole has less effect on blood glucose,lipids and weight than risperidone.

  14. Combination treatment of tamoxifen with risperidone in breast cancer.

    Directory of Open Access Journals (Sweden)

    Wei-Lan Yeh

    Full Text Available Tamoxifen has long been used and still is the most commonly used endocrine therapy for treatment of both early and advanced estrogen receptor-positive breast cancer in pre- and post-menopause women. Tamoxifen exerts its cytotoxic effect primarily through cytostasis which is associated with the accumulation of cells in the G0/G1 phase of the cell cycle. Apoptotic activity can also be exerted by tamoxifen which involves cleavage of caspase 9, caspase 7, caspase 3, and poly-ADP-ribose polymerase (PARP. Down-regulation of anti-apoptotic proteins Bcl-2 and Bcl-xL and up-regulation of pro-apoptotic proteins Bax and Bak have also been observed. In addition, stress response protein of GRP 94 and GRP 78 have also been induced by tamoxifen in our study. However, side effects occur during tamoxifen treatment in breast cancer patients. Researching into combination regimen of tamoxifen and drug(s that relieves tamoxifen-induced hot flushes is important, because drug interactions may decrease tamoxifen efficacy. Risperidone has been shown to be effective in reducing or eliminating hot flushes on women with hormonal variations. In this present study, we demonstrated that combination of tamoxifen with risperidone did not interfered tamoxifen-induced cytotoxic effects in both in vitro and in vivo models, while fluoxetine abrogated the effects of tamoxifen. This is the first paper suggesting the possibility of combination treatment of tamoxifen with risperidone in breast cancer patients, providing a conceivable resolution of tamoxifen-induced side effects without interfering the efficacy of tamoxifen against breast cancer.

  15. Postmortem Femoral Blood Concentrations of Risperidone

    DEFF Research Database (Denmark)

    Linnet, Kristian; Johansen, Sys Stybe

    2014-01-01

    Postmortem femoral blood concentrations of the antipsychotic drug risperidone and the active metabolite 9-hydroxyrisperidone were determined by an achiral LC-MS/MS method in 38 cases. The cause of death was classified as unrelated to risperidone in 30 cases, in which the sum of the concentration of...... the drug and metabolite ranged from below the limit of quantification to 0.058 mg/kg (median 0.0098 mg/kg). This concentration range, which largely corresponds to published in vivo plasmalevels under therapy, may serve as a reference for judgment of postmortem cases involving risperidone. In one case......, risperidone was judged to be a contributing factor to death, and the sum of concentrations was 0.29 mg/kg. This concentration is of the same order of magnitude as observed for plasma levels in clinical intoxication cases. For the remaining seven cases, the cause of death was unclear. The measurements observed...

  16. Risperidone for Aggressive Behavior in ADHD

    Directory of Open Access Journals (Sweden)

    J Gordon Millichap

    2007-05-01

    Full Text Available The effects of risperidone augmentation for treatment-resistant aggression in children with ADHD were evaluated in a placebo-controlled pilot study at the University of Miami Miller School of Medicine, FL.

  17. Can Aidi injection alleviate the toxicity and improve the clinical efficacy of radiotherapy in lung cancer?

    Science.gov (United States)

    Xiao, Zheng; Liang, Rui; Wang, Cheng-qiong; Xu, Shaofeng; Li, Nana; He, Yuejuan; Tang, Fushan; Chen, Ling; Ma, Hu

    2016-01-01

    Abstract Background/Introduction: Aidi injection plus radiotherapy is widely used for lung cancer in China. Can Aidi injection alleviate the toxicity and improve the clinical efficacy of radiotherapy in lung cancer? Has Aidi injection the attenuation and synergistic efficacy to radiotherapy? There is lack of strong evidence to prove it. Objectives: To reveal its real attenuation and synergistic efficacy to radiotherapy and provide sufficient evidence for adjuvant chemotherapy strategies to lung cancer, we systematically evaluated all related studies. Data Sources: We collected all studies about Aidi injection plus radiotherapy for lung cancer in Medline, Embase, Web of Science, China national knowledge infrastructure database (CNKI), Chinese scientific journals full-text database (VIP), Wanfang database, China biological medicine database (CBM) (established to June 2015), and Cochrane Central Register of Controlled Trials (June 2015), evaluated their quality according to the Cochrane evaluation handbook of randomized controlled trials (5.1.0), extracted data following the PICO principles and synthesized the data by Meta analysis. Results: Sixteen randomized controlled trials (RCTs) with 1192 lung cancer patients were included, with general methodological quality in most trials. The merged relative risk (RR) values and their 95% CI of meta-analysis for objective response rate (ORR), disease control rate (DCR), and quality of life (QOL) were as follows: 1.54, (1.39,1.70), 1.10 (1.02, 1.19), and 2.13 (1.68, 2.68). The merged RR values and their 95% CI of meta-analysis for myelosuppression and neutropenia, radiation pneumonitis, and radiation esophagitis were as follows: 0.51 (0.38, 0.69), 0.53 (0.42, 0.65), 0.52 (0.41, 0.67), and 0.52 (0.40, 0.68). All were statistically significant. The possibility of publication bias was small which objectively reported the results. Conclusions: The evidence available indicates that Aidi injection plus radiotherapy can significantly

  18. Efficacy and safetycomparison on the Amisulpride and risperidone in the treatment offirst-episode schizophrenia%氨磺必利与利培酮治疗首发精神分裂症疗效和安全性对照研究

    Institute of Scientific and Technical Information of China (English)

    唐小辉

    2015-01-01

    目的:对照研究氨磺必利与利培酮治疗首发精神分裂症疗效和安全性。方法选取某院2013年6月至2015年3月的首发精神分裂症患者40例,平均分成试验组和对照组,试验组采用氨磺必利的治疗方式,对照组采用利培酮的治疗方式,比较两组的总有效率和不良反应率。结果试验组的总有效率为90%,不良反应率为50%,与对照组对比差异具有统计学意义(P<0.05)。结论氨磺必利在首发精神分裂症的治疗中,较之利培酮疗效更加明显,但副作用较大,需要在临床应用中根据病人的情况将维持剂量调整到最小有效剂量。%ObjectiveTo compare theefficacy and safety on the amisulpride and risperidone in thetreatment of first-episode schizophrenia.Methods To select 40 cases offirst-episode schizophrenia from June 2013 to March 2015 in a hospital and divide them into experiment group(treated with amisulpride) and control group(treated with risperidone). Compare their total efficiency and the rates of adverse reactions.Results The total effective rate of the experimental group was 50%, the adverse reaction rate was 90%, and the difference was statistically significant (P<0.05).Conclusion Amisulpride in first-episode schizophrenia treatment, compared with risperidone efficacy isbetter, yet the side effects is larger. It is need to adjust maintain dose to the minimum effective dose in clinical application according to the patient’s condition.

  19. 利培酮治疗痴呆患者精神行为的临床疗效及护理效果分析%Risperidone in the treatment of dementia in patients with clinical efficacy and behavioral and psychological care benefits analysis

    Institute of Scientific and Technical Information of China (English)

    冉海珍

    2015-01-01

    目的:探讨利培酮治疗痴呆患者精神行为的临床疗效及护理效果。方法:选取2014年2月至2015年3月我院收治的痴呆患者80例,随机分成两组,每组40例,观察组采用利培酮治疗,对照组采用氟哌啶醇治疗,观察两组治疗效果。结果:经治疗后,观察组患者的治疗有效率明显高于对照组,且观察组患者出现胃肠道反应症状以及锥体外系反应症状的不良反应发生率明显低于对照组(P <0.05),有统计学意义。结论:对痴呆患者实施利培酮治疗以及必要的护理干预,能够有效提升患者的治疗有效率,降低患者的不良反应发生率,效果显著,值得临床推广。%To investigate the risperidone in the treatment of dementia in patients with clinical efficacy and behavioral and psychological care benefits. Methods:patients with dementia from February 2014 to March 2015 in our hospital,80 patients were randomly divided into two groups of40 patients treated with risperidone observation group,the control group,haloperidol,observe two group therapy.Results:After treatment,the treatment of patients in the observation group was significantly higher efficiency,and the observation group were gastrointestinal reactions symptoms and extrapyramidal symptoms of adverse reactions were significantly lower than the control group (P <0.05)there was statistically significant.Conclusion:Risperidone treatment for patients with dementia and the necessary nursing intervention can effectively improve the patient's treatment efficiency,reduce incidence of adverse reactions in patients,the effect is signifi-cant,worthy of promotion.

  20. NINE-YEAR EFFICACY OF HEPATITIS B VACCINATION WITHLOW-DOSE IN THE THIRD INJECTION

    Institute of Scientific and Technical Information of China (English)

    2000-01-01

    Objective In order to observe the efficacy of low-dose in the third injection of hepatitis B vaccine. Methods 126 children aged 5~9 years were enrolled in a double-blind, place-controlled and randomized field trial. They were randomly divided into 10μg and 20μg dose group, and were redivided into 2μg, 5μg, 10μg, 20μg or non-in jected subgroups when the third booster injections were given. Results During the 9 years follow-up, the differences of the anti-HBs levels(GMT) among the groups were not significant at every time (P > 0. 05). The GMTs at the ninth year(T108) were 7. 0, 6. 4, 9.9, 6.1, 9.7, 5. 4 and 7.4, respectively (P> 0. 05). The HBV infection rates among the groups had no significant difference (P > 0. 05). The protective rates in the groups were all higher than 75% at T108. Conclusion According to the data, it can be concluded that the third injection with low-dose has no influence on the vaccine efficacy(either short-term or long-term efficacy).

  1. Alterations in brain extracellular dopamine and glycine levels following combined administration of the glycine transporter type-1 inhibitor Org-24461 and risperidone.

    Science.gov (United States)

    Nagy, Katalin; Marko, Bernadett; Zsilla, Gabriella; Matyus, Peter; Pallagi, Katalin; Szabo, Geza; Juranyi, Zsolt; Barkoczy, Jozsef; Levay, Gyorgy; Harsing, Laszlo G

    2010-12-01

    The most dominant hypotheses for the pathogenesis of schizophrenia have focused primarily upon hyperfunctional dopaminergic and hypofunctional glutamatergic neurotransmission in the central nervous system. The therapeutic efficacy of all atypical antipsychotics is explained in part by antagonism of the dopaminergic neurotransmission, mainly by blockade of D(2) dopamine receptors. N-methyl-D-aspartate (NMDA) receptor hypofunction in schizophrenia can be reversed by glycine transporter type-1 (GlyT-1) inhibitors, which regulate glycine concentrations at the vicinity of NMDA receptors. Combined drug administration with D(2) dopamine receptor blockade and activation of hypofunctional NMDA receptors may be needed for a more effective treatment of positive and negative symptoms and the accompanied cognitive deficit in schizophrenia. To investigate this type of combined drug administration, rats were treated with the atypical antipsychotic risperidone together with the GlyT-1 inhibitor Org-24461. Brain microdialysis was applied in the striatum of conscious rats and determinations of extracellular dopamine, DOPAC, HVA, glycine, glutamate, and serine concentrations were carried out using HPLC/electrochemistry. Risperidone increased extracellular concentrations of dopamine but failed to influence those of glycine or glutamate measured in microdialysis samples. Org-24461 injection reduced extracellular dopamine concentrations and elevated extracellular glycine levels but the concentrations of serine and glutamate were not changed. When risperidone and Org-24461 were added in combination, a decrease in extracellular dopamine concentrations was accompanied with sustained elevation of extracellular glycine levels. Interestingly, the extracellular concentrations of glutamate were also enhanced. Our data indicate that coadministration of an antipsychotic with a GlyT-1 inhibitor may normalize hypofunctional NMDA receptor-mediated glutamatergic neurotransmission with reduced

  2. Long-Acting Injectable Antipsychotics for Prevention of Relapse in Bipolar Disorder: A Systematic Review and Meta-Analyses of Randomized Controlled Trials

    Science.gov (United States)

    Oya, Kazuto; Iwata, Nakao

    2016-01-01

    Background: This meta-analysis of randomized controlled trials aimed to examine the advantages of long-acting injectable antipsychotics over placebo or oral medications regarding efficacy and safety for patients with bipolar disorder. Methods: Two categorical meta-analyses of randomized controlled trials were performed to compare study-defined relapse rate (primary), discontinuation rates, and individual adverse events: (1) risperidone-long-acting injectable vs placebo, and (2) long-acting injectable antipsychotics vs oral medications. Results: We identified 7 randomized controlled trials (n=1016; long-acting injectable antipsychotics [flupenthixol (1 randomized controlled trial) and risperidone (6 randomized controlled trials)=449]; oral medications [mood stabilizers, antidepressants, antipsychotic, or any combination of these agents=283]; and placebo=284). Risperidone-long-acting injectable antipsychotic was superior to placebo for study-defined relapse rate (risk ratio=0.63, Psymptoms (risk ratio=0.42, Pprevention in patients with rapid cycling. Furthermore, randomized controlled trials comparing long-acting injectable antipsychotics and oral second-generation antipsychotic using larger samples of rapid cycling patients are warranted. PMID:27207910

  3. Aripiprazole and Risperidone for Treatment of Methamphetamine-Associated Psychosis in Chinese Patients.

    Science.gov (United States)

    Wang, Gang; Zhang, Yao; Zhang, Sheng; Chen, Huijing; Xu, Zaifeng; Schottenfeld, Richard S; Hao, Wei; Chawarski, Marek Cezary

    2016-03-01

    We evaluated tolerability and efficacy of aripiprazole and risperidone for treatment of methamphetamine (METH) associated psychotic symptoms in China. Patients with acute METH-associated psychotic symptoms (N=42) and with Positive and Negative Syndrome Scale (PANSS) total score between 60 and 120 were randomized to aripiprazole (initial dose 5-10mg per day followed by flexible doses 5-15 mg per day) or risperidone (initial dose 2-4 mg per day followed by flexible doses 4-6 mg per day) from day 3 to 25 of inpatient hospital stay. Outcome measures included PANSS and Clinical Global Impressions-Severity of Illness scale (CGI-S), METH craving Visual Analogue Scale (VAS), Simpson Angus Scale (SAS), Barnes Assessments Akathasia Rating Scale (BARS), and self-reported adverse effects evaluated during treatment. Retention was evaluated using Kaplan-Meier survival analysis and the MIXED models procedure was used to compare the groups on measures of psychotic and extra-pyramidal symptoms. Patients in both aripiprazole and risperidone groups showed statistically significant reductions in psychotic symptomatology from baseline during treatment (p<0.001) with no statistically significant differences between the treatment groups (p=0.73 and p=0.15, respectively). Risperidone-treated patients reported significantly greater METH craving reductions (p<0.001). Overall, 71% of patients completed the entire study, but the aripiprazole group had a significantly lower retention than the risperidone group (p=0.007), primarily due to medication related adverse effects. Aripiprazole-treated patients also had significantly more akathisia (p=0.03) and agitation (p=0.02) than risperidone-treated patients. Patients in both groups who tolerated their medications and completed the entire study achieved comparable reductions of psychotic symptoms. PMID:26733277

  4. Risperidone

    Science.gov (United States)

    Risperdal® Oral Solution ... mood) or mixed episodes (symptoms of mania and depression that happen together) in adults and in teenagers ... of age and older with bipolar disorder (manic depressive disorder; a disease that causes episodes of depression, episodes ...

  5. Efficacy and safety study of subcutaneous injection of bortezomib in the treatment of de novopatients with multiple myeloma

    Institute of Scientific and Technical Information of China (English)

    刘辉

    2013-01-01

    Objective To explore the efficacy and safety of subcutaneous injection of bortezomib in the treatment of de novo multiple myeloma (MM) patients.Methods A total of 36 MM patients treated with bortezomib,adriamycin and dexamethason (PAD) from January 2012 to April2013 were analyzed.Among them,18 received improved PAD (improved PAD group) with the subcutaneous injection of bortezomib,another 18 received conventional PAD (PAD group) .The efficacy and safety of two groups

  6. Efficacy of Botulinum Toxin Injections in the Treatment of Various Types of Facial Region Disorders

    Directory of Open Access Journals (Sweden)

    Arzu Çoban

    2012-12-01

    Full Text Available OBJECTIVE: Local injection of botulinum toxin is a highly effective treatment option for a wide range of movement disorders and there are reliable sources of information on its indications, effects and safety in clinical practice. In this study, we report our experience with botulinum toxin in the treatment of facial region disorders. METHODS: Patients who had been followed in the Botulinum Toxin Outpatient Clinic of the Neurology Department were retrospectively evaluated. Two preparations of botulinum toxin type A (BT-A were used. The efficacy of BT-A injections was rated according to the improvement in symptoms as follows: marked - 75-100% improvement, good - 50-74%, moderate - 25-49%, and insufficient - less than 25% symptom relief. RESULTS: One hundred eighty-two patients (73 male, 109 female with various facial region disorders were included. The efficacy rates for patients who had very good and good improvement were high in the treatment of blepharospasm, hemifacial spasm, facial synkinesis, and Meige syndrome and moderate for oromandibular dystonia and hypersalivation. Ptosis was the most common side effect. CONCLUSION: According to our results, botulinum toxin was very effective treatment for blepharospasm, Meige syndrome, hemifacial spasm and facial synkinesis, whereas it demonstrated good efficacy in oromandibular dystonia and hypersalivation.

  7. Efficacy of peripheral streptomycin injection in the treatment of idiopathic trigeminal neuralgia

    International Nuclear Information System (INIS)

    To evaluate the efficacy of peripheral streptomycin injection in relieving the pain of idiopathic trigeminal neuralgia Study Design: Quasi experimental study. Place and duration of Study: Oral and Maxillofacial Surgery Department, Armed Forces Institute of Dentistry Rawalpindi, from 1st June 2006 to 31st December 2007. Patients and Methods: Thirty patients of idiopathic trigeminal neuralgia were selected. They received five consecutive injections of streptomycin 1g in 3 ml of 2% Lignocaine (Septodont) with 1: 100,000 adrenaline at one week interval. Follow up was carried out at one, two and six months after the last injection. Results: Age ranged from 15-78 years (mean 44.67). Male to female ratio was 1:1.14. Right side of the face was involved in 70% and left side in 30% cases. Mandibular division of trigeminal nerve was involved in 43.3% and maxillary division in 40% of the cases. In the rest both maxillary and mandibular divisions were involved. Pain was significantly decreased from baseline to 1 month (p < 0.001). The level of pain was increased a bit but the increase was significant at two months (p = 0.006) and at 6 months (p = 0.020). Conclusion: Best treatment modality for this devastating disease is yet to evolve. Within the confines of the study it can be stated that efficacy combined with low post treatment morbidity makes streptomycin a useful treatment option. (author)

  8. Long-Term Efficacy and Safety of Botulinum Toxin Injections in Dystonia

    Directory of Open Access Journals (Sweden)

    Juan Ramirez-Castaneda

    2013-02-01

    Full Text Available Local chemodenervation with botulinum toxin (BoNT injections to relax abnormally contracting muscles has been shown to be an effective and well-tolerated treatment in a variety of movement disorders and other neurological and non-neurological disorders. Despite almost 30 years of therapeutic use, there are only few studies of patients treated with BoNT injections over long period of time. These published data clearly support the conclusion that BoNT not only provides safe and effective symptomatic relief of dystonia but also long-term benefit and possibly even favorably modifying the natural history of this disease. The adverse events associated with chronic, periodic exposure to BoNT injections are generally minor and self-limiting. With the chronic use of BoNT and an expanding list of therapeutic indications, there is a need to carefully examine the existing data on the long-term efficacy and safety of BoNT. In this review we will highlight some of the aspects of long-term effects of BoNT, including efficacy, safety, and immunogenicity.

  9. A Comparison of Risperidone and Buspirone for Treatment of Behavior Disorders in Children with Phenylketonuria

    Directory of Open Access Journals (Sweden)

    Afshin FAYYAZI

    2014-12-01

    and Lang W .Neurobehavioral Problems Associated with Phenylketonuria. Psychiatry (Edgemont 2009; 7(12:29–32.Luciana M, Hanson K L,Whitley C B.A preliminary report on dopamine system reactivity in PKU: acute effects of haloperidol on neuropsychological, physiological, and neuroendocrine functions. Psychopharmacology 2004;175: 18–25.Pappadopulos E, Woolston S, Chait A, Perkins M, Connor DF, Jensen P S. Pharmacotherapy of Aggression in Children and Adolescents: Efficacy and Effect Size. J CDN ACAD Child Adolesc Psychiatry 2006; 15(1:27-39.Shea S, Turgay A, Carroll A, Schulz M, Orlik H ,Smith I and et al. Risperidone in the Treatment of Disruptive Behavioral Symptoms in Children With Autistic and Other Pervasive Developmental Disorders. Pediatrcs 2004; 114:634-641.Miral S, Gencer O, Inal-Emiroglu F.N, Baykara B, Baykara A, Dirik E. Risperidone versus haloperidol in children and adolescents with AD: a randomized, controlled, doubleblind trial. Eur Child Adolesc Psychiatry 2008; 17:1–8.Aman M.G, Hollway J.A, McDougle C.J, Scahill L, Tierney E, McCracken J.T and et al. Cognitive effects of risperidone in children with autism and irritable behavior. J. Child Adolesc. Psychopharmacol 2008; 18:227–236.Pandina G.J, Bossie C.A, Youssef E, Zhu Y, Dunbar F. Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebocontrolled trial. J Autism Dev Disord 2007; 37:367–373.Luby J, Mrakotsky C, Stalets M.M, Belden A, Heffelfinger A, Williams M and et al. Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy. J. Child Adolesc. Psychopharmacol 2006; 16:575–587.Nagaraj R, Singhi P, Malhi P. Risperidone in children with autism: randomized, placebo controlled, double blind study. J. Child Neurol 2006; 21:450–455.Haas M, Karcher K, Pandina GJ. Treating Disruptive Behavior Disorders with Risperidone: A 1-Year, Open-Label Safety Study in Children and Adolescents. Journal of Child and

  10. Hyperprolactinaemia - a risperidone side-effect.

    Science.gov (United States)

    Grahovac, Tanja; Ruzić, Klementina; Medved, Paola; Pavesić-Radonja, Aristea; Dadić-Hero, Elizabeta

    2010-03-01

    A 47 year old patient has been treated for psychotic depression for the last 5 years. The illness began manifesting through the symptoms of depressive thoughts, intrapsychic tension, projectivity, derealisation phenomena and pre-psychotic fears. She was treated with a combination of antidepressives, anxiolitics and hypnotics in ambulatory conditions. The therapy applied did not obtain the effects expected due to which an atypical antipsychotic was administered subsequently - risperidone, a 2 mg dose in the evening. After commencing the antipsychotic treatment, the symptoms started to weaken and a steady remission was obtained. Two years after a regular risperidone administration (in combination with fluoxetine, alprazolam and flurazepam) the patient reported some "bleeding" in October 2006. Hormonal blood tests were performed and high prolactin values were registered (2567.0 mIJ/L),due to which a gradual risperidone retractement was indicated. Medicamentous hyperprolactinaemia is a well known side effect of risperidone. A gradual risperidone retractement lead to a lowered and normal prolactin level within a month. PMID:20305606

  11. Injectable fipronil for cattle: Plasma disposition and efficacy against Rhipicephalus microplus.

    Science.gov (United States)

    Cid, Yara P; Ferreira, Thais P; Magalhães, Viviane S; Correia, Thais R; Scott, Fábio B

    2016-04-15

    Fipronil is a phenylpyrazole class insecticide. It is widely used as an insecticide in agriculture and in the control of ectoparasites in veterinary medicine. The application of fipronil in an injectable form (subcutaneously) becomes an innovation, since there is no commercially available preparation containing fipronil herein. The present study aimed at fipronil usage, applied subcutaneously in cattle, to control Rhipicephalus microplus. The assessing criteria used in the research have been the construction of the plasma concentration curve and efficacy studies. A method using High Performance Liquid Chromatograph with ultraviolet detection was developed for determination of fipronil in bovine plasma samples, providing a fast and simple process with good reproducibility and low limit of quantification. The validation of the analytical method showed linearity, selectivity, precision, accuracy, sensitivity and stability, thus proving it as suitable for routine analysis. This method showed to be an important investigative tool in the analysis of fipronil plasma concentration in cattle. Fipronil administered via subcutaneous in bovine reached the systemic circulation (Cmax=378.06±137.44 ng/mL), was quickly absorbed (t(max)=10±0.87 h), and its elimination occurred slowly (t(1/2)=12 days), while maintaining quantifiable blood plasma levels (23.79±12.16 ng/mL) for up to 21 days after the treatment with a 1 mg/kg dosage. The in vivo efficacy tests proved that fipronil applied subcutaneously in a single dose of 1 mg/kg in cattle exhibited a mean efficacy of 82.41% against R. microplus. The potential of subcutaneous injection as an alternative treatment route in cattle encourage the development of an injectable formulation of fipronil. PMID:26995714

  12. Injectable fipronil for cattle: Plasma disposition and efficacy against Rhipicephalus microplus.

    Science.gov (United States)

    Cid, Yara P; Ferreira, Thais P; Magalhães, Viviane S; Correia, Thais R; Scott, Fábio B

    2016-04-15

    Fipronil is a phenylpyrazole class insecticide. It is widely used as an insecticide in agriculture and in the control of ectoparasites in veterinary medicine. The application of fipronil in an injectable form (subcutaneously) becomes an innovation, since there is no commercially available preparation containing fipronil herein. The present study aimed at fipronil usage, applied subcutaneously in cattle, to control Rhipicephalus microplus. The assessing criteria used in the research have been the construction of the plasma concentration curve and efficacy studies. A method using High Performance Liquid Chromatograph with ultraviolet detection was developed for determination of fipronil in bovine plasma samples, providing a fast and simple process with good reproducibility and low limit of quantification. The validation of the analytical method showed linearity, selectivity, precision, accuracy, sensitivity and stability, thus proving it as suitable for routine analysis. This method showed to be an important investigative tool in the analysis of fipronil plasma concentration in cattle. Fipronil administered via subcutaneous in bovine reached the systemic circulation (Cmax=378.06±137.44 ng/mL), was quickly absorbed (t(max)=10±0.87 h), and its elimination occurred slowly (t(1/2)=12 days), while maintaining quantifiable blood plasma levels (23.79±12.16 ng/mL) for up to 21 days after the treatment with a 1 mg/kg dosage. The in vivo efficacy tests proved that fipronil applied subcutaneously in a single dose of 1 mg/kg in cattle exhibited a mean efficacy of 82.41% against R. microplus. The potential of subcutaneous injection as an alternative treatment route in cattle encourage the development of an injectable formulation of fipronil.

  13. Comparison of efficacy of kinesiological taping and subacromial injection therapy in subacromial impingement syndrome.

    Science.gov (United States)

    Subaşı, Volkan; Çakır, Tuncay; Arıca, Zuhal; Sarıer, Rahime Nur; Filiz, Meral Bilgilisoy; Doğan, Şebnem Koldaş; Toraman, Naciye Füsun

    2016-03-01

    The aim of the study was to compare the efficacy of kinesiological taping and subacromial injection therapy in patients with subacromial impingement syndrome (SIS). Seventy patients diagnosed with SIS were randomly assigned to group 1 (n = 35, injection group) or group 2 (n = 35, kinesiological taping group). Betamethasone plus prilocaine was injected to subacromial space in the patients in group 1. In group 2, tape was applied three times for a period of five consecutive days with a 2-day recovery interval. A 3-month exercise program was prescribed for both groups including stretching and strengthening exercises. All patients were assessed at baseline and at 1 and 3 months post-intervention. Assessments were made by visual analog scale (VAS) for pain, range of motion (ROM) measurements, specific tests, and Shoulder Pain and Disability Index (SPADI). Significant differences were detected in VAS and SPADI scores as well as ROM measurements in both groups when compared to baseline (p > 0.05). No significant differences were detected between the groups except for active flexion degree in favor of group 1 (p = 0.004). Both kinesiological taping and steroid injection in conjunction with an exercise program were found to be effective in the treatment of SIS. Kinesio taping may be an alternative treatment option in the rehabilitation of SIS especially when a non-invasive technique is needed. PMID:25403253

  14. 精神分裂症患者HTR2A基因多态性与帕利哌酮和利培酮临床疗效及安全性的关联研究%Association study of the HTR2A polymorphisms with efficacy and safety of risperidone or paliperidone in Chinese schizophrenic patients

    Institute of Scientific and Technical Information of China (English)

    杜波; 刘永桥; 刘飞虎; 肖卫东; 卢天兰; 李玲芝; 黄兰; 宓为峰; 张鸿燕

    2011-01-01

    目的 观察中国汉族精神分裂症患者的5-羟色胺2A受体(HTR2A)基因多态性与帕利哌酮和利培酮治疗精神分裂症患者临床疗效与安全性的关联.方法 入组201名精神分裂症患者,133例门诊或住院患者,随机接受12周帕利哌酮棕榈酸盐(50~150 mg/4周)或利培酮长效注射针剂(25~50 mg/4周)治疗,每2周进行1次疗效和安全性的评定;68例住院患者,接受4周利培酮片(2~6 mg·d-1)治疗,每周进行1次疗效和安全性评定;以试验结束时阳性阴性症状评定量表(PANSS)总减分率为主要疗效评价指标.共选择3个多态性位点,采用限制性酶切片段长度多态性或直接测序,获得基因型.结果 rs7997012各基因型可能与I临床疗效相关联(P<0.05),位点rs6313和rs6311的各基因型间临床疗效的差别无统计学意义(P>0.05);位点rs6313和rs6311的各基因型与BARS、SAS评分变化及血AST、ALT升高的水平相关联(P<0.05).结论 HTR2A 基因与帕利哌酮及利培酮治疗的临床疗效和安全性可能有关联.%Objective To study the relationship between gene polymorphisms of 5 - hydroxytryptamine receptor 2A (HTR2A) genes and the clinical efficacy and safety in Han Chinese schizophrenic patients who were treated with risperidone or paliperidone. Methods Two hundreds and one schizophrenic patients were included in this study, one hundred and thirty thee inpatients or outpatients were randomized to take paliperidone palmitate (50 - 150 mg/4 week) or risperidone LAI (25 -50 mg/2 week) for 12 weeks' therapy, efficacy and safety examines were taken at every visit. Sixty eight inpatients or outpatients who were treated with risperidone tablets (2 - 6 mg· d - 1 ) for 4 weeks were chosen. Efficacy and security examines was taken by every week. The main effect assessment was the final and baseline positive and negative syndrome scale(PANSS)total score reduced rate. The trial had chosen 3 SNPs, genotypes were detected by PCR

  15. Long-Acting Injectable Antipsychotics for Prevention of Relapse in Bipolar Disorder: A Systematic Review and Meta-Analyses of Randomized Controlled Trials

    Science.gov (United States)

    Oya, Kazuto; Iwata, Nakao

    2016-01-01

    Background: This meta-analysis of randomized controlled trials aimed to examine the advantages of long-acting injectable antipsychotics over placebo or oral medications regarding efficacy and safety for patients with bipolar disorder. Methods: Two categorical meta-analyses of randomized controlled trials were performed to compare study-defined relapse rate (primary), discontinuation rates, and individual adverse events: (1) risperidone-long-acting injectable vs placebo, and (2) long-acting injectable antipsychotics vs oral medications. Results: We identified 7 randomized controlled trials (n=1016; long-acting injectable antipsychotics [flupenthixol (1 randomized controlled trial) and risperidone (6 randomized controlled trials)=449]; oral medications [mood stabilizers, antidepressants, antipsychotic, or any combination of these agents=283]; and placebo=284). Risperidone-long-acting injectable antipsychotic was superior to placebo for study-defined relapse rate (risk ratio=0.63, P<.0001), relapse of manic symptoms (risk ratio=0.42, P<.00001), and all-cause discontinuation (risk ratio=0.75, P=.007). Risperidone-long-acting injectable was associated with higher incidence of prolactin-related adverse events (risk ratio=4.82, P=.001) and weight gain (risk ratio=3.80, P<.0001) than placebo. The pooled long-acting injectable antipsychotics did not outperform oral medications regarding primary outcome but with significant heterogeneity (I2=74%). Sensitivity analysis, including only studies with rapid cycling or high frequency of relapse patients, revealed that long-acting injectable antipsychotics were superior compared to oral medications (I2=0%, RR=0.58, P=.0004). However, the comparators in this sensitivity analysis did not include second-generation antipsychotic monotherapy. In sensitivity analysis, including only studies with second-generation antipsychotic monotherapy as the comparator, long-acting injectable antipsychotics did not outperform second

  16. Risperidone use in a teaching hospital during its first year after market approval: economic and clinical implications.

    Science.gov (United States)

    Carter, C S; Mulsant, B H; Sweet, R A; Maxwell, R A; Coley, K; Ganguli, R; Branch, R

    1995-01-01

    Risperidone, a new antipsychotic drug, was recently approved by the Food and Drug Administration (FDA) on the basis of its having comparable efficacy and less toxicity than haloperidol. In a preliminary study to evaluate the therapeutic efficiency of this drug, we conducted a survey of resperidone utilization, cost, and safety during its first year of availability at an academic psychiatric hospital. Data were obtained from a computerized, centralized medical record system, from an adverse drug reaction monitoring system, and from pharmacy purchasing records. In its first year of availability, risperidone became the second most widely used antipsychotic agent at our institution. Most of this use extended beyond the adult schizophrenia population, for whom pre-marketing safety and efficacy data are available. The direct institutional cost of risperidone treatment exceeded the entire budget for antipsychotic drugs during the year before its release. Results from the adverse drug reaction reporting system did not indicate a strong advantage of risperidone over more established antipsychotic agents with respect to extrapyramidal side effects. Furthermore, the mean dose of risperidone associated with extrapyramidal symptoms was 3.5 mg/day, considerably lower than that suggested by pre-marketing studies in a more select patient group. These results confirm that new pharmacological agents are generally used in much broader patient populations than those for which efficacy and safety have been established prior to FDA approval. This study also raises questions about the therapeutic efficiency of risperidone compared with other antipsychotic drugs. We conclude that systematic studies of outcome, safety, and cost of new pharmaceuticals in naturalistic settings are needed to provide the data necessary to establish local standards of cost-effective care.

  17. Treatment of anorexia nervosa with long-term risperidone in an outpatient setting: case study

    OpenAIRE

    Kracke, Elsa J; Tosh, Aneesh K.

    2014-01-01

    Introduction There are currently few studies focusing on the efficacy of long-term atypical antipsychotics to treat anorexia nervosa in the pediatric population. Case description This case report follows the treatment of a 17 year-old female with anorexia nervosa over her four-year undergraduate career. After two years of multidisciplinary treatment, low-dose risperidone was initiated due to persistence of her disease. She expressed decreased rigidity around meal times, her weight improved an...

  18. Choline acetyltransferase expression in rat prefrontal cortex and hippocampus after acute and chronic exposure to amisulpride, haloperidol, and risperidone.

    Science.gov (United States)

    Huang, Guang-Biao; Zhao, Tong; Li, Chun-Rong; Sui, Zhi-Yan; Kang, Nam-In; Han, Eui-Hyeog; Chung, Young-Chul

    2012-10-24

    Recently, there has been an increasing concern that atypical antipsychotics as well as typical ones may cause detrimental effects on cognitive function. Supporting evidence comes from many preclinical studies demonstrating that long-term administration of haloperidol, risperidone, and ziprasidone reduced choline acetyltransferase (ChAT) expression in rat hippocampus (HIP). However, to the best of our knowledge, no studies have examined the effects of amisulpride on ChAT expression in rats. Therefore, the aim of this study was to investigate the effects of acute and chronic administration of amisulpride, haloperidol, and risperidone on ChAT expression in the rat prefrontal cortex (PFC) and HIP. Animals received daily intraperitoneal (i.p.) injections of amisulpride (5 or 100mg/kg), haloperidol (1 or 2mg/kg), risperidone (1 or 2mg/kg) or vehicle for 7 or 45 days. One day after the last injection, rats were sacrificed. ChAT immunoreactivity was assessed with immunofluorescence staining. Target areas of brain were PFC and HIP (CA1, CA3 and DG). The short-term administration of haloperidol and risperidone produced significant decrease of ChAT immunoreactivity in the PFC and HIP compared to vehicle whereas amisulpride had no effects on ChAT immunoreactivity in the PFC and HIP. In long-term study, haloperidol and risperidone decreased ChAT-positive cells and/or fiber pixel density in the PFC and HIP whereas amisulpride decreased ChAT-positive cells in the PFC and had no effects on fiber pixel density of ChAT in the HIP. The results suggest that both short-term and long-term administration of haloperidol and risperidone, and long-term administration of amisulpride may produce detrimental effects on cognitive function by reducing ChAT expression in the PFC and/or HIP.

  19. Study on the Long-term Efficacy and Security of Risperidone in the Treatment of Schizophrenia%利培酮治疗精神分裂症长期疗效和安全性对照研究

    Institute of Scientific and Technical Information of China (English)

    杨保成

    2015-01-01

    Objective To summarize the long-term ef icacy and safety of risperidone treatment of schizophrenic patients, to find the best treatment for schizophrenia patients. Methods This research materials selection in February 2012~September 2014 in our hospital for diagnosis and treatment of 74 cases of schizophrenia patients, in a random method wil be divided into two groups, namely, the experimental group and control group. Of 37 cases of control group research object tolbutamide wil benefit as the main drug treatment, and 37 cases of experimental research object and ketone of culture as the main drug treatment, at the same time, contrast and analysis of two groups of subjects basic information such as long-term ef icacy and safety. Results The study found that the experimental group in such aspects as the research object in the long-term ef icacy and safety of has the absolute advantage, comparative dif erence is significant ( <0.05). Conclusion Clinical long-term ef icacy and safety of risperidone treatment of schizophrenia is significant, in addition to schizophrenic patients long-term treatment can ef ectively improve ef iciency, but also has the clinical advantages of smal side ef ects, it is recommended that promotion.%目的总结利培酮治疗精神分裂症长期疗效和安全性,寻找适合精神分裂症患者的最佳治疗方案。方法本次研究资料选取2012年2月~2014年9月在本院进行诊治的74例精神分裂症患者,以随机法将其划分成两个小组,即实验组以及对照组。其中,37例对照组研究对象以氨磺必利为主要药物进行治疗,而37例实验组研究对象则以利培酮为主要药物进行治疗,同时对比及分析两组研究对象长期疗效和安全性等基本信息。结果本次研究发现,实验组研究对象在长期疗效和安全性等方面都存在着绝对性优势,比较差异较为显著(<0.05)。结论临床上利培酮治疗精神分裂症长期疗效和安全性较

  20. Effectiveness of the behavior change intervention to improve harm reduction self-efficacy among people who inject drugs in Thailand

    Science.gov (United States)

    Pawa, Duangta; Areesantichai, Chitlada

    2016-01-01

    Background People who inject drugs (PWID) in Thailand reported unsafe injection practices resulting in injection-related health consequences. Harm reduction self-efficacy plays an important role and could be improved to reduce harm associated with injecting drugs. Evidence-based interventions targeting PWID are needed. This study sought to evaluate the effectiveness of the behavior change intervention within the PWID population. Methods The behavior change intervention, Triple-S, was designed to improve harm reduction self-efficacy among PWID. This quasi-experimental study was a pre- and post-comparison with a control group design. Participants were PWID, aged 18–45 years, and located in Bangkok. Changes in harm reduction self-efficacy of the intervention group were compared with the control group using paired and independent t-test. Results Most of PWID were male (84%), had a secondary school and lower education (71%), were single, and had a mean age of 41 years. They had been injecting drugs for an average of 20 years, and the median of drug injections per week was ten times in the past month. Pre- and post-intervention effects were measured and results showed that the intervention group reported improvement in harm reduction self-efficacy in negative emotional conditions (P=0.048). Conclusion Our findings suggest that Triple-S intervention can significantly improve harm reduction self-efficacy in negative emotional conditions. The results may suggest the importance of behavior change intervention, especially when integrated with services provided by drop-in centers. The intervention can be further developed to cover other harm reduction behaviors and improve harm reduction self-efficacy. PMID:27660503

  1. Efficacy and Tolerability of Fixed-Dose Combination of Dexketoprofen and Dicyclomine Injection in Acute Renal Colic

    OpenAIRE

    Porwal, A.; A. D. Mahajan; Oswal, D. S.; Erram, S. S.; D. N. Sheth; Balamurugan, S.; V. Kamat; R. P. Enadle; Badadare, A.; Bhatnagar, S. K.; Walvekar, R. S.; Dhorepatil, S.; R. C. Naik; Basu, I; Kshirsagar, S. N.

    2012-01-01

    Objective. To evaluate the efficacy and tolerability of a fixed-dose combination of dexketoprofen and dicyclomine (DXD) injection in patients with acute renal colic. Patients and Methods. Two hundred and seventeen patients were randomized to receive either DXD (n = 109) or fixed-dose combination of diclofenac and dicyclomine injection (DLD; n = 108), intramuscularly. Pain intensity (PI) was self-evaluated by patients on visual analogue scale (VAS) at baseline and at 1, 2, 4, 6, and 8 hours. E...

  2. Efficacy and Safety of Intravesical OnabotulinumtoxinA Injection in Patients with Detrusor Hyperactivity and Impaired Contractility

    OpenAIRE

    Chung-Cheng Wang; Cheng-Ling Lee; Hann-Chorng Kuo

    2016-01-01

    We investigated the efficacy and safety of intravesical onabotulinumtoxinA injection in patients with detrusor hyperactivity and impaired contractility (DHIC). Twenty-one patients with urodynamically proven DHIC and 21 age-matched patients with overactive bladder (OAB) with urodynamic detrusor overactivity were treated with intravesical injections of 100 U of onabotulinumtoxinA. The overactive bladder symptom score, urgency severity score, patient perception of bladder condition, global respo...

  3. Efficacy of Optical Internal Urethrotomy and Intralesional Injection of Vatsala-Santosh PGI Tri-Inject (Triamcinolone, Mitomycin C, and Hyaluronidase in the Treatment of Anterior Urethral Stricture

    Directory of Open Access Journals (Sweden)

    Santosh Kumar

    2014-01-01

    Full Text Available Purpose. To study the efficacy of optical internal urethrotomy with intralesional injection of Vatsala-Santosh PGI tri-inject (triamcinolone, mitomycin C, and hyaluronidase in the treatment of anterior urethral stricture. Material and Methods. A total of 103 patients with symptomatic anterior urethral stricture were evaluated on the basis of clinical history, physical examination, uroflowmetry, and retrograde urethrogram preoperatively. All patients were treated with optical internal urethrotomy followed by injection of tri-inject at the urethrotomy site. Tri-inject was prepared by diluting the combination of triamcinolone 40 mg, mitomycin C 2 mg, and hyaluronidase 3000 in 5–10 mL of saline according to length of stricture. An indwelling 18 Fr silicone catheter was left in place for a period of 7–21 days. All patients were followed up for 6–18 months postoperatively on the basis of history, uroflowmetry, and, if required, retrograde urethrogram and micturating urethrogram every 3 months. Results. The overall recurrence rate after first OIU is 19.4% (20 out of 103 patients, that is, a success rate of 80.6%. Overall recurrence rate after second procedure was 5.8% (6 out of 103 patients, that is, a success rate of 94.2%. Conclusion. Optical internal urethrotomy with intralesional injection of Vatsala-Santosh PGI tri-inject (triamcinolone, mitomycin C, and hyaluronidase is a safe and effective minimally invasive therapeutic modality for short segment anterior urethral strictures.

  4. 小剂量利培酮强化抗抑郁剂治疗双相抑郁发作的疗效和安全性研究%Efficacy and safety of low dosage risperidone added on valproate and citalopram in the treatment of acute bipolar depression

    Institute of Scientific and Technical Information of China (English)

    王健; 王刚; 马辛

    2014-01-01

    目的考察小剂量利培酮强化抗抑郁剂治疗对双相抑郁发作的疗效和安全性。方法符合入组标准的住院患者,先接受2周的丙戊酸钠( valproate,VPA)合并西酞普兰( citalopram,CIT)治疗。2周末相对于基线的蒙哥马利抑郁量表( Montgomery and Asberg Depression Scale,MADRS)减分率0.05)。 CGI-I 2组对比,差异具有统计学意义(P0.05)。随机治疗第1周末BPRS阳性因子评分VPA+CIT+RIS组较VPA+CIT组明显降低,差异有统计学意义(P<0.05),显示VPA+CIT+RIS组较VPA+CIT组在改善阳性精神病性症状方面起效更快。在随机治疗第2周,VPA+CIT+RIS组有效率为66.0%,VPA+CIT组为33.3%,显示VPA+CIT+RIS组较VPA+CIT组起效更快。结论 VPA+CIT+RIS与VPA+CIT治疗双相抑郁发作均安全有效。在快速起效及降低转相风险方面,VPA+CIT+RIS组优于VPA+CIT组。%Objective To evaluate the augmentation efficacy and safety of low dosage risperidone, added on the usual treatment ( valproate and citalopram) in the acute treatment of bipolar depression. Methods A total of 46 inpatients with a diagnostic criteria for acute depression episode with bipolar disorder according to DSM-IV-TR were first given valproate and citalopram treatment. The subjects who achieve little clinical response( i. e. reduction from baseline in total MADRS score by<50%) at the end of 2-week will enter into the randomized open-label 6-week treatment phase. The eligible subjects will be randomized to treatment with valproate & citalopram or valproate & citalopram & risperidone in a 1:1 ratio. Efficacy rating scales to be used in the study include MADRS, YMRS, BPRS( total score and positive subscale), CGI-S, and CGI-I. The evaluations of safety and tolerability include SAS, treatment-emergent mania, clinical laboratory tests, vital signs , ECG, and adverse events reports. Results At the end of treatment, the scores of MADRS, BPRS, GIC-I, and CGI-S in both treatment groups decreased significantly compared

  5. Efficacy of multimodal cocktail periarticular injection with or without steroid in total knee arthroplasty

    Institute of Scientific and Technical Information of China (English)

    YUE De-bo; WANG Bai-liang; LIU Kun-peng; GUO Wan-shou

    2013-01-01

    Background Multimodal cocktail periarticular injection (MCPI) with a large volume of low concentration local anesthetics,adrenaline,and anti-inflammatory agents such as non-steroidal anti-inflammatory drug or steroids have shown good pain control and improvement in range of motion after surgery.This study compares the efficacy of pain control after total knee arthroplasty,using multimodal cocktail periarticular injection with steroid or without steroid.Methods This is a prospective,double-blinded,randomized and control study.Seventy-two patients with osteoarthritis that met clinical criteria for total knee arthroplasty were recruited into the study,and were randomized to receive either multimodal cocktail periarticular injection with steroid or without steroid.Pain was assessed by visual analogue scale (VAS) at preoperative and postoperative at rest,and during activity.The range of motion was recorded preoperatively and postoperatively.The amount of daily and cumulative morphine consumption were measured by patient-controlled analgesia in the first 72 hours postoperatively.The duration of celecoxib usage was also recorded at the last follow-up.Results There were no differences between the non-steroid and steroid groups with regard to VAS at rest and during activity,or range of motion,at any postoperative observation time.The postoperative Knee Society Knee Score in the steroid group improved significantly as compared with that in non-steroid group at the one-month (84.1±13.1 and 65.9±12.1; P <0.0045),three-month follow-up (90.2±16.3 and 72.5±16.6; P <0.0027),but after postoperative six-month the Knee Society Knee Score showed no significant difference between the groups.There was no significant difference in consumption of the morphine about daily or total consumption within 72 hours between the two groups.The duration of celecoxib usage in patients in the steroid group was significantly shorter than that in the non-steroid group ((7.2±0.7) compared with

  6. The Efficacy and Safety of Concurrent Collagenase Clostridium Histolyticum Injections for 2 Dupuytren Contractures in the Same Hand

    DEFF Research Database (Denmark)

    Gaston, R. G.; Larsen, Søren; Pess, G. M.;

    2015-01-01

    Purpose To evaluate efficacy and safety of concurrent administration of 2 collagenase clostridium histolyticum (CCH) injections to treat 2 joints in the same hand with Dupuytren fixed flexion contractures (FFCs). Methods Patients with 2 or more contractures in the same hand caused by palpable cor...

  7. Efficacy of injections of phosphatidylcholine into fat deposits-a non-surgical alternative to liposuction in body-contouring

    Directory of Open Access Journals (Sweden)

    Karl-G Heinrich

    2005-01-01

    Full Text Available Injecting phosphatidylcholine has been used in South America as a non-surgical treatment in body contouring. The objective of this study was to demonstrate the efficacy of injecting phosphatidylcholine in the reduction of localised fat deposits. 86 patients were included in the study. Patients received 1-3 treatments in localised fat deposits in various areas of the body using phosphatidylcholine. After treatment with phosphatidylcholine (250 mg / 5 ml, fat deposits show an average circumferential reduction per application of 2.70 cm. No patient showed irregularities, dimples or any serious side effect after treatment. Results remained stable during the time of follow up. All patients showed remarkable reductions of the fat deposits treated with phosphatidylcholine. Using the correct technique, injecting phosphatidylcholine may be a safe and efficacious alternative to liposuction in patients objecting to surgery.

  8. Efficacy of oral and intraperitoneal administration of CBMIDA for removing uranium in rats after parenteral injections of depleted uranium

    International Nuclear Information System (INIS)

    The efficacy of oral administration of the chelating agent catechol-3, 6-bis(methyliminodiacetic acid) (CBMIDA) for removing uranium from rats after intraperitoneal (i.p.) and intramuscular (i.m.) injections of depleted uranium (DU) was examined and the results with those by the i.p. injection of CBMIDA were compared. In Experiment 1, after a single i.p. injection of 8 mg kg-1 of DU of rat's body weight, 35 8-week-old male rats were divided into seven groups consisting of five rats each. Three groups were administered with CBMIDA 240, 720 or 1200 mg kg-1 of rat's body weight orally once a day, and three other groups received an i.p. injection of 240, 480 or 720 mg kg-1 CBMIDA for 3 d, starting 30 min after DU injection on the first day. One DU group received no CBMIDA. The remaining five intact rats were used as a control group. Rats were killed 6 d after DU injection. In Experiment 2, the 35 male rats that received a single i.m. injection of 8 mg kg-1 DU were divided into seven groups, and the rats of each group received the same doses of CBMIDA on the same schedules of treatment as those described in Experiment 1. The results obtained in Experiment 1 indicated that orally administered CBMIDA significantly increased the excretion of uranium at doses of 720 and 1200 mg kg-1 and decreased uranium concentrations, particularly in the kidney, at all the doses tested, and the effects were almost equal to those of the i.p. injection. The lack of increases in creatinine and blood urea nitrogen in serum indicated that CBMIDA is efficacious in preventing the renal dysfunction caused by uranium. In Experiment 2, oral administration of CBMIDA significantly increased uranium excretion and significantly decreased uranium concentrations, particularly in the kidneys, at all the doses tested, and the effects were almost equal to those of the i.p. injection. However, these effects of CBMIDA on the i.m.-injected DU were lower than those of the i.p.-injected DU in Experiment 1. These

  9. Preparation and Biological Evaluation of Radioiodinated Risperidone and Lamotrigine as Models for Brain Imaging

    International Nuclear Information System (INIS)

    Brain imaging technology is becoming an important tool in both research and clinical care. Due to the sensitivity of brain imaging technology, neuroscientists are able to visualize brain structure and function from the level of individual molecules to the whole brain, recognize and diagnose neurological disorders, develop new strategies for treatment and determine how therapies work. The study aimed to take advantages from drugs that are able to cross the brain barrier for the development of potential radiopharmaceuticals for non-invasive brain imaging. Risperidone and lamotrigine were successfully labeled with 125I via direct electrophilic substitution reaction at 80 degree C. The reaction parameters affecting the preparation process were studied. 125I-risperidone and 125I-lamotrigine gave maximum labeling yield of 89 % ± 3.75 and 97.5 % ± 1.0 %, respectively and their stability were up to 6 and 24 h, respectively. Biodistribution studies showed that maximum uptake of 125I-risperidone and 125I-lamotrigine in the brain of mice were 4.27 % ± 0.38 and 2.45 % ± 0.18 of the injected activity/g tissue organ, at 10

  10. Efficacy and Safety of Intravesical OnabotulinumtoxinA Injection in Patients with Detrusor Hyperactivity and Impaired Contractility.

    Science.gov (United States)

    Wang, Chung-Cheng; Lee, Cheng-Ling; Kuo, Hann-Chorng

    2016-03-01

    We investigated the efficacy and safety of intravesical onabotulinumtoxinA injection in patients with detrusor hyperactivity and impaired contractility (DHIC). Twenty-one patients with urodynamically proven DHIC and 21 age-matched patients with overactive bladder (OAB) with urodynamic detrusor overactivity were treated with intravesical injections of 100 U of onabotulinumtoxinA. The overactive bladder symptom score, urgency severity score, patient perception of bladder condition, global response assessment, voiding diary, and procedure-related adverse events (AE) at baseline, two weeks, one, three, and six months after treatment were assessed. The results showed that the subjective symptom scores improved significantly in both groups, and the scores did not differ between the groups. The decrease in urgency episodes and urgency urinary incontinence were noted in OAB patients but not in DHIC patients. Although the incidence of AEs was comparable between the groups, the therapeutic efficacy lasted for a mean of 4.9 ± 4.8 months in DHIC patients and 7.2 ± 3.3 months in OAB patients (p = 0.03). We concluded that the efficacy of intravesical onabotulinumtoxinA injection for DHIC patients was limited and short-term. Nevertheless, AEs did not increase in DHIC. Intravesical onabotulinumtoxinA might not be a good indication in patients with DHIC and high post-voiding residual urine. Physicians should inform patients of the potential benefits and risks of onabotulinumtoxinA injection for treatment of DHIC. PMID:26999209

  11. Efficacy and Safety of Intravesical OnabotulinumtoxinA Injection in Patients with Detrusor Hyperactivity and Impaired Contractility

    Directory of Open Access Journals (Sweden)

    Chung-Cheng Wang

    2016-03-01

    Full Text Available We investigated the efficacy and safety of intravesical onabotulinumtoxinA injection in patients with detrusor hyperactivity and impaired contractility (DHIC. Twenty-one patients with urodynamically proven DHIC and 21 age-matched patients with overactive bladder (OAB with urodynamic detrusor overactivity were treated with intravesical injections of 100 U of onabotulinumtoxinA. The overactive bladder symptom score, urgency severity score, patient perception of bladder condition, global response assessment, voiding diary, and procedure-related adverse events (AE at baseline, two weeks, one, three, and six months after treatment were assessed. The results showed that the subjective symptom scores improved significantly in both groups, and the scores did not differ between the groups. The decrease in urgency episodes and urgency urinary incontinence were noted in OAB patients but not in DHIC patients. Although the incidence of AEs was comparable between the groups, the therapeutic efficacy lasted for a mean of 4.9 ± 4.8 months in DHIC patients and 7.2 ± 3.3 months in OAB patients (p = 0.03. We concluded that the efficacy of intravesical onabotulinumtoxinA injection for DHIC patients was limited and short-term. Nevertheless, AEs did not increase in DHIC. Intravesical onabotulinumtoxinA might not be a good indication in patients with DHIC and high post-voiding residual urine. Physicians should inform patients of the potential benefits and risks of onabotulinumtoxinA injection for treatment of DHIC.

  12. Risperidone-associated ejaculatory and urinary dysfunction in male adolescents.

    Science.gov (United States)

    Holtmann, Martin; Gerstner, Sandra; Schmidt, Martin H

    2003-01-01

    We report two male adolescents who developed partial or complete retrograde ejaculation during risperidone treatment. Additionally, one patient complained of bladder outflow obstruction, and the other reported a reduced ejaculatory volume and decreased viscosity of semen. On rechallenge with risperidone, patient A showed a prompt recurrence of the ejaculatory dysfunction. The side effects were highly disturbing and led to reduced treatment compliance in both patients. The impact of risperidone, a strong alpha(1)-receptor antagonist, on the adrenergic system might induce retrograde ejaculation by altering the sympathetic tonus, allowing semen to pass retrogradely into the bladder during ejaculation. The reduced ejaculatory volume may be caused by risperidone-induced hyperprolactinemia. Clinicians should regularly inquire about sexual dysfunction and symptoms suggestive of hyperprolactinemia before starting risperidone treatment and regularly thereafter. PMID:12804132

  13. Treatment Efficacy of Electromyography versus Fiberscopy-Guided Botulinum Toxin Injection in Adductor Spasmodic Dysphonia Patients: A Prospective Comparative Study

    Directory of Open Access Journals (Sweden)

    Jae Wook Kim

    2014-01-01

    Full Text Available Introduction. This study prospectively evaluates and compares the treatment efficacy of botulinum toxin injection under electromyography guidance (EMG group and percutaneous botulinum toxin injection under flexible fiberscopic guidance (fiberscopy group. Methods. Thirty patients with adductor spasmodic dysphonia (ADSD, who had never received treatment, were randomly allocated into EMG- or fiberscopy-guided botulinum toxin injections between March 2008 and February 2010. We assessed acoustic and aerodynamic voice parameters, and the voice handicap index (VHI before injection and at 1, 3, and 6 months after injection. Results. The mean total dosage of botulinum toxin was similar for both groups: 1.7 ± 0.5 U for the EMG group and 1.8 ± 0.4 U for the fiberscopy group (P>0.05. There were no significant differences in outcomes between the two groups in either the duration of effectiveness or complications such as breathy voice and aspiration. Conclusion. Botulinum toxin injection under fiberscopic guidance is a viable alternative to EMG-guided botulinum toxin injection for the treatment of adductor spasmodic dysphonia when EMG equipment is unavailable.

  14. A Double-Blind, Placebo-Controlled Study of Risperidone for the Treatment of Adolescents and Young Adults with Anorexia Nervosa: A Pilot Study

    Science.gov (United States)

    Hagman, Jennifer; Gralla, Jane; Sigel, Eric; Ellert, Swan; Dodge, Mindy; Gardner, Rick; O'Lonergan, Teri; Frank, Guido; Wamboldt, Marianne Z.

    2011-01-01

    Objective: The purpose of this double-blind, placebo-controlled exploratory pilot study was to evaluate the safety and efficacy of risperidone for the treatment of anorexia nervosa. Method: Forty female subjects 12 to 21 years of age (mean, 16 years) with primary anorexia nervosa in an eating disorders program were randomized to receive…

  15. Efficacy of a single ultrasound-guided injection for the treatment of hip osteoarthritis.

    LENUS (Irish Health Repository)

    Atchia, Ismaël

    2011-01-01

    Intra-articular injection is effective for osteoarthritis, but the best single injection strategy is not known, nor are there established predictors of response. The objectives of this study were to assess and predict response to a single ultrasound-guided injection in moderate to severe hip osteoarthritis.

  16. Spectrophotometric estimation of risperidone in tablets

    OpenAIRE

    B. K. Jayanna; Devaraj, T. D.; Roopa, K. P.; G. Nagendrappa; H R Arun Kumar; Gowda, N.

    2014-01-01

    A simple, rapid and highly sensitive spectrophotometric method is developed for the determination of risperidone in tablet formulation. The method is based on the oxidation of drug using potassium permanganate in alkaline medium and excess potassium permanganate oxidizes 1,10-phenanthroline Fe(II). The measurement of decrease in absorbance of 1,10-phenanthroline Fe (II) was done at 415 nm. The beer′s law is obeyed in the concentration range of 5.0 to 40.0 μg/ml and molar absorptivity is found...

  17. Efficacy and Tolerability of Fixed-Dose Combination of Dexketoprofen and Dicyclomine Injection in Acute Renal Colic

    Directory of Open Access Journals (Sweden)

    A. Porwal

    2012-01-01

    Full Text Available Objective. To evaluate the efficacy and tolerability of a fixed-dose combination of dexketoprofen and dicyclomine (DXD injection in patients with acute renal colic. Patients and Methods. Two hundred and seventeen patients were randomized to receive either DXD (n=109 or fixed-dose combination of diclofenac and dicyclomine injection (DLD; n=108, intramuscularly. Pain intensity (PI was self-evaluated by patients on visual analogue scale (VAS at baseline and at 1, 2, 4, 6, and 8 hours. Efficacy parameters were proportion of responders, difference in PI (PID at 8 hours, and sum of analogue of pain intensity differences (SAPID. Tolerability was assessed by patients and physicians. Results. DXD showed superior efficacy in terms of proportion of responders (98.17% versus 81.48; P<0.0001, PID at 8 hours (P=0.002, and SAPID0–8 hours (P=0.004. The clinical global impression for change in pain was significantly better for DXD than DLD. The incidence of adverse events was comparable in both groups. However, global assessment of tolerability was rated significantly better for DXD. Conclusion. DXD showed superior efficacy and tolerability than DLD in patients clinically diagnosed to be suffering from acute renal colic.

  18. P-glycoprotein interaction with risperidone and 9-OH-risperidone studied in vitro, in knock-out mice and in drug-drug interaction experiments

    DEFF Research Database (Denmark)

    Ejsing, Thomas B.; Pedersen, Anne D.; Linnet, Kristian

    2005-01-01

    P-glycoprotein, risperidone, nortriptyline, cyclosporine A, drug-drug interaction, blood-brain barrier, knock-out mice......P-glycoprotein, risperidone, nortriptyline, cyclosporine A, drug-drug interaction, blood-brain barrier, knock-out mice...

  19. 利培酮口服液与奥氮平治疗老年痴呆精神行为症状的疗效比较%Comparison efficacy of risperidone oral solution and olanzapine in the treatment of elderly dementia behavioral and psychological symptoms

    Institute of Scientific and Technical Information of China (English)

    曲春晖; 孙平; 孙忠国

    2016-01-01

    Objective To discuss the clinical value and safety of risperidone oral solution and olanzapine in treatment of elderly dementia behavioral and psychological symptoms (BPSD).Methods 120 patients with BPSD were randomly divided into research group and control group ,each of 60 cases.Research group were treated with risperidone oral solution ,control group were treated with olanzapine ,the treatment course was 8 weeks.Used BEHAVE-AD to evaluate the efficacy ,evaluated the agitated behavior improvement by CMAI , assessed the adverse drug reactions by TESS assessment , observed the medication compliance by self compliance scale .Results 4 weeks after treatment ,the BEHAVE-AD score and CMAI scores of two groups than before treatment decreased ,but the difference was not statistically significant (P>0.05),8 weeks after treatment,the BE-HAVE-AD score and CMAI scores of two groups decreased significantly ,compared with before treatment difference was statisti-cally significant(P0.05).The incidence rate of weight gain,lethargy in research group were lower than control group ,the difference was statistically significant (P0.05),4 weeks,8 weeks after treatment the compliance of research group was better than control group ,the difference was statistically significant(P<0.05).Conclusion Risperidone oral solu-tion is applied to the clinical treatment of elderly dementia with BPSD effective and relatively safe ,patients with better compli-ance .%目的:比较利培酮口服液与奥氮平治疗老年痴呆精神行为症状( BPSD )的疗效和安全性。方法将120例BPSD患者随机分为研究组和对照组各60例。研究组患者给予利培酮口服液治疗,对照组患者给予奥氮平治疗,疗程为8周。2组患者均采用痴呆病理行为评定量表(BEHAVE-AD)评定疗效,Cohan Mansfield 激越行为量表(CMAI)评定激越行为的改善程度,副反应量表(TESS)评定药物不良反应,自编依从性量表观察患者服药

  20. Control study of efficacy and safety of Paliperidone and Risperidone in treatment of alcohol-induced mental disorder%帕利哌酮与利培酮治疗酒精所致精神障碍疗效及安全性对照研究

    Institute of Scientific and Technical Information of China (English)

    田文聪

    2014-01-01

    目的:探讨帕利哌酮缓释片与利培酮片治疗酒精所致精神障碍的临床疗效及安全性。方法:共纳入40例酒精所致精神障碍患者进行6周的研究。将患者分为帕利哌酮缓释片组(研究组)和利培酮组(对照组)各20例。在患者治疗前及治疗第1、2、4、6周末采用阳性和阴性症状量表( PANSS)评定临床疗效;治疗中需处理的不良反应量表( TESS)评定不良反应;两组患者均入院即使用相同护肝药物,定期检测肝功能,监测肝功能各项指标变化。结果:两药对酒精所致精神障碍的疗效无显著性差异(P>0.05);在不良反应方面,帕利哌酮缓释片组患者低于利培酮组,两组患者比较有显著差异(P0. 05). The study group had significant less side effects than control group, and the difference was significant (P<0. 05). The study group had more significant improvement in liver function compared to control group 2 weeks after the treatment, and the difference was significant (P<0. 05). Conclusions: Paliperidone ER has good efficacy in the treatment of alcohol-induced mental disorder. It has less side effects than Risperidone and helps the improvement of liver function. Paliperidone ER is worth further clinical application.

  1. Efficacy and safety of 10,600-nm carbon dioxide fractional laser on facial skin with previous volume injections

    Directory of Open Access Journals (Sweden)

    Josiane Hélou

    2013-01-01

    Full Text Available Background: Fractionated carbon dioxide (CO 2 lasers are a new treatment modality for skin resurfacing. The cosmetic rejuvenation market abounds with various injectable devices (poly-L-lactic acid, polymethyl-methacrylate, collagens, hyaluronic acids, silicone. The objective of this study is to examine the efficacy and safety of 10,600-nm CO 2 fractional laser on facial skin with previous volume injections. Materials and Methods: This is a retrospective study including 14 patients treated with fractional CO 2 laser and who have had previous facial volume restoration. The indication for the laser therapy, the age of the patients, previous facial volume restoration, and side effects were all recorded from their medical files. Objective assessments were made through clinical physician global assessment records and improvement scores records. Patients′ satisfaction rates were also recorded. Results: Review of medical records of the 14 patients show that five patients had polylactic acid injection prior to the laser session. Eight patients had hyaluronic acid injection prior to the laser session. Two patients had fat injection, two had silicone injection and one patient had facial thread lift. Side effects included pain during the laser treatment, post-treatment scaling, post-treatment erythema, hyperpigmentation which spontaneously resolved within a month. Concerning the previous facial volume restoration, no granulomatous reactions were noted, no facial shape deformation and no asymmetry were encountered whatever the facial volume product was. Conclusion: CO 2 fractional laser treatments do not seem to affect facial skin which had previous facial volume restoration with polylactic acid for more than 6 years, hyaluronic acid for more than 0.5 year, silicone for more than 6 years, or fat for more than 1.4 year. Prospective larger studies focusing on many other variables (skin phototype, injected device type are required to achieve better

  2. Comparison of Efficacy and Prolactin Concentrations between Aripiprazole and Risperidone Treat-ments in Patients with Schizophrenia%阿立哌唑替换利培酮治疗对精神分裂症患者血清催乳素水平的影响

    Institute of Scientific and Technical Information of China (English)

    马筠; 李轶琛; 李毅; 房茂胜; 钟宝亮

    2013-01-01

    Objective: To compare the prolactin concentrations between aripiprazole and risperidone treatment in patients with schizophrenia. Methods: One hundred and twenty-eight schizophrenic patients with hy-perprolactinemia were randomly divided into risperidone group and aripiprazole group. Patients in the risperidone group were treated with risperidone and in the aripiprazole group were treated with aripiprazol instead of risperidone for 8 weeks. The prolactin concentrations were assessed and compared between two groups at weeks 0, 1,2, 4, 6, and 8. The clinical status was assessed by using the positive and negative syndrome scale (PANSS) and the clinical global impressions scale (CGIS) atweeks0 and 8. Results: Fifty-three in the risperidone group and 48 in the aripiprazole group were available for analyzing. Shift risperidone to aripiprazole was effective in reducing serum prolactin levels. The serum prolactin levels in the risperidone group was significantly lower than that in the aripiprazole group at week 8 (P<0.001). No significant changes was found in the PANSS and CGI-S scores between the two groups. Conclusion: Shift risperidone to aripiprazole was effective in reducing serum prolactin levels of schizophrenia patients with hyperprolactinemia.%目的:研究阿立哌唑替换利培酮治疗对精神分裂症患者血清催乳素水平的影响.方法:伴有高催乳素血症的精神分裂症患者128 例,随机分为利培酮组(维持利培酮治疗)和阿立哌唑(阿立哌唑替代利培酮治疗)组,治疗8 周.于第0、1、2、4、6 及8 周测血清催乳素水平及身体质量指数(BMI);在入组时和治疗8 周时采用阳性与阴性症状量表(PANSS)和临床总体印象量表(CGIS)测定疗效.结果:可用于评估的数据101 例,利培酮组53 例,阿立哌唑组48 例.阿立哌唑组替换治疗后第1 周血清催乳素水平即明显下降,第8 周时,显著低于利培酮组(P<0.001);2 组BMI 、PANSS 及CGIS 评分及变化差异无统计

  3. Clinical Controlled Study on the Effect of Risperidone Microsphere on Schizophrenia%利培酮微球治疗精神分裂症疗效的临床对照研究

    Institute of Scientific and Technical Information of China (English)

    秦国兴; 甘建光; 田国强

    2013-01-01

    score differences ≤5 were selected as control group. The experiment group was given long - acting injection of 25. 0 mg or 37. 5 mg risperidone microspheres by intramuscular injection once every two weeks. While the control group was given 1 mg risperidone tablets two times a day per os, and the amount was increased to 3 ~6 mg/d within one week. The dosage, PANSS score, efficiency and adverse e-vents were observed in the two groups. Results The average dose of long - acting risperidone injection microsphere in the 2nd, 4th, and 6th month was respectively ( 31. 2 ± 7. 0 ) mg/2 weeks, (33.8 ±6.6) mg/2 weeks, ( 30. 2 ±7. 0 ) mg/2 weeks and the average dose of risperidone tablets in control group was (4.5 ±1.0) mg/d ,(4.1 ±0.8) mg/d, ( 4. 1 ± 0. 9 ) mg/d. The PANSS scores at different times before and after treatment in the two groups showed statistically significant differences ( Ftime = 53. 34, P (). 05 ) . The PANSS scores before treatment in both the two groups showed statistically significant differences compared with those in the 2nd, 4th and 6th month after treatment ( P 0. 05 ) . Conclusion Injections of long - acting risperidone microsphere and risperidone tablets have equivalent efficacy and safety, so it is a good choice for us to use the long - acting antipsychotic drug injection as a maintenance treatment of schizophrenia due to its inherent advantages of coerciveness.

  4. Efficacy of sofosbuvir-based therapies in HIV/HCV infected patients and persons who inject drugs.

    Science.gov (United States)

    Puoti, Massimo; Panzeri, Claudia; Rossotti, Roberto; Baiguera, Chiara

    2014-12-15

    In the era of Directly Acting anti HCV Antivirals treatment of hepatitis C is successful in the majority of persons treated. However, treatment of persons with HIV or who inject drugs remains challenging because of special issues: drug-drug interactions with antiretroviral, psychiatric and drug substitution therapies, treatment adherence, impact of treatment on HIV disease course or on risk of bacterial infections. Sofosbuvir induced sustained virologic response in 91% of 23 HIV/HCV coinfected persons treated in combination with ribavirin and pegylated interferon, in 83% of 497 treated in combination with ribavirin and in all 50 patients infected with HCV GT1 treated in combination with ledipasvir and ribavirin. The rates of efficacy in HCV-HIV coinfected were almost the same as those observed in HCV monoinfected suggesting that the efficacy of sofosbuvir is not reduced by HIV coinfection. There are no data on the efficacy of sofosbuvir in injection drugs users. The pangenotypic activity, the high barrier to resistance, the modest potential for drug-drug interactions makes sofosbuvir a reference drug for the treatment of these two special populations.

  5. Risperidone treatment increases CB1 receptor binding in rat brain

    DEFF Research Database (Denmark)

    Secher, Anna; Husum, Henriette; Holst, Birgitte;

    2010-01-01

    BACKGROUND/AIMS: Body weight gain is a common side effect of treatment with antipsychotics, but the mechanisms underlying this weight gain are unknown. Several factors may be involved in antipsychotic-induced body weight gain including the cannabinoid receptor 1 (CB(1)), the serotonin receptor 2C...... positively correlated with visceral fat mass. Risperidone treatment increased CB(1) receptor binding in the arcuate nucleus (40%), hippocampus (25-30%) and amygdala (35%) without concurrent alterations in the CB(1) receptor mRNA. Risperidone treatment increased adiponectin mRNA. CONCLUSION: The present study...... showed that risperidone treatment altered CB(1) receptor binding in the rat brain. Risperidone-induced adiposity and metabolic dysfunction in the clinic may be explained by increased CB(1) receptor density in brain regions involved in appetite and regulation of metabolic function....

  6. Risperidone as a treatment for childhood habitual behavior

    OpenAIRE

    Omranifard, Victoria; Najafi, Mostafa; Sharbafchi, Mohammad Reza; Emami, Parisa; Maracy, Mohammad

    2013-01-01

    Objective: The aim of this study was to investigate the effect of adding risperidone to the general behavioral treatment of masturbation in children 3-7 years old. Methods: A 4 week randomized clinical controlled trial was designed in year 2009. Samples have been chosen from children who have been referred to the Child and Adolescence Psychiatric Clinic of Isfahan University of Medical Sciences. Ninety children were recruited at the study and randomly allocated into the risperidone and contro...

  7. Very Low-Dose Risperidone in First-Episode Psychosis: A Safe and Effective Way to Initiate Treatment

    Directory of Open Access Journals (Sweden)

    Patrick D. McGorry

    2011-01-01

    Full Text Available Patients experiencing a first psychotic episode have high rates of extrapyramidal symptoms (EPSs when treated with the doses of neuroleptics used in multiepisode or chronic schizophrenia. There is some evidence that lower doses may be equally, if not more, effective but less toxic in this population. Here, we report the results of a biphasic open label trial designed to assess the efficacy, safety, and tolerability of low-dose (2–4 mg/day risperidone treatment in a group of 96 first-episode nonaffective psychosis patients. At the end of the trial, 62% of patients met the response criteria although approximately 80% had achieved a response at some time during the study. Reports of EPS remained low, and there were no dystonic reactions. We conclude that even at a dose of 2 mg/day, risperidone was highly effective in reducing acute symptomatology in a real world sample of young first-episode psychosis patients.

  8. Short- and long-term efficacy of intra-articular injections with betamethasone as part of a treat-to-target strategy in early rheumatoid arthritis

    DEFF Research Database (Denmark)

    Hetland, Merete Lund; Østergaard, Mikkel; Ejbjerg, Bo;

    2012-01-01

    OBJECTIVE: To investigate the short-term and long-term efficacy of intra-articular betamethasone injections, and the impact of joint area, repeated injections, MRI pathology, anticyclic citrullinated peptide (CCP) and immunoglobulin M rheumatoid factor (IgM-RF) status in patients with early...

  9. Cervical interlaminar epidural steroid injection for unilateral cervical radiculopathy: Comparison of midline and paramedian approaches for efficacy

    Energy Technology Data Exchange (ETDEWEB)

    Yoon, Ji Young; Kwon, Jong Won; Yoon, Young Cheol [Dept. of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul (Korea, Republic of); Lee, Jong Seok [School of Business Administration, Hallym University, Chuncheon (Korea, Republic of)

    2015-06-15

    The objective of this study was to compare the clinical outcomes of the cervical interlaminar epidural steroid injection (CIESI) for unilateral radiculopathy by the midline or paramedian approaches and to determine the prognostic factors of CIESI. We retrospectively analyzed 182 patients who underwent CIESI from January 2009 to December 2012. Inclusion criteria were no previous spinal steroid injection, presence of a cross-sectional image, and presence of follow-up records. Exclusion criteria were patients with bilateral cervical radiculopathy and/or dominant cervical axial pain, combined peripheral neuropathy, and previous cervical spine surgery. Short-term clinical outcomes were evaluated at the first follow-up after CIESI. We compared the clinical outcomes between the midline and paramedian approaches. Possible prognostic factors for the outcome, such as age, gender, duration of radiculopathy, and cause of radiculopathy were also analyzed. Cervical interlaminar epidural steroid injections were effective in 124 of 182 patients (68.1%) at the first follow-up. There was no significant difference in the clinical outcomes of CIESI, between midline (69.6%) and paramedian (63.7%) approaches (p = 0.723). Cause of radiculopathy was the only significant factor affecting the efficacy of CIESI. Patients with disc herniation had significantly better results than patients with neural foraminal stenosis (82.9% vs. 56.0%) (p < 0.001). There is no significant difference in treatment efficacy between the midline and paramedian approaches in CIESI, for unilateral radiculopathy. The cause of the radiculopathy is significantly associated with the treatment efficacy; patients with disc herniation experience better pain relief than those with neural foraminal stenosis.

  10. Increasing the efficacy of antitumor glioma vaccines by photodynamic therapy and local injection of allogeneic glioma cells

    Science.gov (United States)

    Christie, Catherine E.; Peng, Qian; Madsen, Steen J.; Uzal, Francisco A.; Hirschberg, Henry

    2016-03-01

    Immunotherapy of brain tumors involves the stimulation of an antitumor immune response. This type of therapy can be targeted specifically to tumor cells thus sparing surrounding normal brain. Due to the presence of the blood-brain barrier, the brain is relatively isolated from the systemic circulation and, as such, the initiation of significant immune responses is more limited than other types of cancers. The purpose of this study was to show that the efficacy of tumor primed antigen presenting macrophage vaccines could be increased by: (1) PDT of the priming tumor cells, and (2) injection of allogeneic glioma cells directly into brain tumors. Experiments were conducted in an in vivo brain tumor model using Fisher rats and BT4C (allogeneic) and F98 (syngeneic) glioma cells. Preliminary results showed that vaccination alone had significantly less inhibitory effect on F98 tumor growth compared to the combination of vaccination and allogeneic cell (BT4C) injection.

  11. Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis

    OpenAIRE

    Braune, Stefan; Lang, M.; Bergmann, A; ,

    2015-01-01

    Although fingolimod is registered in Europe for treatment of relapsing-remitting multiple sclerosis (RRMS) if earlier disease modifying therapy (DMT) has failed, no data regarding its efficacy in this patient group are available. This observational cohort study of the NeuroTransData network includes German RRMS outpatients with failure of earlier therapy with injectable DMT (iDMT), therefore switching to either another iDMT (n = 133) or to fingolimod (n = 300). Statistical comparison of clini...

  12. Comparison of the efficacy of physical therapy and corticosteroid injection in the treatment of pes anserine tendino-bursitis.

    Science.gov (United States)

    Sarifakioglu, Banu; Afsar, Sevgi Ikbali; Yalbuzdag, Seniz Akcay; Ustaömer, Kubra; Bayramoğlu, Meral

    2016-07-01

    [Purpose] The aims of this study were twofold. The first was to compare the functional capacity and pain of patients with knee osteoarthritis (KOA), with or without pes anserine tendino-bursitis (PATB). The second is to compare the efficacy of two treatment methods (physical therapy and corticosteroid injection) for patients with PATB. [Subjects and Methods] Sixty patient with KOA and PATB (Group 1) and 57 patients with KOA but without PATB (Group 2) were enrolled in the study. The patients' visual analog scale (VAS), Western Ontario and McMaster Universities osteoarthritis index (WOMAC) scores and three-meter timed-up and go scores were measured. The PATB group was randomly divided into two groups (Group A and B). Physical therapy (PT) modalities were applied to the first group (Group A), and the second group (Group B) received corticosteroid injections to the pes anserine area. Eight weeks later, patients' parameters were measured again. [Results] Initial WOMAC scores and timed up-and-go times were significantly higher in Group 1 than in Group 2. Both treatments resulted in significant improvements in all measured parameters, but no significant difference was detected between Group A and B. [Conclusion] Patients with PATB tend to have more severe pain, more altered functionality, and greater disability than those with KOA but without PATB. Both corticosteroid injection and PT are effective methods of treatment for PATB. Injection therapy can be considered an effective, inexpensive and fast therapeutic method. PMID:27512249

  13. A comparison of low-dose risperidone to paroxetine in the treatment of panic attacks: a randomized, single-blind study

    Directory of Open Access Journals (Sweden)

    Galynker Igor I

    2009-05-01

    Full Text Available Abstract Background Because a large proportion of patients with panic attacks receiving approved pharmacotherapy do not respond or respond poorly to medication, it is important to identify additional therapeutic strategies for the management of panic symptoms. This article describes a randomized, rater-blind study comparing low-dose risperidone to standard-of-care paroxetine for the treatment of panic attacks. Methods Fifty six subjects with a history of panic attacks were randomized to receive either risperidone or paroxetine. The subjects were then followed for eight weeks. Outcome measures included the Panic Disorder Severity Scale (PDSS, the Hamilton Anxiety Scale (Ham-A, the Hamilton Depression Rating Scale (Ham-D, the Sheehan Panic Anxiety Scale-Patient (SPAS-P, and the Clinical Global Impression scale (CGI. Results All subjects demonstrated a reduction in both the frequency and severity of panic attacks regardless of treatment received. Statistically significant improvements in rating scale scores for both groups were identified for the PDSS, the Ham-A, the Ham-D, and the CGI. There was no difference between treatment groups in the improvement in scores on the measures PDSS, Ham-A, Ham-D, and CGI. Post hoc tests suggest that subjects receiving risperidone may have a quicker clinical response than subjects receiving paroxetine. Conclusion We can identify no difference in the efficacy of paroxetine and low-dose risperidone in the treatment of panic attacks. Low-dose risperidone appears to be tolerated equally well as paroxetine. Low-dose risperidone may be an effective treatment for anxiety disorders in which panic attacks are a significant component. Trial Registration ClinicalTrials.gov Identifier: NCT100457106

  14. Spectrophotometric estimation of risperidone in tablets.

    Science.gov (United States)

    Jayanna, B K; Devaraj, T D; Roopa, K P; Nagendrappa, G; Kumar, H R Arun; Gowda, N

    2014-09-01

    A simple, rapid and highly sensitive spectrophotometric method is developed for the determination of risperidone in tablet formulation. The method is based on the oxidation of drug using potassium permanganate in alkaline medium and excess potassium permanganate oxidizes 1,10-phenanthroline Fe(II). The measurement of decrease in absorbance of 1,10-phenanthroline Fe (II) was done at 415 nm. The beer's law is obeyed in the concentration range of 5.0 to 40.0 μg/ml and molar absorptivity is found to be 7.3932 × 10(4) l/mol/cm. The proposed method is well suited for the pharmaceutical formulations. PMID:25425761

  15. Spectrophotometric estimation of risperidone in tablets

    Directory of Open Access Journals (Sweden)

    B K Jayanna

    2014-01-01

    Full Text Available A simple, rapid and highly sensitive spectrophotometric method is developed for the determination of risperidone in tablet formulation. The method is based on the oxidation of drug using potassium permanganate in alkaline medium and excess potassium permanganate oxidizes 1,10-phenanthroline Fe(II. The measurement of decrease in absorbance of 1,10-phenanthroline Fe (II was done at 415 nm. The beer′s law is obeyed in the concentration range of 5.0 to 40.0 μg/ml and molar absorptivity is found to be 7.3932 × 10 4 l/mol/cm. The proposed method is well suited for the pharmaceutical formulations.

  16. Effects of Risperidone on Cognitive-Motor Performance and Motor Movements in Chronically Medicated Children

    Science.gov (United States)

    Aman, Michael G.; Hollway, Jill A.; Leone, Sarah; Masty, Jessica; Lindsay, Ronald; Nash, Patricia; Arnold, L. Eugene

    2009-01-01

    This study was designed to explore the placebo-controlled effects of risperidone on cognitive-motor processes, dyskinetic movements, and behavior in children receiving maintenance risperidone therapy. Sixteen children aged 4-14 years with disruptive behavior were randomly assigned to drug order in a crossover study of risperidone and placebo for 2…

  17. Adjunctive long-acting risperidone in patients with bipolar disorder who relapse frequently and have active mood symptoms

    Directory of Open Access Journals (Sweden)

    Haskins John T

    2011-10-01

    Full Text Available Abstract Background The objective of this exploratory analysis was to characterize efficacy and onset of action of a 3-month treatment period with risperidone long-acting injection (RLAI, adjunctive to an individual's treatment regimen, in subjects with symptomatic bipolar disorder who relapsed frequently and had significant symptoms of mania and/or depression. Methods Subjects with bipolar disorder with ≥4 mood episodes in the past 12 months entered the open-label stabilization phase preceding a placebo-controlled, double-blind study. Subjects with significant depressive or manic/mixed symptoms at baseline were analyzed. Significant depressive symptoms were defined as Montgomery-Åsberg Depression Rating Scale (MADRS ≥16 and Young Mania Rating Scale (YMRS t tests; categorical differences were assessed using Fisher exact test. No adjustment was made for multiplicity. Results 162 subjects who relapsed frequently met criteria for significant mood symptoms at open-label baseline; 59/162 (36.4% had depressive symptoms, 103/162 (63.6% had manic/mixed symptoms. Most subjects (89.5% were receiving ≥1 medication for bipolar disorder before enrollment. Significant improvements were observed for the total population on the CGI-BP-S, MADRS, and YMRS scales (p Conclusions Exploratory analysis of changes in overall clinical status and depression/mania symptoms in subjects with symptomatic bipolar disorder who relapse frequently showed improvements in each of these areas after treatment with RLAI, adjunctive to a subject's individualized treatment. Prospective controlled studies are needed to confirm these findings.

  18. The efficacy and safety of urethral injection therapy for urinary incontinence in women: a systematic review

    OpenAIRE

    Priscila Katsumi Matsuoka; Rafael Fagionato Locali; Aparecida Maria Pacetta; Edmund Chada Baracat; Jorge Milhem Haddad

    2016-01-01

    To evaluate the efficacy and safety of different bulking agents for treating urinary incontinence in women, a systematic review including only randomized controlled trials was performed. The subjects were women with urinary incontinence. The primary outcomes were clinical and urodynamic parameters. The results were presented as a weighted mean difference for non-continuous variables and as relative risk for continuous variables, both with 95% confidence intervals. Initially, 942 studies were ...

  19. RP-HPLC estimation of risperidone in tablet dosage forms

    Directory of Open Access Journals (Sweden)

    Bladania S

    2008-01-01

    Full Text Available A simple, specific, accurate, and precise reverse phase liquid chromatographic method was developed and validated for the estimation of risperidone in tablet dosage forms. A Phenomenex Gemini C-18, 5 µm column having 250x4.6 mm i.d. in isocratic mode, with mobile phase containing methanol: acetonitrile: 50 mM potassium dihydrogen orthophosphate (80:10:10 v/v was used. The flow rate was 1.3 ml/min and effluents were monitored at 234 nm. Clozapine was used as an internal standard. The retention time of risperidone and clozapine were 2.5 min and 3.3 min, respectively. The method was validated for linearity, accuracy, precision, specificity, limit of quantification, limit of detection, robustness and stability. The limit of detection and limit of quantification for estimation of risperidone was found to be 500 ng/ml and 990 ng/ml, respectively. Recovery of risperidone was found to be in the range of 99.02-101.68%. Proposed method was successfully applied for the quantitative determination of risperidone in tablet formulations.

  20. Efficacy and safety of motherwort injection and oxytocin in preventing postpartum hemorrhage after vaginal delivery: a Meta analysis

    Directory of Open Access Journals (Sweden)

    Lin-miao ZENG

    2015-11-01

    Full Text Available Objective To evaluate the clinical efficacy and safety of motherwort injection and oxytocin in preventing postpartum hemorrhage after vaginal delivery. Methods Data of randomly controlled trials (RCTs of motherwort injection and oxytocin in preventing postpartum hemorrhage after vaginal delivery were collected by searching PubMed (1980-2013.9, Wiley Online Library (1990-2013.9, Embase (1990-2013.9, CNKI (1990-2013.9, VIP database (1990-2013.9 and WanFang Data (1990-2013.9. The amount and incidence of postpartum hemorrhage and quantity of blood loss, as well as the incidence of postpartum morbidity were then collected in those puerperal women treated with motherwort injection and oxytocin. The quality of included studies was assessed according to Cochrane Systematic Review, and Meta-analysis was conducted by RevMan 5.1 software. Results A total of 13 studies involving 2186 patients were included. Compared with oxytocin group, motherwort and oxytocin decreased the amount of vaginal bleeding within 2 hours after delivery and 24 hours after delivery. Furthermore, motherwort and oxytocin significantly decreased the incidence of postpartum hemorrhage (RR=0.30, 95%CI 0.19-0.47, P<0.00001. No difference was found between the two groups in the postpartum adverse reaction rate (RR=0.63, 95%CI 0.37-1.05, P=0.08. Conclusions Motherwort injection and oxytocin are effective in preventing postpartum hemorrhage after vaginal delivery, and they can effectively reduce incidence of postpartum hemorrhage and the amount of blood loss without increasing the side effects in patients. DOI: 10.11855/j.issn.0577-7402.2015.10.11

  1. Factors associated with uptake, adherence, and efficacy of hepatitis C treatment in people who inject drugs: a literature review

    Directory of Open Access Journals (Sweden)

    Mravčík V

    2013-10-01

    Full Text Available Viktor Mravčík,1,2 Lisa Strada,3 Josef Štolfa,4,5 Vladimir Bencko,6 Teodora Groshkova,7 Jens Reimer,3 Bernd Schulte3 1National Monitoring Centre for Drugs and Drug Addiction, 2Department of Addictology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic; 3Centre for Interdisciplinary Addiction Research, University of Hamburg, Hamburg, Germany; 4Department of General Practice, Institute for Postgraduate Medical Education in Prague, 5Department of General Practice, Second Faculty of Medicine, 6Institute of Hygiene and Epidemiology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic; 7European Monitoring Centre for Drugs and Drug Addiction, Lisbon, Portugal Introduction and methods: Hepatitis C virus (HCV infections are highly prevalent amongst people who inject drugs (PWID. Despite well documented evidence of its effectiveness, suggested cost-effectiveness, and potential to reduce HCV prevalence rates, the uptake of antiviral HCV treatment by PWID is low. This nonsystematic literature review describes factors associated with the uptake, adherence, and efficacy of HCV treatment among PWID and discusses strategies to increase their uptake of treatment. Results: Low HCV treatment uptake among PWID is associated with a number of patient-related and provider-related barriers. Beliefs and fears about low efficacy and adverse effects on the patient’s part are common. A substantial number of factors are associated with the chaotic lifestyle and altered social functioning of PWID, which are often associated with decompensation or relapsing into drug addiction. This may lead to perceived low adherence with treatment and low efficacy on the provider’s part too, where lack of support, inadequate management of addiction, and other drug-related problems and poor treatment of side effects have been described. Practical issues such as the accessibility of treatment and finances also play a role

  2. Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis.

    Science.gov (United States)

    Braune, Stefan; Lang, M; Bergmann, A

    2016-02-01

    Although fingolimod is registered in Europe for treatment of relapsing-remitting multiple sclerosis (RRMS) if earlier disease modifying therapy (DMT) has failed, no data regarding its efficacy in this patient group are available. This observational cohort study of the NeuroTransData network includes German RRMS outpatients with failure of earlier therapy with injectable DMT (iDMT), therefore switching to either another iDMT (n = 133) or to fingolimod (n = 300). Statistical comparison of clinical baseline characteristics showed more severely affected patients in the fingolimod group. A propensity-score matched group comparison was performed (n = 99 in each group) covering more than 2-year observation time. Fingolimod showed statistically significant superior efficacy in comparison to iDMT regarding annualized relapse rate (0.21 versus 0.33 per year), time-to-relapse and likelihood of relapse (iDMT hazard ratio 1.7), proportion and likelihood of patients with EDSS progression (15.10 versus 31.00%; iDMT hazard ratio 1.7), persistence on medication and likelihood of discontinuation (iDMT hazard ratio 3.0). Significantly more patients were free of relapse and EDSS progression with fingolimod than with their second iDMT (64.4 versus 46.5%, p < 0.03). This real-life evidence in German RRMS outpatients support data from controlled clinical studies and can quantitatively support clinical decision finding processes if iDMT therapy fails in RRMS. PMID:26645389

  3. 氯硝西泮对偏执型精神分裂症的辅助治疗作用%An efficacy study of risperidone combined with clonazepam injection in the treatment of paranoid schizophrenia

    Institute of Scientific and Technical Information of China (English)

    王小全; 王晓峰; 周海晓

    2003-01-01

    目的:评价利培酮配合氯硝西泮注射液治疗偏执型精神分裂症的疗效.方法:对病程<3年的80例首次住院,选用利培酮治疗的偏执型精神分裂症患者,随机分为合用氯硝西泮(合用组)和未合用氯硝西泮(对照组)各40例,进行8周治疗.采用阳性症状与阴性症状量表(PANSS)评定疗效,副反应量表(TESS)评定不良反应.结果:合用组治疗2周后PANSS量表总分、阳性症状分、精神病理因子分及症状群中激活性、偏执、攻击性分值均显著下降;治疗4周末时利培酮剂量合用组显著低于对照组.结论:利培酮配合氯硝西泮注射液治疗偏执型精神分裂症可缩短疗程,改善其阳性症状及攻击行为.

  4. Olanzapine vs. Risperidone in Patients with First-Episode Schizophrenia and a Lifetime History of Cannabis Use Disorders: 16-Week Clinical and Substance Use outcomes

    OpenAIRE

    Sevy, Serge; Robinson, Delbert G.; Sunday, Suzanne; Napolitano, Barbara; Miller, Rachel; McCormack, Joanne; Kane, John M.

    2011-01-01

    The purpose of this study is to compare the efficacy of olanzapine and risperidone for the acute treatment of first-episode schizophrenia patients with cannabis use disorders. This secondary analysis of a previously published study included forty-nine first-episode patients with a diagnosis of schizophrenia, schizophreniform disorder, or schizoaffective disorder and a co-occurring lifetime diagnosis of cannabis use disorders randomly assigned to treatment with either olanzapine (n=28) or risp...

  5. Paliperidone palmitate injection for the acute and maintenance treatment of schizophrenia in adults

    Directory of Open Access Journals (Sweden)

    Kim S

    2012-07-01

    Full Text Available Shiyun Kim,1 Hugo Solari,2 Peter J Weiden,2 Jeffrey R Bishop11Department of Pharmacy Practice, University of Illinois at Chicago College of Pharmacy, 2Department of Psychiatry, University of Illinois at Chicago College of Medicine, Chicago, IL, USAPurpose: To review the use of paliperidone palmitate in treatment of patients with schizophrenia.Methods: Published clinical trial data for the development and utilization of paliperidone palmitate for the treatment of schizophrenia were assessed in this review. Four short-term, randomized, double-blind, placebo-controlled trials investigated the efficacy of paliperidone palmitate in acute exacerbation of schizophrenia. Paliperidone palmitate was also studied as a maintenance treatment to prevent or delay relapse in stable schizophrenia. In addition, paliperidone palmitate was compared to risperidone long-acting injection for noninferiority in three studies.Results: Paliperidone palmitate has been shown to be effective in reducing symptoms as measured by the Positive and Negative Syndrome Scale total scores in the four acute treatment studies. In the maintenance treatment studies, paliperidone palmitate was found to be more effective than placebo in preventing or delaying the time to first relapse in stable schizophrenia patients. In addition, paliperidone palmitate was shown to be noninferior to risperidone long-acting injection in two studies. It was shown to be reasonably well tolerated in all clinical trials. Acute treatment phase should be initiated with a dose of 234 mg on day one and 156 mg on day eight, followed by a recommended monthly maintenance dose of 39–234 mg based on efficacy and tolerability results from the clinical studies.Conclusion: Providing an optimal long-term treatment can be challenging. Paliperidone palmitate can be used as an acute treatment even in outpatient setting, and it has shown to be well tolerated by patients. Also, it does not require overlapping oral

  6. The efficacy and safety of urethral injection therapy for urinary incontinence in women: a systematic review

    Directory of Open Access Journals (Sweden)

    Priscila Katsumi Matsuoka

    2016-02-01

    Full Text Available To evaluate the efficacy and safety of different bulking agents for treating urinary incontinence in women, a systematic review including only randomized controlled trials was performed. The subjects were women with urinary incontinence. The primary outcomes were clinical and urodynamic parameters. The results were presented as a weighted mean difference for non-continuous variables and as relative risk for continuous variables, both with 95% confidence intervals. Initially, 942 studies were identified. However, only fourteen eligible trials fulfilled the prerequisites. Altogether, the review included 1814 patients in trials of eight different types of bulking agents, and all studies were described and analyzed. The measured outcomes were evaluated using a large variety of instruments. The most common complications of the bulking agents were urinary retention and urinary tract infection. Additionally, there were certain major complications, such as one case of death after use of autologous fat. However, the lack of adequate studies, the heterogeneous populations studied, the wide variety of materials used and the lack of long-term follow-up limit guidance of practice. To determine which substance is the most suitable, there is a need for more randomized clinical trials that compare existing bulking agents based on standardized clinical outcomes.

  7. Long-acting injectable antipsychotics: focus on olanzapine pamoate

    Directory of Open Access Journals (Sweden)

    JP Lindenmayer

    2010-05-01

    Full Text Available JP LindenmayerDepartment of Psychiatry, New York University School of Medicine, New York NY, USAAbstract: Medication non-adherence in patients with schizophrenia continues to be a significant problem and threatens successful treatment outcomes. Medication non-adherence is often associated with negative consequences, including symptom exacerbation, more frequent emergency room visits, re-hospitalizations and relapse. Long-acting injectable (LAI forms of antipsychotics allow for rapid identification of non-adherence, obviate the need for the patient to take the medication on a daily basis and increase adherence to some significant degree. Eli Lilly has developed a long-acting depot formulation of olanzapine, olanzapine pamoate, which has recently been approved by the FDA for the US market, and which will be reviewed here. Olanzapine LAI appears to be an effective antipsychotic at dosages of 210 mg every 2 weeks, 300 mg every 2 weeks and 405 mg every 4 weeks in patients with acute schizophrenia, and at 150 mg every 2 weeks, 300 mg every 2 weeks and at 405 mg every 4 weeks for the maintenance treatment of stable patients. Oral supplementation appears not to be needed, particularly not at the onset of treatment with the LAI as is necessary with risperidone LAI. Its efficacy is in general comparable to the efficacy seen with oral olanzapine at a corresponding dose. The side effect profile is also comparable to the side effects observed with oral olanzapine, including lower rates of extrapyramidal symptoms, prolactin elevation and cardiovascular side effects, but significant metabolic effects. The latter include significant weight gain, lipid abnormalities and glucose dysregulation. While the injection site adverse events are overall mild, the most significant serious adverse event is the post-injection delirium sedation syndrome (PDSS. While rare, this syndrome results from inadvertent intravascular injection of olanzapine LAI and can cause a range of

  8. Co-injection of a targeted, reversibly masked endosomolytic polymer dramatically improves the efficacy of cholesterol-conjugated small interfering RNAs in vivo.

    Science.gov (United States)

    Wong, So C; Klein, Jason J; Hamilton, Holly L; Chu, Qili; Frey, Christina L; Trubetskoy, Vladimir S; Hegge, Julia; Wakefield, Darren; Rozema, David B; Lewis, David L

    2012-12-01

    Effective in vivo delivery of small interfering (siRNA) has been a major obstacle in the development of RNA interference therapeutics. One of the first attempts to overcome this obstacle utilized intravenous injection of cholesterol-conjugated siRNA (chol-siRNA). Although studies in mice revealed target gene knockdown in the liver, delivery was relatively inefficient, requiring 3 daily injections of 50 mg/kg of chol-siRNA to obtain measurable reduction in gene expression. Here we present a new delivery approach that increases the efficacy of the chol-siRNA over 500-fold and allows over 90% reduction in target gene expression in mice and, for the first time, high levels of gene knockdown in non-human primates. This improved efficacy is achieved by the co-injection of a hepatocyte-targeted and reversibly masked endosomolytic polymer. We show that knockdown is absolutely dependent on the presence of hepatocyte-targeting ligand on the polymer, the cognate hepatocyte receptor, and the cholesterol moiety of the siRNA. Importantly, we provide evidence that this increase in efficacy is not dependent on interactions between the chol-siRNA with the polymer prior to injection or in the bloodstream. The simplicity of the formulation and efficacy of this mode of siRNA delivery should prove beneficial in the use of siRNA as a therapeutic.

  9. Dystonia with MPH/Risperidone Combined Therapy for ADHD.

    Science.gov (United States)

    Millichap, J Gordon; Yee, Michelle M

    2016-01-01

    Investigators from Child Neurology and Pediatrics, University of Texas Health Science Center, Houston, report extrapyramidal symptoms in a 13-year-old boy with a psychiatric history of schizophrenia, bipolar disorder, ADHD, and autism, responsive to combination risperidone, oxcarbazepine, and MPH. PMID:27004141

  10. Clinical efficacy of intra-articular injections in knee osteoarthritis: a prospective randomized study comparing hyaluronic acid and betamethasone

    Directory of Open Access Journals (Sweden)

    Trueba Davalillo CA

    2015-01-01

    Full Text Available Cesáreo Ángel Trueba Davalillo,1,2 Cesáreo Trueba Vasavilbaso,2 José Mario Navarrete Álvarez,2 Pilar Coronel Granado,3 Ozcar Alejandro García Jiménez,2 Mercedes Gimeno del Sol,3 Félix Gil Orbezo2 1School of Medicine (UNAM, México DF, Mexico; 2Orthopedic Service, Hospital Español de México, México DF, Mexico; 3Scientific Department, TEDEC-MEIJI FARMA,SA, Alcalá de Henares, Spain Background: Osteoarthritis (OA is the most common joint disease and leading cause of disability. Intra-articular (IA administration of hyaluronic acid (HA or corticosteroids (CS have been previously studied, though using insufficient number of patients or short follow-up periods.Objective: We evaluate HA and CS in patients with knee OA in terms of clinical efficacy over 12 months.Methods: We used a prospective, randomized study with parallel groups. Randomized patients received IA injections of HA or betamethasone (BM. The primary outcomes were improvement in pain using Visual Analog Scale and function in the Western Ontario and McMaster University Osteoarthritis Index (Likert scale. Follow-up visits were scheduled at 3 months, 6 months, 9 months, and 12 months.Results: A total of 200 patients were included. Pain was significantly reduced in both groups at the first follow-ups. At 12 months, the mean pain reduction in the HA group was 33.6% (95% CI: 31.1–36.1 compared to 8.2% (95% CI: 5.2–11.1 in BM (P<0.0001. Function improvement was higher in HA through every visit, and mean improvement at 12 months was 47.5% (95% CI: 45.6–49.3 in HA patients vs 13.2% (95% CI: 11.4–14.9 in the BM group (P<0.0001. All patients from both groups achieved the Minimal Clinically Important Improvement (MCII for both pain and function up to 6 months. At 9 months and 12 months, the MCII figures were higher in HA group with ≥80% compared to ≤10% in BM group (P<0.0001. Adverse reactions were rare and related to the administration procedure.Conclusion: Both treatments

  11. Clinical efficacy of intra-articular injections in knee osteoarthritis: a prospective randomized study comparing hyaluronic acid and betamethasone

    Science.gov (United States)

    Trueba Davalillo, Cesáreo Ángel; Trueba Vasavilbaso, Cesáreo; Navarrete Álvarez, José Mario; Coronel Granado, Pilar; García Jiménez, Ozcar Alejandro; Gimeno del Sol, Mercedes; Gil Orbezo, Félix

    2015-01-01

    Background Osteoarthritis (OA) is the most common joint disease and leading cause of disability. Intra-articular (IA) administration of hyaluronic acid (HA) or corticosteroids (CS) have been previously studied, though using insufficient number of patients or short follow-up periods. Objective We evaluate HA and CS in patients with knee OA in terms of clinical efficacy over 12 months. Methods We used a prospective, randomized study with parallel groups. Randomized patients received IA injections of HA or betamethasone (BM). The primary outcomes were improvement in pain using Visual Analog Scale and function in the Western Ontario and McMaster University Osteoarthritis Index (Likert scale). Follow-up visits were scheduled at 3 months, 6 months, 9 months, and 12 months. Results A total of 200 patients were included. Pain was significantly reduced in both groups at the first follow-ups. At 12 months, the mean pain reduction in the HA group was 33.6% (95% CI: 31.1–36.1) compared to 8.2% (95% CI: 5.2–11.1) in BM (P<0.0001). Function improvement was higher in HA through every visit, and mean improvement at 12 months was 47.5% (95% CI: 45.6–49.3) in HA patients vs 13.2% (95% CI: 11.4–14.9) in the BM group (P<0.0001). All patients from both groups achieved the Minimal Clinically Important Improvement (MCII) for both pain and function up to 6 months. At 9 months and 12 months, the MCII figures were higher in HA group with ≥80% compared to ≤10% in BM group (P<0.0001). Adverse reactions were rare and related to the administration procedure. Conclusion Both treatments effectively controlled OA symptoms. BM showed higher short-term effectiveness, while HA showed better long-term effectiveness, maintaining clinical efficacy in a large number of patients 1 year after administration.

  12. Efficacy of perioperative parecoxib injection on postoperative pain relief after laparoscopic cholecystectomy: A prospective,randomized study

    Institute of Scientific and Technical Information of China (English)

    Thawatchai Akaraviputh; Charay Leelouhapong; Varut Lohsiriwat; Somkiat Aroonpruksakul

    2009-01-01

    AIM: To determine the efficacy of perioperative parecoxib injection on postoperative pain relief after laparoscopic cholecystectomy.METHODS: A prospective, double-blind, randomized,placebo-controlled study was conducted on 70 patients who underwent elective laparoscopic cholecystectomy under general anesthesia at Siriraj Hospital, Bangkok,from January 2006 to December 2007. Patients were randomized to receive either 20 mg parecoxib infusion 30 min before induction of anesthesia and at 12 h after the first dose (treatment group), or normal saline infusion, in the same schedule, as a placebo (control group). The degree of the postoperative pain was assessed every 3 h in the first 24 h after surgery, and then every 12 h the following day, using a visual analog scale. The consumption of analgesics was also recorded.RESULTS: There were 40 patients in the treatment group, and 30 patients in the control group. The pain scores at each time point, and analgesic consumption did not differ between the two groups. However,there were fewer patients in the treatment group than placebo group who required opioid infusion within the first 24 h (60% vs 37%, P = 0.053).

  13. Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany.

    Science.gov (United States)

    Laux, Gerd; Heeg, Bart; van Hout, Ben A; Mehnert, Angelika

    2005-01-01

    Schizophrenia is one of the most expensive psychiatric conditions because of high direct and indirect costs associated with the nature of the illness, its resistance to treatment and the consequences of relapse. Long-acting risperidone is a new formulation of an atypical antipsychotic drug that also offers the improvements in compliance associated with haloperidol depot. The aim of this simulation study was to compare the benefits and costs of three pharmacological treatment strategies comprising first-line treatment with long-acting risperidone injection, a haloperidol depot or an oral atypical antipsychotic agent, over a 5-year period in Germany. A discrete event simulation model was developed to compare three treatment scenarios from the perspective of major third-party payers (sickness funds and social security 'Sozialversicherung'). The scenarios comprised first-line treatment with haloperidol depot (scenario 1), long-acting risperidone (scenario 2) and oral olanzapine (scenario 3). Switches to second or third-line options were allowed when side-effects occurred or a patient suffered more than a fixed number of relapses. The model accounted for fixed patient characteristics, and on the basis of these, simulated patient histories according to several time-dependent variables. The time horizon for this model was limited to 5 years, and in accordance with German guidelines, costs and effects were discounted by between 3 and 10%. Direct costs included medication, type of physician visits and treatment location. Indirect costs were not included. Information on treatment alternatives, transition probabilities, model structure and healthcare utilization were derived from the literature and an expert panel. Outcomes were expressed in terms of the number and duration of psychotic episodes, cumulative symptom scores, costs, and quality-adjusted life-years (QALY). Univariate sensitivity analyses were carried out, as were subgroup analyses based on disease severity and

  14. A brief review on the efficacy of different possible and nonpharmacological techniques in eliminating discomfort of local anesthesia injection during dental procedures

    Science.gov (United States)

    Davoudi, Amin; Rismanchian, Mansour; Akhavan, Ali; Nosouhian, Saeid; Bajoghli, Farshad; Haghighat, Abbas; Arbabzadeh, Farahnaz; Samimi, Pouran; Fiez, Atiyeh; Shadmehr, Elham; Tabari, Kasra; Jahadi, Sanaz

    2016-01-01

    Dental anxiety and fear of needle injection is one of the most common problems encountered by dental practitioners, especially in the pediatric patient. In consequences, it might affect the patient's quality of life. Several methods are suggested to lower the discomfort of local anesthesia injection during dental procedures. Desensitization of injection site is one of the recommended strategies. Among chemical anesthetic topical agents that are effective but might have allergic side effects, using some nonpharmacological and safe techniques might be useful. This study aimed to overview the efficacy of using cooling techniques, mostly by ice or popsicles, warming or pH buffering of drug, and using modern devices to diminish the discomfort of local anesthesia injection during dental procedures. PMID:26957683

  15. A comparative study between risperidone and ritalin in the treatment of attention deficit hyperactivity disorder%利培酮治疗注意缺陷障碍对照观察

    Institute of Scientific and Technical Information of China (English)

    兰利明; 薛漳

    2001-01-01

    目的:观察小剂量利培酮治疗注意缺陷障碍(ADHD) 的疗效和安全性。 方法:前瞻性研究,以利他林作为对照,采用 康纳多动症评定量表及不良反应症状量表(TESS)评定,观察4周。 结果:利培酮有效率为77%,利他林为78%;未见锥体外系副反应。 结论:利培酮与利他林的疗效相似,小剂量使用时安全有效。%Objective:To observe the efficacy and security of small doses risperidone in the treatment of attention deficit hyperactivity diso rder(ADHD). Method:Compared with ritalin group,the patients wer e treated with small doses risperidone for 4 weeks.Conner hyperactivety rating s cale (CHRS) and the treatment emergent symptom scale (TESS) were completed by th em. Results:The efficacy rate in risperidone group was 77%, a nd in ritalin group was 78%. No extrapyramidal side effect was found. C onclusion:It suggests that small doses risperidone is effective and safe in the treatment of ADHD, being similar to ritalin.

  16. Multiple dose pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female patients with schizophrenia

    Institute of Scientific and Technical Information of China (English)

    Zhi-ling ZHOU; Qiu-xiong LIN; Chuan-yue WANG; Wen-biao LI; Shu-guang LIN; Huan-de LI; Xin LI; Huai-yan PENG; Xi-yong YU; Ming YANG; Feng-li SU; Feng WANG; Rong-hua ZHU; Chun-yu DENG

    2006-01-01

    Aim: To study the multiple dose clinical pharmacokinetics of risperidone and its main active metabolite, 9-hydroxyrisperidone, in Chinese female patients with schizophrenia. Methods: The subjects were 23 Chinese female inpatients aged 18-65 years who met the CCMD-Ⅲ (third revision of the Chinese Criteria of Mental Disorders) criteria for schizophrenia. Subjects were tested after 17 d of treatment with 2 mg risperidone twice daily. Plasma concentrations of risperidone and 9-hydroxy-risperidone were assayed by using validated high performance liquid chromatography-mass spectrometry (HPLC-MS) methods. Results: Risperidone was rapidly absorbed (Tmax was 1.6 h) and its Tin in plasma was short (3.2 h).9-hydroxy-risperidone was quickly metabolized from the parent drug with a mean Tmax of 2.5 h. It had a long half-life of 24.7 h. The Cssav of risperidone and 9-hydroxyrisperidone were 36.9±33.1 and 110.6±30.5 μg·h·L-1, respectively, and the AUCss0-12 were 443.2±397.4 and 1327.2±402.3 μg·h·L-1, respectively. CL/F and V/F of risperidone were 8.7±6.2 L/h and 34.1±24.3 L, respectively. Interindividual variations for pharmacokinetic parameters were quite large for risperidone. All 23 subjects experienced high prolactin levels when treated with risperidone. However there was no correlation between prolactin level and the concentration of risperidone, 9-hydroxy-risperidone, or the active moiety. Conclusion: Risperidone showed large interindividual variations in pharmacokinetics. Administration of risperidone resulted in high serum prolactin levels. The results indicate that systemic exposure to risperidone and 9-hydroxy-risperidone in female Chinese schizophrenic patients is higher relative to published data for white Caucasian patients. Larger studies regarding the PK/PD relationship may be required to develop a reasonable clinical dosage regimen for Chinese female patients.

  17. Controlled clinical treatment of the domestic Ziprasidone and risperidone%国产齐拉西酮与维思通的临床对照治疗

    Institute of Scientific and Technical Information of China (English)

    李永强; 冯金河

    2013-01-01

    Objective:comparison curative effect and untoward effect between Ziprasidone and risperidone. Methods:Sixty patients with schizophrenia were randomly divided into two groups: thirty patients were in Ziprasidone's group and the other thirty patients were in risperidone's group, after treatment for six weekends, used positive and negative symptom scale (PANSS) and treatment emergent symptoms scale (TESS) to evaluate the efficacy. Results: Ziprasidone and risperidone have equal therapy, but the incidence of adverse reaction and symptom severity of Ziprasidone was significantly lower than risperidone, especially, Ziprasidone has a small influence in mammotropic hormone and weight. Conclusion: Ziprasidone for schizophrenia have a good efficacy, few untoward effects and good compliance.%目的对比国产齐拉西酮与维思通的疗效和不良反应。方法对60例精神分裂症患者随机分为国产齐拉西酮组30例和维思通组30例,进行相应的药物治疗,疗程6周,采用PANSS量表和TESS副反应量表进行评价。结果国产齐拉西酮和维思通疗效相当,但国产齐拉西酮的不良反应发生率和症状严重程度显著低于维思通,特别对催乳素和体重的影响明显较小,同时具有良好的依从性。结论国产齐拉西酮治疗精神分裂症疗效确切,不良反应少,依从性好。

  18. Clinical result of intra-arterial lymphocyte injection therapy for treatment of lymphedema and the evaluation of the efficacy of the therapy. Quantitative analysis by an injection of {sup 111}In-labeled lymphocytes and by MR imaging

    Energy Technology Data Exchange (ETDEWEB)

    Yoshizumi, Masanori; Kitagawa, Tetsuya; Hori, Takaki; Katoh, Itsuo; Harada, Masashi; Matsumoto, Takahiro; Nishitani, Hiromu [Tokushima Univ. (Japan). School of Medicine

    1995-11-01

    We have employed the intra-arterial lymphocytes injection therapy for treatment of lymphedema of the limbs with various causes. In the present study, we observed the clinical outcome of our therapy in 38 patients with lymphedema of the limbs. Results showed that the therapy was effective in 26 of 38 patients (68% of the total). Moreover, a marked efficacy was obtained in 13 of 38 patients (34% of the total). In the latest 5 patients, to evaluate the efficacy of our therapy, we examined the distribution of the {sup 111}In-oxine labeled lymphocytes injected into the proximal artery of the affected limb. The radioactivities of the affected limbs were apparently higher than that of the healthy limbs in effective cases. Moreover, MR imaging showed that the reduction of STIR ratio and T{sub 2} ratio well correlate with the results of clinical course. Thus, the efficacy of the lymphocyte injection therapy is able to be evaluated by radiolabeled lymphocytes and MR imaging. (author).

  19. Peripheral Edema Occurring during Treatment with Risperidone Combined with Citalopram

    OpenAIRE

    Seyed Hamzeh Hosseini; Amirhossein Ahmadi

    2012-01-01

    An 80-year-old female presented with symptoms of depression, worthlessness, hopelessness, loss of energy, insomnia, impatience, and forgetfulness associated with persecutory delusion that had begun about one year before her visit. She was diagnosed with major depression with psychotic signs and began treatment with risperidone (2 mg/night) and citalopram (20 mg/day). After 20 days, she returned and reported partial improvement in her symptoms, although she had developed severe swelling of the...

  20. Idiopathic granulomatous mastitis associated with risperidone-induced hyperprolactinemia

    OpenAIRE

    Lin Chih-Hsun; Hsu Chih-Wei; Tsao Tang-Yi; Chou Jason

    2012-01-01

    Abstract Idiopathic granulomatous mastitis (IGM) is a rare inflammatory breast disease. The etiology and treatment options of IGM remain controversial. Previous case reports have suggested that hyperprolactinemia may be associated with IGM. In the present report, we describe the first case of IGM associated with risperidone-induced hyperprolactinemia. Virtual slides The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/8120093785928228

  1. Adjunctive Aripiprazole Treatment for Risperidone-Induced Hyperprolactinemia: An 8-Week Randomized, Open-Label, Comparative Clinical Trial.

    Directory of Open Access Journals (Sweden)

    Jingyuan Zhao

    Full Text Available The present study aimed to evaluate the efficacy and safety of adjunctive aripiprazole treatment in schizophrenia patients with risperidone-induced hyperprolactinemia.One hundred and thirteen patients who were receiving a stable dose of risperidone were randomly assigned to either adjunctive aripiprazole treatment (10 mg/day (aripiprazole group or no additional treatment (control group at a 1:1 ratio for 8 weeks. Schizophrenia symptoms were measured using the Positive and Negative Syndrome Scale (PANSS. Rating scales and safety assessments (RSESE, BARS, UKU were performed at baseline and at weeks 4 and 8. Serum levels of prolactin were determined at baseline and at weeks 2, 4, 6 and 8. Metabolic parameters were determined at baseline and again at weeks 4 and 8.One hundred and thirteen patients were enrolled in this study, and 107 patients completed the study (54 in the aripiprazole group, and 53 in the control group. PANSS-total scores in the aripiprazole group decreased significantly at week 4 (P = 0.003 and week 8 (P = 0.007 compared with the control group. PANSS-negative scores in the aripiprazole group also decreased significantly at week 4 (P = 0.005 and week 8 (P< 0.001 compared with the control group. Serum levels of prolactin in the aripiprazole group decreased significantly at week 2 (P< 0.001, week 4 (P< 0.001, week 6 (P< 0.001 and week 8 (P< 0.001 compared with the control group. There were no significant differences in changes of Fasting Plasma Glucose, Total cholesterol, Triglycerides and High Density Lipoprotein within each group at week 4 and 8 execpt low density lipoproteins. There was no significant difference in the incidence of adverse reactions between the two groups.Adjunctive aripiprazole treatment may be beneficial in reducing serum levels of prolactin and improving negative symptoms in schizophrenia patients with risperidone-induced hyperprolactinemia.chictr.org ChiCTR-IOR-15006278.

  2. Potential bias in testing for hyperprolactinemia and pituitary tumors in risperidone-treated patients: a claims-based study

    OpenAIRE

    Wu Jasmanda; Mahmoud Ramy; Pandina Gahan; Gianfrancesco Frank D; Wang Ruey H

    2009-01-01

    Abstract Background A reporting association of risperidone with pituitary tumors has been observed. Because such tumors are highly prevalent, there may be other reasons why they were revealed in association with risperidone treatment. We assessed two potential explanations: disproportionately more prolactin assessment and head/brain imaging in risperidone-treated patients vs patients treated with other antipsychotics. Methods Treatment episodes with risperidone, clozapine, olanzapine, quetiap...

  3. Ultrasound-guided retro-calcaneal bursa corticosteroid injection for refractory Achilles tendinitis in patients with seronegative spondyloarthropathy: efficacy and follow-up study.

    Science.gov (United States)

    Srivastava, Puja; Aggarwal, Amita

    2016-06-01

    Ultrasound (US)-guided corticosteroid injection has been shown to be safe and effective for varied causes of plantar fasciitis; however, its use for Achilles tendinitis is controversial. We studied the efficacy and changes in US findings at Achilles enthesitis after corticosteroid injection in patients with spondyloarthropathy (SpA). Patients with SpA with symptomatic Achilles enthesitis, refractory to 6 weeks of full-dose NSAIDs, were offered US-guided local corticosteroid injection. Injected entheses were examined by US (both B mode and power Doppler) at baseline and 6 weeks after injection. Standard OMERACT definitions were used to define enthesitis. Achilles tendon thickness >5.29 mm, 2 cm proximal to insertion in long axis, was considered thickened. Twenty-seven symptomatic Achilles tendons (in 18 patients) were injected with 20 mg methylprednisolone under US guidance baseline, and 6-week follow-up US features were compared. All patients reported improvement in pain (VAS) in the affected tendon after injection (p < 0.0001). Simultaneously, improvement in local inflammatory changes were noted, in the form of significant reduction in tendon thickness (p < 0.0001), vascularity (p < 0.0001), peritendinous oedema (p = 0.001), bursitis and bursal vascularity (p < 0.001 and < 0.0001, respectively). There was no change in bone erosions and enthesophyte. None of the patients had tendon rupture or other injection-related complications at 6 weeks of follow-up. US-guided local corticosteroid injection is an effective and safe modality for refractory Achilles enthesitis in patients with SpA and leads to reversion of acute changes at entheseal site. PMID:26894910

  4. 利培酮合并氯氮平治疗难治性精神分裂症对照研究%Comparative Study on Risperidone Combined Clozapine and Risperidone in the Treatment of Refractory Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    高亚娇; 安红伟; 靳红强

    2011-01-01

    Objective To compare the efficacy and safety of clozapine combined with risperidone in the treatment of refractory schizophrenia. Methods 63 cases were divided into two groups randomly,32 cases of treatment-refractory schizophrenia were treated with risperidone combined clozapine( the treatment group ) and 31 cases were treated with risperidone( the control group ). The clinical effect of patients were measured with positive and negative symptoms scale( PANSS ), and side effects were assessed with treatment emergent symptoms scale( TESS )respectively before and after 4,8,12 week treatment. Results There were significant differences in the curative effect between the two groups( P <0.05 ). After eight weeks treatment, total score of PANSS in two groups were much lower than before,the treatment group had greater decreases. After twelve weeks treatment,total score of PANSS in the treatment group was lower than that in the control group. There were statistical differences between the two groups( P <0. 05 ). Conclusion Clozapine combined with risperidone has curative effect affirmation to treat TRS,this deserves utilization in the clinical area.%目的 探讨利培酮联合氯氮平治疗难治性精神分裂症(TRS)的疗效及安全性.方法 将63例TRS患者随机分为利培酮合并氯氮平组(治疗组)32例和利培酮组(对照组)31例,两组治疗后4、8、12周均以阳性与阴性症状量表(PANSS)评定疗效,治疗意外症状量表(TESS)评定不良反应.结果 治疗组和对照组治疗TRS的疗效比较差异有统计学意义(P<0.05).治疗后8周,两组PANSS总分均较治疗前下降,治疗组下降更明显.两组治疗12周后PANSS总分比较,治疗组明显低于对照组,差异有统计学意义(P<0.05).结论 利培酮联合氯氮平治疗TRS的疗效肯定,值得临床应用.

  5. Adjunctive treatment with aripiprazole for risperidone-induced hyperprolactinemia

    Directory of Open Access Journals (Sweden)

    Ranjbar F

    2015-03-01

    Full Text Available Fatemeh Ranjbar,1 Homayoun Sadeghi-Bazargani,2,3 Parisa Niari Khams,1 Asghar Arfaie,1 Azim Salari,4 Mostafa Farahbakhsh1 1Clinical Psychiatry Research Center, Tabriz University of Medical Sciences, Tabriz, East Azerbaijan, Iran; 2Road Traffic Injury Research Center, Department of Statistics & Epidemiology, Tabriz University of Medical Sciences, Tabriz, Iran; 3World Health Organization Collaborating Center on Community Safety Promotion, Karolinska Institute, Stockholm, Sweden; 4Emam Khomeini Hospital, Naghadeh, West Azerbaijan, Iran Background: Antipsychotics have been used for more than 50 years in the treatment of schizophrenia and many other psychiatric disorders. Prolactin levels usually increase in patients treated with risperidone. Aripiprazole, which has a unique effect as an antipsychotic, is a D2 receptor partial agonist. It is an atypical antipsychotic with limited extrapyramidal symptoms. Since it acts as an antagonist in hyperdopaminergic conditions and as an agonist in hypodopaminergic conditions, it does not have adverse effects on serum prolactin levels. The present study aimed to investigate the effect of aripiprazole on risperidone-induced hyperprolactinemia. Methods: This before-and-after clinical trial was performed in 30 patients. Baseline prolactin levels were measured in all patients who were candidates for treatment with risperidone. In subjects with elevated serum prolactin, aripiprazole was added to their treatment. Serum prolactin levels were measured during the first week, second week, and monthly thereafter for at least 3 months or until prolactin levels became normal. The data were analyzed using Stata version 11 software. Survival analysis and McNemar’s test were also performed. Results: The mean age of the participants was 30.8 years. Prolactin levels normalized in 23 (77% participants during the study, and menstrual disturbances normalized in 25 (83.3%. Prolactin levels normalized in most patients between days 50

  6. Prolactin release in children treated with risperidone: impact and role of CYP2D6 metabolism.

    NARCIS (Netherlands)

    Troost, P.W.; Lahuis, B.E.; Hermans, M.H.; Buitelaar, J.K.; Engeland, H. van; Scahill, L.; Minderaa, R.B.; Hoekstra, P.J.

    2007-01-01

    OBJECTIVE: Little is known about the role of CYP2D6 polymorphism in risperidone-induced prolactin release in children. METHOD: Twenty-five children (aged 5-15 years) with pervasive developmental disorders were genotyped for CYP2D6 polymorphisms. Serum prolactin, risperidone, and 9-hydroxyrisperidone

  7. Prolactin release in children treated with risperidone - Impact and role of CYP2D6 metabolism

    NARCIS (Netherlands)

    Troost, Pieter W.; Lahuis, Bertine E.; Hermans, Mirjam H.; Buitelaar, Jan K.; van Engeland, Herman; Scahill, Lawrence; Minderaa, Ruud B.; Hoekstra, Pieter J.

    2007-01-01

    Objective: Little is known about the role of CYP2136 polymorphism in risperidone-induced prolactin release in children. Method: Twenty-five children (aged 5-15 years) with pervasive developmental disorders were genotyped for CYP2D6 polymorphisms. Serum prolactin, risperidone, and 9-hydroxyrisperidon

  8. The Efficacy of Botulinum Toxin Type a Injection in the Hamstring and Calf Muscles With and Without Serial Foot Casting in Gait Improvement in Children With Cerebral Palsy

    Directory of Open Access Journals (Sweden)

    Shamsodini A

    2011-11-01

    Full Text Available Background: The goal of this study was to compare the efficacy of botulinum toxin type A (BTX-A injection in the hamstring and calf muscles with and without ankle serial casting in the improvement of gait in children with cerebral palsy (CP.Methods : This double-blind prospective clinical trial was performed on 25, 2 to 8-year-old children with hemiplegic or diplegic CP in Tehran, Iran in 2010. The participants were chosen by simple randomized sampling and were matched for age, gross motor function classification system (GMFCS and type of CP and were randomly divided into two groups: children in the first group (13 only received BTX-A injection, but the second group (12 received BTX-A and serial foot casting starting one week after the injection.Results : Comparison of the gross motor function, right and left knee spasticities and passive ROM of both knees between the two groups before and 1, 3, 6 and 12 months after the injections were not statistically significant (P>0.1. Furthermore, comparison of the right and left ankle spasticities and passive ROM before the injections and in1 and 3-month follow-ups did not show a statistically significant difference (P>0.1, but the differences were significant in 6 and 12-month follow-ups (P<0.05.Conclusion: BTX-A injection with serial foot casting vs. BTX-A alone was more effective in decreasing spasticity and improving passive ROM in the ankle of children with CP, but such injections in the hamstrings were not useful in these regards.

  9. Efficacy and safety of cross-linked hyaluronic acid single injection on osteoarthritis of the knee: a post-marketing phase IV study

    Directory of Open Access Journals (Sweden)

    Bashaireh K

    2015-04-01

    Full Text Available Khaldoon Bashaireh,1 Ziad Naser,2 Khaled Al Hawadya,2 Sorour Sorour,2 Rami Nabeel Al-Khateeb3 1Department of Orthopedics Surgery, King Abdullah University Hospital, Jordan University of Science and Technology, Irbid, Jordan; 2Private Clinic, 3Elaf Medical Supplies Company, Amman, Jordan Purpose: The primary objective of this study was to evaluate the efficacy, safety, and duration of action of viscosupplementation with Crespine® Gel over a 9-month period.Materials and methods: The study was a post-marketing phase IV study. A total of 109 participants with osteoarthritis of the knee (grades 1–4 in the tibio–femoral compartment were recruited in Jordan. Data were collected from each participant during the baseline visit. Each participant received Crespine® Gel injection, and follow-up visits took place at 3 months, 6 months, and 9 months post-injection.Main outcome measure(s: An assessment of participants by phone was conducted at 1 month, 2 months, 4 months, 5 months, 7 months, and 8 months post-injection. Western Ontario and McMaster Universities Arthritis Index questionnaires were completed during each visit. A 72-hour visit questionnaire was used to assess the safety of the injection. Statistical analysis included a two-sided 95% confidence interval for the difference between pain scores across visits, and the percent change from baseline was calculated.Main results: The full analysis included 84 participants who gave their informed consent and finished the necessary baseline and follow-up visits needed to assess efficacy and safety. Peak improvement was noted at 5 months post-injection, when pain and physical performance scores had decreased to 2.60 and 9.90, respectively, and the stiffness score was 0.33. The peak improvement in stiffness was noted at 8 months post-injection, when the stiffness score had decreased to 0.32. Significant improvements were still apparent at 9 months post-injection, when the pain score was 3

  10. Comparison of Hemostatic Efficacy of Argon Plasma Coagulation with and without Distilled Water Injection in Treating High-Risk Bleeding Ulcers

    Directory of Open Access Journals (Sweden)

    Yuan-Rung Li

    2014-01-01

    Full Text Available Background. Argon plasma coagulation (APC is useful to treat upper gastrointestinal bleeding, but its hemostatic efficacy has received little attention. Aims. This investigation attempted to determine whether additional endoscopic injection before APC could improve hemostatic efficacy in treating high-risk bleeding ulcers. Methods. From January 2007 to April 2011, adult patients with high-risk bleeding ulcers were included. This investigation compared APC plus distilled water injection (combined group to APC alone for treating high-risk bleeding ulcers. Outcomes were assessed based on initial hemostasis, surgery, blood transfusion, hospital stay, rebleeding, and mortality at 30 days posttreatment. Results. Totally 120 selected patients were analyzed. Initial hemostasis was accomplished in 59 patients treated with combined therapy and 57 patients treated with APC alone. No significant differences were noted between these groups in recurred bleeding, emergency surgery, 30-day mortality, hospital stay, or transfusion requirements. Comparing the combined end point of mortality plus the failure of initial hemostasis, rebleeding, and the need for surgery revealed an advantage for the combined group (P=0.040. Conclusions. Endoscopic therapy with APC plus distilled water injection was no more effective than APC alone in treating high-risk bleeding ulcers, whereas combined therapy was potentially superior for patients with poor overall outcomes.

  11. A prospective, comparative, evaluator-blind clinical study investigating efficacy and safety of two injection techniques with Radiesse ® for the correction of skin changes in aging hands

    Directory of Open Access Journals (Sweden)

    Elena I Gubanova

    2015-01-01

    Full Text Available Background: Dermal fillers are used to correct age-related changes in hands. Aims: Assess efficacy and safety of two injection techniques to treat age-related changes in the hands using calcium hydroxylapatite filler, Radiesse ® . Settings and Design: This was a prospective, comparative, evaluator-blind, single-center study. Materials and Methods: Radiesse ® (0.8 mL/0.2 mL 2% lidocaine was injected subdermally on Day (D01, using a needle multipoint technique in one hand (N and a fan-like cannula technique in the other (C. Assessments were made pre-injection, on D14, Month (M02, M03 and M05 using the Merz Aesthetics Hand Grading Scale (MAS and Global Aesthetic Improvement Scale (GAIS. Participants completed questionnaires on satisfaction, pain and adverse events (AEs. Statistical Analysis Used: Data distribution was tested with the Shapiro-Wilk and Levene′s tests. The Wilcoxon signed-rank and Chi-square tests were employed to evaluate quantitative and qualitative data, respectively. Results: All 10 participants completed the study, four opted for a M03 touch-up (0.8 mL Radiesse ® . Evaluator-assessed mean GAIS scores were between 2 (significant improvement but not complete correction and 3 (optimal cosmetic result at each time point. The MAS score improved from D01 to M05 (N: 2.60 to 1.40; C: 2.20 to 1.30. Following treatment, participants reported skin was softer, more elastic, more youthful and less wrinkled. Other than less noticeable veins and tendons on the C hand, no differences in participant satisfaction were noted. All AEs were mild, with no serious AEs reported. Conclusions: Both injection techniques (needle and cannula demonstrated equivalent clinical efficacy with a comparable safety profile for the correction of age-related changes in hands with Radiesse ® .

  12. 利培酮与氯氮平治疗精神分裂症对照研究%Effect of risperidone and clozapine on the treatment of schizophrenia

    Institute of Scientific and Technical Information of China (English)

    李月霞

    2009-01-01

    目的 比较利培酮和氯氮平治疗精神分裂症的疗效和不良反应.方法 将40例精神分裂症患者随机分成两组,利培酮组和氯氮平组各20例,于治疗前和治疗第2、4、6周末采用症状量表(PANSS)及副反应量表(TESS)评定疗效及不良反应.结果 两组PANSS减分率比较差异无统计学意义(P>0.05),利培酮组不良反应少.结论 利培酮与氯氮平治疗精神分裂症疗效相当,但利培酮不良反应少.%Objective To comparie effect of risperidone and clozapine on the treatment of schizophrenia and adverse reactions. Methods 40 cases were randomly divided into two groups of patients with schizophrenia, risperi-done and clozapine group 20 cases, pre-treatment and treatment in the first weekend 2,4,6 Symptom Rating Scale (PANSS) and the reaction volume Table (TESS) were used to assess the efficacy and adverse reactions. Results Comparison of reduction rate PANSS, there was no significant difference(P > 0. 05), compared with clozapine group, risperidone group had less adverse reactions. Conclusion Risperidone and clozapine group had considerable effect in the treatment of schizophrenia, but risperidone had fewer adverse reactions.

  13. Effectiveness of Risperidone Augmentation in Obsessive-Compulsive Disorder: Experience From a Specialty Clinic in India.

    Science.gov (United States)

    Hegde, Aditya; Kalyani, Bangalore G; Arumugham, Shyam Sundar; Narayanaswamy, Janardhanan C; Math, Suresh Bada; Reddy, Y C Janardhan

    2016-08-01

    Risperidone is the most widely used augmenting agent in the treatment of obsessive-compulsive disorder (OCD). However, a recent controlled study found risperidone to be no different from placebo, raising doubts about its effectiveness. In this context, we sought to examine the real-world effectiveness of risperidone from the large database of an OCD clinic in India. A total of 1314 consecutive patients who registered at the OCD clinic between 2004 and 2014 were evaluated with structured interviews and scales. Patients with OCD initiated on risperidone augmentation without concurrent cognitive behavior therapy and who were on stable and adequate doses of serotonin reuptake inhibitors for at least 12 preceding weeks were included for analysis. The primary outcome measure was all-cause discontinuation. Logistic regression was performed to identify the factors predicting improvement with risperidone augmentation. A total of 92 patients were eligible for analysis. Risperidone continued to be used in 23 patients (25%) at the time of last follow-up, and the remaining discontinued either because of ineffectiveness or intolerability. The fall in the Yale-Brown Obsessive-Compulsive Scale scores was significantly greater in patients who continued to take risperidone when compared with those who did not (41.6% vs 3.7%, t = 6.95, P Obsessive-Compulsive Scale scores. On regression analysis, no predictors of improvement with risperidone augmentation could be identified. The study demonstrated, in a real-world setting, that risperidone may be a useful augmenting agent in a proportion of patients with partial/poor response to serotonin reuptake inhibitors. PMID:27219093

  14. Comparative safety, efficacy, and cycle control of Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension) and Ortho-Novum 7/7/7 oral contraceptive (norethindrone/ethinyl estradiol triphasic). Lunelle Study Group.

    Science.gov (United States)

    Kaunitz, A M; Garceau, R J; Cromie, M A

    1999-10-01

    An open-label, nonrandomized, parallel, controlled study compared the efficacy, safety, and cycle control of a new monthly injectable contraceptive containing 25 mg of medroxyprogesterone acetate (MPA) and 5 mg of estradiol cypionate (E2C) (MPA/E2C) (Lunelle Monthly Contraceptive Injection) with that of a norethindrone 0.5, 0.75, 1.0 mg/0.035 mg ethinyl estradiol (NET/EE) triphasic oral contraceptive (Ortho-Novum 7/7/7). At study enrollment, women chose either the injections or the oral contraceptive. A higher proportion of women in the NET/EE group (65.1%) than in the MPA/E2C group (48.7%) had used hormonal contraception during the month before the study (p < 0.01). Overall, 55.5% (434/782) of MPA/E2C users and 67.6% (217/321) of NET/EE users completed the 60-week trial. One-year contraceptive efficacy (13 cycles of 28 days) for MPA/E2C and NET/EE was based on 8008 and 3434 woman-cycles of use, respectively. During the first year, one pregnancy occurred in an NET/EE user for a life table rate of 0.3; no pregnancies occurred in users of MPA/E2C. One additional pregnancy in the NET/EE group occurred during the 15th treatment cycle. After the first treatment cycle, women in both groups experienced regular menses, with an average cycle length of 28 days in MPA/E2C users and 27 days in NET/EE users. Although MPA/E2C users were more likely to experience bleeding irregularities, only 2.5% (19/775) cited metrorrhagia as a reason for discontinuing treatment. The adverse events reported in both treatment groups are consistent with those expected with the use of combined hormonal contraceptives. Overall, the results of this first Phase III US clinical trial of MPA/E2C confirm this method's high contraceptive efficacy and safety, as shown in previous studies by the World Health Organization. These results suggest that a monthly combination injectable would represent a welcome new contraceptive option for women in the US. PMID:10640164

  15. Comparative Study on the Efficacy and Safety of Olanzapine and Risperidone in the Treatment of Behavioral and Psychological Symptoms of Dementia%奥氮平与利培酮治疗痴呆精神行为症状的疗效及安全性比较研究

    Institute of Scientific and Technical Information of China (English)

    梁静涛; 吴丽娟

    2016-01-01

    目的探讨奥氮平与利培酮治疗痴呆精神行为症状的临床效果以及安全性。方法将我院2013年1月~2014年1月收治的70例患有痴呆精神行为症状的患者随机分成对照组和治疗组,对照组行利培酮进行治疗,治疗组行奥氮平进行治疗,比较两组患者的治疗效果。结果治疗后,治疗组总有效率为85.71%,对照组为91.43%,对比显示差异无统计学意义(>0.05);与治疗前相比,两组患者治疗2、4、8w后的BEHAVE-AD评分均有明显改善,且差异显示具有统计学意义(0.05);治疗组不良反应率为11.43%,明显低于对照组的31.43%,且差异显示具有统计学意义( 0.05); compared with before treatment, the two groups of patients after treatment BEHAVE 2,4,8w -AD scores showed significant improvement, and show a statistically significant difference ( 0.05); adverse reaction rate was 11.43% in treatment group was significantly 31.43% lower than the control group, and the difference was statistically significant display ( <0.05). Conclusion Olanzapine and risperidone behavioral and psychological symptoms of dementia have some clinical effect, but Olanzapine security even more significant, can reduce the incidence of adverse events, help patients get better treatment, worthy of promotion.

  16. Assessment on the Efficacy and Safety of Aidi Injection Combined with Vinorelbine and Cisplatin for Treatment of Advanced Nonsmall Cell Lung Cancer

    Institute of Scientific and Technical Information of China (English)

    Hua-Ye Zhao; Hai-Yan Zhou; Yan-Ting Wang; Wei Chen; Shu-Ya Qi; Jun-Ling Cao; Guo-Hui Li

    2016-01-01

    Background:The aim of this study was to assess the efficacy and safety of vinorelbine and cisplatin (NP chemotherapy) alone or in combination with Aidi injection for the treatment of advanced nonsmall cell lung cancer (NSCLC).Methods:Pertinent publications were identified in PubMed,EMBASE,Cochrane Library,CNKI,CQVIP,and Wanfang databases,up to December 8,2015.After quality assessment of all included randomized controlled trials evaluating Aidi injection combined with NP chemotherapy for the treatment of advanced NSCLC,a meta-analysis was performed by Review Manager 5.2 and STATA 12.0 for statistical analyses.Results:Twelve studies including 509 and 503 cases in the experimental and control groups,respectively,were finally analyzed.The meta-analysis revealed that when cisplatin dose ranging from 20 to 40 mg/m2,combination of Aidi injection and NP chemotherapy was statistically different compared with NP chemotherapy alone in enhancing efficiency (relative risk [RR] =1.24,95% confidence interval [CI] [1.05-1.47],P =0.010) and reducing the incidence of Grade Ⅱ or above nausea and vomiting (RR =0.49,95% CI [0.30-0.80],P =0.005).Meanwhile,with cisplatin ranging from 80 to 120 mg/m2,no significant differences in efficiency (RR =1.11,95% CI [0.87-1.42],P =0.390) and Grade Ⅱ or above nausea and vomiting (RR =0.88,95% CI [0.71-1.10],P =0.260) were obtained.In addition,Aidi injection combined with NP chemotherapy was superior to NP chemotherapy alone in improving the quality of life,alleviating Grade Ⅱ or above leukopenia and thrombocytopenia.Conclusions:Aidi injection combined with NP chemotherapy can enhance efficiency,improve the quality of life,and decrease adverse effects in patients with advanced NSCLC.

  17. Efficacy of injections with Disci/Rhus toxicodendron compositum for chronic low back pain--a randomized placebo-controlled trial.

    Directory of Open Access Journals (Sweden)

    Daniel Pach

    Full Text Available BACKGROUND: The effectiveness of injection therapy for low-back pain is still debatable. We compared the efficacy of local injections of the homeopathic preparation Disci/Rhus toxicodendron compositum (verum with placebo injections and with no treatment in patients with chronic low back pain. METHODOLOGY/PRINCIPAL FINDINGS: In a randomized controlled partly double blind multicenter trial patients with chronic low back pain from 9 German outpatient clinics were enrolled and randomly allocated in a 1∶1∶1 ratio to receive subcutaneous injections (verum or placebo into painful sites on the lower back over 12 treatment sessions within eight weeks, or no treatment (rescue pain medication with paracetamol or NSAIDs. All trial personnel and participants were masked to treatment allocation. The primary outcome measure was the average pain intensity over the last seven days on a visual analogue scale (0-100 mm, 0 = no pain, 100 = worst imaginable pain after eight weeks. Follow-up was 26 weeks. Primary analysis was by intention to treat. Between August 2007 and June 2008, 150 patients were randomly allocated to three groups (51 verum, 48 placebo and 51 no treatment. The mean baseline-adjusted low back pain intensity at week eight was: verum group 37.0 mm (97.5% CI 25.3;48.8, no treatment group 53.0 (41.8;64.2, and placebo group 41.8 (30.1;53.6. The verum was significantly superior to no treatment (P = 0.001, but not to placebo (P = 0.350. No significant side effects were reported. CONCLUSIONS/SIGNIFICANCE: The homeopathic preparation was not superior to placebo. Compared to no treatment injections resulted in significant and clinical relevant chronic back pain relief. TRIAL REGISTRATION: ClinicalTrials.gov NCT00567736.

  18. Efficacy and safety of alcohol sclerotherapy involving single-session multiple injections to treat simple renal cysts:a multicenter, prospective, randomized, controlled trial

    Institute of Scientific and Technical Information of China (English)

    LI Yong-zhong; LI Ming-xing; WANG Tao; YANG Li-chuan; FENG Ping; GOU Zhong-ping; YUAN Jia-ying

    2013-01-01

    Background Alcohol has been used for treating simple renal cysts since 1981.Since then,various observational studies have examined the technique,but they differ significantly in the details of the procedures and efficacy measures used.This has made it difficult to assess the safety and efficacy of this technique.We carried out a randomized controlled trial to evaluate the efficacy and safety of ultrasound-guided alcohol sclerotherapy involving single-session multiple injections to treat simple renal cysts.Methods A total of 144 patients with simple renal cysts were randomly allocated to either the treatment group (ultrasound-guided percutaneous drainage and alcohol sclerotherapy with single-session multiple injections) or control group (ultrasound-guided simple percutaneous drainage).Follow-up CT scans of ablated cysts were collected 3 and 6 months after the procedure.The outcome was considered successful if cyst volume between baseline and 6 months decreased by at least 87.5%.Results Intention-to-treat analysis revealed an average volume reduction of 94.2% in the treatment group and 50.8% in the control group (P <0.0001).The percentage of patients achieving successful outcomes was 88.9% (95% CI 77.0%-100.0%) in the treatment group and 22.2% (95% CI 6.54%-37.9%) in the control group (P <0.0001).The corresponding results in the per-protocol analysis were an average volume reduction of 96.4% in the treatment group and 50.8% in the control group (P <0.0001).The percentage of patients achieving a successful outcome was 94.3% (95% CI 85.6%-100.0%) in the treatment group and 22.2% (95% CI 6.54%-37.9%) in the control group (P <0.0001).Conclusion Alcohol sclerotherapy involving single-session multiple injections is safe and efficacious in the treatment of renal cysts.(ChiCTR-TRC-10001114,http://www.chictr.org)

  19. Risperidone in Children and Adolescents with Conduct Disorder: A Single-Center, Open-Label Study

    OpenAIRE

    Ercan, Eyüp Sabri; Kutlu, Ayşe; Çıkoğlu, Sibel; Veznedaroğlu, Baybars; Erermiş, Serpil; Varan, Azmi

    2003-01-01

    Background: Risperidone is one of the most commonly used atypical antipsychotic drugs in the treatment of children and adolescents. However, the data about its use in children and adolescents with conduct disorder (CD) are limited.

  20. Serum prolactin levels and sexual dysfunctions in antipsychotic medication, such as risperidone : a review

    NARCIS (Netherlands)

    Knegtering, H; Lambers, PA; Prakken, G; ten Brink, C

    2000-01-01

    Classical antipsychotic drugs increase the level of serum prolactin. The atypical antipsychotic clozapine barely increases prolactin levels. An open naturalistic study in the University Hospital of Groningen suggests that treatment with risperidone in comparison to classical antipsychotics seems to

  1. Double jeopardy--drug and sex risks among Russian women who inject drugs: initial feasibility and efficacy results of a small randomized controlled trial

    Directory of Open Access Journals (Sweden)

    Wechsberg Wendee M

    2012-01-01

    Full Text Available Abstract Background With HIV prevalence estimated at 20% among female injecting drug users (IDUs in St. Petersburg, Russia, there is a critical need to address the HIV risks of this at-risk population. This study characterized HIV risks associated with injecting drug use and sex behaviors and assessed the initial feasibility and efficacy of an adapted Woman-Focused intervention, the Women's CoOp, relative to a Nutrition control to reduce HIV risk behaviors among female IDUs in an inpatient detoxification drug treatment setting. Method Women (N = 100 were randomized into one of two one-hour long intervention conditions--the Woman-Focused intervention (n = 51 or a time and attention-matched Nutrition control condition (n = 49. Results The results showed that 57% of the participants had been told that they were HIV-positive. At 3-month follow-up, both groups showed reduced levels of injecting frequency. However, participants in the Woman-Focused intervention reported, on average, a lower frequency of partner impairment at last sex act and a lower average number of unprotected vaginal sex acts with their main sex partner than the Nutrition condition. Conclusion The findings suggest that improvements in sexual risk reduction are possible for these at-risk women and that more comprehensive treatment is needed to address HIV and drug risks in this vulnerable population.

  2. Anesthetic efficacy of the supplemental X-tip intraosseous injection using 4% articaine with 1:100,000 adrenaline in patients with irreversible pulpitis: An in vivo study

    Directory of Open Access Journals (Sweden)

    Atool Chandra Bhuyan

    2014-01-01

    Full Text Available Introduction: Pain management remains the utmost important qualifying criteria in minimizing patient agony and establishing a strong dentist-patient rapport. Symptomatic irreversible pulpitis is a painful condition necessitating immediate attention and supplemental anesthetic techniques are often resorted to in addition to conventional inferior alveolar nerve block. Aim: The purpose of the study was to evaluate the anesthetic efficacy of X-tip intraosseous injection in patients with symptomatic irreversible pulpitis, in mandibular posterior teeth, using 4% Articaine with 1:100,000 adrenaline as local anesthetic, when the conventional inferior alveolar nerve block proved ineffective. Materials and Methods: X-tip system was used to administer 1.7 ml of 4% articaine with 1:100,000 adrenaline in 30 patients diagnosed with irreversible pulpitis of mandibular posterior teeth with moderate to severe pain on endodontic access after administration of an inferior alveolar nerve block. Results: The results of the study showed that 25 X-tip injections (83.33% were successful and 5 X-tip injections (16.66% were unsuccessful. Conclusion: When the inferior alveolar nerve block fails to provide adequate pulpal anesthesia, X-tip system using 4% articaine with 1:100,000 adrenaline was successful in achieving pulpal anesthesia in patients with irreversible pulpitis.

  3. Antipsychotic discontinuation syndrome following risperidone withdrawal: a case report from rural India

    OpenAIRE

    Sanivarapu, Sravanti L.; Krishnamurthy CN

    2014-01-01

    Risperidone is an atypical antipsychotic agent used primarily to treat schizophrenia. It is a dopamine antagonist with antiserotonergic, antihistaminergic and antiadrenergic properties. Antipsychotic discontinuation symptoms have been described in the literature following abrupt or rapid reduction in the dose. This unusual case demonstrates that sudden withdrawal of even a modest dose of risperidone may cause significant discontinuation symptoms in susceptible individuals. Hence, there is a n...

  4. A Comparison of Risperidone and Buspirone for Treatment of Behavior Disorders in Children with Phenylketonuria

    OpenAIRE

    FAYYAZI, Afshin; Elham SALARI*; Ali KHAJEH; Abdi GAJARPOUR

    2014-01-01

    How to Cite This Article: Fayyazi A, Salari E, Khajeh A, Ghajarpour A. A Comparison of Risperidone and Buspirone for Treatment ofBehavior Disorders in Children with Phenylketonuria. Iran J Child Neurol. 2014 Autumn; 8(4):33-38.AbstractObjectiveMany patients with late-diagnosed phenylketonuria (PKU) suffer from severe behavior problems. This study compares the effects of buspirone and risperidone on reducing behavior disorders in these patients.Materials & MethodsIn this crossover clinical...

  5. Normalization of Risperidone-Induced Hyperprolactinemia with the Addition of Aripiprazole

    OpenAIRE

    Shores, Larry E.

    2005-01-01

    The objective of this study was to monitor metabolic changes, including hyperprolactinemia, in adolescents medicated with atypical antipsychotics, especially when polypharmacy is involved. This study specifically followed risperidone-induced hyperprolactinemia in adolescents (14 male patients and 2 female patients) after aripiprazole was added to begin transitioning to another atypical antipsychotic. No other changes were made in the medication regimen. Risperidone was continued at the previo...

  6. Efficacy of caudal epidural injection of lidocaine, xylazine and xylazine plus hyaluronidase in reducing discomfort produced by electroejaculation in bulls

    OpenAIRE

    PAGLIOSA, Ronaldo C.; DEROSSI, Rafael; COSTA, Deiler S.; FARIA, Fabio J.C.

    2015-01-01

    To test the hypothesis that epidural administration of lidocaine, xylazine or xylazine plus hyaluronidase provides reduced pain and stress during electroejaculation in bulls, eight 30-month-old Nellore bulls received saline solution (control), 2% lidocaine, 2% xylazine or 2% xylazine plus hyaluronidase injected into the first intercoccygeal (Co1–Co2) epidural space in randomized order. Heart rate, respiratory rate, mean arterial pressure, analgesia, animal behavior and motor blockade were eva...

  7. Efficacy of imidacloprid, trunk-injected into Acer platanoides, for control of adult Asian longhorned beetles (Coleoptera: Cerambycidae).

    Science.gov (United States)

    Ugine, Todd A; Gardescu, Sana; Lewis, Phillip A; Hajek, Ann E

    2012-12-01

    Feeding experiments with Asian longhorned beetles (Anoplophora glabripennis (Motschulsky)) in a quarantine laboratory were used to assess the effectiveness of imidacloprid in reducing adult fecundity and survival. The beetles were fed twigs and leaves cut between June-September 2010 from Norway maples (Acer platanoides L.) in the beetle-infested area of Worcester, MA. Treated trees had been trunk-injected once with imidacloprid in spring 2010 under the U.S. Department of Agriculture-Animal and Plant Health Inspection Service operational eradication program. The 21 d LC50 value for adult beetles feeding on twig bark from imidacloprid-injected trees was 1.3 ppm. Adult reproductive output and survival were significantly reduced when beetles fed on twig bark or leaves from treated trees. However, results varied widely, with many twig samples having no detectable imidacloprid and little effect on the beetles. When twigs with > 1 ppm imidacloprid in the bark were fed to mated beetles, the number of larvae produced was reduced by 94% and median adult survival was reduced to 14 d. For twigs with 1 ppm). When given a choice of control twigs and twigs from injected trees, beetles did not show a strong preference.

  8. Pain and efficacy rating of a microprocessor-controlled metered injection system for local anaesthesia in minor hand surgery.

    Science.gov (United States)

    Nimigan, André S; Gan, Bing Siang

    2011-01-01

    Purpose. Little attention has been given to syringe design and local anaesthetic administration methods. A microprocessor-controlled anaesthetic delivery device has become available that may minimize discomfort during injection. The purpose of this study was to document the pain experience associated with the use of this system and to compare it with use of a conventional syringe. Methods. A prospective, randomized clinical trial was designed. 40 patients undergoing carpal tunnel release were block randomized according to sex into a two groups: a traditional syringe group and a microprocessor-controlled device group. The primary outcome measure was surgical pain and local anaesthetic administration pain. Secondary outcomes included volume of anaesthetic used and injection time. Results. Analysis showed that equivalent anaesthesia was achieved in the microprocessor-controlled group despite using a significantly lower volume of local anaesthetic (P = .0002). This same group, however, has significantly longer injection times (P microprocessor controlled methods of administering local anaesthetic showed similar levels of discomfort in both groups. While the microprocessor-controlled group used less volume, the total time for the administration was significantly greater.

  9. In vitro-in vivo correlation of parenteral risperidone polymeric microspheres.

    Science.gov (United States)

    Shen, Jie; Choi, Stephanie; Qu, Wen; Wang, Yan; Burgess, Diane J

    2015-11-28

    The objective of the present study was to determine whether an in vitro-in vivo correlation (IVIVC) can be established for polymeric microspheres that are equivalent in formulation composition but prepared with different manufacturing processes. Risperidone was chosen as a model therapeutic and poly(lactic-co-glycolic acid) (PLGA) with similar molecular weight as that used in the commercial product Risperdal® Consta® was used to prepare risperidone microspheres. Various manufacturing processes were investigated to produce the risperidone microspheres with similar drug loading (approx. 37%) but distinctly different physicochemical properties (e.g. porosity, particle size and particle size distribution). In vitro release of the risperidone microspheres was investigated using different release testing methods (such as sample-and-separate and USP apparatus 4). In vivo pharmacokinetic profiles of the risperidone microsphere formulations following intramuscular administration were determined using a rabbit model. Furthermore, the obtained pharmacokinetic profiles were deconvoluted using the Loo-Riegelman method and the calculated in vivo release was compared with the in vitro release of these microspheres. Level A IVIVCs were established and validated for the compositionally equivalent risperidone microspheres based on the in vitro release data obtained using USP apparatus 4. The developed IVIVCs demonstrated good predictability and were robust. These results showed that the developed USP apparatus 4 method was capable of discriminating PLGA microspheres that are equivalent in formulation composition but with manufacturing differences and predicting their in vivo performance in the investigated animal model. PMID:26423236

  10. Early onset of treatment effects with oral risperidone

    Directory of Open Access Journals (Sweden)

    Naber Dieter

    2007-01-01

    Full Text Available Abstract Background The dogma of a delayed onset of antipsychotic treatment effects has been maintained over the past decades. However, recent studies have challenged this concept. We therefore performed an analysis of the onset of antipsychotic treatment effects in a sample of acutely decompensated patients with schizophrenia. Methods In this observational study, 48 inpatients with acutely decompensated schizophrenia were offered antipsychotic treatment with oral risperidone. PANSS-ratings were obtained on day 0, day 1, day 3, day 7 and day 14. Results Significant effects of treatment were already present on day 1 and continued throughout the study. The PANSS positive subscore and the PANSS total score improved significantly more than the PANSS negative subscore. Conclusion Our results are consistent with the growing number of studies suggesting an early onset of antipsychotic treatment effects. However, non-pharmacological effects of treatment also need to be taken into consideration.

  11. Adjunctive Aripiprazole Treatment for Risperidone-Induced Hyperprolactinemia: An 8-Week Randomized, Open-Label, Comparative Clinical Trial

    Science.gov (United States)

    Zhao, Jingyuan; Song, Xueqin; Ai, Xiaoqing; Gu, Xiaojing; Huang, Guangbiao; Li, Xue; Pang, Lijuan; Ding, Minli; Ding, Shuang; Lv, Luxian

    2015-01-01

    Objective The present study aimed to evaluate the efficacy and safety of adjunctive aripiprazole treatment in schizophrenia patients with risperidone-induced hyperprolactinemia. Methods One hundred and thirteen patients who were receiving a stable dose of risperidone were randomly assigned to either adjunctive aripiprazole treatment (10 mg/day) (aripiprazole group) or no additional treatment (control group) at a 1:1 ratio for 8 weeks. Schizophrenia symptoms were measured using the Positive and Negative Syndrome Scale (PANSS). Rating scales and safety assessments (RSESE, BARS, UKU) were performed at baseline and at weeks 4 and 8. Serum levels of prolactin were determined at baseline and at weeks 2, 4, 6 and 8. Metabolic parameters were determined at baseline and again at weeks 4 and 8. Results One hundred and thirteen patients were enrolled in this study, and 107 patients completed the study (54 in the aripiprazole group, and 53 in the control group). PANSS-total scores in the aripiprazole group decreased significantly at week 4 (P = 0.003) and week 8 (P = 0.007) compared with the control group. PANSS-negative scores in the aripiprazole group also decreased significantly at week 4 (P = 0.005) and week 8 (P< 0.001) compared with the control group. Serum levels of prolactin in the aripiprazole group decreased significantly at week 2 (P< 0.001), week 4 (P< 0.001), week 6 (P< 0.001) and week 8 (P< 0.001) compared with the control group. There were no significant differences in changes of Fasting Plasma Glucose, Total cholesterol, Triglycerides and High Density Lipoprotein within each group at week 4 and 8 execpt low density lipoproteins. There was no significant difference in the incidence of adverse reactions between the two groups. Conclusions Adjunctive aripiprazole treatment may be beneficial in reducing serum levels of prolactin and improving negative symptoms in schizophrenia patients with risperidone-induced hyperprolactinemia. Trial Registration chictr.org Chi

  12. Pharmacogenetics of Risperidone and Cardiovascular Risk in Children and Adolescents

    Directory of Open Access Journals (Sweden)

    Amilton Dos Santos-Júnior

    2016-01-01

    Full Text Available Objective. To identify the frequency of obesity and metabolic complications in child and adolescent users of risperidone. Potential associations with clinical parameters and SNPs of the HTR2C, DRD2, LEP, LEPR, MC4R, and CYP2D6 genes were analyzed. Methods. Samples from 120 risperidone users (8–20 years old were collected and SNPs were analyzed, alongside assessment of chronological and bone ages, prescribed and weight-adjusted doses, use of other psychotropic drugs, waist circumference, BMI z-scores, blood pressure, HOMA-IR index, fasting levels of serum glucose, insulin, cholesterol, triglycerides, transaminases, and leptin. Results. Thirty-two (26.7% patients were overweight and 5 (4.2% obese. Hypertension was recorded in 8 patients (6.7%, metabolic syndrome in 6 (5%, and increased waist circumference in 20 (16.7%. The HOMA-IR was high for 22 patients (18.3%, while total cholesterol and triglycerides were high in 20 (16.7% and 41 (34.2% patients, respectively. SNP associations were found for LEP, HTR2C, and CYP2D6 with BMI; CYP2D6 with blood pressure, ALT, and HOMA-IR; HTR2C and LEPR with leptin levels; MC4R and DRD2 with HOMA-IR; HTR2C with WC; and LEP with ALT. Conclusions. Although not higher than in the general pediatric population, a high frequency of patients was overweight/obese, with abnormalities in metabolic parameters and some pharmacogenetic associations.

  13. COMPARATIVE STUDY OF EFFICACY OF LOCAL STEROID INJECTION AND EXTRACORPOREAL SHOCKWAVE THERAPY IN THE TREATMENT OF PLANTAR FASCITIS

    Directory of Open Access Journals (Sweden)

    Rajan

    2014-04-01

    Full Text Available INTRODUCTION: Plantar fasciitis is a common condition causing misery to lot of patients. The etiology and treatment of plantar fasciitis are poorly understood. The results from such treatments vary considerably, and there is no consensus of opinion on the best method. MATERIAL AND METHODS: We conducted a controlled trial in our institute to compare the results of local steroid injections & the use of Extra-corporeal shock wave therapy (ESWT for managing plantar fasciitis. 200 patients with 240 painful heels were evaluated. All patients with moderate to severe heel pain who had already taken ten days of unsatisfactory treatment with oral NSAIDS were divided in two main groups. Group A of 100 patients received 1000 impulses of shock waves in three sessions at weekly interval. In Group B of 100 patients up to three local injections of 40 mg methyl prednisone mixed with 1 ml. of 2% lignocaine were given at biweekly interval. Pain assessment was done using VAS scale and the results were evaluated at six weeks, three months and six months after the completion of the therapy. CONCLUSIONS: There was a significant difference between two groups of patients being treated. The group B patients had significantly greater improvement in pain scale and early return to daily activities

  14. Influence of aripiprazole, risperidone, and amisulpride on sensory and sensorimotor gating in healthy 'low and high gating' humans and relation to psychometry.

    Science.gov (United States)

    Csomor, Philipp A; Preller, Katrin H; Geyer, Mark A; Studerus, Erich; Huber, Theodor; Vollenweider, Franz X

    2014-09-01

    Despite advances in the treatment of schizophrenia spectrum disorders with atypical antipsychotics (AAPs), there is still need for compounds with improved efficacy/side-effect ratios. Evidence from challenge studies suggests that the assessment of gating functions in humans and rodents with naturally low-gating levels might be a useful model to screen for novel compounds with antipsychotic properties. To further evaluate and extend this translational approach, three AAPs were examined. Compounds without antipsychotic properties served as negative control treatments. In a placebo-controlled, within-subject design, healthy males received either single doses of aripiprazole and risperidone (n=28), amisulpride and lorazepam (n=30), or modafinil and valproate (n=30), and placebo. Prepulse inhibiton (PPI) and P50 suppression were assessed. Clinically associated symptoms were evaluated using the SCL-90-R. Aripiprazole, risperidone, and amisulpride increased P50 suppression in low P50 gaters. Lorazepam, modafinil, and valproate did not influence P50 suppression in low gaters. Furthermore, low P50 gaters scored significantly higher on the SCL-90-R than high P50 gaters. Aripiprazole increased PPI in low PPI gaters, whereas modafinil and lorazepam attenuated PPI in both groups. Risperidone, amisulpride, and valproate did not influence PPI. P50 suppression in low gaters appears to be an antipsychotic-sensitive neurophysiologic marker. This conclusion is supported by the association of low P50 suppression and higher clinically associated scores. Furthermore, PPI might be sensitive for atypical mechanisms of antipsychotic medication. The translational model investigating differential effects of AAPs on gating in healthy subjects with naturally low gating can be beneficial for phase II/III development plans by providing additional information for critical decision making.

  15. Comparison of efficacy of lignocaine anesthesia of vocal cords by spray as you go through a bronchoscope with lignocaine injection through the cricothyroid membrane

    International Nuclear Information System (INIS)

    To assess and compare the efficacy of lignocaine anesthesia of vocal cords by spray as you go through a bronchoscope with lignocaine injection through the cricothyroid membrane. Study Design: Quasi experimental study. Place and Duration of Study:This study was done in Combined Military Hospital Peshawar form May 2009 to June 2010. Material and method: Thirty patients in each group were given local anesthesia to the vocal cords. With lignocaine either via intratracheal instillation through the cricothyroid membrane or through a fibreoptic bronchoscope spray as you go. A cough score was calculated by recording the number of coughs as the bronchoscope was advanced through the cords into the trachea. A twenty point unpleasantness score was marked by the patient 2 hours after the procedure. Result: Cough score and unpleasantness score was compared among the two groups using SPSS version 19. Median unpleasantness score was 6 (Inter quartile range (IQR) 4-8) whereas median cough score was 2(IQR 0-3). The difference was statistically significant among the two groups for both cough and unpleasant scores (p< 0.001 and p< 0.001 respectively). Conclusion: Intratracheal injection of lignocaine is more comfortable for the patient. It induces much less cough and irritability to the patient than the spray as you go technique. (author)

  16. Efficacy of a single intramuscular injection of porcine FSH in hyaluronan prior to ovum pick-up in Holstein cattle.

    Science.gov (United States)

    Vieira, L M; Rodrigues, C A; Netto, A Castro; Guerreiro, B M; Silveira, C R A; Freitas, B G; Bragança, L G M; Marques, K N G; Sá Filho, M F; Bó, G A; Mapletoft, R J; Baruselli, P S

    2016-03-15

    Plasma FSH profiles, in vitro embryo production (IVP) after ovum pickup (OPU), and establishment of pregnancy with IVP embryos were compared in untreated Holstein oocyte donors and those superstimulated with multiple injections or a single intramuscular (IM) injection of porcine FSH (pFSH) in hyaluronan (HA). Plasma FSH profiles were determined in 23 heifers randomly allocated to one of four groups. Controls received no treatment, whereas the F200 group received 200 mg of pFSH in four doses, 12 hours apart. The F200HA and F300HA groups received 200- or 300-mg pFSH in 5 mL or 7.5 mL, respectively of a 0.5% HA solution by a single IM injection. Plasma FSH levels were determined before the first pFSH treatment and every 6 hours over 96 hours. All data were analyzed by orthogonal contrasts. Circulating FSH area under curve (AUC) in pFSH-treated animals was greater than that in the control group (P = 0.02). Although the AUC did not differ among FSH-treated groups (P = 0.56), the total period with elevated plasma FSH was greater in the F200 group than in the HA groups (P FSH (P = 0.17). The IVP was performed in 90 nonlactating Holstein cows randomly allocated to one of the four treatment groups as in the first experiment. A greater proportion of medium-sized (6-10 mm) follicles was observed in cows receiving pFSH, regardless of the treatment group (P oocyte complexes (COCs) retrieved (P = 0.01) and matured (P = 0.02), cleavage rates (P = 0.002), and blastocysts produced per OPU session (P = 0.06) were greater in cows receiving pFSH, regardless of the treatment group. Cows in the F200HA group had a greater recovery rate (P = 0.009), number of COCs cultured (P = 0.04), and blastocysts produced per OPU session (P = 0.06) than cows in the F300HA group. Similar pregnancy rates were observed 50 to 60 days after transferring IVP embryos from donors in the different treatment groups (P > 0.05). In conclusion, a single IM injection of pFSH combined in 0.5% HA resulted in similar

  17. Risperidone in children with autism: randomized, placebo-controlled, double-blind study.

    Science.gov (United States)

    Nagaraj, Ravishankar; Singhi, Pratibha; Malhi, Prahbhjot

    2006-06-01

    Some open-label studies suggest that risperidone can be useful in the treatment of certain target symptoms in children with autism. We aimed to study whether the use of risperidone in comparison with placebo improved functioning in children with autism with regard to behavior (aggressiveness, hyperactivity, irritability), social and emotional responsiveness, and communication skills. We conducted a randomized, double-blind, placebo-controlled trial with 40 consecutive children with autism, whose ages ranged from 2 to 9 years, who were receiving either risperidone or placebo given orally at a dose of 1 mg/day for 6 months. Autism symptoms were monitored periodically. The outcome variables were total scores on the Childhood Autism Rating Scale (CARS) and the Children's Global Assessment Scale (CGAS) after 6 months. Of the 40 children enrolled, 39 completed the trial over a period of 18 months; 19 received risperidone, and 20 received placebo. In the risperidone group, 12 of 19 children showed improvement in the total Childhood Autism Rating Scale score and 17 of 19 children in the Children's Global Assessment Scale score compared with 0 of 20 children for the Childhood Autism Rating Scale score and 2 of 20 children for the Children's Global Assessment Scale score in the placebo group (P social responsiveness and nonverbal communication and reduced the symptoms of hyperactivity and aggression. Risperidone was associated with increased appetite and a mild weight gain, mild sedation in 20%, and transient dyskinesias in three children. Risperidone improved global functioning and social responsiveness while reducing hyperactivity and aggression in children with autism and was well tolerated. PMID:16948927

  18. Comparison of the Efficacy of Oral and Injectable Forms of Prophylactic Antibiotics in Grade Ii Traumatic Ulcers in Emergency Wards of University Hospitals of Yazd

    Directory of Open Access Journals (Sweden)

    MR Hajiesmaieli

    2007-12-01

    Full Text Available Introduction: Traumatic ulcers are one of the most common causes of referral to emergency wards and interfere with wound healing. Even in a complete sterile condition, all of the ulcers may be contaminated with bacteria, but a few of them progress and cause clinical manifestations. There is a controversy on the use prophylactic antibiotics in traumatic ulcers. In this study we compare the efficacy of oral and injectable forms of antibiotics in prophylaxis of infection. Methods: In this clinical trial study, 237 cases suffering from grade II traumatic ulcers were selected by simple random method and divided into 2 groups; first group was administered 1 gram cephazoline prior to suturing and received no other antibiotics , while the second group received 500 mg cephalexin capsule before suturing and continued the treatment for 24 hours. (500 mg QID .Patients were followed up on day 7, 10 and 30 after discharge from hospital for infection of the wounds. The collected data was analyzed by SPSS 11 software using Chi-squire and Fisher exact tests. Results: According to the findings, confounding variables such as sex, age, width of the wound, traumatic cause and site and also the time course until referral to the emergency ward were similar in both groups. Prevalence of infection in the group receiving oral and injection forms of antibiotic was 2.5% and 1.7%, respectively, difference of which was not significant.(P=0.683 Conclusion: As the prevalence of wound infection is similar in both groups, oral forms of antibiotics can be used instead of injectable forms for wound infection prophylaxis.

  19. A Risperidone-Induced Prolactinoma Resolved when a Woman with Schizoaffective Disorder Switched to Ziprasidone: A Case Report

    OpenAIRE

    Arcari, Gail T.; Mendes, Asante K.; Sothern, Robert B.

    2012-01-01

    Antipsychotic drug therapy, e.g., risperidone, can be associated with endocrine abnormalities, including an increase in serum prolactin level (sPrl) due to a drug-induced benign pituitary tumor (prolactinoma). A few case reports have noted a resolution of hyperprolactinemia and prolactinoma after cessation of risperidone treatment. We report a similar finding for a woman with schizoaffective disorder, manic type.

  20. Risperidone – Solid-state characterization and pharmaceutical compatibility using thermal and non-thermal techniques

    Energy Technology Data Exchange (ETDEWEB)

    Daniel, Josiane Souza Pereira; Veronez, Isabela Pianna; Rodrigues, Larissa Lopes [Laboratório de Análise e Caracterização de Fármacos – LACFar, Instituto de Química, Universidade Federal de Alfenas, Alfenas, Minas Gerais (Brazil); Trevisan, Marcello G. [Laboratório de Análise e Caracterização de Fármacos – LACFar, Instituto de Química, Universidade Federal de Alfenas, Alfenas, Minas Gerais (Brazil); National Institute of Bioanalytics Science and Technology – INCTBio, Institute of Chemistry – UNICAMP, 13084-653, Campinas, São Paulo (Brazil); Garcia, Jerusa Simone, E-mail: jerusa.garcia@unifal-mg.edu.br [Laboratório de Análise e Caracterização de Fármacos – LACFar, Instituto de Química, Universidade Federal de Alfenas, Alfenas, Minas Gerais (Brazil)

    2013-09-20

    Highlights: • DSC was used to characterize Risperidone and study its compatibility with excipients. • FT-IR associated with PCA was used to complement DSC data. • LC analyzes confirmed the DSC and FT-IR/PCA results. • Risperidone was incompatible with three among five excipients evaluated. - Abstract: A full solid-state characterization of risperidone was conducted using differential scanning calorimetry (DSC), thermogravimetry (TG), powder X-ray diffraction (PXRD), Fourier transform infrared spectroscopy (FT-IR) and scanning electron microscopy (SEM) to examine its physicochemical properties and polymorphism. The primary aim of this work was to study the compatibility of risperidone with pharmaceutical excipients using DSC to obtain and compare the curves of the active pharmaceutical ingredient (API) and the excipients with their 1:1 (w/w) binary mixtures. These same binary mixtures were turned to room temperature and analyzed by FT-IR combined with principal component analysis (PCA) to evaluate solid-state incompatibilities. The chemical incompatibilities of these samples were verified using a stability-indicating liquid chromatography (LC) method to assay for the API and evaluate the formation of degradation products. All of these methods showed incompatibilities between risperidone and the excipients magnesium stearate, lactose and cellulose microcrystalline.

  1. Optimization and in vivo toxicity evaluation of G4.5 PAMAM dendrimer-risperidone complexes.

    Directory of Open Access Journals (Sweden)

    Maria Jimena Prieto

    Full Text Available Risperidone is an approved antipsychotic drug belonging to the chemical class of benzisoxazole. This drug has low solubility in aqueous medium and poor bioavailability due to extensive first-pass metabolism and high protein binding (>90%. Since new strategies to improve efficient treatments are needed, we studied the efficiency of anionic G4.5 PAMAM dendrimers as nanocarriers for this therapeutic drug. To this end, we explored dendrimer-risperidone complexation dependence on solvent concentration, pH and molar relationship. The best dendrimer-risperidone incorporation (46 risperidone molecules per dendrimer was achieved with a mixture of chloroform:methanol 50∶50 v/v solution pH 3. In addition, to explore the possible effects of this complex, in vivo studies were carried out in the zebrafish model. Changes in the development of dopaminergic neurons and motoneurons were studied using tyrosine hydroxylase and calretinin, respectively. Physiological changes were studied through histological sections stained with hematoxylin-eosin to observe possible morphological brain changes. The most significant changes were observed when larvae were treated with free risperidone, and no changes were observed when larvae were treated with the complex.

  2. Optimization and in vivo toxicity evaluation of G4.5 PAMAM dendrimer-risperidone complexes.

    Science.gov (United States)

    Prieto, Maria Jimena; del Rio Zabala, Nahuel Eduardo; Marotta, Cristian Hernán; Carreño Gutierrez, Hector; Arévalo Arévalo, Rosario; Chiaramoni, Nadia Silvia; del Valle Alonso, Silvia

    2014-01-01

    Risperidone is an approved antipsychotic drug belonging to the chemical class of benzisoxazole. This drug has low solubility in aqueous medium and poor bioavailability due to extensive first-pass metabolism and high protein binding (>90%). Since new strategies to improve efficient treatments are needed, we studied the efficiency of anionic G4.5 PAMAM dendrimers as nanocarriers for this therapeutic drug. To this end, we explored dendrimer-risperidone complexation dependence on solvent concentration, pH and molar relationship. The best dendrimer-risperidone incorporation (46 risperidone molecules per dendrimer) was achieved with a mixture of chloroform:methanol 50∶50 v/v solution pH 3. In addition, to explore the possible effects of this complex, in vivo studies were carried out in the zebrafish model. Changes in the development of dopaminergic neurons and motoneurons were studied using tyrosine hydroxylase and calretinin, respectively. Physiological changes were studied through histological sections stained with hematoxylin-eosin to observe possible morphological brain changes. The most significant changes were observed when larvae were treated with free risperidone, and no changes were observed when larvae were treated with the complex.

  3. Risperidone and NAP protect cognition and normalize gene expression in a schizophrenia mouse model.

    Science.gov (United States)

    Vaisburd, Sinaya; Shemer, Zeev; Yeheskel, Adva; Giladi, Eliezer; Gozes, Illana

    2015-11-10

    Mutated disrupted in schizophrenia 1 (DISC1), a microtubule regulating protein, leads to schizophrenia and other psychiatric illnesses. It is hypothesized that microtubule stabilization may provide neuroprotection in schizophrenia. The NAP (NAPVSIPQ) sequence of activity-dependent neuroprotective protein (ADNP) contains the SxIP motif, microtubule end binding (EB) protein target, which is critical for microtubule dynamics leading to synaptic plasticity and neuroprotection. Bioinformatics prediction for FDA approved drugs mimicking SxIP-like motif which displace NAP-EB binding identified Risperidone. Risperidone or NAP effectively ameliorated object recognition deficits in the mutated DISC1 mouse model. NAP but not Risperidone, reduced anxiety in the mutated mice. Doxycycline, which blocked the expression of the mutated DISC1, did not reverse the phenotype. Transcripts of Forkhead-BOX P2 (Foxp2), a gene regulating DISC1 and associated with human ability to acquire a spoken language, were increased in the hippocampus of the DISC1 mutated mice and were significantly lowered after treatment with NAP, Risperidone, or the combination of both. Thus, the combination of NAP and standard of care Risperidone in humans may protect against language disturbances associated with negative and cognitive impairments in schizophrenia.

  4. Efficacy of caudal epidural injection of lidocaine, xylazine and xylazine plus hyaluronidase in reducing discomfort produced by electroejaculation in bulls.

    Science.gov (United States)

    Pagliosa, Ronaldo C; Derossi, Rafael; Costa, Deiler S; Faria, Fabio J C

    2015-11-01

    To test the hypothesis that epidural administration of lidocaine, xylazine or xylazine plus hyaluronidase provides reduced pain and stress during electroejaculation in bulls, eight 30-month-old Nellore bulls received saline solution (control), 2% lidocaine, 2% xylazine or 2% xylazine plus hyaluronidase injected into the first intercoccygeal (Co1-Co2) epidural space in randomized order. Heart rate, respiratory rate, mean arterial pressure, analgesia, animal behavior and motor blockade were evaluated before treatment and at predetermined intervals during and after treatment. Pain and stress were scored subjectively, and semen quality was evaluated. The onset of anesthetic action was significantly faster with lidocaine (3.0 ± 1.2 min) than with xylazine or xylazine plus hyaluronidase (8.9 ± 1.5 and 5.5 ± 2.6 min, P=0.021 and P=0.012, respectively), and the onset of anesthesia with xylazine plus hyaluronidase was significantly faster than that with xylazine alone (P=0.032). Treatment with xylazine or xylazine plus hyaluronidase resulted in less discomfort than treatment with lidocaine, as indicated by animal behavior. Changes in heart rate, respiratory rate and arterial pressure were within acceptable limits. Penile protrusion and semen emission occurred in all animals during all four treatments. Our results suggest that xylazine plus hyaluronidase reduced discomfort during electroejaculation more effectively than xylazine or lidocaine alone. Further experiments are necessary to determine whether electroejaculation with xylazine plus hyaluronidase is feasible for obtaining semen from Nellore bulls unaccustomed to being handled or restrained. PMID:26097016

  5. 利培酮合并氯氮平治疗难治性精神分裂症临床分析%Clinical Effect of Risperidone Combined with Clozapine in Treatment of Re-fractory Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    赵圣兰; 郭晓静

    2015-01-01

    Objective To investigate the clinical effect of risperidone combined with clozapine in the treatment of refractory schizophrenia. Methods The control group received conventional treatment with risperidone; study group received combined treat-ment of risperidone and clozapine. Outcomes and adverse reaction of the patients with refractory schizophrenia in the two groups were recorded and statistically analyzed. Results Clinical total efficiency of the study group, 88.37%, was significantly higher than that of the control group, 69.77% (P 0.05). Conclusion Risperidone combined with clozapine used in the treatment of patients with refractory schizophrenia can significantly improve the clinical effi-cacy and quality of life and protect the safety of patients.%目的:探讨利培酮合并氯氮平治疗难治性精神分裂症临床应用效果。方法对照组给予利培酮常规治疗;研究组实施利培酮联合氯氮平片疗法。将两组中难治性精神分裂症患者的疗效及不良反应发生状况记录,通过统计学分析得出结论。结果研究组临床治疗的总有效率为88.37%,明显优于对照组临床治疗总有效率69.77%(P0.05)。结论难治性精神分裂症患者经利培酮联合氯氮平治疗可显著提高其临床疗效,有效保障患者生活质量及生命安全。

  6. 利培酮、氯氮平治疗精神分裂症的药物经济学评估%Pharmacoeconomic Evaluation of Schizophrenia in Risperidon and Cloza-pine Treatment

    Institute of Scientific and Technical Information of China (English)

    郑冰

    2014-01-01

    目的:比较利培酮、氯氮平治疗住院精神分裂症的成本-效果。方法对82例住院精神分裂症患者应用利培酮或氯氮平进行治疗,根据PANSS量表减分率评定疗效,对住院花费运用药物经济学成本-效果分析法进行评价。结果利培酮、氯氮平治疗精神分裂症的显效率分别为77.8%、71.4%,二者比较无显著性差异( P>0.05);产生单位效果所需成本二者无显著差异。结论利培酮与氯氮平治疗住院精神分裂症的疗效及费用基本相当。%OBJECTIVE To compare the efficiency and economic cost between Risperidon and Clozapine in the treatment of schizophrenia.METHODS 82 in-patients with schizophrenia were treated with Risperidon or Clozap-ine.PANSS was used to assess the clinical efficacy and pharmacoeconomic cost-effectiveness analysis was used to e-valuate costs.RESULTS The effective rates of Risperidon and Clozapine were 77.8% and 71.4% respectively with no significant difference ( P>0.05 ).There was no significant difference in the costs for an identical effect be-tween two drugs.CONCLUSION The ef-ective and costs of Risperidon and Clozapine are almost equal in the treat-ment of schizophrenia.

  7. Study on the luminescence behavior of sulfobutylether-β-cyclodextrin with risperidone and its analytical application

    Science.gov (United States)

    Wu, Min; Chen, Donghua; Song, Zhenghua

    2012-10-01

    The interaction of sulfobutylether-β-cyclodextrin (SBE-β-CD) with risperidone (RISP) was first described with luminol-SBE-β-CD chemiluminescence (CL) system by flow injection analysis (FIA). In luminol-SBE-β-CD CL system, the 1:1 SBE-β-CD⋯luminol∗ complexation could enhance CL intensity of luminol and produce the effect of complexation enhancement of CL (CEC). It was found that RISP could quench the CL intensity of SBE-β-CD⋯luminol∗ and caused the effect of complexation enhancement of quenching (CEQ), the formation constant KR-CD 3.4 × 104 L mol-1 and the stoichiometric ratio 1:1 of RISP⋯SBE-β-CD complex were obtained by the proposed CL model. Association degree α 0.036 of RISP⋯SBE-β-CD complex was also given by CL method. Based on the linear relationship to the decrement of luminol-SBE-β-CD-RISP CL intensity and the logarithm of RISP concentration, RISP also can be quantified in the linear range of 3.0-500.0 nmol L-1 with a detection limit of 1.0 nmol L-1 (3σ). The proposed method was successfully applied to monitoring excreted RISP in human urine. It was found that RISP reached its maximum after oral administration for 1.5 h with the total excretion of 14.26% within 8.5 h; the elimination rate constant k and half-life time t1/2 were 0.474 and 1.5 h, respectively.

  8. A clinical study on substitution of risperidone for clozapine in the treatment of schizophrenia%利培酮替换氯氮平治疗精神分裂症临床研究

    Institute of Scientific and Technical Information of China (English)

    梅其一; 王晓龙; 杨小男; 方建中

    2001-01-01

    Objective:To explore a clinical optimal regime of substitutingrisperidone for clozapine. Method:Subjects were randomly enrolled into three groups: risperidone group, combination of risperidone and benzhexol group and combination of risperdone and alprazolam group. The efficacy and side effects were accessed with the positive and negative symptom scale (PANSS), a rating scale for extramidal side-effects (ESRS) and the treatment emergent symptom scale (TESS) before and after treatment. Results:The efficacy of all regimes was significant, and no significant differences were found among them. The female patients had more severe side effects than the male patients. The side effects were slightest in the combination of risperidone and alprazolam group and most severe in the risperidone group. Conclusion:Substituting risperidone and alprazolam for clozapine is the optimal regime in the treatment of schizophrenia.%目的:探索以利培酮替换氯氮平的临床换药方案。 方法:受试患者随机进入3组:单用利培酮组,利培酮+安坦组,利培酮+阿普唑仑组。在治疗前、治疗后1、2、4、6周用阳性症状与阴性症状量表(PANSS)、锥体外系副反应量表(ESRS)、不良反应症状量表(TESS)比较其疗效和副反应。 结果:3组换药后疗效均显著(P0.05)。女性较男性副反应大一些;利培酮+阿普唑仑组副反应最轻,单用利培酮组副反应最大。 结论:利培酮+阿普唑仑替换氯氮平方案较佳。

  9. Pregnancy exposure to olanzapine, quetiapine, risperidone, aripiprazole and risk of congenital malformations. A systematic review

    DEFF Research Database (Denmark)

    Ennis, Zandra Nymand; Damkier, Per

    2015-01-01

    To review available data on first-trimester exposure to olanzapine, quetiapine, risperidone and aripiprazole and risk of congenital malformations. We performed a systematic literature search in accordance with PRISMA guidelines identifying studies containing original data on first....../22 (5.1%) and 100/5 (5.0%), respectively. Relative risk estimates and 95% confidence intervals were 1.0 (0.7-1.4) (olanzapine), 1.0 (0.6-1.7) (quetiapine), 1.5 (0.9-2.2) (risperidone) and 1.4 (0.5-3.1) (aripiprazole). First-trimester exposure to olanzapine is not associated with an increased risk...... of congenital malformation. Data for quetiapine and risperidone do not suggest a substantially increased risk, while the risk estimate for aripiprazole remains imprecise owing to a low amount of data....

  10. 利培酮口服液治疗首发精神分裂症急性期对照观察%A control study of risperidone oral solution in treating first-episode schizophrenia patients in acute phase

    Institute of Scientific and Technical Information of China (English)

    黄卓玮; 龚传鹏

    2011-01-01

    目的:探讨利培酮13服液治疗首发精神分裂症急性期的疗效和安全性.方法:96例精神分裂症的急性期患者随机分为两组,分别给予利培酮口服液(研究组,n=49)和氯氮平(对照组,n=47)单药治疗4周.采用阳性和阴性症状量表(PANSS)评定临床疗效,临床总体印象量表(CGI-SI)评定病情严重程度,治疗中出现的症状量表(TESS)评定不良反应,自编依从性量表评定依从性.结果:治疗后两组患者PANSS及CGI-SI评分显著下降(P0.05).治疗后第4天,研究组兴奋、敌对、不合作、冲动控制缺乏因子分下降较对照组显著(P<0.05);研究组不良反应发生率明显低于对照组(P<0.05);研究组治疗依从性在治疗14 d、28 d、3个月和6个月时均优于对照组(P<0.05).结论:利培酮口服液对首发精神分裂症急性期患者的疗效和氯氮平相当,但利培酮口服液改善兴奋、敌对性等因子分较迅速,耐受性和依从性较好.%Objective: To evaluate the efficacy and safety of risperidone oral solution in the treatment of patients on the acute phase with first-episode schizophrenia. Method:96 schizophrenia patients were randomly assigned to the group treated with risperidone oral solution group ( n = 49 ) and the other group treated with clozapine (n =47 ),respectively for 4 weeks. The positive and negative syndrome scale (PANSS) and clinical global impressions-severity of illness rating scale(CGI-SI) were used to rate the efficacy;the treatment emergent symptom scale (TESS) was used to measure side effects and the compliance scale was used to assess the subjects'compliance with the treatment. Results:Both risperidone and clozapine group significantly showed score decrease on PANSS and CGI-SI after 4 weeks (P <0.01 ), but no significant difference was found between two groups ( P > 0.05 ). Excitement, hostility, uncooperativeness and poor impulse control of PANSS significantly decreased more in risperidone oral solution group

  11. Antipsychotic discontinuation syndrome following risperidone withdrawal: a case report from rural India

    Directory of Open Access Journals (Sweden)

    Sravanti L. Sanivarapu

    2014-02-01

    Full Text Available Risperidone is an atypical antipsychotic agent used primarily to treat schizophrenia. It is a dopamine antagonist with antiserotonergic, antihistaminergic and antiadrenergic properties. Antipsychotic discontinuation symptoms have been described in the literature following abrupt or rapid reduction in the dose. This unusual case demonstrates that sudden withdrawal of even a modest dose of risperidone may cause significant discontinuation symptoms in susceptible individuals. Hence, there is a need for caution while taking a patient off antipsychotic medications in view of the vulnerable subgroup. [Int J Basic Clin Pharmacol 2014; 3(1.000: 233-234

  12. Comparison the effectiveness of aripiprazole and risperidone for the treatment of acute bipolar mania

    Directory of Open Access Journals (Sweden)

    Amir Akhavan Rezayat

    2014-01-01

    Full Text Available Background: Second-generation antipsychotics, approved for the treatment of mania, are associated with adverse effects such as weight gain and metabolic disorders. Aripiprazole, a recently introduced second-generation antipsychotic, are thought to account for its low propensity for weight gain, metabolic disturbances and sedation. The purpose of this study was to investigate the effect of risperidone versus aripiprazole in the treatment of acute mania. Materials and Methods: Fifty patients with acute episodes of mania were enrolled in this study, and they were randomly assigned into a risperidone group of 24 cases and an aripiprazole group of 26 cases. In group A, aripiprazole with a dose of 5-30 mg/day and in group B, risperidone with a dose of 2-8 mg/day was given to patients. The average dose of aripiprazole was 27 mg/day, and the average dose of risperidone was 6 mg/day. The effects of each drug for the treatment of acute mania were assessed on the 1 st day of admission and on days 2, 4, 6, 8 and at weeks 2, 4 and 6 after therapy using the young mania rating scale (YMRS and at the baseline and on weeks 3 and 6 after admission using the clinical global impression (CGI scale. Results: The mean age of the group of risperidone was 34 ± 8.6 years and in a group of aripiprazole it was 34 ± 9.1 years (P = 0.83. Comparison of YMRS scores over the period of 6 weeks revealed a statistically significant difference in both groups (P < 0.0001.There was also a statistically significant difference in YMRS scores between risperidone and aripiprazole at day 8 (P = 0.026 and weeks 2 (P = 0.035 and 4 (P = 0.042. There was also a statistically significant difference in CGI-Severity scale score at weeks 3 (P = 0.003 and 6 (P = 0.000 and in CGI-Improvement scale score at weeks 3 (P = 0.005 and 6 (P = 0.002. The most common side-effect observed in both groups was headache (0%15/4 in aripiprazole vs. %16/7 in risperidone Conclusion: Aripiprazole that is readily

  13. Therapeutic Efficacy and Safety of Percutaneous Ethanol Injection with or without Combined Radiofrequency Ablation for Hepatocellular Carcinomas in High Risk Locations

    Energy Technology Data Exchange (ETDEWEB)

    Cha, Dong Ik; Lee, Min Woo; Rhim, Hyunchul; Choi, Dongil; Kim, Young-sun; Lim, Hyo K. [Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135-710 (Korea, Republic of)

    2013-07-01

    To evaluate the therapeutic efficacy and safety of percutaneous ethanol injection (PEI) alone and combined with radiofrequency ablation (RFA) for hepatocellular carcinomas (HCCs) in high risk locations. We performed PEI for HCCs in RFA-high risk locations, either alone or in combination with RFA. There were 20 HCCs (1.7 ± 0.9 cm) in 20 patients (PEI group: n = 12; PEI + RFA group: n = 8). We evaluated technical success, local tumor progression and complications in both groups. Technical success was achieved in all HCCs in both groups. During follow-up, local tumor progression was found in 41.7% (5/12) in the PEI group, whereas 12.5% (1/8) for the PEI + RFA group (p = 0.32). Bile duct dilatation was the most common complication, especially when the tumors were in periportal locations; 55% (5/9) in the PEI group and 50% (2/4) in the PEI + RFA group (p = 1.00). One patient in the PEI group developed severe biliary stricture and upstream dilatation that resulted in atrophy of the left hepatic lobe. One patient treated with PEI + RFA developed cholangitis and an abscess. Combined PEI and RFA treatment has a tendency to be more effective than PEI alone for managing HCCs in high risk locations, although the difference is not statistically significant. Even though PEI is generally accepted as a safe procedure, it may cause major biliary complications for managing HCCs adjacent to the portal vein.

  14. Risperidone-induced weight gain is mediated through shifts in the gut microbiome and suppression of energy expenditure

    Directory of Open Access Journals (Sweden)

    Sarah M. Bahr

    2015-11-01

    Full Text Available Risperidone is a second-generation antipsychotic that causes weight gain. We hypothesized that risperidone-induced shifts in the gut microbiome are mechanistically involved in its metabolic consequences. Wild-type female C57BL/6J mice treated with risperidone (80 μg/day exhibited significant excess weight gain, due to reduced energy expenditure, which correlated with an altered gut microbiome. Fecal transplant from risperidone-treated mice caused a 16% reduction in total resting metabolic rate in naïve recipients, attributable to suppression of non-aerobic metabolism. Risperidone inhibited growth of cultured fecal bacteria grown anaerobically more than those grown aerobically. Finally, transplant of the fecal phage fraction from risperidone-treated mice was sufficient to cause excess weight gain in naïve recipients, again through reduced energy expenditure. Collectively, these data highlight a major role for the gut microbiome in weight gain following chronic use of risperidone, and specifically implicates the modulation of non-aerobic resting metabolism in this mechanism.

  15. Enhancement of the anti-immobility action of antidepressants by risperidone in the forced swimming test in mice.

    Science.gov (United States)

    Rogóż, Zofia; Kabziński, Marcin

    2011-01-01

    The aim of the present study was to examine the effect of antidepressants (ADs) belonging to different pharmacological groups and risperidone (an atypical antipsychotic drug), given separately or jointly, on immobility time in the forced swimming test in male C57BL/6J mice. The antidepressants: citalopram, fluvoxamine, sertraline, reboxetine, milnacipran (5 and 10 mg/kg), or risperidone in low doses (0.05 and 0.1 mg/kg) given alone did not change the immobility time of mice in the forced swimming test. Co-treatment with reboxetine or milnacipran (10 mg/kg) and risperidone in a lower dose of 0.05 mg/kg or with sertraline, reboxetine (5 and 10 mg/kg), citalopram, fluvoxamine, milnacipran (10 mg/kg) and risperidone in a higher dose of 0.1 mg/kg produced antidepressant-like effect in the forced swimming test. WAY100635 (a 5-HT(1A) receptor antagonist) inhibited the effects induced by co-administration of ADs and risperidone. Active behavior in the forced swimming test was not a consequence of an increased general activity, since the combined treatment with ADs and risperidone failed to enhance the locomotor activity of mice. The obtained results indicate that a low dose of risperidone enhances the activity of ADs in an animal model of depression, and that, among other mechanisms, 5-HT(1A) receptors may play a role in these effects.

  16. Publication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration database.

    Directory of Open Access Journals (Sweden)

    Erick H Turner

    Full Text Available BACKGROUND: Publication bias compromises the validity of evidence-based medicine, yet a growing body of research shows that this problem is widespread. Efficacy data from drug regulatory agencies, e.g., the US Food and Drug Administration (FDA, can serve as a benchmark or control against which data in journal articles can be checked. Thus one may determine whether publication bias is present and quantify the extent to which it inflates apparent drug efficacy. METHODS AND FINDINGS: FDA Drug Approval Packages for eight second-generation antipsychotics-aripiprazole, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, risperidone long-acting injection (risperidone LAI, and ziprasidone--were used to identify a cohort of 24 FDA-registered premarketing trials. The results of these trials according to the FDA were compared with the results conveyed in corresponding journal articles. The relationship between study outcome and publication status was examined, and effect sizes derived from the two data sources were compared. Among the 24 FDA-registered trials, four (17% were unpublished. Of these, three failed to show that the study drug had a statistical advantage over placebo, and one showed the study drug was statistically inferior to the active comparator. Among the 20 published trials, the five that were not positive, according to the FDA, showed some evidence of outcome reporting bias. However, the association between trial outcome and publication status did not reach statistical significance. Further, the apparent increase in the effect size point estimate due to publication bias was modest (8% and not statistically significant. On the other hand, the effect size for unpublished trials (0.23, 95% confidence interval 0.07 to 0.39 was less than half that for the published trials (0.47, 95% confidence interval 0.40 to 0.54, a difference that was significant. CONCLUSIONS: The magnitude of publication bias found for antipsychotics was less

  17. 喹硫平与利培酮对女性精神分裂症患者血清泌乳素水平的影响%Effects of quetiapine and risperidone on serum prolactin levels of female schizophrenia

    Institute of Scientific and Technical Information of China (English)

    孙海华; 杨焕

    2013-01-01

    Objective To explore the effects of quetiapine and risperidone in the treatmemt of female schizophrenic patients and the effect of levels on serum prolactin. Methods 76 female schizophrenic patients were treated with quetiapine and risperidone randomly. The serum prolactin were measured and the scores of PANSS were evaluated before treatment and at the 1st、2nd、4th、8th week respectively. TESS was used to evaluate side effect. Results There were no significant differences in PANSS basal scores and the decreased scores after the treatment in two groups. The level of serum prolactin in risperidone group increased markedly than quetiapine group, and the serum prolactin level in quetiapine group were not increase significantly. Conclusion Quetiapine and risperidone have similar efficacy in the treatment of femal patients with schizophrenia. Risperidone produced increases in plasma prolactin levels in femal patients.%目的:评价喹硫平与利培酮对女性精神分裂症患者疗效和血清泌乳素水平的影响。方法选择女性精神分裂症患者76例,随机分为喹硫平与利培酮组治疗8周。采用阳性和阴性症状量表(PANSS)在治疗前及治疗第1周、2周、4周、8周末分别评定疗效,检测血清泌乳素水平,同时精神药物副反应量表(TESS)评定药物副反应。结果治疗前和治疗8周,两组在PANSS总分无显著差异。利培酮组血清泌乳素水平显著升高,并显著高于喹硫平组。喹硫平组血清泌乳素水平治疗前后无显著变化。结论喹硫平与利培酮对女性精神分裂症的疗效相似,利培酮对女性精神病患者的血清泌乳素水平有较大影响。

  18. Stability Indicating HPLC Determination of Risperidone in Bulk Drug and Pharmaceutical Formulations

    Directory of Open Access Journals (Sweden)

    Zarna R. Dedania

    2011-01-01

    Full Text Available The objective of the current study was to develop a validated stability-indicating assay method (SIAM for risperidone after subjecting it to forced decomposition under hydrolysis, oxidation, photolysis, and thermal stress conditions. The liquid chromatographic separation was achieved isocratically on a symmetry C18 column (5 μm size, 250 mm × 4.6 mm i.d. using a mobile phase containing methanol: acetonitrile (80 : 20, v/v at a flow rate of 1 mL/min and UV detection at 280 nm. Retention time of risperidone was found to be 3.35±0.01. The method was linear over the concentration range of 10–60 μg/mL(2=0.998 with a limit of detection and quantitation of 1.79 and 5.44 μg/mL, respectively. The method has the requisite accuracy, specificity, sensitivity, and precision to assay risperidone in bulk form and pharmaceutical dosage forms. Degradation products resulting from the stress studies did not interfere with the detection of Risperidone, and the assay is thus stability indicating.

  19. Sustained release of risperidone from biodegradable microspheres prepared by in-situ suspension-evaporation process.

    Science.gov (United States)

    An, Taekun; Choi, Juhyuen; Kim, Aram; Lee, Jin Ho; Nam, Yoonjin; Park, Junsung; Sun, Bo kyung; Suh, Hearan; Kim, Cherng-ju; Hwang, Sung-Joo

    2016-04-30

    Risperidone-loaded poly (D,L-lactide-co-glycolide) (PLGA) microspheres were prepared with a suspension-evaporation process with an aqueous suspension containing an in situ-formed aluminum hydroxide inorganic gel (SEP-AL process) and evaluated for encapsulation efficiency, particle size, surface morphology, glass transition temperature, in vitro drug release profile, and in vivo behavior. The SEP-AL microspheres were compared with conventional oil-in-water (O/W) emulsion solvent evaporation method using polyvinylalcohol (PVA) as an emulsifier (CP-PVA process). The microspheres were spherical in shape. DSC measurements showed that risperidone crystallinity was greatly reduced due to the homogeneous distribution of risperidone in PLGA microspheres. In vitro drug release profile from the microspheres showed a sigmoidal pattern of negligible initial burst up to 24h and minimal release (time-lag) for 7 days. After the lag phase, slow release took a place up to 25 days and then rapid release occurred sharply for 1 week. In vivo rat pharmacokinetic profile from the microspheres showed very low blood concentration level at the initial phase (up to 24h) followed by the latent phase up to 21 days. At the 3rd week, main phase started and the blood concentration of the drug increased up to the 5th week, and then gradually decreased. The risperidone-loaded PLGA microspheres produced by SEP-AL process showed excellent controlled release characteristics for the effective treatment of schizophrenia patients. PMID:26899975

  20. Sexual dysfunction and hormonal changes in first episode psychosis patients on olanzapine or risperidone

    NARCIS (Netherlands)

    M. van Bruggen; T. van Amelsvoort; L. Wouters; P. Dingemans; L. de Haan; D. Linszen

    2009-01-01

    Atypical antipsychotics interfere with central and peripheral neurotransmitter systems and with hormonal production. In this study we compared the effect of olanzapine and risperidone on hormonal state and sexual function (by using the Questionnaire for Sexual Dysfunction, QSD) in 40 patients with a

  1. Risperidone treatment for ADHD in children and adolescents with bipolar disorder

    Directory of Open Access Journals (Sweden)

    Joseph Biederman

    2008-03-01

    Full Text Available Joseph Biederman, Paul Hammerness, Robert Doyle, Gagan Joshi, Megan Aleardi, Eric MickPediatric Psychopharmacology Research Department, Massachusetts General Hospital, Boston, MA, USAObjective: Children and adolescents with bipolar disorder are also at high risk of having comorbid attention-deficit hyperactivity disorder (ADHD. The objective of this study was to estimate improvement in ADHD symptoms in children with bipolar disorder.Methods: This was an open-label, study of risperidone monotherapy for the treatment of pediatric bipolar disorder. Thirty-one children and adolescents 4–15 years of age (7.2 ± 2.8 years of both sexes (71%, N = 22 male with pediatric bipolar disorder (YMRS score = 32.9 ± 8.8 and ADHD (ADHD-RS score = 37.9 ± 8.9 were included in these analyses.Results: Improvement in ADHD symptoms was contingent on improvement in manic symptoms. Although both hyperactive/impulsive (−7.5 ± 5.5.6, p < 0.05 and inattentive (−6.8 ± 5.0, p < 0.05 ADHD symptoms were significantly improved with risperidone, improvement was modest, and only 29% of subjects (N = 6 showed a 30% reduction in ADHD rating scale scores and had a CGI-I ≤ 2.Conclusions: These results suggest that that treatment with risperidone is associated with tangible but generally modest improvement of symptoms of ADHD in children with bipolar disorder.Keywords: ADHD, bipolar disorder, children, risperidone

  2. Switching to quetiapine for risperidone-induced amenorrhea: Report of two cases

    Directory of Open Access Journals (Sweden)

    P K Pardal

    2010-01-01

    Full Text Available Almost all the antipsychotics can cause hyperprolactinemia-related side-effects like amenorrhea. Quetiapine has been reported to have minimal propensity to cause hyperprolactinemia. We report here two cases of risperidone-induced amenorrhea, who resumed their normal cycle on switching over the medication to quetiapine.

  3. Switching to quetiapine for risperidone-induced amenorrhea: Report of two cases

    OpenAIRE

    Pardal, P. K.; Raaj Konwar; Jyoti Prakash

    2010-01-01

    Almost all the antipsychotics can cause hyperprolactinemia-related side-effects like amenorrhea. Quetiapine has been reported to have minimal propensity to cause hyperprolactinemia. We report here two cases of risperidone-induced amenorrhea, who resumed their normal cycle on switching over the medication to quetiapine.

  4. Trabecular bone loss after administration of the second-generation antipsychotic risperidone is independent of weight gain.

    Science.gov (United States)

    Motyl, Katherine J; Dick-de-Paula, Ingrid; Maloney, Ann E; Lotinun, Sutada; Bornstein, Sheila; de Paula, Francisco J A; Baron, Roland; Houseknecht, Karen L; Rosen, Clifford J

    2012-02-01

    Second generation antipsychotics (SGAs) have been linked to metabolic and bone disorders in clinical studies, but the mechanisms of these side effects remain unclear. Additionally, no studies have examined whether SGAs cause bone loss in mice. Using in vivo and in vitro modeling we examined the effects of risperidone, the most commonly prescribed SGA, on bone in C57BL6/J (B6) mice. Mice were treated with risperidone orally by food supplementation at a dose of 1.25 mg/kg daily for 5 and 8 weeks, starting at 3.5 weeks of age. Risperidone reduced trabecular BV/TV, trabecular number and percent cortical area. Trabecular histomorphometry demonstrated increased resorption parameters, with no change in osteoblast number or function. Risperidone also altered adipose tissue distribution such that white adipose tissue mass was reduced and liver had significantly higher lipid infiltration. Next, in order to tightly control risperidone exposure, we administered risperidone by chronic subcutaneous infusion with osmotic minipumps (0.5 mg/kg daily for 4 weeks) in 7 week old female B6 mice. Similar trabecular and cortical bone differences were observed compared to the orally treated groups (reduced trabecular BV/TV, and connectivity density, and reduced percent cortical area) with no change in body mass, percent body fat, glucose tolerance or insulin sensitivity. Unlike in orally treated mice, risperidone infusion reduced bone formation parameters (serum P1NP, MAR and BFR/BV). Resorption parameters were elevated, but this increase did not reach statistical significance. To determine if risperidone could directly affect bone cells, primary bone marrow cells were cultured with osteoclast or osteoblast differentiation media. Risperidone was added to culture medium in clinically relevant doses of 0, 2.5 or 25 ng/ml. The number of osteoclasts was significantly increased by addition in vitro of risperidone while osteoblast differentiation was not altered. These studies indicate that

  5. Use of a Direct Observational Measure in a Trial of Risperidone and Parent Training in Children with Pervasive Developmental Disorders

    OpenAIRE

    HANDEN, BENJAMIN L.; JOHNSON, CYNTHIA R.; Butter, Eric M.; LECAVALIER, LUC; SCAHILL, LAWRENCE; Aman, Michael G; McDougle, Christopher J.; Arnold, L. Eugene; Swiezy, Naomi B.; Sukhodolsky, Denis G.; Mulick, James A.; White, Susan W.; Bearss, Karen; Hollway, Jill A.; Stigler, Kimberly A.

    2012-01-01

    A Structured Observational Analog Procedure (SOAP), an analogue measure of parent-child interactions, was used to assess treatment outcome in children with Autism Spectrum Disorder and serious behavior problems. It served as a secondary outcome measure in a 24-week, randomized trial of risperidone (MED; N=49) versus risperidone plus parent training (COMB; n=75) (ages 4–13 years). At 24-weeks, there was 28 % reduction in child inappropriate behavior during a Demand Condition (p=.0002) and 12 %...

  6. 穴位注射配合牵引治疗神经根型颈椎病疗效观察%Observations on the Efficacy of Acupuncture Point Injection plus Traction in Treating Cervical Spondylotic Radiculopathy

    Institute of Scientific and Technical Information of China (English)

    汪崇淼; 吴耀持; 张峻峰; 黄承飞

    2012-01-01

    目的 观察穴位注射配合牵引治疗神经根型颈椎病的临床疗效.方法 将122例神经根型颈椎病患者随机分为3组,观察组42例,进行穴位注射配合牵引治疗;穴位注射组40例,进行穴位注射治疗;牵引组40例进行牵引治疗.治疗结束比较3组间疗效差异.结果 观察组总有效率为92.9%,穴位注射组总有效率为72.5%,牵引组总有效率为75.0%,观察组总有效率与穴位注射组、牵引组比较差异均有统计学意义(P<0.05),穴位注射组与牵引组比较差异无统计学意义(P>0.05).结论 穴位注射配合牵引治疗神经根型颈椎病总有效率优于单纯穴位注射及单纯牵引治疗.%Objective To investigate the clinical efficacy of acupuncture point injection plus traction in treating cervical spondylotic radiculopathy. Method One hundred and twenty-two patients with cervical spondylotic radiculopathy were randomly allocated to three groups. The observation group of 42 patients received acupuncture point injection plus traction. The acupuncture point injection group of 40 patients and the traction group of 40 patients received corresponding treatments. The therapeutic effects were compared between the three groups after treatment. Result The total efficacy rate was 92.9% in the observation group, 72.5% in the acupuncture point injection group and 75.0% in the traction group; there was a statistically significant difference between the observation group and the acupuncture point injection group or the traction group (P 0.05). Conclusion The total efficacy rate of acupuncture point injection plus traction for cervical spondylotic radiculopathy is higher than that of acupuncture point injection alone and that of traction alone.

  7. 针刀配合痛点注射治疗肱骨外上髁炎疗效观察%Efficacy Observation on Acupotomology Combined with Trigger Point Injection for External Humeral Epicondylitis

    Institute of Scientific and Technical Information of China (English)

    姜丰山; 朱佩仪; 曾幸丽; 郭振宇; 卢利国

    2015-01-01

    目的:探讨针刀配合痛点注射治疗肱骨外上髁炎的疗效。方法:将105例肱骨外上髁炎患者随机分为三组:治疗组(35例)采用针刀配合痛点注射治疗,对照I组(35例)单纯采用针刀治疗,对照II组(35例)单纯采用痛点注射治疗,观察三组临床疗效。结果:治疗组总有效率高于对照I组、对照II组(P0.05)。结论:针刀配合痛点注射疗法能有效提高肱骨外上髁炎的临床疗效,安全有效,值得临床推广应用。%Objective:To investigate the efficacy of acupotomology combined with trigger point injection for external humeral epicondylitis. Meth-ods:105 cases of patients with external humeral epicondylitis were randomly divided into 3 groups:the treatment group (35 cases) treated by acu-potomology combined with trigger point injection, the control group I (35 cases) only by acupotomology, and control group II (35 cases) only by trig-ger point injection. observed the efficacy of 3 groups. Results:The total effective rate of treatment group was higher than that of control group I and control group II (P0.05). Conclusion:The treatment of acupotomology combined with trigger point injection ca n effictively improve the efficacy of external humeral epicon-dylitis, and its safety and effiective makes it worthy of promotion and application.

  8. 酮咯酸氨丁三醇穴位注射治疗肾绞痛的疗效观察%Efficacy of ketorolac tromethamine acupuncture point injection in the treatment of renal colic

    Institute of Scientific and Technical Information of China (English)

    代蓉; 杨鼎君

    2014-01-01

    Objective To evaluate the efficacy of ketorolac tromethamine with acupuncture point injection in the treatment of renal colic. Methods 176 patients with renal colic were randomly and equally divided into two groups,The control group was administrated with ketorolac tromethamine 30 mg with intramuscular injection. The treatment group was administrated with acupuncture point injection(bilateral Sanyinjiao and kidney shu points). The total effective rate, analgesic onset time and complete pain relief time were analyzed and compared between the two groups. Results The efficacy of the treatment group was better than that of the control group, the difference was statistically significant(P<0.05). Conclusion The efficacy of ketorolac tromethamine with acupuncture point injection is significantly improved and this approach was worthy of clinical.%目的:观察酮咯酸氨丁三醇穴位注射治疗肾绞痛的疗效。方法将176例肾绞痛患者随机分为治疗组和对照组,每组88例,均使用酮咯酸氨丁三醇30 mg,对照组采用肌肉注射,治疗组采用穴位注射(双侧三阴交和肾腧穴),对比2组疗效(包括总有效率、止痛起效时间、疼痛完全缓解时间)。结果治疗组疗效优于对照组,差异具有统计学意义(P<0.05)。结论将酮咯酸氨丁三醇用药途径由肌肉注射改为穴位注射后,可显著提高疗效,值得临床推广。

  9. Efficacy of risperidone, olanzapine and clozapine in the treatment of therapy resistant schizophrenia

    NARCIS (Netherlands)

    Wardenier, M; Slooff, CJ; Arends, J

    2000-01-01

    Therapy-resistance for positive symptoms is one of the most important problems that occurs with the medical treatment of schizophrenia. In the past years, clozapine has proven its effectiveness in this area and has been included in the treatment protocols and guidelines, Because of the risk of agran

  10. Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial

    Directory of Open Access Journals (Sweden)

    Ma Yi-Wen

    2011-04-01

    Full Text Available Abstract Background This post hoc analysis (trial registration: ClinicalTrials.gov NCT00590577 assessed onset of efficacy and tolerability of acute treatment with once-monthly paliperidone palmitate (PP, a long-acting atypical antipsychotic initiated by day 1 and day 8 injections, in a markedly to severely ill schizophrenia population. Methods Subjects entering the 13-week, double-blind trial were randomized to PP (39, 156, or 234 mg [25, 100, and 150 mg eq of paliperidone, respectively] or placebo. This subgroup analysis included those with a baseline Clinical Global Impressions-Severity (CGI-S score indicating marked to severe illness. PP subjects received a 234-mg day 1 injection (deltoid, followed by their assigned dose on day 8 and monthly thereafter (deltoid or gluteal. Thus, data for PP groups were pooled for days 4 and 8. Measures included Positive and Negative Syndrome Scale (PANSS, CGI-S, Personal and Social Performance (PSP, and adverse events (AEs. Analysis of covariance (ANCOVA and last-observation-carried-forward (LOCF methodologies, without multiplicity adjustments, were used to assess changes in continuous measures. Onset of efficacy was defined as the first time point a treatment group showed significant PANSS improvement (assessed days 4, 8, 22, 36, 64, and 92 versus placebo, which was maintained through end point. Results A total of 312 subjects met inclusion criterion for this subgroup analysis. After the day 1 injection, mean PANSS total scores improved significantly with PP (all received 234 mg versus placebo at day 4 (P = 0.012 and day 8 (P = 0.007. After the day 8 injection, a significant PANSS improvement persisted at all subsequent time points in the 234-mg group versus placebo (P P P P Conclusions In this markedly to severely ill population, acute treatment with 234 mg PP improved psychotic symptoms compared with placebo by day 4. After subsequent injections, observed improvements are suggestive of a dose

  11. 利培酮联合舍曲林治疗精神分裂症阴性症状临床研究%Combination of Risperidone and Sertraline in Negative Symptoms of Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    江永

    2013-01-01

    Objective:To explore the efficacies and safety of combination of risperidone and sertraline in negative symptoms of schizo -phrenia.Methods:60 schizophrenics were randomly divided into treatment (n=30,took risperidone combined with sertraline ) and control group (n=30,took risperidone ) dose of risperidone was 2~6mg/d and that of sertraline 100~200mg/d for 8 weeks.Before and after treatment , efficacies and side effects were assessed using the Negative Syndrome Scale ( NSS) and the Treatment Emergent Symptom Scale ( TESS) .Results:After treatment total score and factors , score of the NSS of both 2 groups obviously reduced and differences were signifi-cant (P<0.05).compared with the control group the total score of the NSS and factors',score of apathy poverty of thought abulia and in-terest blank obviously reduced in the treatment group and differences were significant (P<0.05).there was no difference in side effects between the 2 groups.Conclusion:combination of risperidone and sertraline is better than single risperidone in the treatment of negative symptoms of schizophrenia .%目的:探讨利培酮联合舍曲林治疗精神分裂症阴性症状的临床疗效和安全性。方法:将60例精神分裂症患者随机分为治疗组(利培酮+舍曲林)和对照组(利培酮)各30例,利培酮治疗剂量2~6mg/d,舍曲林50mg~200mg/d,疗程8周,治疗后采用阴性症状量表和副反应量表[1]评定临床疗效与不良反应。结果:2组治疗后阴性症状量表总分和因子分均显著下降,差异有统计学意义(P<0.05),治疗组阴性症状量表总分、情感平淡、思维贫乏、意志缺乏、兴趣缺乏等因子分较对照组下降明显,差异有统计学意义(P<0.05)。不良反应2组无显著性差异(P>0.05)。结论:利培酮联合舍曲林治疗精神分裂症阴性症状疗效优于单用利培酮治疗。

  12. Non-destructive quantitative analysis of risperidone in film-coated tablets.

    Science.gov (United States)

    Orkoula, M G; Kontoyannis, C G

    2008-07-15

    A simple, non-destructive, methodology based on FT-Raman spectroscopy was developed for the quantitative analysis of risperidone in commercially available film-coated tablets. A simple linear regression model was constructed based on standard tablets, prepared using the same manufacturing process as the commercially available. The tablets contained 0.27, 0.54, 1.08, 1.62, 2.16, 3.24 and 4.32 wt% risperidone. The most prominent Raman vibration of the active pharmaceutical ingredient at 1533 cm(-1), recorded using a home-made rotating system, was plotted against concentration. The model was tested on commercial film-coated tablets. The results were compared against those obtained by application of HPLC on the same samples. PMID:18359600

  13. A controlled study of risperidone oral solution combine with clonazepam tablet in the treatment of acute agitation in patients with schizophrenia%利培酮口服液合并氯硝西泮片治疗精神分裂症急性激越的对照研究

    Institute of Scientific and Technical Information of China (English)

    张庆娥; 王刚; 张玲; 王雪; 罗炯; 路亚洲; 姜涛; 王智民; 朱辉

    2012-01-01

    Objective: To compare the efficacy and safety of risperidone oral solution combined with clonazepam tablet versus haloperidol intramuscular treatment in the treatment of acute agitation in patients with schizophrenia. Method: A total of 60 schizophrenic patients with acute agitation were equally randomly assigned to receive either risperidone oral solution (2-6 mg/d) and clonazepam tablets (2-8 mg/d) ( RIS) or haloperidol intramuscular injection treatment( 10-20 mg/d) ( HAL) for 7 days. The efficacy outcome was measured by using the positive and negative syndrome scale (PANSS) , the positive and negative syndrome scale excited component(PANSS-EC) ,the assessment of patients'cooperation, the modified overt aggression scale( MOAS) and the clinical global impression scale (CGI). Safety was evaluated by using the Simpson-Angus rating scale (SAS) ,the Barnes Akathisia scale(BAS) ,the treatment emergent symptom scale(TESS) .adverse events and lab tests. Results:At the end of study,the mean scores of PANSS-EC were (11.1,3.6) and (12.9,5.2)respectively in RIS and HAL, with the significant reduction from baseline (P>0.05). There were no differences of the PANSS-EC scores and the total PANSS scores between two groups (P > 0.05). The improvements of the PANSS positive scores,the MOAS scores and the assessment of patients'cooperation scores were significant higher in RIS than in HAL( P < 0.05). The rates of myotonia and akathisia in RIS were significantly lower than in HAL (P<0. 01 ). Conclusion:The efficacy of risperidone oral solution combined with clonazepam tablet in the treatment of acute agitation in patients with schizophrenia is comparable to haloperidol intramuscular treatment. Treatment with risperidone oral solution combine with clonazepam tablet does better in controlling positive symptoms, aggressive behavior,compliance and tolerability than haloperidol intramuscular treatment.%目的:比较利培酮口服液合并氯硝西泮片与氟哌啶醇肌内注射治疗

  14. CHALLENGE WITH ATYPICAL ANTIPSYCHOTIC DRUGS IN RISPERIDONE INDUCED NEUROLEPTIC MALIGNANT SYNDROME: A CASE REPORT

    OpenAIRE

    Mendhekar, D.N.; Jiloha, R.C.; M M Mehndiratta; War, L.

    2002-01-01

    There are several reports available on neuroleptic malignant syndrome (NMS) associated with risperidone but when a more stringent criterion is applied there are only a few. Report on challenge and rechallenge with various atypical antipsychotic drugs in re-emergence of post NMS psychosis is scanty. Our aim of presenting this is to highlight the differential response of various atypical antipsychotic drugs in the treatment of post NMS psychosis. This paper reports a young male with mild mental...

  15. Risperidone treatment for ADHD in children and adolescents with bipolar disorder

    OpenAIRE

    Biederman, Joseph

    2008-01-01

    Joseph Biederman, Paul Hammerness, Robert Doyle, Gagan Joshi, Megan Aleardi, Eric MickPediatric Psychopharmacology Research Department, Massachusetts General Hospital, Boston, MA, USAObjective: Children and adolescents with bipolar disorder are also at high risk of having comorbid attention-deficit hyperactivity disorder (ADHD). The objective of this study was to estimate improvement in ADHD symptoms in children with bipolar disorder.Methods: This was an open-label, study of risperidone monot...

  16. Comparison the effectiveness of aripiprazole and risperidone for the treatment of acute bipolar mania

    OpenAIRE

    Amir Akhavan Rezayat; Paria Hebrani; Fatemeh Behdani; Mohamad Salaran; Majid Nabizadeh Marvast

    2014-01-01

    Background: Second-generation antipsychotics, approved for the treatment of mania, are associated with adverse effects such as weight gain and metabolic disorders. Aripiprazole, a recently introduced second-generation antipsychotic, are thought to account for its low propensity for weight gain, metabolic disturbances and sedation. The purpose of this study was to investigate the effect of risperidone versus aripiprazole in the treatment of acute mania. Materials and Methods: Fifty patients wi...

  17. 氨磺必利与利培酮治疗首发精神分裂症的疗效对照研究%Amisulpride and Risperidone Treatment First-episode Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    李婕

    2014-01-01

    Objective To analysis efficacy of amisulpride and risperidone treatment first -episode schizophrenia.Methods 74 patients with first -episode schizo-phrenia were given Amisulpride and risperidone therapy,BPRS score,adverse reaction were compared.Result BPRS rating scale values were significantly reduced,be-tween groups was no significant difference;observation group adverse reactions(18.92%) was obviously lower than the control group.Conclusion Amisulpride and risper-idone can be effective in the treatment of first-episode schizophrenia,Amisulpride low adverse reaction,good safety.%目的:分析氨磺必利与利培酮治疗首发精神分裂症的疗效差异。方法选择74例首发精神分裂症患者为研究对象,分别给予氨磺必利及利培酮治疗,比较BPRS量表评分、不良反应发生率。结果观察组与对照组BPRS量表评分值均明显降低,组间比较无明显差异(P>0.05);观察组不良反应发生率(18.92%)明显低于对照组(P<0.05)。结论氨磺必利与利培酮均可有效治疗首发精神分裂症,氨磺必利不良反应较少,具有优良的治疗安全性。

  18. Effervescent tablet formulation for enhanced patient compliance and the therapeutic effect of risperidone.

    Science.gov (United States)

    Mohammed, Kareem Abu Bakr; Ibrahim, Howida Kamal; Ghorab, Mahmoud Mohammed

    2016-01-01

    Risperidone is a poorly water soluble atypical antipsychotic drug. This work investigated the potential of developing risperidone effervescent tablets to facilitate drug administration and mask drug taste. The solid dispersion technique was selected to improve drug solubility due to its ease of scaling up, reproducibility and affordable cost. Thirty formulas were prepared adopting a 5(1).2(1).3(1) full factorial design. Trehalose, Inulin, pregelatinized starch, carboxymethylcellulose sodium and Eudragit E100 were used as hydrophilic carriers at different ratios. Rotovap, lyophilization and the kneading-oven were applied as solvent evaporation techniques. Differential scanning calorimetry, X-ray powder diffraction, Fourier transform infrared spectroscopy and scanning electron microscopy showed that the drug was present as amorphous material entrapped within the carrier matrix. Eight tablet blends were prepared using different effervescent mixture ratios with or without binder and lubricant/glidant mixture. All of the blends had acceptable flowability, acceptable effervescence times and immediate drug release that could not be achieved by any of the control formulas. The formula of choice contained 40% effervescent mixture, 5% starch, 1% boric acid, 1% aspartame and sufficient lactose. The relative bioavailability (RB) of risperidone from this formula was 161.41% with a significantly higher extent of absorption compared to the market conventional tablets. This formula may be promising in improving patient compliance and drug efficiency. PMID:24833273

  19. Clozapine and risperidone influence on cortisol and estradiol levels in male patients with schizophrenia.

    Science.gov (United States)

    Piriu, G; Torac, E; Gaman, L E; Iosif, L; Tivig, I C; Delia, C; Gilca, M; Stoian, I; Atanasiu, V

    2015-01-01

    Estrogens role in schizophrenia patients is a subject, which has gained an increased attention from the medical community. Estrogens have been shown to inhibit dopamine actions, improve neuronal regeneration, and overall, have a protective role in the pathology of schizophrenia. The adjunctive estrogen therapy for men is currently under debate. Antipsychotic medication is known to influence the hypothalamo-hypophyseal - gonadal axis by inducing variable degrees of hyperprolactinemia. Several studies have found that some of the atypical antipsychotics lower cortisol levels in patients and also in healthy controls. We have investigated the effects of clozapine and risperidone on estradiol levels in men with schizophrenia. We have also evaluated the levels of prolactin and cortisol, taking into account the possible influence of antipsychotic drugs on both these hormones. Both prolactin and cortisol also have the potential to regulate sexual hormones biosynthesis. Our study found decreased estradiol levels in men with schizophrenia treated with clozapine and risperidone, while prolactin levels were increased only in the risperidone treated group. Cortisol levels are not statistically significant different between groups. PMID:26664488

  20. Anesthetic efficacy of X-tip intraosseous injection using 2% lidocaine with 1:80,000 epinephrine in patients with irreversible pulpitis after inferior alveolar nerve block: A clinical study

    Directory of Open Access Journals (Sweden)

    Pushpendra Kumar Verma

    2013-01-01

    Full Text Available Introduction: The inferior alveolar nerve block (IAN is the most frequently used mandibular injection technique for achieving local anesthesia in endodontics. Supplemental injections are essential to overcome failure of IAN block in patients with irreversible pulpitis. Aim: To evaluate the anesthetic efficacy of X-tip intraosseous injection (2% lidocaine with 1:80,000 epinephrine in patients with irreversible pulpitis in mandibular posterior teeth when conventional IAN block failed. Materials and Methods: Thirty emergency patients diagnosed with irreversible pulpitis in a mandibular posterior tooth received an IAN block and experienced moderate to severe pain on endodontic access or initial instrumentation. The X-tip system was used to administer 1.8 ml of 2% lidocaine with 1:80,000 epinephrine. The success of X-tip intraosseous injection was defined as none or mild pain (Heft-Parker visual analogue scale ratings < 54 mm on endodontic access or initial instrumentation. Results: Ninety-three percent of X-tip injections were successful and 7% were unsuccessful. Discomfort rating for X-tip perforation: 96.66% patients reported none or mild pain, whereas 3.34% reported moderate to severe pain. For discomfort rating during solution deposition, 74.99% patients reported none or mild pain and 24.92% reported moderate to severe pain. Ninety-six percent of the patients had subjective/objective increase in heart rate. Conclusions: Supplemental X-tip intraosseous injection using 2% lignocaine with 1:80,000 epinephrine has a statistically significant influence in achieving pulpal anesthesia in patients with irreversible pulpitis.

  1. A comparison of the oral application and injection routes using the Onderstepoort Biological Products Fowl Typhoid vaccine, its safety, efficacy and duration of protection in commercial laying hens : article

    Directory of Open Access Journals (Sweden)

    C. Purchase

    2008-05-01

    Full Text Available This study was undertaken to establish whether the Onderstepoort Biological Products Fowl Typhoid (OBPft vaccine registered as an injectable vaccine was effective and safe when administered orally to commercial layers. Its efficacy and duration of protection were compared with application by intramuscular injection. Commercial brown layer hens were used as they were found to be highly susceptible to Salmonella gallinarum infections. In the vaccine safety trial birds were euthanased at timed intervals spanning 4 weeks post-vaccination. Necropsies were performed and samples were taken and tested. No clinical signs or mortalities could be attributed to the OBPft vaccine nor could active shedding of the vaccine strain be detected. Slight pathological changes were noted with both routes of vaccination; however, these changes were transient, returning to normal within the observation period. The injected groups showed a better serological response with the rapid serum plate agglutination (RSPA test than the orally vaccinated groups. In the duration of protection trial, birds were challenged at 3-8-week intervals post-vaccination. All unvaccinated birds died. Protection 8 and 16 weeks after vaccination was above 60 %, by 24 weeks after challenge, the vaccine protection was below 30 %. It was found that there was no significant difference (P < 0.05 in the protection offered by either the oral or injected route of vaccination with the OBPft vaccine.

  2. Botulinum toxin A injection for facial analysis the clinical efficacy and safety of facial wrinkles%A型肉毒毒素面部除皱的临床观察

    Institute of Scientific and Technical Information of China (English)

    王忠志; 刘茜

    2014-01-01

    目的:了解A型肉毒毒素面部注射进行面部除皱的临床疗效及安全性。方法回顾性分析我院2012年3月至2014年3月收治的64例行面部除皱的患者的临床资料,均应用A型肉毒毒素进行面部注射治疗,分析其临床疗效与安全性。结果64例患者经由A型肉毒毒素面部注射治疗后,所取得的效果较为理想,仅1例鼻部除皱术疗效欠佳。结论 A型肉毒毒素面部注射进行面部除皱临床疗效确切,不良反应少,值得临床大力推广与应用。%Objective: To investigate the botulinum toxin type A injection for facial clinical efficacy and safety of facial wrinkles. Methods: retrospective analysis of clinical data in our hospital from 2012 March to 2014 March treated 64 cases of facial wrinkles patients, both the application of botulinum toxin type A injection in the treatment of facial, analyze its clinical efficacy and safety. Results: 64 patients with botulinum toxin A injection for facial treatment, the effect is more ideal, only 1 cases of nasal rhytidectomy curative effect. Conclusion: botulinum toxin A injection for facial facial rhytidectomy clinical curative effect, less adverse reaction, it is worthy of clinical popularization and application.

  3. 鱼腥草注射液对急性咽炎治疗作用的实验研究%Experimental Research on the Efficacy of Yuxingcao Injection in Treating Acute Pharyngitis

    Institute of Scientific and Technical Information of China (English)

    王君

    2016-01-01

    Objective To observe the anti-inflammatory efficacy of Yuxingcao Injection in treating acute pharyngitis. Methods The anti-inflammation efficacy of Yuxingcao Injection was evaluated by the rat ear swelling test, judging from the histopathology of SD rat acute pharyngitis model with 15% ammonia. After 2 d of modeling, the administration was continued for 5 d. The blood routine examination of rats was measured, meanwhile the pharyngeal mucosa pathological section of SD rat acute pharyngitis model was detected. Results Yuxingcao Injection could inhibit the rat ear swelling;it had an obvious antipyretic effect and could alleviate the pathological changes on inflammatory mucous membrane in rat acute pharyngitis model. Conclusion Yuxingcao Injection can inhibit the acute inflammation, and it has the alleviating effect of the acute pharyngitis.%目的:观察鱼腥草注射液对急性咽炎大鼠的抗炎作用。方法运用小鼠耳肿胀试验评价鱼腥草注射液的抗炎消肿作用;采用15%氨水制备大鼠急性咽炎模型,造模2 d后,连续给药5 d,测定大鼠血常规,并做咽部黏膜病理切片,评价鱼腥草注射液抗急性咽炎的作用。结果鱼腥草注射液可抑制小鼠耳肿胀,降低急性咽炎模型大鼠血浆中白细胞含量,改善急性咽炎大鼠模型咽部黏膜病理变化。结论鱼腥草注射液具有较好的抗急性炎症,缓解急性咽炎作用。

  4. The antidepressant- and anxiolytic-like effects following co-treatment with escitalopram and risperidone in rats.

    Science.gov (United States)

    Kaminska, K; Rogoz, Z

    2016-06-01

    Several clinical reports have documented a beneficial effect of the addition of a low dose of risperidone to the ongoing treatment with antidepressants, in particular selective serotonin reuptake inhibitors (SSRI), in the treatment of drug-resistant depression and treatment-resistant anxiety disorders. In the present study, we investigated the effect of treatment with the antidepressant escitalopram (SSRI) given separately or jointly with a low dose of risperidone (an atypical antipsychotic) in the forced swim test and in the elevated plus-maze test in rats. The obtained results showed that escitalopram at doses of 2.5 or 5 mg/kg evoked antidepressant-like effect in the forced swim test. Moreover, risperidone at low doses (0.05 or 0.1 mg/kg) enhanced the antidepressant-like activity of escitalopram (1 mg/kg) in this test by increasing the swimming time and decreasing the immobility time in those animals. WAY 100635 (a serotonin 5-HT1A receptor antagonist) at a dose of 0.1 mg/kg abolished the antidepressant-like effect induced by co-administration of escitalopram and risperidone. The active behavior in that test did not reflect an increase in general activity, since the combined treatment with escitalopram and risperidone failed to enhance the exploratory activity of rats. In the following experiment, we showed that escitalopram (5 mg/kg) and mirtazapine (5 or 10 mg/kg) or risperidone (0.1 mg/kg) induced an anxiolytic-like effect in the elevated plus-maze test, and the combined treatment with an ineffective dose of risperidone (0.05 mg/kg) enhanced the anxiolytic-like effects of escitalopram (2.5 mg/kg) or mirtazapine (1 and 2.5 mg/kg) in this test. The obtained results suggest that risperidone applied at a low dose enhances the antidepressant-like activity of escitalopram in the forced swim test, and that 5-HT1A receptors may play some role in these effects. Moreover, a low dose of risperidone may also enhance the anxiolytic-like action of the studied

  5. The antidepressant- and anxiolytic-like effects following co-treatment with escitalopram and risperidone in rats.

    Science.gov (United States)

    Kaminska, K; Rogoz, Z

    2016-06-01

    Several clinical reports have documented a beneficial effect of the addition of a low dose of risperidone to the ongoing treatment with antidepressants, in particular selective serotonin reuptake inhibitors (SSRI), in the treatment of drug-resistant depression and treatment-resistant anxiety disorders. In the present study, we investigated the effect of treatment with the antidepressant escitalopram (SSRI) given separately or jointly with a low dose of risperidone (an atypical antipsychotic) in the forced swim test and in the elevated plus-maze test in rats. The obtained results showed that escitalopram at doses of 2.5 or 5 mg/kg evoked antidepressant-like effect in the forced swim test. Moreover, risperidone at low doses (0.05 or 0.1 mg/kg) enhanced the antidepressant-like activity of escitalopram (1 mg/kg) in this test by increasing the swimming time and decreasing the immobility time in those animals. WAY 100635 (a serotonin 5-HT1A receptor antagonist) at a dose of 0.1 mg/kg abolished the antidepressant-like effect induced by co-administration of escitalopram and risperidone. The active behavior in that test did not reflect an increase in general activity, since the combined treatment with escitalopram and risperidone failed to enhance the exploratory activity of rats. In the following experiment, we showed that escitalopram (5 mg/kg) and mirtazapine (5 or 10 mg/kg) or risperidone (0.1 mg/kg) induced an anxiolytic-like effect in the elevated plus-maze test, and the combined treatment with an ineffective dose of risperidone (0.05 mg/kg) enhanced the anxiolytic-like effects of escitalopram (2.5 mg/kg) or mirtazapine (1 and 2.5 mg/kg) in this test. The obtained results suggest that risperidone applied at a low dose enhances the antidepressant-like activity of escitalopram in the forced swim test, and that 5-HT1A receptors may play some role in these effects. Moreover, a low dose of risperidone may also enhance the anxiolytic-like action of the studied

  6. Risperidone and Divalproex Differentially Engage the Fronto-Striato-Temporal Circuitry in Pediatric Mania: A Pharmacological Functional Magnetic Resonance Imaging Study

    Science.gov (United States)

    Pavuluri, Mani N.; Passarotti, Alessandra M.; Fitzgerald, Jacklynn M.; Wegbreit, Ezra; Sweeney, John A.

    2012-01-01

    Objective: The current study examined the impact of risperidone and divalproex on affective and working memory circuitry in patients with pediatric bipolar disorder (PBD). Method: This was a six-week, double-blind, randomized trial of risperidone plus placebo versus divalproex plus placebo for patients with mania (n = 21; 13.6 [plus or minus] 2.5…

  7. Xuesaitong injection point injection of spastic limb spasticity after stroke improved clinical efficacy%血塞通注射液痉挛点注射治疗脑卒中后肢体痉挛22例临床观察

    Institute of Scientific and Technical Information of China (English)

    蒋再轶; 韩国栋; 冯建宏

    2011-01-01

    Objective Xuesaitong injection point injection for spasticity after stroke improved clinical efficacy of limb spasticity. Methods 51 patients were randomly divided into A, B group and C group, A group given Xuesaitong injection injection combined hemiplegic limb rehabilitation, B group was given acupuncture treatment acupuncture and rehabilitation of hemiplegic limb, C group only to be hemiplegic limb rehabilitation treatment, 4 weeks for a course of treatment, were treated with a course of treatment, in the treatment of 2 weeks, 4 weeks to Ashworth spasticity scale for efficacy evaluation. Results Three groups of patients with limb spasticity were improved, A group and the other two groups, the difference was statistically significant (P <0.05), for improving the physical state of spasm, spasm Xuesaitong injection point injection group was better than the other two group. Conclusion Xuesaitong injection point injection combined spastic hemiplegic limb rehabilitation after stroke can improve limb spasticity.%目的:观察血塞通注射液痉挛点注射对改善脑卒中后肢体痉挛状态的临床疗效.方法:将51例患者随机分为A组、B组与C组,A组给予血塞通注射液痉挛点注射联合偏瘫肢体康复治疗,B组给予穴位针刺联合偏瘫肢体康复治疗,C组只予以偏瘫肢体康复治疗.3组均以4周为1个疗程,共治疗1个疗程,在治疗2周、4周末以Ashworth痉挛量表进行疗效评价.结果:3组患者患肢痉挛状态均有改善,A组与其他两组疗效比较,差异有统计学意义(P<0.05),优于B、C组.结论:血塞通注射液痉挛点注射,联合偏瘫肢体康复治疗能够改善脑卒中后肢体痉挛状态.

  8. Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study

    Directory of Open Access Journals (Sweden)

    Sacristán Jose A

    2001-12-01

    Full Text Available Abstract Background In order to compare the effectiveness of different antipsychotic drugs in the treatment of schizophrenia it is very important to evaluate subjective response and compliance in patient cohorts treated according to routine clinical practice. Method Outpatients with schizophrenia entered this prospective, naturalistic study when they received a new prescription for an antipsychotic drug. Treatment assignment was based on purely clinical criteria, as the study did not include any experimental intervention. Patients treated with olanzapine, risperidone or haloperidol were included in the analysis. Subjective response was measured using the 10-item version of the Drug Attitude Inventory (DAI-10, and treatment compliance was measured using a physician-rated 4 point categorical scale. Results A total of 2128 patients initiated treatment (as monotherapy with olanzapine, 417 with risperidone, and 112 with haloperidol. Olanzapine-treated patients had significantly higher DAI-10 scores and significantly better treatment compliance compared to both risperidone- and haloperidol-treated patients. Risperidone-treated patients had a significantly higher DAI-10 score compared to haloperidol-treated patients. Conclusion Subjective response and compliance were superior in olanzapine-treated patients, compared to patients treated with risperidone and haloperidol, in routine clinical practice. Differences in subjective response were explained largely, but not completely, by differences in incidence of EPS.

  9. Risperidone and Clozapine on Blood Glucose and Lipid Metabolism in Patients With Schizophrenia%利培酮和氯氮平对精神分裂症患者血糖和脂代谢的影响

    Institute of Scientific and Technical Information of China (English)

    刘召英

    2016-01-01

    目的:研究利培酮和氯氮平对精神分裂症患者血糖和脂代谢的影响。方法选择2014年1月~2015年1月来我院精神科治疗精神分裂症的患者62例,随机分成利培酮组和氯氮平组,各31例,观察两组患者治疗效果。结果治疗后,利培酮组 TC 水平为(4.81±0.15) mmol/L 低于氯氮平组 TC 水平(5.25±0.24)mmol/L,两组血糖及血脂指标相比,差异均有统计学意义(P <0.05)。结论采用利培酮和氯氮平治疗精神分裂症对患者的血糖和脂代谢水平均有影响,相对而言氯氮平影响较大,临床医生在治疗精神分裂症时应该慎重使用药物。%Objective To observe the efficacy of risperidone and clozapine on blood glucose and lipid metabolism in patients with schizophrenia. Methods Selected 62 patients with schizophrenia from January 2014 to January 2015 in our hospital were randomly divided into risperidone group and clozapine group,31 cases,the treatment groups were observed. Results After treatment,the levels of TC risperidone group(4.81±0.15)mmol/L group was significantly lower than clozapine TC levels(5.25±0.24)mmol/L,glucose and lipid levels compared to the two groups,the differences were statistical y significance(P< 0.05). Conclusion Use wil significantly affect the treatment of schizophrenia with risperidone and clozapine on blood glucose and lipid metabolism in patients with relatively greater impact in terms of clozapine,clinicians in the treatment of schizophrenia drugs should be used with caution.

  10. Efficacy of a Multi-level Intervention to Reduce Injecting and Sexual Risk Behaviors among HIV-Infected People Who Inject Drugs in Vietnam: A Four-Arm Randomized Controlled Trial.

    Directory of Open Access Journals (Sweden)

    Vivian F Go

    Full Text Available Injecting drug use is a primary driver of HIV epidemics in many countries. People who inject drugs (PWID and are HIV infected are often doubly stigmatized and many encounter difficulties reducing risk behaviors. Prevention interventions for HIV-infected PWID that provide enhanced support at the individual, family, and community level to facilitate risk-reduction are needed.455 HIV-infected PWID and 355 of their HIV negative injecting network members living in 32 sub-districts in Thai Nguyen Province were enrolled. We conducted a two-stage randomization: First, sub-districts were randomized to either a community video screening and house-to-house visits or standard of care educational pamphlets. Second, within each sub-district, participants were randomized to receive either enhanced individual level post-test counseling and group support sessions or standard of care HIV testing and counseling. This resulted in four arms: 1 standard of care; 2 community level intervention; 3 individual level intervention; and 4 community plus individual intervention. Follow-up was conducted at 6, 12, 18, and 24 months. Primary outcomes were self-reported HIV injecting and sexual risk behaviors. Secondary outcomes included HIV incidence among HIV negative network members.Fewer participants reported sharing injecting equipment and unprotected sex from baseline to 24 months in all arms (77% to 4% and 24% to 5% respectively. There were no significant differences at the 24-month visit among the 4 arms (Wald = 3.40 (3 df; p = 0.33; Wald = 6.73 (3 df; p = 0.08. There were a total of 4 HIV seroconversions over 24 months with no significant difference between intervention and control arms.Understanding the mechanisms through which all arms, particularly the control arm, demonstrated both low risk behaviors and low HIV incidence has important implications for policy and prevention programming.ClinicalTrials.gov NCT01689545.

  11. 齐拉西酮与利培酮治疗精神分裂症的临床对照研究%The Comparative Investigation between Ziprasidone and Risperidone in the Treatment of Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    潘勇; 王皖生; 支瑞瑞

    2011-01-01

    目的 探讨齐拉西酮与利培酮治疗精神分裂症的临床疗效与安全性.方法 将60例符合第三版(CCMD-3)诊断的精神分裂症患者随机分为研究组和对照组各30例,分别予以齐拉西酮与利培酮治疗,疗程8周.分别于治疗前及治疗第8周末采用阳性症状和阴性症状量表(positive symptoms and negative symp-toms scale,PANSS)评定疗效,以治疗中出现的不良反应采用副反应量表(treatment emersent symptom scale,TESS)进行评定.结果 治疗8周后,齐拉西酮组的显效率为66.7%,总有效率为86.7%,利培酮组的显效率为70%,总有效率为90%,两组比较,差异无统计学意义(P>0.05).两组PANSS评分治疗后均较治疗前明显下降,两组比较,差异有统计学意义(P<0.05).齐拉西酮组引起患者锥体外系副反应,体重增加,女性月经改变等方面的几率明显少于利培酮组.结论 齐拉西酮对精神分裂症疗效与利培酮相当,不良反应较少,依从性好.%Objective To explore the clinical efficacy and safety of ziprasidone and risperidone in the treatment of schizophrenia. Methods 60 patients cases met the CCMD-3 diagnosis of schizophrenia were randomly assigned to ziprasidone group( n=30)or risperidone group( n=30 ). The efficacy of patients were assessed with the positive symptoms and negative symptoms scale (PANSS), and the side efficacy was evaluated with treatment emergent symptom scale (TESS). Results After 8 weeks treatment,the marked improvement rate was 66.7% and effective rate was 86.7% in ziprasidone group,while 70% and 90% in risperidone group, and there were no significant differences between two groups( P > 0. 05 ). After treatment, the two groups showed significant differences compared with the PANSS. Frequency of extrapyramidal reactions, weight gain, and menstrual changes in women were significantly less in ziprasidone group than in risperidone. Conclusion Ziprasidone was as effective as risperidone for the

  12. Atypical antipsychotics olanzapine, quetiapine, and risperidone and risk of acute major cardiovascular events in young and middle-aged adults

    DEFF Research Database (Denmark)

    Pasternak, Björn; Svanström, Henrik; Ranthe, Mattis F;

    2014-01-01

    risperidone (n = 14,134). The primary outcome was any major cardiovascular event (composite of cardiovascular mortality, acute coronary syndrome, or ischemic stroke) within 1 year following treatment initiation. Cox regression was used to estimate hazard ratios (HRs) while on current antipsychotic monotherapy......BACKGROUND: A number of serious cardiovascular safety concerns related to the use of atypical antipsychotics, compared with no use, have emerged, but nearly all reports are from studies of older patients. We aimed to compare the risk of cardiovascular events between the three most commonly used...... in the outpatient setting, adjusting for an outcome-specific disease risk score. RESULTS: The crude rate of any major cardiovascular event was 5.3 per 1,000 person-years among olanzapine users, 3.4 in quetiapine users, and 5.2 in risperidone users. Compared with risperidone, the risk of any major cardiovascular...

  13. Evaluations of therapeutic efficacy of intravitreal injected polylactic-glycolic acid microspheres loaded with triamcinolone acetonide on a rabbit model of uveitis.

    Science.gov (United States)

    Li, Wenchang; He, Bing; Dai, Wenbing; Zhang, Qiang; Liu, Yuling

    2014-06-01

    Conventional treatments of uveitis are not ideal because of the short period of therapeutic efficacy. In the present study, biodegradable polylactic-glycolic acid microspheres loaded with triamcinolone acetonide (TA) were prepared to achieve sustained drug release and their therapeutic efficacy was investigated on a rabbit model of uveitis. TA-loaded microspheres (TA-MS) were prepared by the solvent evaporation method and characterized for encapsulation efficiency, particle size, morphology and in vitro release. The therapeutic efficacy was studied on the rabbit experimental uveitis model based on scoring of the inflammation, aqueous leukocyte counting, aqueous protein determination and histological examination. The TA-MS exhibited smooth and intact surfaces with an average diameter of 50.87 μm. The drug-loading coefficient and encapsulation efficiency were 15.2 ± 0.6 % and 91.24 ± 3.77 %, respectively. The drug release from TA-MS lasted up to 87 days, but only 46 days for TA suspension. The change in surface morphology also showed sustained drug release from TA-MS. TA-MS exhibited improved therapeutic efficacy in lipopolysaccharide -induced uveitis compared to TA suspension, especially in regard to the inhibition of inflammation. The TA-MS had a longer-term therapeutic effect on intraocular inflammation in LPS-induced uveitis in rabbits compared to TA suspension. The results suggested that TA-MS can be developed as a potential sustained-release system for the treatment of uveitis.

  14. Soft tissue injections

    OpenAIRE

    Inês, Luís P. B. S.; Silva, José António P. da

    2005-01-01

    Soft tissue rheumatism includes a wide spectrum of common lesions of the tendons, enthesis, tendon sheaths, bursae, ligaments and fasciae as well as nerve compression syndromes. Studies on the pathogenesis of these lesions do not support a major role for inflammation, thus questioning the rationale for glucocorticoid injections. This chapter reviews current indications for local glucocorticoid injections and available evidence on its efficacy, as well as contraindications and potential risks....

  15. Dopamine transporter density assessed with [123]IPT SPECT before and after risperidone treatment in children with tourette's disorder

    International Nuclear Information System (INIS)

    Tourette's disorder (TD), which is characterized by multiple waxing and waning motor tics and one or more vocal tics, is known to be associated with abnormalities in the dopaminergic system. To testify our hypothesis that risperidone would improve tic symptoms of TD patients through the change of the dopaminergic system, we measured the dopamine transporter (DAT) densities between drug-naive children with TD and normal children, and investigated the DAT density before and after treatment with risperidone in drug-naive children with TD, using iodine-123 labelled N-(3-iodopropen-2-yl)-2β-carbomethoxy-3beta-(4-chlorophenyl)tropane ([123I]IPT) single photon emission computed tomography (SPECT). [123I]IPT SPECT imaging and Yale Global Tic Severity Scale-Korean version (YGTSS-K) for assessing the tic symptom severity were carried out before and after treatment with risperidone for 8 weeks in nine drug-naive children with TD. Eleven normal children also underwent SPECT imaging 2 hours after an intravenous administration of [123I]IPT. Drug-naive children with TD had a significantly greater increase in the specific/nonspecific DAT binding ratio of both basal ganglia compared with the normal children. However, no significant difference in the specific/nonspecific DAT binding ratio of the basal ganglia before and after treatment with risperidone in children with TD was found, although tic symptoms were significantly improved with risperidone. These findings suggest that DAT densities are directly associated with the pathophysiology of TD, however, that the effect of risperidone on tic symptoms in children with TD is not attributed to the change of dopaminergic system

  16. Risperidone regulates Dopamine D2-like receptors expression in rat brain in a time-dependent manner

    Directory of Open Access Journals (Sweden)

    Ni Peiyan

    2015-03-01

    Full Text Available Background and Objectives: Antipsychotics can elicit dopamine super-sensitivity by up-regulation of D2-like receptors (DRD2, DRD3, and DRD4 expression. Nevertheless, the expression profile of dopamine D2-like receptors in different brain regions and peripheral blood mononuclear cells (PBMCs, and changes following risperidone administration were still unclear. In this study, we would investigate the expression of D2-like receptors mRNA in different brain regions and the peripheral blood mononuclear cells (PBMCs in rats after 2, 6 weeks risperidone administration. Methods: The experimental rats were given risperidone (0.25mg/kg/day, i.p., and the control rats were given 0.9% NaCl. The rats were sacrificed at 0 week, 2 weeks and 6 weeks after the drug administration. Expression of the dopamine D2-like receptors was quantified by Real-time PCR method. Results: Dopamine D2-like receptors expressed in all the examined regions of rat brain. Their expression significantly increased 2weeks after risperidone administration in different brain regions. However, the changed expression of DRD2 and DRD3 turned back to the basal level 6weeks later, while the increased DRD4 expression remained in left parietal cortex. Meanwhile, DRD2 and DRD3 but not DRD4 expressed in PBMCs, however, the risperidone could not affect their expression. Conclusions: The risperidone could change the dopamine D2-like receptors expression in a time-dependent manner in different brain regions, which might guide the clinical use in the near future.

  17. Motherwort Injection Associate with Oxytocin Prevention and Treatment of Postpartum Hemorrhage Efficacy%益母草注射液与催产素联用防治产后出血的疗效观察

    Institute of Scientific and Technical Information of China (English)

    刘淑芳

    2013-01-01

    Objective:The contrast observed motherwort injection and oxytocin in combination in the prevention of postpartum hemorrhage clinical efficacy. Method:We randomly selected 180 cases of pregnant women giving birth in our hospital September 2009 to September 2012 conducted a case-control study,all patients randomized divided into the control group and the test group.control group after delivery of the fetus 20 U injection oxytocin Suji;joint injection motherwort injection 2 ml of test group on the basis of the control group;compare the number of record the two groups of patients 2 and 24 hours post-partum bleeding,to assess of motherwort injection of oxytocin joint applications clinical efficacy. Result:motherwort injection combined with oxytocin treatment group 2 hours postpartum hemorrhage(164.3 ± 30.2)ml significantly less than a single injection of oxytocin group( 254.1±29.3) ml;cases of postpartum hemorrhage(3/3.3%)was significantly less than the control group(9/10);significant difference between the two sets of data,a statistically significant(P0.05). Conclusion:Postpartum joint the intramuscular injection Motherwort injection and oxytocin to effective prevention of maternal postpartum hemorrhage.%  目的:对比观察益母草注射液与催产素联合应用在预防产后出血中的临床疗效.方法:随机选取于本院分娩的孕妇的180例2009年9月-2012年9月进行病例对照研究,将所有患者随机分为对照组和试验组.对照组在胎儿分娩后给予20 U 催产素肌内注射;试验组在对照组的基础上联合注射益母草注射液2 ml;记录两组患者产后2 h 和24 h 的出血数量,进行比较,评定益母草注射液与催产素联合应用的临床疗效.结果:益母草注射液联合催产素治疗组2 h 的产后出血量(164.3±30.2)ml 明显少于单独注射催产素组(254.1±29.3)ml;产后出血的例数(3/3.3%)明显少于对照组(9/10%),差异均有统计学意义(P0.05).结论:产后联

  18. Randomized Controlled Study on Combination Treatment with Oral Risperidone and Clonazepam versus Initial Treatment with Intramuscular Haloperidol Followed by Oral Risperidone%利培酮口服液合并氯硝西泮与氟哌啶醇肌注后换用利培酮口服液临床对照研究

    Institute of Scientific and Technical Information of China (English)

    蒋幸衍; 徐清; 周德祥; 方馨怡; 陆雅娜; 夏鸣华

    2012-01-01

    目的 比较利培酮口服液合并氯硝西泮片与氟哌啶醇肌注控制精神分裂症兴奋激越症状的疗效和安全性,以及在兴奋激越控制后以利培酮口服液替换氟哌啶醇肌注的疗效及安全性.方法 纳入65例兴奋激越的精神分裂症患者:33例随机分入研究组,利培酮口服液(2~6m/d)合并氯硝西泮(2~4mg/d),第8天起氯硝西泮逐渐减量,共观察49d;32例分入对照组,前7天氟哌啶醇肌注(10~20mg/d),第8天起逐渐替换为利培酮口服液(2~6ml/d),共观察49d.以阳性与阴性症状量表(PANSS)及兴奋激越项目(PANSS-EC)和治疗中出现的症状量表(TESS)评定疗效和不良反应,分别在入组时及治疗第7天、第14天、第49天各评定1次.结果 两组有效率比较无显著性差异(x2=0.14,P>0.05).治疗前后比较,两组PANSS总分从治疗第7天起下降有显著性差异(t=2.27,2.39;P均<0.05),从治疗第14天起下降有非常显著性差异(t=3.40,4.30;P均<0.01);两组PANSS-EC评分从治疗第7天起下降并有非常显著性差异(t=7.01,8.44;P均<0.01);两组治疗同期PANSS总分、PANSS-EC评分比较无显著性差异(t=0.49~1.82;P均>0.05).研究组肌强直、震颤、静坐不能的发生率均明显低于对照组(x2=5.63~10.46;P均<0.05).结论 利培酮口服液合并氯硝西泮可有效安全地治疗精神分裂症急性兴奋激越.用氟哌啶醇肌注控制兴奋激越后直接换用利培酮口服液,也能保持疗效.%Objective To explore the efficacy and safety of psychotic agitation in schizophrenic patients comparing combination treatment with oral risperidone and clonazepam versus initial treatment with intramuscular haloperidol followed by oral risperidone. Methods A total of 63 schizophrenic patients with acute psychotic agitation were randomly assigned to two groups. The 33 subjects in the study group were given 7 days of combined treatment with oral risperidone (2 - 6mg/d)and clonazepam(2-4mg

  19. The efficacy of potato chips combined with hot compress in the prevention of callus formation after intramuscular injections%土豆片联合热敷对预防肌注后硬结的疗效观察

    Institute of Scientific and Technical Information of China (English)

    李姣红; 罗燕; 陆月明

    2012-01-01

    Objective To compare the efficacy of hot compress alone with that of hot water bag plus warm moist compress with potato chips in the prevention of callus formation after intramuscular injections,and the seek the most effective method to prevent calluses caused by chronic intramuscular injections.Methods A self-controlled study were conducted on 120 patients who received intramuscular injections of progesterone.Hot compress and hot water bag plus warm moist compress with potato chips were applied on the deltoid muscle in each arm after the patients received first injection.The incidence rate of callus at the injection site and the pain levels were observed in all the patients.Results The incidence rates of injection-induced pain and callus formation were lower in the group with hot water bag plus warm moist compress with potato chips than the group with hot compress alone,with a statistical difference ( P< 0.001 ).Conclusions Hot water bag plus warm moist compress with potato chips is superior to hot compress alone in the prevention of callus formation and the relief of pain after intramuscular injections.%目的 比较单用热敷法与热水袋+土豆片湿热敷法预防肌注后硬结发生的疗效,寻找预防长期肌注后硬结的最有效方法.方法 选择120例肌注黄体酮的患者,采用自身对照,在每例患者的两侧臂大肌首次注射后,分别用热敷法(热敷组)和热水袋+土豆片湿热敷(联用组),观察患者注射局部硬结的发生率,疼痛程度.结果 联用组较热敷组局部硬结的形成及疼痛发生率低,两者比较差异有统计学意义(P< 0.001).结论 联用法预防肌注后硬结的发生,减轻患者疼痛效果优于单用热敷法.

  20. Double-blind randomized trial of risperidone versus divalproex in pediatric bipolar disorder: fMRI outcomes

    OpenAIRE

    Pavuluri, Mani N.; Passarotti, Alessandra M.; Lu, Lisa H.; Carbray, Julie A; Sweeney, John A.

    2011-01-01

    To determine the relative effects of risperidone and divalproex on brain function in pediatric mania. This is a double-blind 6-week fMRI trial with 24 unmedicated manic patients randomized to risperidone or divalproex, and 14 healthy controls (HC) matched for IQ and demographic factors (mean age: 13.1±3.3 years). A pediatric affective color matching task, in which subjects matched the color of a positive, negative or neutral word with one of two colored circles, was administered. The primary ...

  1. 胸椎旁注射治疗带状疱疹后神经痛%Clinical efficacy of thoracic paravertebral injection in post-herpetic neuralgia cases

    Institute of Scientific and Technical Information of China (English)

    施小妹; 宋涛; 王秋石; 崔文瑶; 奚奇; 吴兆奇

    2012-01-01

    Objective To analyze the effects of thoracic paravertebral injection on post-herpetic neuralgia pa tients. Methods 30 patients underwent post-herpetic neuralgia received thoracic paravertebral injection with neuro tropin,diprospan,lidocaine and ropivacaine weekly for 4 weeks. The pain intensity, sleep quality, symptom of allodynia and side effects during the therapy were observed. The intensity of pain was assessed by Visual analogue scale( VAS ), and the quality of sleep was measured by Pittsburge sleep quality index( PSQI ). Results The VAS and PSQI de creased definitely( P <0. 01 ),each injection showed definite reduction on VAS compared with the last one except the fourth injection,and the symptom of allodynia was mostly cured( 78. 26% ). No obvious side effect was found. Conclu sion Thoracic paravertebral injection is effective and safe for post-herpetic neuralgia patients and injection for more than three times is unnecessary.%目的 研究胸椎旁注射治疗胸背部带状疱疹后神经痛的疗效.方法 胸背部带状疱疹后神经痛患者30例,给予胸椎旁注射,药物:神经妥乐平、得宝松、利多卡因、罗哌卡因.每周1次,共4周.记录治疗前后的VAS值,匹兹堡睡眠质量指数PSQI,是否存在痛觉超敏以及治疗过程中的不良反应.结果 与治疗前比较,VAS值和PSQI均显著降低(P<0.01);VAS值:前3次注射每次均较上一次显著降低,但第4次与第3次比较,差异无统计学意义;痛觉超敏缓解率为78.26%;胸椎旁注射治疗中和治疗后未出现明显不良反应.结论 胸椎旁注射治疗带状疱疹后神经痛疗效确切,安全可行.但3次以上的治疗则无必要.

  2. Gabapentin adjunctive to risperidone or olanzapine in partially responsive schizophrenia: an open-label pilot study

    Directory of Open Access Journals (Sweden)

    Adel Gabriel

    2010-10-01

    Full Text Available Adel GabrielDepartments of Psychiatry and Community Health Sciences, University of Calgary, Alberta, CanadaBackground: There is a great need in the treatment of schizophrenia for a drug, or drug ­combinations, to improve clinical response with fewer serious side effects. The objective of this study was to explore the therapeutic effects and tolerability of the anticonvulsant gabapentin as an adjunctive in the treatment of patients with partially responsive schizophrenia.Methods: Ten consenting patients with a confirmed Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision diagnosis of schizophrenia were identified. All patients failed at least one 12-week treatment trial with risperidone or olanzapine. Gabapentin was added to ongoing antipsychotic treatment with olanzapine or risperidone for eight weeks. The primary outcome measure was the Positive and Negative Syndrome Scale (PANSS. Other scales included the Calgary Depression Scale (CDSS and the Abnormal Involuntary Movement Scale (AIMS. Repeated-measures multivariate analysis of variance was utilized to examine changes in outcome measures over time with adjunctive treatment with gabapentin.Results: There was a significant drop in the PANSS and CDSS scores at endpoint (week 8. There were no significant differences between the two treatment groups with regard to changes in all outcome measures or in AIMS score. The adjunctive treatments were well tolerated and side effects were transient.Conclusion: Gabapentin could be used successfully as an adjunct to novel antipsychotics in partially responsive schizophrenia. However, large controlled studies are needed to examine the effectiveness of gabapentin in psychotic disorders.Keywords: schizophrenia, refractory, adjunctive treatment, gabapentin, risperidone, olanzapine

  3. Extrapyramidal Symptoms During Risperidone Maintenance Treatment in Schizophrenia: A Prospective, Multicenter Study.

    Science.gov (United States)

    Bo, Qi-Jing; Li, Xian-Bin; Wang, Zhi-Min; Li, An-Ning; Ma, Xin; Wang, Chuan-Yue

    2016-04-01

    The risperidone maintenance treatment in schizophrenia study was designed to identify the duration of maintenance treatment required with an initial therapeutic dose in contrast to reducing the dose over time. This study investigated extrapyramidal symptoms (EPSs) in different risperidone maintenance treatment paradigms over 1 year. Clinically stabilized patients with schizophrenia (n = 374) were randomized to a no-dose-reduction group and 4-week and 26-week reduction groups, in which the dose was gradually reduced by 50% over 8 weeks and maintained. Extrapyramidal symptoms were assessed at baseline and monthly for 6 months, followed by every 2 months. The Simpson-Angus Scale of Extrapyramidal Symptoms-Chinese version assessed EPS severity. Data were analyzed by a generalized linear mixed model (GLMM). The frequency of EPS at baseline was 23.2%, 20.0%, and 21.3% in the 4-week, 26-week, and no-dose-reduction groups, respectively. Risperidone dosage, positive symptoms, and disorganized thoughts at baseline predicted development of EPS. The GLMM indicated that a significant decrease in EPS was maintained, and different trajectories occurred over time across groups. In the 235 patients who continued treatment after 1 year, the incidence of EPS decreased to 4.1%, 2.8%, and 10.0% in the 4-week, 26-week, and no-dose-reduction groups, respectively, whereas the numbers of dropouts because of intolerable EPS were not significantly different (4.8%, 6.7%, and 6.2%, respectively). These novel findings indicate EPSs were tolerable and differentially decreased depending on the dose paradigm during the 1-year treatment period. Future studies should implement a GLMM to investigate antipsychotic adverse effects during long-term treatment. PMID:26848792

  4. Bioequivalence study of a generic Risperidone (Iperdal® in healthy Thai male volunteers

    Directory of Open Access Journals (Sweden)

    Werawath Mahatthanatrakul

    2008-05-01

    Full Text Available The objective of this study was to compare the rate and extent of absorption of a generic risperidone (Iperdal® with a reference formulation (Risperdal® when given orally. The study was an open label, randomized, two-period, two-sequence,single dose cross-over design with a 2 weeks washout period in 16 healthy Thai male volunteers. Single oral dose of two 2-mg tablets of risperidone were administered and serial blood samples were collected from the antecubital vein before and at0.17, 0.33, 0.5, 0.75, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 12, 24 and 48 hours post dose. Risperidone plasma concentrations were assayed using a validated High Performance Liquid Chromatographic (HPLC-UV method modified from Avenosoet al. (2000. Pharamcokinetic parameters i.e. Cmax, AUC0à48 and Tmax were analyzed by noncompartment analysis. Variations of the data were analyzed by “Two Way Analysis of Variance” (ANOVA. Statistics were tested as stated in USP 28 guidelinefor bioequivalence study. The maximum concentration (Cmax, ng/ml of risperidone for the innovator and the generic product were 31.11±17.24 (range 5.64-56.78 and 32.58±19.77 (range 5.29-84.56 ng/ml, respectively. The area under theplasma concentration-time curve (AUC0®48 of the innovator and the generic product were 160.64±152.89 (range 18.57- 550.32 and 144.03±127.37 (range 16.27-456.0 ng.hr/ml, respectively. The time to maximum concentration (Tmax of theinnovator and the generic product were 0.97±0.41(range 0.5-2 and 1.02±0.32 (range 0.5-1.5 hr, respectively. The 90% confidence interval of the ratio of the ln-transformed of Cmax and AUC0à48 of both preparations were 89.39-112.99% and80.02-107.28% respectively which were within the acceptance range of 80.00-125.00%. Therefore, it can be concluded that both preparations used in this study are bioequivalent in terms of both the rate and extent of absorption.

  5. Safety and efficacy findings from a non-interventional study of a new hyaluronic acid/sorbitol formulation (GO-ON® matrix) for intra-articular injection to relieve pain and disability in osteoarthritis patients.

    Science.gov (United States)

    Heisel, J; Kipshoven, C

    2013-09-01

    This non-interventional study was intended to examine the efficacy and tolerability of intra-articular injections with the GO-ON® matrix, a new viscosupplement product made of non-animal sodium hyaluronate combined with the oxygen free radical scavenger sorbitol, when used in routine clinical practice. A total of 1 147 patients (43.5% male, 53,5% female, 3% missing) aged on average 63.3 years with osteoarthritis were enrolled in 398 centers and treated with the product. The most commonly treated joint was the knee (92.9%) with a Kellgren-Lawrence classification of Grade I (6.7%), Grade II (31.4%), Grade III (48.0%), and Grade IV (13.9%).Most patients (58-66%, imputing for missing data) received 1 injection, 29-40% received 3 injections. Using a Likert scale to asses pain, the mean change in pain due to osteoarthritis was a reduction of 56.5% from baseline (2.61±0.80) to 6 months (1.07±0.86). At baseline, 56.2% of patients reported severe/very severe pain versus 5.9% after 6 months. Accordingly, 6.8% of patients reported no pain/mild pain at baseline vs. 67.1% after 6 months. At baseline, 28.9% reported no pain/mild pain vs. to 66.4% after 6 months. At baseline, 29.1% of patients reported severe/very severe functional impairment vs. 3.9% 6 months after the first injection. The 3 and 6 month results were comparable.Adverse reactions were rare and confined to musculoskeletal and connective tissue disorders. No infections were reported in any treated joints. The results confirm that the GO-ON matrix® treatment is effective and well tolerated in the treatment of symptoms due to osteoarthritis.

  6. A double-blind, placebo-controlled study of traditional Chinese medicine sarsasapogenin added to risperidone in patients with negative symptoms dominated schizophrenia%利培酮合并知母皂甙元治疗阴性症状为主的精神分裂症的双盲随机对照研究

    Institute of Scientific and Technical Information of China (English)

    肖世富; 薛海波; 李霞; 陈超; 李冠军; 苑成梅; 张明园

    2011-01-01

    Objective To identify whether sarsasapogenin,a sapogenin from the Chinese medicinal herb Anemarrhena Asphodeloides Bunge,would augment the efficacy of risperidone and significantly improve cognitive functions in patients with negative symptoms dominated schizophrenia.Methods The trial was a double-blind,placebo-controlled,parallelgroup design.The eligible patients were randomized into 2 treatment groups:sarsasapogenin group (sarsasapogenin plus risperidone for 8 weeks,n = 41) and placebo group (risperidone only for 8 weeks,n = 39).At the baseline,as well as at weeks 2,4 and 8 of treatment,the therapeutic response was measured by using scales including Positive and Negative Symptoms Scale (PANSS),Wechsler Memory Scale (WMS),modified Chinese Wechsler Adult Intelligence Scale (mWAIS),Clinical Global Impression (CGI) and Brief Psychiatry Rating Scale (BPRS).The study period for each subject was 8 weeks and duration of overall trial was 2 years.Results Patients treated with sarsasapogenin plus risperidone demonstrated no statistically significant differences in changes in PANSS,WMS or mWAIS score at the end-point of the trial compared with patients treated with placebo plus risperidone.The incidence of treatment-emergent adverse events in patients treated with sarsasapogenin was not different from that observed in placebo group.Conclusion Sarsasapogenin did not augment the efficacy of risperidone in treating negative symptoms dominated schizophrenia.Sarsasapogenin at a dosage of 200 mg per day added to a flexible dosage of risperidone at 2-4 mg per day is safe and well tolerated by patients with negative symptoms dominated schizophrenia.%目的 探讨知母皂甙元是否能增强利培酮的治疗作用,以及两者联用是否能显著提高阴性症状为主的精神分裂症病人的认知功能.方法 本研究采用双盲、安慰剂对照的平行设计方案.研究对象随机分为知利培酮合并母皂甙组(n= 41)和利培酮合并安慰剂组(n=39

  7. Safe and Efficacious Use of Automated Bolus Advisors in Individuals Treated With Multiple Daily Insulin Injection (MDI) Therapy: Lessons Learned From the Automated Bolus Advisor Control and Usability Study (ABACUS).

    Science.gov (United States)

    Parkin, Christopher G; Barnard, Katharine; Hinnen, Deborah A

    2015-03-20

    Numerous studies have shown that use of integrated automated bolus advisors (BAs) provides significant benefits to individuals using insulin pump devices, including improved glycemic control and greater treatment satisfaction. Within the past few years, BA devices have been developed specifically for individuals treated with multiple daily insulin injection (MDI) therapy; however, many clinicians who treat these individuals may be unfamiliar with insulin pump therapy and, thus, BA use. Findings from the Automated Bolus Advisor Control and Usability Study (ABACUS) revealed that BA use can be efficacious and clinically meaningful in MDI therapy, and that most patients are willing and able to use this technology appropriately when adequate clinical support is provided. The purpose of this article is to review key learnings from ABACUS and provide practical advice for initiating BA use and monitoring therapy.

  8. Clinical efficacy of multiple injection of morphine combined with phloroglucin in the treatment of renal colic%吗啡分次注射联合间苯三酚治疗肾绞痛的疗效观察

    Institute of Scientific and Technical Information of China (English)

    宋小兵; 赵剡; 潘正启; 杨奇盛; 王翔; 沈俊

    2011-01-01

    目的:评价吗啡分次注射联合间苯三酚治疗肾绞痛的疗效及安全性.方法:患者100例,随机分为2组,每组50例.实验组给予生理盐水100 ml+间苯三酚80 mg静脉滴注+吗啡9 mg静脉分3次推注,对照组给予生理盐水100 ml+山莨菪碱10 mg静脉滴注+肌注哌替啶50 mg.于注射后40 min、6 h 2个时间段观察解痉镇痛效果及其不良反应.结果:治疗40 min后,实验组和对照组的显效率分别为46%和38%,两组比较差异无统计学意义(P>0.05).实验组总有效率和6 h内疼痛再发率分别为94%、16%,对照组为80%、34%,两组比较差异有统计学意义(P<0.05);实验组、对照组的不良反应发生率分别为18%、68%,两组比较差异有统计学意义(P<0.01).结论:吗啡分次注射联合间苯三酚用治疗肾绞痛疗效好,不良反应少,值得临床推广应用.%Objective:To evaluate the efficacy and the safety of multiple injection of morphine combined with phloroglucin in the treatment of renal colic. Method: One hundred patients with severe renal colic were randomly divided into two groups. The experiment group was administrated with NS 100 ml + phloroglucinol 80 mg intravenous drop infusion + morphine 9 mg fractionated intravenous injection for three times. The control group was administrated with NS 100 ml+ anisodamine 10 mg intravenous drop infusion+ pethidine 50 mg intra muscular injection. The efficacy and the side effect were analyzed and compared between the two groups after administration for 40 min and 6 hours. Result: After 40 min treatment, the efficacy rate between the experiment group and the control group was not significant(46 % vs 38 % ). The total efficacy of the experiment group was higher than the control group (94 % vs 80 % ), and the pain recurrence rate in 6 hours of the experiment group was lower than the control group (16% vs 34%). The incidence of adverse effect of the experiment group was lower than the control group (18 % vs 68

  9. Clinical efficacy of botulinum toxin type A injected by BellaVita in treatment of focal hyperhidrosis%A型肉毒毒素治疗局部多汗症的临床效果

    Institute of Scientific and Technical Information of China (English)

    陈凤超; 杨俊革; 夏秉成; 侯俊杰; 刘林嶓

    2016-01-01

    目的 探讨A型肉毒毒素治疗多汗症的临床效果.方法 观察28例多汗症患者132个部位治疗效果.用微碘-淀粉试验判定多汗症程度及范围.将A型肉毒毒素加入水光注射仪,单侧腋窝、手掌及脚掌注射剂量各50 U,额部30 U.注射后1周、2周和每月复查1次,随访8个月.每次随访根据微碘-淀粉试验的客观效果评价及主观效果评价得出分值,再进行综合效果评价.结果 注射前综合效果评价(1.34±3.94)分,A型肉毒毒素注射后1周综合效果评价(23.21±9.44)分,注射后1个月(92.41±11.95)分,2个月(98.21±5.60)分,3个月(95.98±5.94)分,4个月(86.61±10.17)分.与注射前比较,差异有统计学意义(P<0.05).之后效果慢慢减退,最长疗效维持可达8个月,综合效果评价(4.46±6.98)分,与注射前比较,差异无统计学意义(P>0.05).注射后6个月和注射后l周比较;差异无统计学意义(P>0.05).结论 A型肉毒毒素通过水光注射仪给药途径治疗局部多汗症见效快,疗效确切.%Objective To explore the new way of administration and clinical effect of botulinum toxin A in the treatment of focal hyperhidrosis.Methods The clinical efficacy was observed in 132 sites of 28 patients with focal hyperhidrosis,and the degree and range of focal hyperhidrosis were determined by the minor iodine-starch test.50 U of botulinum toxin A was injected in unilateral axillary,palms and soles with BellaVita instrument and 30 U for forehead.Each patient was followed-up in 1 week,2 weeks and every month after injection for 8 months.According to the results of the minor iodine-starch test the objective effect and evaluation score were obtained,and the comprehensive effect evaluation score was calculated with the objective effect evaluation score and the subjective effect evaluation score in each follow-up.Results The comprehensive effect evaluation score before injection of botulinum toxin A was 1.34±3.94,and that after injection was 23

  10. 氨磺必利与利培酮治疗精神分裂症对照研究%A control study of amisulpride vs .risperidone in the treatment of schizophrenia

    Institute of Scientific and Technical Information of China (English)

    张华江; 徐清

    2014-01-01

    Objective To explore the efficacy and safety of amisulpride vs .risper-idone in the treatment of schizophrenia .Methods Sixty schizophrenics were randomly divided into two groups of 30 ones each ,research group took orally amisulpride and control group did risperidone for 8 weeks .Efficacies were assessed with the Positive and Negative Syndrome Scale (PANSS) and adverse re-actions with the Treatment Emergent Symptom Scale (TESS) .Results At the end of the 8th week obvious effective and effective rate were respectively 70 .0% and 93 .3% in research and 66 .7% and 93 .3% in con-trol group ,which showed no significant differences (P> 0 .05) .Incidences of extrapyramidal reactions , dysfunction of liver and weight gain were significantly lower in research than in control group (P<0 .05) . Conclusion Amisulpride has an evident effect equivalent to risperidone ,higher safety and better compli-ance in the treatment of schizophrenia .%目的:探讨氨磺必利与利培酮治疗精神分裂症的临床疗效和安全性。方法将60例精神分裂症患者随机分为两组,每组30例,研究组口服氨磺必利治疗,对照组口服利培酮治疗。观察8周。采用阳性与阴性症状量表评定临床疗效,副反应量表评定不良反应。结果治疗8周末,研究组显效率为70.0%、有效率为93.3%,对照组分别为66.7%、93.3%,两组比较差异无显著性(P>0.05)。研究组锥体外系反应、肝功能异常及体质量增加发生率均显著低于对照组(P<0.05)。结论氨磺必利治疗精神分裂症疗效显著且与利培酮相当,安全性高,依从性好。

  11. 利培酮治疗难治性分裂情感性精神病临床研究%Clinical research on risperidone in the treatment of refractory schizoaffective psychosis

    Institute of Scientific and Technical Information of China (English)

    刘元华

    2014-01-01

    Objective To evaluate the clinical efficacy of risperidone for the treatment of refractory schizoaffective psychosis. Methods 84 patients with refractory schizoaffective psychosis were randomly divided into observation group and control group, and 42 cases were in each group.The two groups were received lithium treatment, and risperidone was added in observation group, while the control group added clozapine. The clinical efficacy of two groups were compared. Results After treatment, the HAMD, BRMS and the PANSS factor scores were significantly lower, but the observation group was significantly lower than the control group(P<0.05);the total effective rate of HAMD,BRMS and PANSS in observation group were significantly higher than the control group (P<0.05);the TESS score of observation group was significantly lower than the control group(P<0.05). Conclusion Risperidone for the treatment of refractory schizoaffective psychosis has a significant effect and less adverse reactions, it should be widely applied.%目的:探讨利培酮用于治疗难治性分裂情感性精神病的临床疗效。方法84例分裂情感性精神病患者随机分为观察组与对照组,各42例,两组均予以碳酸锂治疗,观察组加用利培酮,对照组加用氯氮平,比较两组的临床疗效。结果两组治疗后HAMD、BRMS以及PANSS各项因子评分均降低,且观察组各因子评分低于对照组,差异具统计学意义(P<0.05);观察组的临床总有效率均高于对照组,差异具统计学意义(P<0.05);观察组的TESS评分显著低于对照组,差异具统计学意义(P<0.05)。结论利培酮用于治疗难治性分裂情感性精神病疗效显著,不良反应少。

  12. A Double-Blind Placebo Controlled Trial of "Ginkgo Biloba" Added to Risperidone in Patients with Autistic Disorders

    Science.gov (United States)

    Hasanzadeh, Elmira; Mohammadi, Mohammad-Reza; Ghanizadeh, Ahmad; Rezazadeh, Shams-Ali; Tabrizi, Mina; Rezaei, Farzin; Akhondzadeh, Shahin

    2012-01-01

    "Ginkgo biloba" has been reported to affect the neurotransmitter system and to have antioxidant properties that could impact the pathogenesis of Autism Spectrum Disorder. Based on these studies, we decided to assess the effectiveness of "Ginkgo biloba" extract (Ginko T.D., Tolidaru, Iran) as an adjunctive agent to risperidone in the treatment of…

  13. Effects of risperidone on core symptoms of autistic disorder based on childhood autism rating scale: An open label study

    Directory of Open Access Journals (Sweden)

    Padideh Ghaeli

    2014-01-01

    Full Text Available Background: The aim of the present study was to evaluate the effect of risperidone in patients afflicted by autistic disorder especially with regards to its three core symptoms, including "relating to others", "communication skills", and "stereotyped behaviors" based on Childhood Autism Rating Scale (CARS. Materials and Methods: An 8-week open-label study of risperidone for treatment of autistic disorder in children 4-17 years old was designed. Risperidone dose titration was as follow: 0.02 mg/kg/day at the first week, 0.04 mg/kg/day at the second week, and 0.06 mg/kg/day at the third week and thereafter. The outcome measures were scores obtained by CARS, Aberrant Behavior Checklist (ABC, and Clinical Global Impression-Improvement (CGI-I scale. Results: Fifteen patients completed this study. After 8 weeks, CARS total score decreased significantly, (P=0.001. At the end of the study, social interactions and verbal communication skills of the patients were significantly improved (P<0.001, P=0.03, respectively. However, stereotypic behaviors did not show any significant change in this study. Increase in appetite and somnolence were the most reported side effects. Conclusion: This study suggests that risperidone may be an effective treatment for the management of core symptoms of autistic disorder.

  14. Risperidone-associated adverse drug reactions and CYP2D6 polymorphisms in a South African cohort

    Directory of Open Access Journals (Sweden)

    Tyren M. Dodgen

    2015-06-01

    Conclusion: CYP2D6 variation appeared not to be a good pharmacogenetic marker for predicting risperidone-related ADRs in this naturalistic South African cohort. Evaluation of a larger cohort would be needed to confirm these observations, including an examination of the role of potential intermediaries between the hypothesised genetic and clinical phenotypes.

  15. Add-on effects of a low-dose aripiprazole in resolving hyperprolactinemia induced by risperidone or paliperidone.

    Science.gov (United States)

    Qiao, Ying; Yang, Fuzhong; Li, Chunbo; Guo, Qian; Wen, Hui; Zhu, Suoyu; Ouyang, Qiong; Shen, Weidi; Sheng, Jianhua

    2016-03-30

    This study investigated the effects of a low-dose aripiprazole adjunctive treatment for risperidone- or paliperidone-induced hyperprolactinemia in Han Chinese women with schizophrenia. After 4 weeks of risperidone or paliperidone treatment, 60 out of 66 patients improved significantly and experienced hyperprolactinemia. They were randomly assigned to the treatment group (aripiprazole adjunctive treatment) (n=30) or control group (non-adjunctive treatment) (n=30). The dosage of risperidone and paliperidone were maintained; and aripiprazole was maintained at 5mg/day during the 8-week study period. The prolactin levels at the end of the 8th week were significantly lower in the treatment group than in the control group. The estradiol level correlated negatively with serum prolactin level both in the treatment group and the control group at the end of the 8th week and the 4th week respectively. The Positive and Negative Syndrome Scale score improved significantly during the 8-week study period in both groups. The incidence of treatment-emergent adverse event was similar in two groups. Low-dose aripiprazole adjunctive treatment is effective in relieving risperidone- and paliperidone-induced hyperprolactinemia in female schizophrenic patients without increasing adverse event. PMID:26921057

  16. An open-label trial of risperidone and fluoxetine in children with autistic disorder

    Directory of Open Access Journals (Sweden)

    Desousa Avinash

    2010-01-01

    Full Text Available Objective: Various studies have shown the effectiveness of risperidone and fluoxetine in the management of behavioral problems in autism. Aim: The purpose of this study was to compare these two drugs in the management of behavioral problems in autism. Materials and Methods: Forty children with autism were divided into 2 groups in a 16-week open trial that compared these two drugs. Parents rated the children using the Aberrant Behavior Checklist (ABC and the Conners′ Parent Rating Scale - Revised (CPRS-R. The author rated the children using the Children′s Psychiatric Rating Scale and Clinical Global Impression (CGI Scale. Results: The risperidone group showed significant improvement in areas like irritability and hyperactivity, while the fluoxetine group showed significant improvement in speech deviance, social withdrawal and stereotypy. When the two drugs were compared, fluoxetine showed greater improvement in stereotypy, while both drugs showed improvement on the general autism scale; and on anger, hyperactivity and irritability scales. Conclusions : In this open trial, both drugs were well tolerated and appeared to be beneficial in the treatment of common behavioral problems in children with autism. Further controlled and double-blind studies in larger samples are warranted.

  17. Efficacy and safety of once-monthly injection of paliperidone palmitate in hospitalized Asian patients with acute exacerbated schizophrenia: an open-label, prospective, noncomparative study

    Directory of Open Access Journals (Sweden)

    Li HF

    2015-12-01

    Full Text Available HuaFang Li,1 Ibrahim Turkoz,2 Fan Zhang3 1Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China; 2Janssen Research & Development, LLC, Titusville, NJ, USA; 3Xi’an Janssen Pharmaceutical Ltd., Beijing, People’s Republic of China Introduction: This single-group, open-label, prospective, noncomparative, multicenter, Phase IV study explored the efficacy and tolerability of paliperidone palmitate (PP in hospitalized patients with acute exacerbation of schizophrenia.Methods: Asian patients of either sex, between 18 and 65 years of age, diagnosed with schizophrenia (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition with acute exacerbations within the previous 4 weeks, were enrolled. Intramuscular PP was initiated at doses of 150 milligram equivalent (mg eq (day 1 and 100 mg eq (day 8, followed by a monthly maintenance dose between 75 mg eq and 150 mg eq (days 36 and 64. Primary efficacy endpoint was the change from baseline in the Positive and Negative Syndrome Scale (PANSS total score (last-observation-carried-forward at week 13.Results: Of the 212 enrolled patients, 152 (71.7% completed the 13-week treatment; withdrawal of consent (24 [11.3%] patients was the most common reason for study discontinuation. Mean (standard deviation PANSS total score from baseline (90.0 [17.41] improved significantly at day 4 (-6.1 [9.27]; 95% confidence interval: -7.38, -4.85; P<0.001 and week 13 endpoint (-23.9 [23.24]; 95% confidence interval: -27.10, -20.78; P<0.001. Similarly, the secondary endpoints (Clinical Global Impression-Severity, Physical and Social Performance, each PANSS subscale, and Marder factor scores improved significantly from baseline to week 13 endpoint (P<0.001 for all. At week 13, 112/210 (53.3% patients had a 40% improvement in the PANSS total score (responder rate, and 133/212 (62.7% patients were ready for hospital discharge. Overall, 139 (65

  18. Comparison of the efficacy of saline, local anesthetics, and steroids in epidural and facet joint injections for the management of spinal pain: A systematic review of randomized controlled trials

    Directory of Open Access Journals (Sweden)

    Laxmaiah Manchikanti

    2015-01-01

    Full Text Available Background: The efficacy of epidural and facet joint injections has been assessed utilizing multiple solutions including saline, local anesthetic, steroids, and others. The responses to these various solutions have been variable and have not been systematically assessed with long-term follow-ups. Methods: Randomized trials utilizing a true active control design were included. The primary outcome measure was pain relief and the secondary outcome measure was functional improvement. The quality of each individual article was assessed by Cochrane review criteria, as well as the criteria developed by the American Society of Interventional Pain Physicians (ASIPP for assessing interventional techniques. An evidence analysis was conducted based on the qualitative level of evidence (Level I to IV. Results: A total of 31 trials met the inclusion criteria. There was Level I evidence that local anesthetic with steroids was effective in managing chronic spinal pain based on multiple high-quality randomized controlled trials. The evidence also showed that local anesthetic with steroids and local anesthetic alone were equally effective except in disc herniation, where the superiority of local anesthetic with steroids was demonstrated over local anesthetic alone. Conclusion: This systematic review showed equal efficacy for local anesthetic with steroids and local anesthetic alone in multiple spinal conditions except for disc herniation where the superiority of local anesthetic with steroids was seen over local anesthetic alone.

  19. A pilot double-blind placebo-controlled trial of pioglitazone as adjunctive treatment to risperidone: Effects on aberrant behavior in children with autism.

    Science.gov (United States)

    Ghaleiha, Ali; Rasa, Soudeh Mohebbi; Nikoo, Mohammadali; Farokhnia, Mehdi; Mohammadi, Mohammad-Reza; Akhondzadeh, Shahin

    2015-09-30

    To assess the safety and efficacy of pioglitazone added to risperidone in the treatment of irritability in autistic disorder (AD), we conducted this study. In a 10-week, randomized, double-blind, parallel-group, placebo-controlled clinical trial, 44 outpatients of both genders aged 4-12 years with a diagnosis of AD and a score of ≥12 on the Aberrant Behavior Checklist-Community (ABC-C) irritability subscale were included. Mean change of ABC-C irritability subscale score as primary outcome, change in other ABC-C subscale scores and partial and complete responses were compared between two groups. Twenty patients completed the trial in each group. Level of reduction and effect of time×treatment interaction in the treatment group were significant for irritability (P=0.03), lethargy/social withdrawal (P=0.04) and hyperactivity/non-compliance (P=0.03) but not for stereotypic behavior and inappropriate speech subscales compared with the placebo group. Vomiting and headache were the most frequent reported side-effects. Results of this preliminary study indicate positive effects of pioglitazone compared with placebo in improving the behavioral symptoms of AD.

  20. Efficacy of pour-on and injectable formulations of moxidectin and ivermectin in cattle naturally infected with Psoroptes ovis: parasitological, clinical and serological data.

    Science.gov (United States)

    Lonneux, J F; Nguyen, T Q; Losson, B J

    1997-05-01

    On the basis of Psoroptes ovis counts performed on day -7, 32 animals were randomly allocated to a control group of five animals or to four groups comprising six or seven animals which were treated, respectively, with pour-on ivermectin (IPO), injectable ivermectin (II), pour-on moxidectin (MPO) and injectable moxidectin (IM). Living mites were counted in skin scrapings on days 0, 7, 14, 28, 42 and 56 post-treatment (PT). Lesions were recorded on a standardized map on days 0 and 56 PT. Antibody kinetics were studied using ELISA on serially diluted sera. The antibody titres were expressed as the dilution giving the positive/negative cut-off. Until their treatment on day 28, the control animals remained parasitologically positive and their antibody titres increased. In treated groups, all living mite counts were negative on days 28 and 42 PT but some animals were still infected on days 7 and 14 PT. On day 56, living P. ovis were found in one animal of the IPO group. An equation of regression describing the antibody decrease was calculated with each individual data set. In most of the treated animals, the coefficient of determination R2, which describes the closeness of fit to the linear model, was above 0.9. The linear model could not be applied (low R2) to the antibody kinetics of four animals: the day 56 positive animal and its two neighbours in the IPO group and one animal from the MPO group. In the treated groups, the differences between the numbers of infected animals, the mean daily weight gains or the mean antibody titres were not statistically significant. Mean daily weight gains of the treated groups were higher than in control animals. PMID:9195741

  1. Study on Clozapine combined with Risperidone in replacement of single Clozapine in treatment of schizophrenia%氯氮平联合利培酮替代单用氯氮平治疗精神分裂症患者的研究

    Institute of Scientific and Technical Information of China (English)

    胡小平

    2014-01-01

    Objective:To observe clinical efficacy and safety of Clozapine combined with Risperidone and single Clozapine in treatment of schizophrenia. Methods:60 patients with schizophrenia were randomly divided into Clozapine combined with Risperidone group (30 cases) and Clozapine group (30 cases), and the treatments lasted for 12 weeks. Clinical global impression scale (CGI) was used to assess the efficacy, and treatment emergent symptom scale ( TESS) was selected to assess the adverse reactions and safety. Results:At the end of the treatment, there was no significant difference in the efficacy between the two groups; however, there were less adverse reactions in Clozapine combined with Risperidone group. Conclusions:Clozapine Combined with Risperidone can replace single Clozapine in the treatment of schizophrenia, their curative effects are similar, but the former has less adverse reactions.%目的::观察氯氮平联合利培酮与单用氯氮平治疗精神分裂症患者的临床疗效和安全性。方法:将60例精神分裂症患者随机分为观察组(氯氮平联合利培酮治疗)30例和对照组(氯氮平治疗)30例,疗程12周,采用临床总体疗效量表CGI评定疗效,用不良反应量表TESS评估患者出现的不良反应和安全性。结果:疗程结束时,两组患者疗效无显著性差异,观察组不良反应较少。结论:氯氮平联合利培酮可以替代单用氯氮平治疗精神分裂症,疗效与单用氯氮平相当,不良反应比单用氯氮平小。

  2. 红花佐治重症急性胰腺炎肝损伤的临床研究%Efficacy of Honghua injection in treatment of hepatic injury of severe acute pancreatitis

    Institute of Scientific and Technical Information of China (English)

    吴天军

    2011-01-01

    Objective To investigate the efficacy of Honghua injection in treatment of hepatic injury of svere acute pancretitis ( SAP). Methods Totally 17 patients with hepatic injury of SAP were involved, Honghua injection were provided with intravenous drip on the basis of taditional therapies. We observed the level of liver function and prognosis. Results After treatment, acute phsiology and chronic health evaluaion (APACHE II ) , serum amylase and C - recative protein were decreased, in addition, the level of liver function were improved (P < 0. 05). The mortality rate was 17. 65% . Conclusions Early use of Honghua injection in hepatic injury of SAP may improve the conditions and reduce the mortality.%目的 探讨红花注射液在重症急性胰腺炎(severe acute pancreatitis,SAP)肝损伤治疗中的应用价值.方法 17例SAP肝损伤患者采用传统治疗的同时予红花注射液静脉滴注,观察患者肝功能的变化及预后.结果 治疗后患者APACH EⅡ评分、血淀粉酶及C-反应蛋白下降,肝功能明显改善(P均<0.05),病死率为17.65%.结论 早期应用红花注射液治疗SAP肝损伤,可改善其病情,降低病死率.

  3. Clinical efficacy of pantoprazole sodium diluted in xylitol injection in treating digestive ulcer%木糖醇注射液稀释泮托拉唑钠治疗消化性溃疡的临床疗效

    Institute of Scientific and Technical Information of China (English)

    梁茂本; 葛东明; 梁素娥; 许翔宇

    2011-01-01

    Objective To observe the clinical efficacy of pantoprazole sodium in xylitol injection in treating digestive ulcer(DU). Methods Sixty DU patients were treated with conventional therapy plus pantoprazole sodium 80 mg ]V. Daily. Pantoprazole sodium was diluted in xylitol injection (group A,29 cases) or in normal saline(group B?31 cases). Results The overall therapeutic effectiveness rate was 100% in two groups. Conclusion Xylitol injection can be used as a diluent for pantoprazole sodium in treating DU, which is particularly suitable for DU patients with diabetes mellitus or renal diseases.%目的 观察木糖醇注射液作为泮托拉唑钠稀释剂治疗消化性溃疡的临床疗效.方法 消化性溃疡患者60例,在常规治疗的基础上应用泮托拉唑钠80 mg静脉滴注.随机分为两组:观察组29例,用木糖醇注射液稀释泮托拉唑钠;对照组31例,用0.9%氯化钠注射液稀释泮托拉唑钠.结果 两组治疗消化性溃疡的总有效率均为100%.结论 木糖醇注射液可以作为注射用泮托拉唑钠的稀释剂应用于临床,特别适用于消化性溃疡合并糖尿病、肾病综合征等疾病的患者.

  4. Clinical observations on the efficacy of point-injection with NGF in treatment of infantile cerebral palsy%神经生长因子穴位注射治疗小儿脑性瘫痪疗效观察

    Institute of Scientific and Technical Information of China (English)

    陈维华; 黄嫚; 周江

    2013-01-01

    目的 探讨神经生长因子穴位注射治疗小儿脑性瘫痪的临床疗效.方法 50例脑瘫患儿按就诊时间顺序随机分为治疗组30例,对照组20例,两组均采用Bobath法为主的运动疗法、作业疗法及语言治疗等常规治疗,治疗组在此治疗基础上加用神经生长因子穴位注射.所有患儿在训练前及训练后采用Gesell量表进行评估.结果 两组治疗前Gesell量表评分差异均无统计学意义(均P>0.05),两组治疗后Gesell量表评分差异均有统计学意义(t=-2.096、-2.187、-2.048、-2.053、-2.225,均P<0.05).结论 在康复训练的基础上应用神经生长因子穴位注射对改善小儿脑性瘫痪智能、运动等有较好的效果.%Objective To discuss the clinical efficacy of point-injection with nerve growth factor (NGF) in treatment of infantile cerebral palsy.Methods According to the time order,50 cases with cerebral palsy were randomly divided into the treatment group(30 cases) and the control group (20 cases).Both groups were given the conventional treatment of Bobath mainly exercise therapy,homework therapy and the language therapy.In addition,the treatment group was given the treatment of point-injection with NGF.Gesell scale was used to evaluate all the patients before and after treatment.Results After treatment,the Gesell evaluation of the treatment group was higher than control group,and the difference was statistically significant (t =-2.096,-2.187,-2.048,-2.053,-2.225,all P <0.05).Conclusion On the basis of rehabilitation training,point-injection with NGF could improve intelligence,motor function and language in children with cerebral palsy,and the efficacy was obvious.

  5. 电针配合穴位注射治疗腕管综合征疗效观察%Observations on the Efficacy of Electroacupuncture plus Acupuncture Point Injection in Treating Carpal Tunnel Syndrome

    Institute of Scientific and Technical Information of China (English)

    叶爱萍; 邹燃

    2014-01-01

    Objective To assess the clinical efficacy of electroacupuncture plus acupuncture point injection in treating carpal tunnel syndrome. Method Sixty-three patients with carpal tunnel syndrome were allocated, using a random number table, to a treatment group (32 cases) and a control group (31 cases). The treatment group received electroacupuncture plus acupuncture point injection and the control group, conventional acupuncture. One course of treatment was given. After treatment, the clinical therapeutic effects and the recurrence rates based on the symptoms and signs were compared between the two groups. Result The total efficacy rates in the treatment and control groups were 93.8% and 77.4%, respectively. There was a statistically significant difference in clinical therapeutic effect between the two groups (P<0.05). There was a statistically significant posttreatment difference in the recurrence rate between the two groups of patients (P<0.05). Conclusion Electroacupuncture plus acupuncture point injection is easy to perform and has a good effect in treating carpal tunnel syndrome.%目的:评价电针配合穴位注射治疗腕管综合征的临床疗效。方法将63例腕管综合征患者按入组先后根据随机数字表法分为治疗组(32例)和对照组(31例)。治疗组予电针配合穴位注射治疗,对照组予普通针刺治疗,共治疗1个疗程。经治疗后,从症状和体征上比较两组临床疗效及复发率。结果治疗组、对照组总有效率分别为93.8%和77.4%,两组总有效率比较差异有统计学意义(P<0.05);两组患者治疗后复发率比较差异有统计学意义(P<0.05)。结论电针配合穴位注射治疗腕管综合征操作简单、疗效好。

  6. Review of the safety, efficacy, costs and patient acceptability of recombinant follicle-stimulating hormone for injection in assisting ovulation induction in infertile women

    Directory of Open Access Journals (Sweden)

    Marleen Nahuis

    2009-11-01

    Full Text Available Marleen Nahuis1,2,3, Fulco van der Veen1, Jur Oosterhuis2, Ben Willem Mol1, Peter Hompes3, Madelon van Wely11Center for Reproductive Medicine, Department of Obstetrics and Gynaecology (H4-205, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; 2Department of Obstetrics and Gynaecology, Medisch Spectrum Twente, Enschede, The Netherlands; 3Department of Obstetrics and Gynaecology, Free Medical University, Amsterdam, The NetherlandsAbstract: Anovulation is a common cause of female subfertility. Treatment of anovulation is aimed at induction of ovulation. In women with clomiphene-citrate resistant WHO group II anovulation, one of the treatment options is ovulation induction with exogenous follicle-stimulating hormone (FSH or follitropin. FSH is derived from urine or is produced as recombinant FSH. Two forms of recombinant FSH are available – follitropin alpha and follitropin beta. To evaluate the efficacy, safety, costs and acceptability of recombinant FSH, we performed a review to compare recombinant FSH with urinary-derived FSH products. Follitropin alpha, beta and urinary FSH products appeared to be equally effective in terms of pregnancy rates. Patient safety was also found to be comparable, as the incidence of side effects including multiple pregnancies was similar for all FSH products. In practice follitropin alpha and beta may be more convenient to use due to the ease of self-administration, but they are also more expensive than the urinary products.Keywords: follitropin apha, follitropin beta, urinary gonadotropins, polycystic ovary syndrome

  7. Comparison Of Effect Of Addition Of Fluvoxamine Or Risperidone To Clozapine In Chronic Partially Responsive Schizophrenic Patients On Clinical Response, QTc interval And Lipid profile

    Directory of Open Access Journals (Sweden)

    Sunil Mahakalkar

    2016-07-01

    Full Text Available Objective – To study & compare the augmentation effect of addition of fluvoxamine or risperidone in chronic partially responsive schizophrenic patients receiving clozapine on clinical and laboratory parameters.Methods - A prospective, randomized, parallel, open label 12 weeks study. The schizophrenic patients, aged 20-60 years, who followed the DSM-IV diagnostic criteria and receiving clozapine therapy, showing partial response to the treatment were recruited and the study was carried out from January 2007 to June 2008. Subjects were randomized into two groups: Group A (n=28: fluvoxamine (25-50mg/day was added to clozapine (25-200mg/day & Group B (n=27: risperidone (1-5mg/day was added to clozapine therapy. The effect of drugs was assessed by PANSS, BPRS scale and ECG and lipid profile were done at 6 and 12 weeks.Result - There was significant decrease in PANSS and BPRS score in both groups.Fluvoxamine + clozapine significantly reduced PANSS score as compared to risperidone + clozapine compared to baseline and between 6 and 12 weeks. Risperidone +clozapine prolonged QTc interval (at 12 weeks and elevated serum TG, VLDL, HDL significantly at 6 and 12 weeks.Conclusion – Although addition of fluvoxamine and risperidone to clozapine are effective in management of chronic partially responsive schizophrenia on clozapine, fluvoxamine is more effective as well as safer compared to Risperidone when compared for 6 and 12 weeks in these patients.

  8. Effects of co-treatment with mirtazapine and low doses of risperidone on immobility time in the forced swimming test in mice.

    Science.gov (United States)

    Rogóż, Zofia

    2010-01-01

    The aim of the present study was to examine the effect of mirtazapine (MIR) and risperidone (an atypical antipsychotic drug), given separately or jointly, on immobility time in the forced swimming test in male C57BL/6J mice. Fluoxetine (FLU) was used as a reference drug. MIR (2.5, 5 and 10 mg/kg) and FLU (5 and 10 mg/kg), or risperidone in low doses (0.05 and 0.1 mg/kg) given alone did not change the immobility time of mice in the forced swimming test. Joint administration of MIR (5 and 10 mg/kg) or FLU (10 mg/kg) and risperidone (0.1 mg/kg) produced antidepressant-like activity in the forced swimming test. WAY100636 (a 5-HT(1A) receptor antagonist) inhibited, while yohimbine (an α(2)-adrenergic receptor antagonist) potentiated the antidepressant-like effect induced by co-administration of MIR and risperidone. Active behavior in that test did not reflect an increase in general activity, since combined administration of antidepressants and risperidone failed to enhance the locomotor activity of mice. The obtained results indicate that risperidone applied in a low dose enhances the antidepressant-like activity of MIR and that, among other mechanisms, 5-HT(1A)-, and α(2)-adrenergic receptors may play a role in this effect.

  9. The efficacy and safety of systemic injection of Ginkgo biloba extract, EGb761, in idiopathic sudden sensorineural hearing loss: a randomized placebo-controlled clinical trial.

    Science.gov (United States)

    Koo, Ja-Won; Chang, Mun Young; Yun, Sung-Cheol; Kim, Tae Su; Kong, Soo-Keun; Chung, Jong Woo; Goh, Eui-Kyung

    2016-09-01

    Steroids are currently the most frequently accepted agents for idiopathic sudden sensorineural hearing loss (ISSNHL). However, the therapeutic effect of steroids is not always satisfactory. In this pilot study, we evaluated whether systemic treatment with Ginkgo biloba extract (EGb761) has an additive therapeutic effect in patients receiving a systemic steroid due to ISSNHL. A multicenter, randomized, double-blind clinical trial was performed. Fifty-six patients with ISSNHL were allocated to either EGb761 or placebo. In both groups, methylprednisolone was administered for 14 days. EGb761 was infused intravenously for 5 days in the EGb761 group, while the same amount of normal saline was infused in the placebo group. For the efficacy evaluation, pure-tone audiometry, speech audiometry, tinnitus handicap inventory (THI) and short form-36 health (SF-36) survey outcomes were obtained before administration and on days 3, 5, 14 and 28 of administration. Twenty-four patients in each group completed the study protocol. There was no difference in hearing loss between the two groups before treatment. At day 28, air conduction threshold values in the placebo and EGb761 groups were 34.63 ± 28.90 and 23.84 ± 25.42 dB, respectively (p = 0.082). Speech discrimination scores in the placebo and EGb761 groups were 69.17 ± 40.89 and 87.48 ± 28.65 %, respectively (p = 0.050). THI and SF-36 scores in the placebo and EGb761 groups were similar. Although a combination of steroid and EGb761 for initial treatment did not show better pure tone threshold, compared with steroid alone, speech discrimination was significantly improved in combination therapy. Further studies will be needed to know if addition of EGb761 actually improves the outcome of ISSNHL treatment. PMID:26559533

  10. The efficacy and safety of systemic injection of Ginkgo biloba extract, EGb761, in idiopathic sudden sensorineural hearing loss: a randomized placebo-controlled clinical trial.

    Science.gov (United States)

    Koo, Ja-Won; Chang, Mun Young; Yun, Sung-Cheol; Kim, Tae Su; Kong, Soo-Keun; Chung, Jong Woo; Goh, Eui-Kyung

    2016-09-01

    Steroids are currently the most frequently accepted agents for idiopathic sudden sensorineural hearing loss (ISSNHL). However, the therapeutic effect of steroids is not always satisfactory. In this pilot study, we evaluated whether systemic treatment with Ginkgo biloba extract (EGb761) has an additive therapeutic effect in patients receiving a systemic steroid due to ISSNHL. A multicenter, randomized, double-blind clinical trial was performed. Fifty-six patients with ISSNHL were allocated to either EGb761 or placebo. In both groups, methylprednisolone was administered for 14 days. EGb761 was infused intravenously for 5 days in the EGb761 group, while the same amount of normal saline was infused in the placebo group. For the efficacy evaluation, pure-tone audiometry, speech audiometry, tinnitus handicap inventory (THI) and short form-36 health (SF-36) survey outcomes were obtained before administration and on days 3, 5, 14 and 28 of administration. Twenty-four patients in each group completed the study protocol. There was no difference in hearing loss between the two groups before treatment. At day 28, air conduction threshold values in the placebo and EGb761 groups were 34.63 ± 28.90 and 23.84 ± 25.42 dB, respectively (p = 0.082). Speech discrimination scores in the placebo and EGb761 groups were 69.17 ± 40.89 and 87.48 ± 28.65 %, respectively (p = 0.050). THI and SF-36 scores in the placebo and EGb761 groups were similar. Although a combination of steroid and EGb761 for initial treatment did not show better pure tone threshold, compared with steroid alone, speech discrimination was significantly improved in combination therapy. Further studies will be needed to know if addition of EGb761 actually improves the outcome of ISSNHL treatment.

  11. Meta-Analysis of Efficacy and Safety of Bivalirudin for Injection%注射用比伐芦定疗效和安全性的Meta分析

    Institute of Scientific and Technical Information of China (English)

    徐文英; 何继明; 张少恩; 孟强

    2015-01-01

    目的 评价注射用比伐芦定在经皮冠状动脉介入治疗(PCI)抗凝应用的有效性和安全性.方法 在英文数据库(Pubmed、Medline、Elsevier Science、JAMA、New England Journal of Medicine、Cochran Library)和中文数据库(CNKI、万方数据库、维普数据库)中检索有关比伐芦定随机对照试验(RCT)研究文献,在对文献的质量评价后进行Meta分析.结果 经筛选后纳入Meta分析的文献有12篇,其中5篇文献比较了比伐芦定与肝素的临床疗效与安全性,有8篇文献比较了比伐芦定与肝素联合糖蛋白受体抑制剂(GPI)的临床疗效与安全性.比伐芦定组抗凝治疗获得的缺血净效应(30 d内死亡、再次心肌梗死)并不优于肝素组,支架内栓塞的发生率差异无统计学意义.但比伐芦定组发生TIMI大出血、小出血发生率明显低于肝素组(RR 0.586,95%CI:0.367~0.935,P<0.026),(RR 0.601,95%CI:0.473~0.763,P<0.015).应用比伐芦定组抗凝效果与肝素联合GPI的效果相似.比伐芦定组的大出血发生率较低(RR 0.562,95%CI:0.463~0.681,P<0.000),小出血组发生率也低于肝素联合GPI组(RR 0.561, 95%CI:0.498~0.631,P<0.000).结论 在PCI中应用比伐芦定抗凝治疗,在不增加PCI不良事件发生的情况下,能明显降低 PCI围术期大出血和小出血的发生率.对于有高出血风险患者,在 PCI过程中单独应用比伐芦定替代肝素或者肝素联合替罗非斑进行抗凝治疗是有意义的.%Objective This study sought to investigate the relative safety and efficacy of bivalirudin inhibitting blood coagulation in patients undergoing percutaneous coronary intervention(PCI).Methods Literature of rand- omized controled trials about bivalirudin is choosed from the databases including foreign and Chinese databases, after the evaluation of the quality of the literature for meta analysis.Results By screening into the meta analysis of 8 pieces of literature,of which 5 papers are clinical efficacy and safety

  12. Safety and efficacy of botox injection in alleviating post-operative pain and improving quality of life in lower extremity limb lengthening and deformity correction

    Directory of Open Access Journals (Sweden)

    Finley Allen

    2007-09-01

    Full Text Available Abstract Background Distraction osteogenesis is the standard treatment for the management of lower limb length discrepancy of more than 3 cm and bone loss secondary to congenital anomalies, trauma or infection. This technique consists of an osteotomy of the bone to be lengthened, application of an external fixator, followed by gradual and controlled distraction of the bone ends. Although limb lengthening using the Ilizarov distraction osteogenesis principle yields excellent results in most cases, the technique has numerous problems and is not well tolerated by many children. The objective of the current study is to determine if Botulinum Toxin A (BTX-A, which is known to possess both analgesic and paralytic actions, can be used to alleviate post-operative pain and improve the functional outcome of children undergoing distraction osteogenesis. Methods/Design The study design consists of a multi centre, randomized, double-blinded, placebo-controlled trial. Patients between ages 5–21 years requiring limb lengthening or deformity correction using distraction will be recruited from 6 different sites (Shriners Hospital for Children in Montreal, Honolulu, Philadelphia and Portland as well as DuPont Hospital for Children in Wilmington, Delaware and Hospital for Sick Children in Toronto, Ont. Approximately 150 subjects will be recruited over 2 years and will be randomized to either receive 10 units per Kg of BTX-A or normal saline (control group intraoperatively following the surgery. Functional outcome effects will be assessed using pain scores, medication dosages, range of motion, flexibility, strength, mobility function and quality of life of the patient. IRB approval was obtained from all sites and adverse reactions will be monitored vigorously and reported to IRB, FDA and Health Canada. Discussion BTX-A injection has been widely used world wide with no major side effects reported. However, to the best of our knowledge, this is the first time BTX

  13. CONTROL STUDY BETWEEN RISPERIDONE ORAL SOLUTION AND OLANZAPINE FOR ALCOHOL -INDUCED MENTAL DISORDER%利培酮口服液与奥氮平治疗酒精所致精神障碍对照研究

    Institute of Scientific and Technical Information of China (English)

    王丽莉; 吕浩; 杨建立

    2012-01-01

    目的:探讨利培酮口服液与奥氮平治疗酒精所致精神障碍的疗效和安全性.方法:将68例男性酒精所致精神障碍患者随机分为利培酮口服液治疗组和奥氮平治疗组.采用阳性与阴性症状量表( PANSS)评定临床疗效;采用治疗副反应量表( TESS)评定药物不良反应.结果:利培酮口服液与奥氮平两组疗效差异无显著性.利培酮口服液主要不良反应为锥外系反应,奥氮平为体重增加.结论:利培酮口服液与奥氮平治疗酒精所致精神障碍疗效及耐受性均好,可根据用药对象对不良反应的耐受等情况进行选择.%Objective: To compare the efficacy and safety of risperidone oral solution and olanzapine in the treatment of alcohol - induced mental disorder. Methods: Sixty - eight male patients with alcohol - induced mental disorder were randomly divided into risperidone oral solution group and olanzapine group. Clinical effect was evaluated by Positive and Negative Syndrome Scale (PANSS) ,and the adverse drug reactions were assessed with Treatment Emergent Symptom Scale ( TESS) . Results: No significant differences were observed in the clinical effect of the two groups. The main side effect experienced by the olanzapine group was body weight gain, while the resperidone oral solution group showed extrapyramidal responses. Conclusion: Both olanzapine and risperidone oral solution are safe and effective for the treatment of alcohol - induced mental disorder,and can be clinically selected according to patients' tolerance of the side effects.

  14. 臭氧联合胶原酶注射与单纯臭氧治疗腰椎间盘突出症的疗效观察%Combined use of ozone and collagenase injection for the treatment of lumbar disc herniation: comparison of therapeutic efficacy with simple ozone injection

    Institute of Scientific and Technical Information of China (English)

    高宗根; 殷世武; 项廷淼; 张惠林; 王菊; 黄守珍; 张武芝

    2011-01-01

    目的 观察臭氧联合胶原酶注射治疗腰椎间盘突出症(LDH)与单纯臭氧治疗椎间盘突出症的不同疗效.方法 在DSA导向下,正侧位透视后准确定位,采用9号穿刺针经皮穿刺向椎间盘内单纯注射臭氧或先后注射臭氧及胶原酶治疗76例腰椎间盘突出患者.结果 治疗后1、3和6个月进行随访.1个月后随访,臭氧联合胶原晦注射治疗组(A组,38例)有效率为89.5%,单纯臭氧注射治疗组(B组,38例)有效率为86.8%;3个月后随访,A组有效率为92.1%,B组有效率为84.2%;6个月后随访,A组有效率为94.7%,B组有妓率为81.6%.结论 臭氧联合胶原酶注射治疗椎间盘突出症较单纯臭氧注射治疗椎间盘突出症,疗效更加显著,且中远期疗效更稳定.%Objective To observe the therapeutic effects of combined use of ozone and collagenase injection in treating lumbar disc herniation and to make a comparison of therapeutic efficacy with simple ozone injection. Methods Under DSA guidance, percutaneous puncturing of diseased lumbar disk with a gauge 9 needle was performed in 76 patient with lumbar disc herniation. After the needle position was confirmed in the right site simple ozone injection (control group, n = 38) or combined use of ozone and collagenase injection (study group, n = 38) was carried outs. The clinical results were evaluated and compared between two groups. Results After the treatment, all 76 patients were followed up regularly at 1,3 and 6 months. At 1. 3 and 6 months after the therapy, the effective rate of study group was 89.5%, 92.1% and 94.7% respectively, while the effective rate of control group was 86.8%, 84.2% and 81.6% respectively.Conclusion For the treatment of lumbar disc herniation, the therapeutic effect of combined use of ozone and collagenase injection is much better than that by using simple ozone injection, moreover. it carries a quite stable long-term efficacy. (J Intervent Radiol. 2011 . 20 : 42-44)

  15. Temozolomide Injection

    Science.gov (United States)

    Temozolomide is used to treat certain types of brain tumors. Temozolomide is in a class of medications called alkylating ... Temozolomide injection comes as a powder to be added to fluid and injected over 90 minutes intravenously ( ...

  16. Methotrexate Injection

    Science.gov (United States)

    Methotrexate injection is used alone or in combination with other medications to treat gestational trophoblastic tumors (a ... in bones) after surgery to remove the tumor. Methotrexate injection is also used to treat severe psoriasis ( ...

  17. Leucovorin Injection

    Science.gov (United States)

    ... injection is used to prevent harmful effects of methotrexate (Rheumatrex, Trexall; cancer chemotherapy medication) when methotrexate is used to to treat certain types of cancer. Leucovorin injection is used to treat people who ...

  18. Pembrolizumab Injection

    Science.gov (United States)

    Pembrolizumab injection is used to treat melanoma (a type of skin cancer) that cannot be treated with ... who have a specific type of melanoma tumor. Pembrolizumab injection is also used to treat a certain ...

  19. Paclitaxel Injection

    Science.gov (United States)

    ... with other medications. Paclitaxel injection manufactured with polyoxyethylated castor oil is used to treat ovarian cancer (cancer that ... cancer, and lung cancer. Paclitaxel injection with polyoxyethylated castor oil is also used to treat Kaposi's sarcoma (a ...

  20. Evolocumab Injection

    Science.gov (United States)

    Evolocumab injection is used along with diet and certain cholesterol-lowering medications, HMG-CoA reductase inhibitors (statins), ... cholesterol cannot be removed from the body normally). Evolocumab injection is in a class of medications called ...

  1. Octreotide Injection

    Science.gov (United States)

    Octreotide immediate-release injection is used to decrease the amount of growth hormone (a natural substance) produced ... be treated with surgery, radiation, or another medication. Octreotide immediate-release injection is also used to control ...

  2. Naltrexone Injection

    Science.gov (United States)

    Naltrexone injection is used along with counseling and social support to help people who have stopped drinking large amounts of alcohol to avoid drinking again. Naltrexone injection is also used along with counseling and ...

  3. Vancomycin Injection

    Science.gov (United States)

    Vancomycin injection is used alone or in combination with other medications to treat certain serious infections such ... infections of the lungs, skin, blood, and bones. Vancomycin injection is in a class of medications called ...

  4. Multicenter contraceptive efficacy trial of injectable testosterone undecanoate in Chinese men%中国男性十一酸睾酮酯注射避孕有效性多中心研究

    Institute of Scientific and Technical Information of China (English)

    梁小薇; 彭林; 姚康寿; 谷翊群; 吴伟雄; 刘敏丽; 宋淑秀; 程立法; 薄立伟; 熊承良; 王兴海; 刘晓章

    2011-01-01

    Objectives: To assess safety, contraceptive efficacy, reversibility, and feasibility of injectable testosterone undecanoate (TU) in tea seed oil as a hormonal male contraceptive.Methods: A total of 1,045 healthy fertile Chinese men were recruited throughout China into the study. Injections of 500 mg TU were administered monthly for 30 months. The primary outcome was pregnancy rate in the partner. Other outcomes include: semen parameters, testis volumes, reproductive hormone levels, and safety laboratory tests.Results: Forty-three participants (4. 8%) did not achieve azoospermia or severe oligozoospermia within the 6-month suppression phase. A total of 855 participants entered into the efficacy phase, and 733 participants completed monthly TU treatment and follow-up. There were nine pregnancies in 1,554/ person-year of exposure in the 24-month efficacy phase for a cumulative contraceptive failure rate of 1. 1 per 100 men. The combined method failure rate was 6. 1%, comprising 4. 8% with inadequate suppression and 1. 3% with postsuppression sperm rebound. No serious adverse events were reported. Spermatogenesis returned to the normal fertile reference range in all but two participants.Conclusion: Monthly injection of 500 mg TU provides safe, effective, reversible, and reliable contraception in a high proportion of healthy fertile Chinese men.%目的 评估十一酸睾酮酯(TU)注射避孕的安全性、有效性、可复性和可接受性. 方法 1,045名健康的有生育力的中国男性,每月一次TU 500 mg肌注共30个月,统计分析其配偶的妊娠率、精液参数、睾丸体积、生殖激素水平及安全性评估. 结果 在6个月的抑制期内有43名对象(4.8%)未达到无精子或严重少精子症;855名对象进入起效期,其中733名完成每月一次TU注射和恢复阶段.在避孕有效期的24个月,暴露1,554/人年中有9次妊娠,累计避孕失败率为1.1/100人;综合失败率6.1%,其中包括1.3%抑制不充分和4

  5. The influence of stratospheric dynamics on the forcing efficacy of tropical volcanic SO2 injection: a case study around the 1991 Mount Pinatubo eruption

    Science.gov (United States)

    Dhomse, Sandip; Mann, Graham; Marshall, Lauren; Schmidt, Anja; Carslaw, Kenneth; Chipperfield, Martyn; Bellouin, Nicolas; Morgenstern, Olaf; Johnson, Colin; O'Connor, Fiona

    2016-04-01

    Major tropical volcanic eruptions exert significant climate impacts principally via enhanced scattering of solar radiation due to the injected SO2 elevating particle concentrations in the stratospheric aerosol layer. The size distribution of stratospheric aerosol particles also shifts to larger sizes in volcanically-enhanced conditions, which promotes absorption and subsequent stratospheric heating as well as causing faster sedimentation. How the volcanic sulphur cloud is dispersed also strongly affects the longevity of its radiative effects. In this presentation we investigate the role of stratospheric dynamical variability in affecting the temporal evolution of the volcanic aerosol, and also its feedback on subsequent chemical and dynamical ozone changes. Among various processes, the Quasi-Biennial Oscillation (QBO), the dominant mode of dynamical variability in the tropical stratosphere, is known to play a key role in determining the meridional dispersion of the volcanic cloud generated by major tropical eruptions. We have carried out a series of interactive stratospheric aerosol simulations with the UM-UKCA composition-climate model, to explore how different QBO phase impact volcanic radiative forcing, with a test case based around Mount Pinatubo. We will present results from an ensemble of simulations for different easterly and westerly phases of QBO, comparing simulated stratospheric aerosol properties (e.g. extinction, AOD, effective radius, particle size distribution) against a range of satellite and in-situ observational datasets. Changes in dynamics and temperatures would be compared against reanalysis (e.g. ERA-interim, HaDCRUT4) datasets followed by an analysis of radiative and dynamical changes for contrasting phases of QBO. References: Dhomse SS, Chipperfield MP, Feng W, Hossaini R, Mann GW, Santee ML (2015) Revisiting the hemispheric asymmetry in midlatitude ozone changes following the Mount Pinatubo eruption: A 3-D model study, Geophysical Research

  6. Sexual dysfunction in patients with schizophrenia treated with conventional antipsychotics or risperidone

    Directory of Open Access Journals (Sweden)

    Hong Liu-Seifert

    2009-01-01

    Full Text Available Hong Liu-Seifert1, Bruce J Kinon1, Christopher J Tennant2, Jennifer Sniadecki1, Jan Volavka31Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA; 2CJT Biomedical Consulting, South Lake Tahoe, CA, USA; 3New York University, New York, NY, USAObjective: To better understand sexual dysfunction in patients with schizophrenia and its associations with prolactin and reproductive hormones.Methods: This was a secondary analysis of an open-label, one-day study (N = 402. The primary objective of the study was to assess the prevalence of hyperprolactinemia in patients with schizophrenia who had been treated with conventional antipsychotics or risperidone. Other atypical antipsychotics available at the time of the study were not included due to a more favorable prolactin profile.Results: The majority of patients (59% of females and 60% of males reported impairment of sexual function. In postmenopausal females, risk of impaired sexual interest was increased by 31% for every 10 ng/ml increase in prolactin (p = 0.035. In males, lower testosterone was associated with higher prolactin (p < 0.001 and with orgasmic (p = 0.004 and ejaculatory dysfunction (p = 0.028.Conclusion: These findings suggest that hyperprolactinemia may be associated with sexual dysfunction. They also provide more information on the relationships between prolactin, reproductive hormones, and sexual dysfunction. Sexual dysfunction is an understudied yet important consideration in the treatment of schizophrenia. More attention is warranted in this area as it may provide opportunities for improved quality of life and adherence to treatment for patients.Keywords: sexual dysfunction, schizophrenia, hyperprolactinemia, antipsychotics, risperidone

  7. Naloxone Injection

    Science.gov (United States)

    ... doctor to get a new injection device.The automatic injection device has an electronic voice system that provides step by step directions ... guard has been removed, safely dispose of the automatic injection ... local garbage/recycling department to learn about take-back programs in ...

  8. Subcutaneous Injections

    DEFF Research Database (Denmark)

    Thomsen, Maria

    at the injection site was influenced by the needle length and the injected volume. Several imaging analysis tools were optimized for the characterization, and these tools were implemented also on subcutaneous injections in rats, visualized by low dose μCT, and used for characterization of the morphology in mouse...

  9. Ustekinumab Injection

    Science.gov (United States)

    ... Do not inject into an area where the skin is tender, bruised, red, or hard or where you have scars or stretch marks.Your doctor or pharmacist will ... injection.you should know that ustekinumab injection may decrease your ability ... new or changing skin lesions, minor infections (such as open cuts or ...

  10. Efficacy of medical ozone injection combined with acupotomy for the treatment of patients with external humeral epicondylitis%医用三氧联合针刀疗法治疗肱骨外上髁炎的疗效

    Institute of Scientific and Technical Information of China (English)

    何天福; 韩长青

    2015-01-01

    Objective To evaluate the clinical efficacy of medical ozone injection combined with acupotomy for the treatment of patients with external humeral epicondylitis.Methods Seventy patients with external humeral epicondylitis were divided randomly into medical ozone combined with acupotomy group and lidocaine with dexamethasone palmitate painful point injection group,35 cases in each group.The efficacy was assessed at one month,three months and six months after treatment.Results The total effective rate had no statistical difference between the two groups at one month after treatment (P > 0.05).The total effective rate was 97.1% (34/35 cases) at three months and 97.1% (34/35 cases) at six months in medical ozone combined with acupotomy group after the treatment,while it was 88.6% (31/35 cases) and 77.1% (27/35 cases) in lidocaine with dexamethasone palmitate painful point injection group,which had significantly statistical difference between the two groups (P< 0.05).Conclusion Medical ozone injection combined with acupotomy is an effective method for the treatment of patients with external humeral epicondylitis.%目的 评价医用三氧联合针刀疗法治疗肱骨外上髁炎的临床疗效.方法 肱骨外上髁炎患者70例,随机分为2组,每组35例.针刀三氧组给予医用三氧联合针刀治疗;痛点注药组给予利多卡因与复方地塞米松棕榈酸脂的混合液痛点注射治疗.治疗后l,3,6个月时评定疗效.结果 治疗后1个月时两组总有效率差异无统计学意义(P>0.05);治疗后3个月时总有效率针刀三氧组97.1%(34/35例)高于痛点注药组88.6%(30/35例),差异有统计学意义(P<0.05);治疗后6个月时总有效率针刀三氧组97.1%(34/35例)高于痛点注药组77.1%(27/35例),差异有统计学意义(P<0.05);治疗后在1、3、6个月时同组疗效比较差异均无统计学意义(P>0.05).结论 医用三氧联合针刀用于肱骨外上髁炎治疗,疗效优于痛点注药,且稳定.

  11. Clinical efficacy of mouse nerve growth factor and cattle encephalon glycoside and ignotin injection on cerebnal palsy%鼠神经生长因子与脑苷肌肽治疗脑性瘫痪的疗效

    Institute of Scientific and Technical Information of China (English)

    孙兴礼

    2015-01-01

    目的 探讨鼠神经生长因子与脑苷肌肽治疗脑性瘫痪的临床效果.方法 选取郸城县第二人民医院收治的脑性瘫痪患儿80例,随机分为观察组(鼠神经生长因子)与对照组(脑苷肌肽),每组40例.两组患儿均接受常规运动康复训练,观察两组患儿治疗前后发育商(DQ)及治疗期间不良反应发生情况.结果 两组患儿发育商治疗后均显著提高(P<0.05),观察组提高程度明显大于对照组(P<0.05),两组患儿接受治疗期间不良反应发生率比较差异未见统计学意义(P>0.05).结论 鼠神经生长因子治疗脑性瘫痪患儿效果显著,安全性较高.%Objective To investigate the clinical efficacy of mouse nerve growth factor and cattle encephalon glycoside and ignotin injection on cerebral palsy.Methods Eighty cases of cerebral palsy were selected and randomly divided into observation group (treated with mouse nerve growth factor) and control group (treated with cattle encephalon glycoside and ignotin injection),with 40 cases in each group.Both two groups received conventional rehabilitation training.Developmental quotient (DQ) before and after treatment,adverse reactions in the two groups were observed.Results DQ after treatment was significantly improved than before treatment in both two groups,and there was better improvement in observation group than that in control group (P < 0.05).The differences of adverse reactions during treatment in the two groups were not statistically significant (P > 0.05).Conclusions Mouse nerve growth factor has good efficacy and high safety in the treatment of cerebral palsy.

  12. Efficacy of intravenous injection of urapidil by micro-pump in treatment of hypertensive emergency patients%经微量泵静脉注射乌拉地尔治疗高血压急症疗效观察

    Institute of Scientific and Technical Information of China (English)

    庄小静; 周朝虹

    2009-01-01

    目的 探讨乌拉地尔微量泵静脉注射治疗高血压急症的疗效和安全性.方法 对78例高血压急症患者用乌拉地尔50mg加入40ml液体中静脉微泵输注,监测并记录用药前及用药后5、10、30、60、120min血压(BP)、心率(HR)、伴随症状及不良反应.结果 应用乌拉地尔后各时段BP较用药前均明显下降,差异有统计学意义(P<0.05),而HR则无明显变化.结论 乌拉地尔微量泵静脉注射治疗高血压急症,疗效确切,不良反应少.%Objective To investigate the efficacy and safety of urapidil intravenous injected by micro-pump in treatment of hypertensive emergency patients. Methods There 78 cases with hypertensive, emergency werereated wih 50rag urapidil by intravenous micro-pump. The blood pressure (BP),heart rate (HR),adverse reactions were monitored and recorded before administration and 5min,10min,30min,60min,120min after administration. Results Compared to that before administration,blood pressure were significantly decreased after administration, showing a significant difference. While there was no significant difference in the heart rate. Conclusion Urapidil intravenous injected by micro-pump is effective for treatment of hypertensive emergency with fewer adverse reactions.

  13. Efficacy of medical ozone intra-articular injection for the treatment of patients with knee joint meniscus injury%医用三氧膝关节腔内注射治疗半月板损伤的疗效

    Institute of Scientific and Technical Information of China (English)

    董俊球; 黎小雅

    2015-01-01

    目的 探讨膝关节腔内注射医用三氧治疗半月板损伤的疗效.方法 半月板损伤患者64例,以随机法分为三氧组和理疗组,每组32例.三氧组采用膝关节腔内医用三氧注射治疗;理疗组采用中西结合物理治疗,两组均配合股四头肌功能训练.于治疗后1个月时行AKS评分及临床疗效评定.结果 治疗后三氧组患者AKS各分项及总评分均高于理疗组,优良率三氧组94%(30/32例)高于理疗组56%(18/32例),差异均有统计学意义(P<0.05).结论 膝关节腔内医用三氧注射治疗半月板损伤疗效良好.%Objective To observe the efficacy of medical ozone intra-articular injection in the treatment of patients with knee joint meniscus injury.Methods Sixty-four patients with knee joint meniscus injury were randomly divided into two groups,32 cases in each group.Patients in ozone group were received intraarticular injection of ozone,while physiotherapy group were received combination of traditional Chinese and Western physical therapy.All of the patients were combined with functional training of quadratus femoris muscle.AKS and clinical effects were evaluated at 1 month after the treatment.Results The total score of AKS and its each item were significantly higher in ozone group than those in physiotherapy group (P < 0.05).The excellent and good rate in ozone group (94%,30/32 cases) was significantly higher than that in physiotherapy group (56%,18/32 cases) (P < 0.05).Conclusion Medical ozone intra-articular injection is effective in the treatment of knee joint meniscus injury.

  14. 氟比洛芬酯联合黄体酮在肾绞痛治疗中的镇痛效果观察%Efficacy of Flurbiprofen Axeyil Injection Combined with Progesterone in the Treatment of Renal Colic

    Institute of Scientific and Technical Information of China (English)

    方志洁

    2015-01-01

    目的:探讨氟比洛芬酯联合黄体酮治疗急性肾绞痛的临床镇痛效果。方法:将97例肾绞痛患者按照随机数字表法分为观察组(氟比洛芬酯联合黄体酮)和对照组(哌替啶联合黄体酮),比较两组的总有效率、起效时间、不良反应及6 h再发率。结果:观察组的镇痛总有效率优于对照组,且起效时间短,不良反应少、6 h再发少,差异均有统计学意义(P<0.05)。结论:氟比洛芬酯联合黄体酮治疗肾绞痛疗效确切、起效快、不良反应率及肾绞痛再发率低,值得临床推广应用。%Objective:To observe the efficacy of Flurbiprofen Axeyil Injection combined with Progesterone in the treatment of renal colic. Method:97 patients were randomly divided into the observation group(Flurbiprofen Axeyil Injection combined with Progesterone) and the control group(Pethidine combined with Progesterone).The total effective rate,onset time,adverse reaction,and 6 hour recurrent rate of two groups were compared.Result:The observation group had higher total effective rate,shorter onset time,less adverse reaction,less 6 hour recurrent rate compared with the control group,the differences were statistically significant(P<0.05).Conclusion:Flurbiprofen Axeyil Injection combined with Progesterone in the treatment of renal colic has a definite therapeutic effect,quicker effect,less adverse reaction and less 6 hour recurrence,which deserves further clinical applications.

  15. Costi ed effetti di Risperidone Long Acting (RLA) rispetto ad antipsicotici atipici nel trattamento dei soggetti schizofrenici in Italia

    OpenAIRE

    Lorenzo G. Mantovani; Patrizia Berto; Anna D. Ausilio; Bart Heeg

    2004-01-01

    Objective: to estimate the costs and effects of long-acting risperidone (LAR) in the treatment of schizophrenic patients in Italy, as compared to conventional and oral atypical antipsychotics. Methods: a discrete event model was used. The model simulates patients. history for every single therapeutic alternative and selects incident events, on the basis of pre-defined probability distribution-powered, randomized repetitions. The model operates on two types of parameters: patient characteristi...

  16. A comparison of the effect between combine citalopram with risperidone citalopram in the treatment of post-stroke depression%西酞普兰合用利培酮与西酞普兰治疗脑卒中后抑郁的疗效比较

    Institute of Scientific and Technical Information of China (English)

    马秀青; 纪爱建

    2013-01-01

    Objective:To explore the effect of combine citalopram with risperidone in the treatment of post-trok depression(PSD). Methods:89 patients with PSD were randomly assigned into two groups treated respectively,such as combine citalopram with risperidone and citalopram combined with placebo for 6 weeks in order to evaluate efficacy and side effects with HAMD,HAMA and TESS after 1、2、6 week. Results:There were differences of decreased scores of HAMD,HAMA between the two groups patients after 1、2、6 week respectively (p<0.05~0.01).There were no differences of scores of TESS between the two groups patients after 1、2、6 week respectively. Conlusion:Combine citalopram with risperidone was much better than citalopram combined with placebo,the former was well tolerated.%目的探讨西酞普兰合用利培酮治疗脑卒中后抑郁的疗效。方法将89例脑卒中后抑郁患者随机分成二组,分别给予西酞普兰和安慰剂与西酞普兰合用利培酮治疗6周,以HAMD及HAMA二种量表观察疗效,以TESS观察副作用。结果二组间HAMD和HAMA于第1、2、6周末减分率比较均有显著性差异(P<0.05~0.01)。TESS各周差异均不明显。结论西酞普兰合用利培酮治疗脑卒中后抑郁的疗效优于西酞普兰,且耐受性好。

  17. 参附注射液治疗心源性休克有效性和安全性系统评价%Systematic review on efficacy and safety of Shenfu Injection for cardiogenic shock

    Institute of Scientific and Technical Information of China (English)

    杨倩春; 毛炜; 刘旭生; 包坤; 邹川; 黎创; 刘帅帅

    2012-01-01

    Objective: To assess the efficacy and safety of Shenfu Injection for cardiogenic shock. Methods: Randomized controlled trials (RCTs) involving Shenfu Injection for cardiogenic shock were included. The quality and risk of bias were evaluated. The Cochrane Collaboration's RevMan 5.1.4 software was used for data analyses and 'GRADE profiler' software was used for the evidence classification of this system review's evaluation results. Results: A total of 6 trials involving 367 patients were included. Meta analyses showed that the mortality, the effective rate, after therapy 2h HR, after therapy 2h SBP, after therapy 2h DBP and EF were higher when Shenfu injection plus basic therapy group compared with basic therapy group. However, in improving ESV and EDV have no significant difference. GRADE evidence classification was very low. Conclusion: Shenfu Injection for cardiogenic shock with few adverse reactions was a relative safe. More high quality and large-scaled randomized controlled trials were required in the future in order to define the role of Shenfu Injection for cardiogenic shock.%目的:评价参附注射液治疗心源性休克有效性和安全性.方法:纳入参附注射液治疗心源性休克为研究对象的随机对照试验,对每个纳入研究进行偏倚风险和质量评估,统计学分析采用RevMan 5.1.4软件.用GRADE profiler软件和标准评估证据质量.结果:本系统评价纳入6个随机对照试验,共367例患者,Meta分析得出参附注射液合基础治疗在治疗病死率、有效率、2h后心率、2h后及2周后收缩压、舒张压及射血分数都优于基础治疗组,但改善收缩末期容积(ESV)和舒张末期容积(EDV)与基础治疗组比较,无统计学差异.GRADE证据质量评估为很低级别证据.参附注射液治疗心源性休克不良反应少,因此相对安全.结论:参附注射液治疗心源性休克安全、有效,但证据质量低,仍需高质量研究产生的证据支持.

  18. Efficacy, adherence and tolerability of once daily tenofovir DF-containing antiretroviral therapy in former injecting drug users with HIV-1 receiving opiate treatment: results of a 48-week open-label study

    Directory of Open Access Journals (Sweden)

    Esser S

    2011-10-01

    Full Text Available Abstract Objective To assess efficacy, adherence and tolerability of once daily antiretroviral therapy containing tenofovir disoproxil fumarate (DF 300 mg in HIV-1-infected former injecting drug users receiving opiate treatment (IVDU. Methods European, 48-week, open-label, single-arm, multicenter study. Patients were either antiretroviral therapy-naïve, restarting therapy after treatment discontinuation without prior virological failure or switching from existing stable treatment. Results Sixty-seven patients were enrolled in the study and 41 patients completed treatment. In the primary analysis (intent-to-treat missing = failure at week 48, 34% of patients (23/67; 95% CI: 23%-47% had plasma HIV-1 RNA 3. Although self-reported adherence appeared high, there were high levels of missing data and adherence results should be treated with caution. No new safety issues were identified. Conclusions Levels of missing data were high in this difficult-to-treat population, but potent antiretroviral suppression was achieved in a substantial proportion of HIV-infected IVDU-patients.

  19. E fficacy of Aripiprazole and Risperidone on Memory Function in Patients with Schizophrenia%阿立哌唑和利培酮对首发精神分裂症患者记忆功能的影响

    Institute of Scientific and Technical Information of China (English)

    胡茂荣; 姜淑珍; 占海燕; 胡斌; 鲍成; 余斌; 周朝雄; 吴慧玲

    2013-01-01

    Objective To explore the efficacy of aripiprazole and risperidone on memory function in patients with schizophrenia. Methods 112 first-episode patients with schizophrenia were random-ized to aripiprazole group(n=56) and risperidone group(n=56). All subjects were assessed with the Wechsler Memory Scale-ⅢSpatial Span Task(WMS-Ⅲ SST), the Hopkins Verbal Learning Test-Re-vised (HVLT-R) and The Brief Visuospatial Memory Test-Revised (BVMT-R).Results Both groups showed no statistical significance in WMS-Ⅲ SST, HVLT-R and BVMT-R scores in the baseline (P>0.05).The performances after 12 weeks of treatment in the both groups was higher than those in the baseline in all tests(P0.05).Aripiprazole group was increased significantly compared with before treatment after treatment WMS-Ⅲ SST score (P<0.05), and after treatment there was a statistical significance between the two groups (P<0.05).Conclusion Memory impairments in the patients with first-episode schizophrenia was im-proved by aripiprazole and risperidone, and effect of aripiprazole on certain memory functions was better than those of risperidone.%目的:探讨阿立哌唑和利培酮对首发精神分裂症患者记忆功能的影响。方法112例首发精神分裂症患者随机分成阿立哌唑组和利培酮组,每组56例。在治疗前和治疗12周末采用韦氏记忆量表-第三版的空间广度测验(WMS-Ⅲ SST)、霍普金斯词汇学习测验-修订版(HVLT-R)、简单视觉空间记忆测验-修订版(BVMT-R)分别对工作记忆、言语记忆和视觉记忆领域进行评定。结果在治疗前,两组的WMS-Ⅲ SST HVLT-R 和BVMT-R得分比较均无统计学意义(P>0.05)。在治疗12周后,两组的HVLT-R 和BVMT-R得分较治疗前比较均有统计学意义(P<0.05)而治疗后两组间比较无统计学意义(P>0.05);阿立哌唑组在治疗后的WMS-Ⅲ SST得分较治疗前显著增加(P<0.05),且治疗后两组间比较有统计学意义(P<0.05

  20. Risperidone combined with clozapine in the treatment of refractory schizophrenia research%利培酮联合氯氮平治疗难治性精神分裂症的临床研究

    Institute of Scientific and Technical Information of China (English)

    谢玲银; 张智勇

    2015-01-01

    目的:探讨使用利培酮联合氯氮平两种药物来治疗难治性精神分裂症的临床效果。方法选取我院收治的难治性精神分裂症患者100例为研究对象,随机将其分为观察组和对照组,其中观察组50例,采用利培酮联合氯氮平进行治疗,对照组50例则只服用氯氮平进行治疗,观察12周,分别于入组前、治疗6周末、12周末应用简明精神病评定量表(BPRS)评定治疗效果,同时应用副反应量表(TESS)评价不良反应发生情况。结果观察组在治疗6周末及12周末的BPRS 评定总分明显低于对照组,差异有统计学意义(P<0.05)。两组TESS总分比较差异无统计学意义(P>0.05)。结论临床上对于难治性精神分裂症这一疾病的治疗可采用利培酮联合氯氮平两种药物进行尝试,其临床效果显著,且安全性有较大程度的保障,值得临床推广应用。%Objective To discuss the clinical effect of risperidone combined with clozapine in the use of two kinds of drugs for the treatment of refractory schizophrenia.Methods 100 patients with refractory schizophrenia of our hospital was selected as the research object, randomly divided into observation group and control group,50 cases in each group,the cases in the observation group was treated by risperidone combined with clozapine,while the cases in the control group only received risperidone treatment,observation of 12 weeks,before entering the group,respectively treatment of 6 weeks and 12 weeks,the efficacy of treatment was assessed by the Brief Psychiatric Rating Scale (BPRS). And using the TESS to evaluate adverse reaction.ResultsIn the observation group,BPRS total score after 6 weeks and 12 weeks were significantly lower than the control group,the difference was statistically significant (P0.05).Conclusion For refractory schizophrenia,we may try to treat them with the combination of risperidone and clozapine,it is safety and

  1. Observation of clinical efficacy of amoxicillin and clavulanate potassium injection combined with compound danshen injection in treatment of community acquired pneumonia%注射用阿莫西林克拉维酸钾联合复方丹参注射液治疗社区获得性肺炎临床疗效观察

    Institute of Scientific and Technical Information of China (English)

    郁殿明

    2014-01-01

    目的:观察注射用阿莫西林克拉维酸钾联合丹参注射液治疗社区获得性肺炎的临床疗效。方法选取我院2013年1月~2014年5月期间收治的社区获得性肺炎患者80例,随机分成治疗组和对照组各40例,治疗组采用注射用阿莫西林克拉维酸钾联合复方丹参注射液静滴,对照组单独应用阿莫西林克拉维酸钾静滴,两组患者均连续静脉用药7d。于疗程结束后1周评价疗效,分别比较两组患者的临床表现,包括体温改变、咳嗽的变化及肺部体征的变化,并进行胸片及血常规检查,同时记录不良反应发生情况及症状消退的时间,对比分析两组的临床效果和用药安全性。结果治疗组总有效率92.50%,明显高于对照组的72.50%,两组患者退热时间方面无显著差异,但治疗组咳嗽消失时间、X线改变恢复正常平均时间及白细胞恢复正常时间均明显短于对照组,差异有统计学意义。结论使用注射用阿莫西林克拉维酸钾联合复方丹参注射液治疗社区获得性肺炎较单独应用阿莫西林克拉维酸钾可以明显缩短疗程,提高疗效,有一定的临床借鉴意义。%Objective To observe the clinical efficacy of amoxicillin and clavulanate potassium injection combined with compound danshen injection in treatment of community acquired pneumonia. Methods Eighty patients with community acquired pneumonia treated in our hospital from January 2013 to May 2014 were selected and randomly divided into the treatment group and the control group, with 40 patients in each group. The treatment group received amoxicillin and clavulanate potassium injection combined with compound danshen injection and the control group received the intra-venous infusion of single amoxicillin and clavulanate potassium. Both groups received intravenous medication for 7 continuous days. The efficacy was evaluated one week after the end of treatment. Clinical

  2. A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study: 12-month analysis

    Directory of Open Access Journals (Sweden)

    Singh RP

    2015-09-01

    Full Text Available Rishi P Singh, Sunil K Srivastava, Justis P Ehlers, Fabiana Q Silva, Rumneek Bedi, Andrew P Schachat, Peter K Kaiser Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA Summary statement: In subjects with active exudative age-related macular degeneration, treating with a fixed intravitreal aflibercept injection dosing regimen for 12 months demonstrated improved anatomic and vision endpoints from baseline.Purpose: Switching therapies in neovascular age-related macular degeneration (AMD may offer an advantage for some patients. This study evaluates the efficacy of intravitreal aflibercept injection (IAI in subjects previously treated with ranibizumab and/or bevacizumab.Methods: Subjects (n=26 were given monthly 2 mg of IAI for 3 months, followed by 2 mg once in every 2 months for up to 12 months. The mean absolute change from baseline in central subfield thickness (CST measured by optical coherence tomography and the mean change from baseline in best-corrected visual acuity (BCVA early treatment in diabetic retinopathy study (ETDRS letter score were obtained. Additionally, the percentage of subjects who gained or lost ≥15 letters of vision and the percentage of subjects who are 20/40 or better or 20/200 or worse were evaluated.Results: There was a mean decrease in CST of -50.3  µm (P<0.001 and a mean increase in ETDRS BCVA of +9.2 letters (P<0.001. Twenty-seven percent of subjects experienced a  ≥15-letter improvement in visual acuity, and no subject lost ≥3 lines of vision from baseline. Fifty percent of subjects were 20/40 or better, and 11.5% of subjects were 20/200 or worse at month 12.Conclusion: Fixed IAI dosing regimen for 12 months demonstrated improved anatomic and vision endpoints in subjects with active exudative AMD. Keywords: aflibercept, age-related macular degeneration, bevacizumab, ranibizumab, vascular endothelial growth factors

  3. 改良性电抽搐联合利培酮治疗甲基苯丙胺所致精神障碍的对照研究%Comparative study of modified electroconvulsive therapy combined with risperidone in the treatment of methamphetamine-induced psychiatric disorder

    Institute of Scientific and Technical Information of China (English)

    姚刚

    2012-01-01

    目的 探讨改良电抽搐治疗(MECT)联合药物治疗甲基苯丙胺所致精神障碍患者的临床疗效及安全性.方法 84例甲基苯丙胺所致精神障碍患者随机分为联合治疗组及单纯药物组各42例,单纯药物组给予利培酮治疗,联合治疗组给予MECT合并利培酮治疗.采用阳性与阴性症状量表(PANSS)及副反应量表(TESS)评定疗效和不良反应.结果 治疗一周后联合治疗组有效率为61.90%,单纯药物组有效率为38.10%,两组差异具有统计学意义(P<0.05).治疗3周后,联合治疗组有效率为88.10%,单纯药物组有效率为85.43%,两组差异无统计学意义(P>0.05).联合治疗组副反应较少,且消失较快.结论 MECT合并利培酮治疗甲基苯丙胺所致精神障碍起效更快,副作用小,且安全.%Objective To evaluate clinical efficacy and safety of modified electroconvulsive treatment (m-ECT) combined with risperidone in the treatment of methamphetamine-induced psychiatric disorder. Methods Eighty-four patients with methamphetamine-induced psychiatric disorder were consecutively divided into the study group and the control group, with 42 cases in each group. Patients in the study group were treated with m-ECT combined with risperidone, while those in the control group were treated with risperidone solely, Positive and Negative Syndromes Scale (PANSS) as well as Treatment Emergent Symptoms Scale (TESS) were used to evaluate the clinical efficacy and side effects. Results After one week of treatment, the effective rates of the study group and the control group were 61.90% and 38.10%, respectively, which showed difference between the two groups (P0.05). The study group was observed with few side effects, which disappeared quickly. Conclusion in For treating of methamphetamine-induced psychiatric disorder, modified electroconvulsive treatment combined with risperidone has better efficacy and less side effects than risperidone.

  4. 奥氮平与利培酮治疗痴呆患者精神行为症状的对照研究%The comparative study of olanzapine and risperidone in the treatment of dementia patients with behavioral and psychological symptoms

    Institute of Scientific and Technical Information of China (English)

    黄文平; 赵祖安; 白玉红; 曾丽苹

    2012-01-01

    Objective To observe the efficacy and safety of Olanzapine and Risperidone in the treatment of dementia patients with behavioral and psychological symptoms. Methods 80 senile dementia patients were selected and divided into two groups randomly, Olanzapine group (40 cases) and Risperidone group (40 cases). Before the treatment and the treatment for two, four and eight weeks, the two groups were both given the BEHAVE-AD scale to evaluate the efficacy and TESS scale to evaluate the adverse reactions. Results In the treatment of the 8th week, the differences of all the BE-HAVE-AD scales compared with before the treatment in the two groups were statistically significant (P < 0.01). In the treatment of the 2nd week, the difference of total scales compared with before the treatment in the Olanzapine group was statistically significant (P < 0.01), the Risperidone group was not; but at the 8th week the difference of efficiency rate between the two groups was not statistically significant. In security, the difference of total adverse reactions rate was not statistically significant, but the incidence of extrapyramidal side effects (EPS) in the Risperidone group was higher than in the Olanzapine group(P < 0.05). Conclusion The efficacy of Olanzapine and Risperidone in the treatment of dementia patients with behavioral and psychological symptoms are equal, but Olanzapine works faster, side effects are less, so Olanzapine is more suitable to treat dementia patients with behavioral and psychological symptoms.%目的 观察奥氮平和利培酮治疗老年痴呆患者精神行为症状的疗效和安全性.方法 将80例老年痴呆患者随机分为奥氮平组和利培酮组,每组各40例,共观察8周.治疗前及治疗第2、4、8周末分别用BEHAVE-AD量表评定疗效,用TESS量表评定不良反应.结果 奥氮平组和利培酮组在治疗第8周末,BEHAVE-AD量所有项目评分与治疗前比较,差异均有高度统计学意义(均P < 0.01),

  5. Clozapine and olanzapine are better antioxidants than haloperidol, quetiapine, risperidone and ziprasidone in in vitro models.

    Science.gov (United States)

    Brinholi, Francis Fregonesi; Farias, Carine Coneglian de; Bonifácio, Kamila Landucci; Higachi, Luciana; Casagrande, Rúbia; Moreira, Estefânia Gastaldello; Barbosa, Décio Sabbatini

    2016-07-01

    Although the etiopathogenic mechanisms of schizophrenia (SCZ) are unknown, evidences suggest that excessive free radical production or oxidative stress may be involved in the pathophysiology of SCZ. Antipsychotics are the drugs used in the treatment of SCZ but it remains controversial the impact that typical vs. atypical antipsychotics has on the oxidative stress status in SCZ patients. In vitro, the antioxidant capacity of six antipsychotics was assessed by their ability to: decrease or scavenge reactive oxygen species in the neutrophil respiratory burst; donate hydrogen and stabilize the free radical 2,2-diphenyl-1-picryl-hydrazyl (DPPH); and scavenge 2,2'-azino-di-(3-ethylbenzthiazoline-6-sulphonic acid) (ABTS(+)). This study demonstrated that both clozapine and olanzapine have antioxidant effects, in vitro, by scavenging superoxide anion on the respiratory burst, donating electron in the ABTS(+) assay and stabilizing the radical DPPH. Ziprasidone significantly scavenged ABTS(+) and stabilized the radical DPPH whereas risperidone significantly reduced the respiratory burst. Haloperidol and quetiapine lacked antioxidant effects. The chemical structure-related antioxidant capacity suggests a possible neuroprotective mechanism of these drugs on the top of their antipsychotic mechanism of action. PMID:27261620

  6. 痰热清注射液治疗小儿急性支气管炎的临床疗效分析%Clinical efficacy analysis of Tanreqing injection for children acute bronchitis

    Institute of Scientific and Technical Information of China (English)

    张雷

    2011-01-01

    目的:探讨痰热清注射液治疗小儿急性支气管炎的临床效果.方法:将116例急性支气管炎随机分为治疗组和对照组各58例,对照组给予常规抗病毒、抗感染、止咳祛痰治疗,治疗组在对照组常规治疗的基础上加用痰热清注射液静脉滴注,剂量为0.5~1.0 ml/(kg·d),比较两组的治疗效果及症状改善情况.结果:治疗1周后,治疗组总有效率为96.55%(56/58),对照组总有效率为77.59%(45/58),两组疗效比较,差异有统计学意义(P<0.05);治疗组平均退热时间、咳嗽消失或明显减轻时间均短于对照组,差异有显著性(P<0.05).结论:在常规治疗的基础上应用痰热清注射液治疗小儿急性支气管炎能迅速缓解症状,缩短疗程,取得较满意的疗效.%Objective: To investigate the clinical efficacy of Tanreqing injection in the treatment of children acute bronchitis. Methods:116 patients with acute bronchitis were randomly divided into control group and treatment group, each 58 cases, the control group was given conventional antivirus, anti-infection, anti-cough expectoranting treatment, the treatment group added Tanreqing injection intravenous drip based on the control group of conventional treatment, dose for 0.5-1.0 ml/(kg·d), therapeutic effect and improvement of symptoms of two groups were compared. Results: After one week's treatment, the total effective rate of the treatment group was 96.55% (56/58), and the control group was 77.59% (45/58), compared with curative effect of the two groups, the difference had statistics significance (P<0.05). The average antifebrile time, cough disappeared or significantly reduced time of the treatment group were shorter than those of control group, there was a significant difference (P<0.05). Conclusion: the conventional treatment added Tanreqing injection in the treatment of children acute bronchitis can rapidly relieve symptoms, shorten the course of treatment, and achieve satisfactory

  7. Clinical efficacy and safety of urinary kallidinogenase injection in patients with acute cerebral infarction%尤瑞克林治疗急性脑梗死的疗效及安全性评价

    Institute of Scientific and Technical Information of China (English)

    谭少华; 林耀波; 刘聪; 李丽娟; 李少梅

    2013-01-01

    Objective To evaluate the clinical efficacy and safety of urinary kallidinogenase injection in patients with acute cerebral infarction.Methods One hundred patients with acute cerebral infarction were included in this trial,which were randomly divided into two groups.Patients in the control group (n=50) were treated with basic therapy,while those in the treatment group (n=50) were treated with urinary kal l idinogenase injection and basic therapy.NIHSS score were evaluated before treatment,7 days and 14 days after treatment,respectively.Hepatic function,renal function,coagulation function and hemorrhagic event were recorded before and after treatment.Results No significant difference was in NIHSS sore found 7 d after treatment (P>0.05),while 14 days after treatment,NIHSS score in the treatment group was significantly lower than that in the control group (P<0.05).No significant difference was found before and after treatment on hepatic,renal,coagulation impairment and hemorrhagic event (P<0.05).Conclusion Urinary kallidinogenase injection is effective and safe for patients with acute cerebral infarction,which is better than single use of basic therapy.%目的 评价注射用尤瑞克林对急性脑梗死的临床疗效及安全性.方法 根据1995年第四届全国脑血管病会议制订的诊断标准,选取急性脑梗死患者100例,入选病例随机分为两组各50例,对照组患者给予缺血性脑卒中基础治疗;治疗组患者除给予基础治疗外,予注射用尤瑞克林0.15 PNA,分别于治疗前、治疗7d及治疗14d行NIHSS评分,并对治疗前后肝肾功能、凝血功能及出血事件作比较.结果 治疗7d两组NIHSS评分差异无统计学意义(P>0.05);治疗14 d治疗组NIHSS评分较对照组明显下降,差异有统计学意义(P<0.05);两组肝肾功能损害、凝血功能及出血事件差异无统计学意义(P>0.05).结论 尤瑞克林治疗急性脑梗死患者安全有效,优于单纯使用缺血性脑卒中基础治疗.

  8. 氨磺必利与利培酮治疗精神分裂症对照研究%A control study of amisulpride vs .risperidone in the treatment of schizophrenia

    Institute of Scientific and Technical Information of China (English)

    邵国艳; 常双海

    2014-01-01

    Objective To explore the efficacy and safety of amisulpride vs .risperidone in the treatment of schizophrenia .Methods Sixty schizophrenics were randomly assigned to two groups of 30 ones each ,re-search group took orally amisulpride and control group did risperidone for 8 weeks .Efficacies were as-sessed with the Positive and Negative Syndrome Scale (PANSS) and adverse reactions with the Treatment Emergent Symptom Scale (TESS) .Results After treatment the total and each factor score of the PANSS of both groups lowered continuously compared with pretreatment (P0 .05);at the end of the 8th week obvious effec-tive and effective rate were respectively 60 .0% and 83 .3% in research and 66 .7% and 86 .7% in control group ,which showed no significant differences (χ2 = 0 .29 ,0 .13 ,P> 0 .05) .There were no significant group differences in incidences of adverse reactions (P>0 .05) .Conclusion Amisulpride has an efficacy equivalent to risperidone ,higher safety and better compliance in the treatment of schizophrenia .%目的:探讨氨磺必利与利培酮治疗精神分裂症的临床疗效和安全性。方法将60例精神分裂症患者随机分为两组,每组30例,研究组口服氨磺必利治疗,对照组口服利培酮治疗,观察8周。采用阳性与阴性症状量表评定临床疗效,副反应量表评定不良反应。结果治疗后两组阳性与阴性症状量表总分及各因子分均较治疗前呈持续性下降(P<0.01),治疗各时段两组评分比较差异均无显著性( P>0.05);治疗8周末研究组显效率60.0%、有效率83.3%,对照组分别为66.7%、86.7%,两组比较差异无显著性(χ2=0.29、0.13,P>0.05)。两组不良反应发生率比较差异均无显著性(P>0.05)。结论氨磺必利治疗精神分裂症的疗效与利培酮相当,安全性高,依从性好。

  9. 甲强龙鼓室注射对三种类型听力下降的疗效报告%Efficacies of intratympanic methylprednisolone injection in three types of hearing loss

    Institute of Scientific and Technical Information of China (English)

    李琦; 莫婷婷; 彭新宇; 刘钊; 刘友利; 梁勇

    2015-01-01

    limited efficacy for high-frequency loss. ALHL appears to respond best to intratympanic injection of methylprednisolone, although the treatment can also be used in SSHL-DM as the first choice treatment, which helps reduce potential systemic adverse effects of steroids. In SSHL-FOH, it may be used as a salvage therapy.%目的:探讨鼓室注射甲强龙在不同类型的听力下降中的疗效。方法收集2012.03至2014.06在我科门诊及住院治疗的不同类型听力下降病人48例。其中,急性低频感音神经性耳聋(acutc low-tone sensorineural hearing loss, ALHL)36例;伴有糖尿病的突发性耳聋7例;口服激素治疗失败的突发性耳聋5例。甲强龙单次注射剂量为0.5-0.7ml(20-28mg)。急性低频感音神经性耳聋患者均在门诊给予一次甲强龙鼓室注射,5天后复查听力,如听力改善不明显,再给予一次注射。伴有糖尿病及口服激素治疗失败的患者均住院治疗,隔天给予甲强龙鼓室注射一次,5次为一疗程。结果急性低频感音神经性耳聋患者治疗前0.25,0.5,1kHz平均听阈51.25±6.84dBHL,治疗后平均听阈19.36±4.85 dBHL,其中痊愈32例,有效4例(总有效率100%,36/36);伴有糖尿病的突发性耳聋患者治疗前0.5,1,2,4,8kHz平均听阈78.31±14.16dBHL,治疗后平均听阈49.36±12.69 dBHL,其中痊愈2例,显效2例,有效1例,无效2例(总有效率71.43%,5/7);其中听力改善主要发生在0.5,1,2kHz,4,8kHz听力均未见明显改善;口服激素治疗失败患者治疗前0.5,1,2,4,8kHz平均听阈79.25±16.28dBHL,治疗后平均听阈69.36±12.27 dBHL,其中显效1例,有效2例,无效2例(总有效率60.00%,3/5),其中听力改善亦主要发生在0.5,1,2kHz,4,8kHz听力亦未见明显改善。结论甲强龙鼓室注射可以有效地改善低频区域的听力下降;对于中、高频区域的听力下降则治疗效果有限。在不同类型的听力下降中

  10. Certolizumab Injection

    Science.gov (United States)

    ... and swelling and scales on the skin), active ankylosing spondylitis (a condition in which the body attacks the ... continues. When certolizumab injection is used to treat ankylosing spondylitis, it is usually given every 2 weeks for ...

  11. Olanzapine Injection

    Science.gov (United States)

    ... of interest in life, and strong or inappropriate emotions). Olanzapine injection is used to treat episodes of ... this medication affects you.you should know that alcohol can add to the drowsiness caused by this ...

  12. Haloperidol Injection

    Science.gov (United States)

    ... of interest in life, and strong or inappropriate emotions). Haloperidol injection is also used to control motor ... this medication affects you.you should know that alcohol can add to the drowsiness caused by this ...

  13. Tigecycline Injection

    Science.gov (United States)

    ... in a person who was not in the hospital), skin infections, and infections of the abdomen (area between the ... that developed in people who were in a hospital or foot infections in people who have diabetes. Tigecycline injection is ...

  14. Golimumab Injection

    Science.gov (United States)

    Golimumab injection is used alone or with other medications to relieve the symptoms of certain autoimmune disorders ( ... did not help or could not be tolerated. Golimumab is in a class of medications called tumor ...

  15. Ferumoxytol Injection

    Science.gov (United States)

    Ferumoxytol injection is used to treat iron-deficiency anemia (a lower than normal number of red blood ... pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or ...

  16. Aripiprazole Injection

    Science.gov (United States)

    ... mixed with water (Abilify Maintena) and as a suspension (liquid) (Aristada) to be injected into a muscle ... decisions, and react quickly. Do not drive a car or operate machinery until you know how this ...

  17. Ertapenem Injection

    Science.gov (United States)

    Ertapenem injection is used to treat certain serious infections, including pneumonia and urinary tract, skin, diabetic foot, ... for the prevention of infections following colorectal surgery. Ertapenem is in a class of medications called carbapenem ...

  18. Testosterone Injection

    Science.gov (United States)

    Testosterone cypionate (Depo-Testosterone), testosterone enanthate (Delatestryl), testosterone undecanoate (Aveed), and testosterone pellet (Testopel) are forms of testosterone injection used to treat symptoms of low testosterone in men who have hypogonadism (a ...

  19. Fludarabine Injection

    Science.gov (United States)

    ... also sometimes used to treat non-Hodgkin's lymphoma (NHL; cancer that begins in a type of white ... this medication. You should not plan to have children while receiving fludarabine injection or for at least ...

  20. Ramucirumab Injection

    Science.gov (United States)

    ... dose of ramucirumab injection. Tell your doctor or nurse if you experience any of the following while you receive ramucirumab: uncontrollable shaking of a part of the body; back pain or spasms; chest pain and tightness; chills; flushing; ...

  1. Basiliximab Injection

    Science.gov (United States)

    ... prescribed for other uses; ask your doctor or pharmacist for more information. ... Ask your pharmacist any questions you have about basiliximab injection.It is important for you to keep a written list of ...

  2. Nafcillin Injection

    Science.gov (United States)

    ... injection is in a class of medications called penicillins. It works by killing bacteria.Antibiotics such as ... and pharmacist if you are allergic to nafcillin; penicillins; cephalosporin antibiotics such as cefaclor, cefadroxil, cefazolin, cefdinir, ...

  3. Oxacillin Injection

    Science.gov (United States)

    ... injection is in a class of medications called penicillins. It works by killing bacteria.Antibiotics such as ... and pharmacist if you are allergic to oxacillin; penicillins; cephalosporin antibiotics such as cefaclor, cefadroxil, cefazolin, cefdinir, ...

  4. Ampicillin Injection

    Science.gov (United States)

    ... injection is in a class of medications called penicillins. It works by killing bacteria.Antibiotics such as ... and pharmacist if you are allergic to ampicillin; penicillins; cephalosporin antibiotics such as cefaclor, cefadroxil, cefazolin (Ancef, ...

  5. Levofloxacin Injection

    Science.gov (United States)

    ... injection is used to treat infections such as pneumonia; chronic bronchitis; and sinus, urinary tract, kidney, prostate ( ... skin or eyes dark urine decreased urination seizures unusual bruising or bleeding joint or muscle pain Levofloxacin ...

  6. Linezolid Injection

    Science.gov (United States)

    Linezolid injection is used to treat infections, including pneumonia, and infections of the skin and blood. Linezolid ... to 2 months or more after your treatment) unusual bleeding or bruising cough, chills, sore throat, and ...

  7. Cefazolin Injection

    Science.gov (United States)

    ... joint, genital, blood, heart valve, respiratory tract (including pneumonia), biliary tract, and urinary tract infections. Cefazolin injection ... effects. Call your doctor if you have any unusual problems while using this medication.If you experience ...

  8. Moxifloxacin Injection

    Science.gov (United States)

    ... appropriate for them to remain available as a therapeutic option.FDA is continuing to assess safety issues ... review has shown that fluoroquinolones when used systemically (i.e. tablets, capsules, and injectable) are associated with disabling ...

  9. Gemcitabine Injection

    Science.gov (United States)

    ... with surgery. Gemcitabine is also used to treat cancer of the pancreas that has spread to other parts of the ... 4 weeks. When gemcitabine is used to treat cancer of pancreas it may be injected once every week. The ...

  10. Fluconazole Injection

    Science.gov (United States)

    ... and fungal infections of the eye, prostate (a male reproductive organ), skin and nails. Fluconazole injection is ... Motrin, others) and naproxen (Aleve, Anaprox, Naprelan); oral contraceptives (birth control pills); oral medication for diabetes such ...

  11. Insulin Injection

    Science.gov (United States)

    ... or buttocks. Do not inject insulin into muscles, scars, or moles. Use a different site for each ... you are using insulin.Alcohol may cause a decrease in blood sugar. Ask your doctor about the ...

  12. Tesamorelin Injection

    Science.gov (United States)

    ... is colored, cloudy, contains particles, or if the expiration date on the bottle has passed.Never reuse ... swelling of the face or throat shortness of breath difficulty breathing fast heartbeat dizziness fainting Tesamorelin injection ...

  13. Secukinumab Injection

    Science.gov (United States)

    ... secukinumab solution before injecting it. Check that the expiration date has not passed and that the liquid ... fever, sweats, or chills, muscle aches, shortness of breath, warm, red, or painful skin or sores on ...

  14. Alirocumab Injection

    Science.gov (United States)

    ... further decrease the amount of low-density lipoprotein (LDL) cholesterol ('bad cholesterol') in the blood. Alirocumab injection is ... antibodies. It works by blocking the production of LDL cholesterol in the body to decrease the amount of ...

  15. Comparison of efficacy and safety of insulin aspart 30 injection and isophane protamine biosynthetic human insulin Injection for type 2 diabetes%双时相门冬胰岛素30与预混人胰岛素30R治疗2型糖尿病的疗效及安全性比较

    Institute of Scientific and Technical Information of China (English)

    谢树桂

    2011-01-01

    目的 比较双时相门冬胰岛素30和预混人胰岛素30R治疗2型糖尿病(T2DM)的疗效及安全性.方法 将本院2007年1月至2010年5月住院的80例T2DM患者采用简单随机方法分为两组,其中预混人胰岛素30R治疗40例(A组),双时相门冬胰岛素30治疗40例(B组),均采用每日早、晚餐前两次皮下注射方案,为期12周,比较两组患者空腹、早餐后2 h、午餐前、午餐后2 h、晚餐前、晚餐后2 h及睡前7个时点血糖的变化,糖化血红蛋白(HbA1c)及血糖控制达标所需要的胰岛素用量、低血糖事件、不良反应发生率.结果 B组三餐后血糖、HbA1c、低血糖事件发生率均低于A组,差异有统计学意义(P<0.05);两组胰岛素用量及其他不良事件发生率差异无统计学意义(P>0.05).结论 双时相门冬胰岛素30能有效降低餐后血糖,且低血糖事件发生率低,是一种简便、有效、安全的治疗方法.%Objective To compare the efficacy and safety between Insulin Aspart 30 Injection and Isophane Protamine Biosynthetic Human Insulin Injection (pre-mixed 30R) in the treatment of type 2 diabetes (T2DM).Methods Eighty patients with T2DM,which were hospitalized in the Chengdu Aerospace Hospital from January 2007 to May 2010,were randomly divided into two groups,group A (40 cases) and group B (40 cases).Patients in group A received pre-mixed 30R b.i.d,and those in group B received Insulin Aspart 30 Injection b.i.d.And a 12-week controlled trial was performed.Changes in blood glucose at 7 time points ( early morning/fasting,2h after breakfast,before lunch,2h after lunch,before dinner,2h after dinner and bedtime) ,glycosylated hemoglobin ( HbA1c ),insulin dosage,incidence of hypoglycemia and other adverse events were observed.Results Postprandial blood glucose levels, HbA1cand hypoglycemia incidence in group B were significantly lower than those in group A ( P < 0.05 ).There was no significant difference in insulin dosage between the two

  16. 氨磺必利与利培酮治疗精神分裂症对照研究%Comparative Study of Amisulpride and Risperidone in Treating 60 Cases of Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    曹国兴; 古淑敏; 程雪

    2014-01-01

    Objective To observe the efficacy and safety of amisulpride in the treatment of schizophrenia. Methods 60 cases of first episode schizophrenia were randomly divided into the amisulpride group and the risperidone group with 30 cases in each group and treated for 8 weeks. The positive and negative symptom scale ( PANSS ) was adopted to evaluate the efficacy and the treatment emergent symptoms effect scale ( TESS ) was used to evaluate the adverse reactions. Results The total effective rate after treatment in the amisul-pride group was 83. 33%, while which in the risperidone group was 80. 00% without statistically significant difference between the two groups ( P > 0. 05 ) . The weight gain of the amisulpride group was significantly less than that of the rispefidone group ( P < 0. 05 ) . Conclusion Amisulpride and rispefidone have a similar therapeutic effect, but the case number of weight gain caused by amisulpride is significantly decreased, amisulpride deserves to be clinically popularized.%目的:观察氨磺必利治疗精神分裂症的临床疗效与安全性。方法将60例首发精神分裂症患者,随机分为氨磺必利组30例,利培酮组30例,疗程8周。采用阳性与阴性症状量表( PANSS )评定疗效,采用副反应量表( TESS )评定治疗中出现的不良反应。结果氨磺必利组的治疗总有效率为83.33%,利培酮组为80.00%,两组疗效差异无统计学意义( P>0.05);氨磺必利组的体重增加明显少于利培酮组( P<0.05)。结论氨磺必利与利培酮治疗精神分裂症疗效相当,且氨磺必利引起体重增加数例明显较少,值得临床推广。

  17. A case of psychosis due to Fahr's syndrome and response to behavioral disturbances with risperidone and oxcarbazepine

    Science.gov (United States)

    Faye, Abhijeet Dhawalram; Gawande, Sushil; Tadke, Rahul; Kirpekar, Vivek C.; Bhave, Sudhir H.

    2014-01-01

    Calcification of basal ganglia or Fahr's syndrome is a rare disease characterized by bilateral and symmetrical intracranial deposition of calcium mainly in cerebral basal ganglia. Motor and neuropsychiatric symptoms are prominent features. We report a case presented with a few motor symptoms, features of delirium and prominent psychiatric symptoms (disorganized behavior) predominantly evident after the improvement in delirium. Radiological findings were suggestive of bilateral basal ganglia calcification. Parathyroid hormone levels were low with no significant findings in other investigations and negative family history. Patient showed significant improvement in behavioral disturbances with risperidone, low dose of lorazepam, oxcarbazepine, and memantine. PMID:24891710

  18. 齐拉西酮与利培酮治疗精神分裂症对照研究%A control study of ziprasidone vs risperidone in the treatment of schizophrenia

    Institute of Scientific and Technical Information of China (English)

    陈卉

    2009-01-01

    Objective To explore the efficacy and safety of ziprasidone vs risperidone in the treatment of schizophrenia. Methods 78 schizophrenics were randomly divided into two groups of 36 patients each, research group took orally ziprasidone and control group did risperidone for 8 weeks. Clinical efficacies were assessed with the Positive and Negative Syndrome Scale( PANSS) and Clinical Global Impression(CGI), adverse reactions with the Treatment Emergent Symptom Scale(TESS) before treatment and at the end of the 8th week. Results At the end of the 8th week,total effective rate was 83.33% in the research and 77.78% in the control group, which showed no significant difference(χ2=0.355,P>0.05).After treatment, the CGI total,PANSS total and each factor score of both groups lowered more significantly compared with pretreatment(P0.05). Adverse reactions of both groups were mild,mostly emerged in initial stage of treatment and could relieve with time of therapy lasting or by symptomatic treatment. Incidences of weight gain,galactorrhea and menstrual disorder were significantly lower in the research than in the control group. Conclusion Ziprasidone is more effective in first-episode schizophrenia equivalent to risperidone, scarcely causes weight gain and changes of serum prolaction,blood sugar and fat, its adverse reactions are mild and is a safe and effective novel antipsychotic.%目的 探讨齐拉西酮与利培酮治疗精神分裂症的临床疗效及安全性. 方法 将72例精神分裂症患者随机分为两组,每组36例,研究组口服齐拉西酮治疗,对照组口服利培酮治疗,观察8 w.于治疗前及治疗8 w末采用阳性与阴性症状量表、临床总体印象量表评定临床疗效,副反应量表评定不良反应.结果治疗8 w末,研究组总有效率为83.33%,对照组为77.78%,两组总有效率无显著性差异(χ2=0.355,P>0.05).治疗后两组临床总体印象量表总分、阳性与阴性症状量表总分及各因子分均

  19. Comparison of efficacy and safety among three injections of fat soluble drugs on fat dissolution%三种注射溶脂药物对脂肪溶解效果及安全性比较

    Institute of Scientific and Technical Information of China (English)

    许柯; 黄曹; 张好云; 刘少雄

    2015-01-01

    Objective To investigate the efficacy and safety of three injections fat soluble drugs to dissolve fat.Methods 3T3-L1 preadipocytes were treated with 5% phosphatidyl choline (PC),4.5% deoxycholate salts (DC) and lipostabil,respectively; thiazolyl tetrazolium (MTT) method was used to measure the different fat cell proliferation activity,the enzyme assay to measure liquid triglyceride (TG) content in culture media and to evaluate the degree of dissolution of the fat cells.16 Hartley white guinea pigs were randomly divided into four groups:shoulder (group a),scapular region (group b),hips (group c),and back (control group) were injected with fat soluble drug 0.5 ml in different parts of the guinea pig fat layer,and at different time points tissues were cut for pathological analysis.Results The proliferative activity of 3T3-L1 preadipocytes were significantly decreased after treatment with three types of fat soluble drugs compared with control group (P<0.05),and their effects on dissolution of fat cells were also significant:the contents were 5% PC (4.14±0.92)mmol/L,4.5% DC (3.91 ±0.67) mmol/L,and lipostabil (4.23± 0.76) mmol/L,respectively,which were significantly higher than that of the control (1.91±0.12) mmol/L (P<0.05); guinea pigs in vivo showed that the three types of fat soluble drugs on dissolving adipose tissue at the injection site had varying degrees of swelling,lymphocytic infiltration,and fat cell degeneration,fusion and decrease in number.Conclusions Three fat soluble injections could dissolve the fat cells in some degree,in whichi lipostabil is stronger than other fat soluble drugs,but their effect on adipose tissue is nonspecific,and therefore clinical application of those fat soluble drugs should be in high caution.%目的 探讨3种注射溶脂药物对脂肪溶解效果及安全性.方法 用5%磷脂酰胆碱(PC)、4.5%脱氧胆酸盐(DC)及Lipostabil,分别作用于3T3-L1前体脂肪细胞,采用四甲基偶氮噻唑蓝(MTT)

  20. 复方苦参注射液腹腔内注射联合体外高频热疗对晚期肝癌腹水患者的疗效%Efficacy of Intraperitoneal Injection of Compound Matrine Injection Combined with External High Frequency Thermotherapy for the Treatment of Ascites in Advanced Liver Cancer

    Institute of Scientific and Technical Information of China (English)

    杨柳; 李小妹

    2015-01-01

    目的:探讨复方苦参腹注射液腔内注射联合体外高频热疗对晚期肝癌腹水患者的疗效。方法:选取我院2012年7月~2014年3月收治的确诊为晚期肝癌腹水患者29例的临床资料,按照随机分组的方法分为对照组和观察组。对照组给予复方苦参注射液腔内注射治疗,观察组在对照组的基础上联合体外高频热疗治疗。比较两组治疗总有效率、细胞免疫学指标、生活质量改善率为及不良反应发生情况。结果:治疗后,观察组治疗总有效率高于对照组(73.33% vs 50.00%,χ2=9.003,P<0.05);观察组治疗CD4+/CD8+及NK细胞数均高于对照组(P<0.05);观察组生活质量改善率高于对照组(73.33% vs 35.71%,χ2=10.324,P<0.05)。两组治疗中均未见明显不良反应发生。结论:复方苦参注射液腹腔内注射联合体外高频热疗可提高晚期肝癌腹水患者的治疗总有效率,改善患者的生活质量和免疫力,且不良反应发生率较低。%Objective: To investigate efficacy of intraperitoneal injection of compound matrine injection combined with external high frequency thermotherapy for the treatment of patients with ascites in advanced liver cancer.Methods:29 cases of patients with ascites in advanced liver cancer in the department of oncology in the Huainan east general hospital from July 2012 to March 2014 were randomly divided into the control group and observation group.The control group were treated by compound matrine injection via intraperitoneal injection,the observation group were treated by external high frequency thermotherapy on the base of the control group.The total efifciency rate,the cell immunological parameters,quality of life and adverse events of the two groups were compared.Results:After treatment,the total efifciency rate of observation group was higher than that of the control group(73.33% vs 50.00%,χ2=9.003,P<0.05).The CD4+/CD8+and NK cells of the

  1. Development of Nutraceutical Emulsions as Risperidone Delivery Systems: Characterization and Toxicological Studies.

    Science.gov (United States)

    Igartúa, Daniela Edith; Calienni, María Natalia; Feas, Daniela Agustina; Chiaramoni, Nadia Silvia; Valle Alonso, Silvia Del; Prieto, María Jimena

    2015-12-01

    Emulsions are gaining increasing interest to be applied as drug delivery systems. The main goal of this work was the formulation of an oil/water nutraceutical emulsion (NE) for oral administration, enriched in omega 3 (ω3) and omega 6 (ω6), and able to encapsulate risperidone (RISP), an antipsychotic drug widely used in the treatment of autism spectrum disorders (ASD). RISP has low solubility in aqueous medium and poor bioavailability because of its metabolism and high protein binding. Coadministration of ω3, ω3, and vitamin E complexed with RISP might increase its bioavailability and induce a synergistic effect on the treatment of ASD. Here, we developed an easy and quick method to obtain NEs and then optimized them. The best formulation was chosen after characterization by particle size, defects of the oil-in-water interface, zeta potential (ZP), and in vitro drug release. The formulation selected was stable over time, with a particle size of around 3 μm, a ZP lower than -20 mV and controlled drug release. To better understand the biochemical properties of the formulation obtained, we studied in vitro toxicity in the Caco-2 cell line. After 4 h of treatment, an increase in cellular metabolism was observed for all RISP concentrations, but emulsions did not change their metabolic rate, except at the highest concentration without drug (25 μg/mL), which showed a significant reduction in metabolism respect to the control. Additionally, locomotor activity and heart rate in zebrafish were measured as parameters of in vivo toxicity. Only the highest concentration (0.625 μg/mL) showed a cardiotoxic effect, which corresponds to the decrease in spontaneous movement observed previously. As all the materials contained in the formulations were US FDA approved, the NE selected would be good candidate for clinical trials.

  2. Influences of risperidone,quetiapine,or ziprasidone on metabolic parameters of first-episode schizophrenics%利培酮喹硫平齐拉西酮对首发精神分裂症患者代谢指标的影响

    Institute of Scientific and Technical Information of China (English)

    王明进; 张宗顺; 寻广磊

    2016-01-01

    Objective To explore the influences of risperidone ,quetiapine ,or ziprasidone on metabolic parameters of first‐episode schizophrenics .Methods A total of 120 first‐episode schizophrenics were ran‐domly divided into 3 groups taking orally risperidone ,quetiapine or ziprasidone for 12 weeks .Efficacies were assessed with the Positive and Negative Syndrome Scale (PANSS) before and after treatment ,the changes of blood pressure (BP) ,waist circumference (WC) ,fasting plasma glucose (FPG) ,triacylglycer‐ol (TG) and high density lipoprotein cholesferol (HDL‐c) detected at the same time ,and the incidences of metabolism syndrome at each time point were added up .Results After treatment the total effective rate was respectively 89 .2% in risperidone ,88 .9% in quetiapine and 86 .5% in ziprasidone group ,which showed no significant group differences (P> 0 .05) .Since the end of the 4th week WC ,TG and FPG levels heightened more significantly in risperidone and quetiapine group compared with pretreatment ,so did those of the 3 groups at the end of the 12th week (P<0 .05 or 0 .01) ,HDL‐c levels lowered more significantly in risperidone and quetiapine group compared with pretreatment (P<0 .05);WCs ,TGs and the incidences of metabolic syndrome were significantly higher in risperidone and quetiapine than in ziprasidone group at each time point (P<0 .05 or 0 .01) .Conclusion Risperidone ,quetiapine and ziprasidone are all effective in first‐epi‐sode schizophrenia ,their total efficacies equivalent ,but have different influences on metabolism , risperidone and quetiapine influences are obvious .%目的:探讨利培酮、喹硫平、齐拉西酮对首发精神分裂症患者代谢指标的影响。方法将120例首发精神分裂症患者按随机数字表法分为3组,分别口服利培酮、喹硫平、齐拉西酮治疗,观察12周。于治疗前后采用阳性与阴性症状量表评定临床疗效,同时检测血压、腰围及空腹血糖、三酰

  3. Observation on Efficacy of Sodium Hyaluronate in Intra-articular Injection Treatment of Osteoarthrosis%玻璃酸钠膝关节腔内注射治疗骨关节病的疗效观察

    Institute of Scientific and Technical Information of China (English)

    王荣

    2016-01-01

    OBJECTIVE:To investigate the efficacy of sodium hyaluronate in treatment of rheumatoid arthritis ,and the nursing method in the treatment .METHODS:120 cases of patients with rheumatoid arthritis admitted into Hubei Shiyan Xunyang District Traditional Chinese Medicine Hospital from Feb .2013 to Mar.2015 were collected to be divided into control group and observation group via the random number table ,with 60 cases in each.The control group were given conventional treatment and care ,namely ,oral Meloxicam tablets ,ultrashort wave and joint function exercise . The observation group additionally received give sodium hyaluronate injection treatment and nursing measures based on the control group .By contrast ,the recovery of two groups were compared .RESULTS:After treatment of five weeks ,the curative effects of two group of patients showed obvious differences .The total effective rate of observation group was 91.67%( 55/60 ) , significantly higher than that of control group 80.00%( 48/60 ) , with statistically significant difference(P<0.05).As for the extent of osteoarthrosis score in observation group ,patients of zero increased 7 cases, patients of more than 11 points decreased 6 cases;while in control group ,patients of zero increased 1 case ,patients of more than 11 points decreased 3 cases.The control effects of observation group was significantly better than that of control group , with statistically significant difference ( P<0.05 ) .CONCLUSIONS:The efficacy of sodium hyaluronate in intra-articular injection treatment of osteoarthrosis in clinic is significant .It is worthy of clinical promotion and application .%目的:探讨应用玻璃酸钠治疗类风湿性关节炎的疗效及治疗中的护理方法。方法:选择湖北省十堰市郧阳区中医医院从2013年2月—2015年3月的类风湿性关节炎患者120例作为研究对象,按随机数字表法分为对照组和观察组,每组各60例。对照组患者给予常规综合治疗和护

  4. Ibritumomab Injection

    Science.gov (United States)

    ... have received ibritumomab injection.do not have any vaccinations without talking to your doctor.you should know ... cells) and myelodysplastic syndrome (condition in which blood cells do not ... online (http://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).

  5. Tositumomab Injection

    Science.gov (United States)

    ... have received tositumomab injection.do not have any vaccinations without talking to your doctor.you should know ... blood cells), myelodysplastic syndrome (condition in which blood cells do not ... online (http://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).

  6. Doxycycline Injection

    Science.gov (United States)

    ... call your doctor.plan to avoid unnecessary or prolonged exposure to sunlight and to wear protective clothing, sunglasses, and sunscreen. Doxycycline injection may make your skin sensitive to sunlight.you should know that when doxycycline is used during pregnancy or in babies or children up to age ...

  7. Adalimumab Injection

    Science.gov (United States)

    ... swelling and scales on the skin), chronic plaque psoriasis (a skin disease in which red, scaly patches form on some areas of the body). Adalimumab injection is in a class of medications called tumor necrosis factor (TNF) inhibitors. It works by blocking the action ...

  8. Medroxyprogesterone Injection

    Science.gov (United States)

    ... injection when you are a teenager or young adult. Tell your doctor if you or anyone in your family has osteoporosis; if you have or have ever had any other bone disease or anorexia nervosa (an eating disorder); or if you drink a ...

  9. Lanreotide Injection

    Science.gov (United States)

    Lanreotide injection is used to treat people with acromegaly (condition in which the body produces too much growth hormone, causing enlargement of the hands, feet, and facial features; joint pain; and other symptoms) who have not successfully, or cannot be treated ...

  10. Paliperidone Injection

    Science.gov (United States)

    Invega® Trinza® ... Paliperidone extended-release injections (Invega® Sustenna, Invega® Trinza) are used to treat schizophrenia (a mental illness that causes disturbed or unusual thinking, loss of interest in life, and strong or ...

  11. Comorbid Anxiety and Social Avoidance in Treatment of Severe Childhood Aggression: Response to Adding Risperidone to Stimulant and Parent Training; Mediation of Disruptive Symptom Response

    OpenAIRE

    Arnold, L. Eugene; Gadow, Kenneth D.; Farmer, Cristan A.; Findling, Robert L; Bukstein, Oscar; Molina, Brooke S. G.; Brown, Nicole V.; Li, Xiaobai; Rundberg-Rivera, E. Victoria; Bangalore, Srihari; Buchan-Page, Kristin; Hurt, Elizabeth A.; Rice, Robert; McNamara, Nora K.; Aman, Michael G

    2015-01-01

    Objective: In the four-site Treatment of Severe Childhood Aggression (TOSCA) study, addition of risperidone to stimulant and parent training moderately improved parent-rated disruptive behavior disorder (DBD) symptoms. This secondary study explores outcomes other than DBD and attention-deficit/hyperactivity disorder (ADHD) as measured by the Child and Adolescent Symptom Inventory-4R (CASI-4R).

  12. The effect of clozapine and risperidone on attentional bias in patients with schizophrenia and a cannabis use disorder: An fMRI study.

    Science.gov (United States)

    Machielsen, Marise Wj; Veltman, Dick J; van den Brink, Wim; de Haan, Lieuwe

    2014-07-01

    Cannabis use disorders (CUDs) are highly comorbid in patients with schizophrenia and are associated with poor outcome. Clozapine has been put forward as the first choice antipsychotic in this comorbid group. However, little is known about the mechanisms underlying the assumed superiority of clozapine. We compared the effects of clozapine and risperidone on attentional bias, subjective craving and associated regional brain activity in patients with schizophrenia and CUD. Overall, 36 patients with schizophrenia and 19 healthy controls were included. Patients were randomised to antipsychotic treatment with clozapine or risperidone. At baseline and after 4 weeks of medication use, regional brain responses were measured during a classical Stroop and a cannabis word Stroop using functional magnetic resonance imaging. Clozapine-treated CUD patients showed a larger reduction in craving and in activation of the insula during the cannabis word Stroop, while risperidone-treated patients showed a larger decrease in activation of the right anterior cingulate cortex during the classical Stroop. A significant association was found between decreases in subjective craving and decreases in insula activation during the cannabis word Stroop. These findings strongly suggest that clozapine may be a better treatment choice in patients with schizophrenia and CUD than risperidone. PMID:24646809

  13. Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia

    OpenAIRE

    Honey, Garry D; Edward T Bullmore; Soni, William; Varatheesan, Malini; Williams, Steve C.R.; Sharma, Tonmoy

    1999-01-01

    Antipsychotic drug treatment of schizophrenia may be complicated by side effects of widespread dopaminergic antagonism, including exacerbation of negative and cognitive symptoms due to frontal cortical hypodopaminergia. Atypical antipsychotics have been shown to enhance frontal dopaminergic activity in animal models. We predicted that substitution of risperidone for typical antipsychotic drugs in the treatment of schizophrenia would be associated with enhanced functional activation of frontal...

  14. Drug induced parkinsonism caused by the concurrent use of donepezil and risperidone in a patient with traumatic brain injuries.

    Science.gov (United States)

    Kang, Si Hyun; Kim, Don-Kyu

    2013-02-01

    A 69-year-old male patient with previous history of traumatic brain injury 5 months ago was admitted to the Department of Neuropsychiatry because of aggressive behavior and delusional features. After starting on 2 mg of risperidone per day, his delusion, anxiety, and aggressive behavior gradually improved. Two weeks later, he was given 10 mg of donepezil per day for his mild cognitive impairment. After 6 weeks of admission in the Department of Neuropsychiatry, he showed parkinsonian features including difficulty in walking, decreased arm swing during walking, narrowed step width, scooped posture, bradykinesia, tremor, and sleep disorder. To rule out the primary Parkinsonism, dopamine transporter imaging technique [18F]fluoropropyl-carbomethoxy-iodopropyl-nor-β-tropane positron emission tomography-computed tomography (18F]FP(IT PET-CT)) was performed, and dopamine transporter activity was not decreased. We considered that his parkinsonian features were associated with the combination of risperidone and donepezil. Both drugs were stopped and symptoms rapidly disappeared in several days. PMID:23526695

  15. Long-Term Risperidone Treatment Induces Visceral Adiposity Associated with Hepatic Steatosis in Mice: A Magnetic Resonance Approach

    Directory of Open Access Journals (Sweden)

    Florent Auger

    2014-01-01

    Full Text Available Although atypical antipsychotic drugs (APDs have led to significant advances in the treatment of psychotic disorders, they still induce metabolic disturbances. We aimed at characterizing the metabolic consequences of a risperidone treatment and at establishing a link with noninvasive MR markers, in order to develop a tool for predicting symptoms of the metabolic syndrome. Fat deposition and liver morphometry were assessed by T1-weighted imaging. Fatty acid composition and fat accumulations in tissues were determined using MR spectroscopy with and without water suppression, respectively. Risperidone treatment induced a weight gain accompanied with metabolic disturbances such as hyperglycemic status, an increase in visceral adipose tissue (VAT, and liver fat depositions. Correlations using Methylene-Water Ratio (MWR and Polyunsaturated Index (PUI demonstrated a concomitant increase in the weight gain, VAT and liver fat depositions, and a decrease in the quantity of polyunsaturated fatty acids. These results were consistent with a hepatic steatosis state. We evaluated the ability of MR techniques to detect subtle metabolic disorders induced by APDs. Thus, our model and methodology offer the possibility to investigate APDs side effects in order to improve the health conditions of schizophrenic patients.

  16. New aspects of injectable contraception.

    Science.gov (United States)

    Phillips, O P

    2001-01-01

    Despite the availability of efficacious and safe contraceptive agents, not all women's contraceptive needs are being met. An injectable contraceptive method offers convenience and encourages compliance, both very important aspects for women seeking ideal contraception. Depot medroxyprogesterone acetate (DMPA) is a long-acting injectable, and is highly effective; one injection provides 3 months of contraception. Drawbacks of DMPA include irregular bleeding and a slow return to fertility. A new monthly injectable contraceptive agent is medroxyprogesterone acetate/estradiol cypionate suspension (Lunelle). It provides menstrual regulation and a rapid return to fertility. The estrogen ensures a withdrawal bleed monthly; however, women with contraindications to estrogen-containing contraception are not candidates for Lunelle. PMID:11294618

  17. Forum for injection techniques, India: The first Indian recommendations for best practice in insulin injection technique

    Directory of Open Access Journals (Sweden)

    Sanjay Kalra

    2012-01-01

    Full Text Available Advances in the treatment of diabetes have led to an increase in the number of injectable therapies, such as human insulin, insulin analogues, and glucagon-like peptide-1 analogues. The efficacy of injection therapy in diabetes depends on correct injection technique, among many other factors. Good injection technique is vital in achieving glycemic control and thus preventing complications of diabetes. From the patients′ and health-care providers′ perspective, it is essential to have guidelines to understand injections and injection techniques. The abridged version of the First Indian Insulin Injection technique guidelines developed by the Forum for Injection Technique (FIT India presented here acknowledge good insulin injection techniques and provide evidence-based recommendations to assist diabetes care providers in improving their clinical practice.

  18. Spectroscopic and thermal investigations on the charge transfer interaction between risperidone as a schizophrenia drug with some traditional π-acceptors: Part 2

    Science.gov (United States)

    El-Habeeb, Abeer A.; Al-Saif, Foziah A.; Refat, Moamen S.

    2013-03-01

    The focus of present investigation was to assess the utility of non-expensive techniques in the evaluation of risperidone (Ris) in solid and solution states with different traditional π-acceptors and subsequent incorporation of the analytical determination into pharmaceutical formulation for a faster release of risperidone. Charge-transfer complexes (CTC) of risperidone with picric acid (PA), 2,3-dichloro-5,6-dicyano-p-benzoquinon (DDQ), tetracyanoquinodimethane (TCNQ), tetracyano ethylene (TCNE), tetrabromo-p-quinon (BL) and tetrachloro-p-quinon (CL) have been studied spectrophotometrically in absolute methanol at room temperature. The stoichiometries of the complexes were found to be 1:1 ratio by the photometric molar ratio between risperidone and the π-acceptors. The equilibrium constants, molar extinction coefficient (ɛCT) and spectroscopic-physical parameters (standard free energy (ΔGo), oscillator strength (f), transition dipole moment (μ), resonance energy (RN) and ionization potential (ID)) of the complexes were determined upon the modified Benesi-Hildebrand equation. Risperidone in pure form was applied in this study. The results indicate that the formation constants for the complexes depend on the nature of electron acceptors and donor, and also the spectral studies of the complexes were determined by (infrared, Raman, and 1H NMR) spectra and X-ray powder diffraction (XRD). The most stable mono-protonated form of Ris is characterized by the formation of +Nsbnd H (pyrimidine ring) intramolecular hydrogen bonded. In the high-wavenumber spectral region ˜3400 cm-1, the bands of the +Nsbnd H stretching vibrations and of the pyrimidine nitrogen atom could be potentially useful to discriminate the investigated forms of Ris. The infrared spectra of both Ris complexes are confirming the participation of +Nsbnd H pyrimidine ring in the donor-acceptor interaction.

  19. Risperidone induces long-lasting changes in the conditioned avoidance response and accumbal gene expression selectively in animals treated as adolescents.

    Science.gov (United States)

    Moe, Aung Aung Kywe; Kurniawan, Nyoman D; Alexander, Suzanne; Cui, Xiaoying; Burne, Thomas H J; Eyles, Darryl W

    2016-09-01

    Adolescence is a period of dynamic remodeling and maturation in the brain. Exposure to psychotropic drugs during adolescence can potentially alter neural maturation in the adolescent brain subsequently altering neural function at maturity. In this regard, antipsychotic drugs (APDs) are important given a notable global increase in prescription of these APDs to adolescents for a variety of behavioural symptoms and conditions over the past twenty years. However, there is a paucity of data on the long-term consequences of APDs on the adolescent brain. In this preclinical study, we have examined whether the adolescent brain is more susceptible than the adult brain to long-term neural changes induced by risperidone, which is the APD most frequently prescribed to adolescents. Rats were chronically treated (21 days) with 1.3 mg/kg/day risperidone or vehicle either as adolescents (postnatal day (PND) 36-56)) or adults (PND80-100). Behaviour was assessed using the well-described suppression of the conditioned avoidance response (CAR) by APDs. We examined CAR after all animals had reached maturity (PND127). We show that mature rats treated with risperidone as adolescents had increased CAR suppression compared to adults when rechallenged with this same drug. In the nucleus accumbens, significant downregulation of serotonergic 5HT2A receptors and catechol-o-methyl transferase mRNA levels was observed only in the adolescent treated animals. Impaired 5HT2A receptor signaling may explain the increased CAR suppression observed in rats treated with risperidone as adolescents. Magnetic resonance imaging (MRI), however, did not detect any risperidone-induced long-term brain structural change at maturity. These findings confirm that APD administration during adolescence may produce long-term behavioural and neurochemical alterations. PMID:27130903

  20. Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia

    Science.gov (United States)

    Honey, Garry D.; Bullmore, Edward T.; Soni, William; Varatheesan, Malini; Williams, Steve C. R.; Sharma, Tonmoy

    1999-01-01

    Antipsychotic drug treatment of schizophrenia may be complicated by side effects of widespread dopaminergic antagonism, including exacerbation of negative and cognitive symptoms due to frontal cortical hypodopaminergia. Atypical antipsychotics have been shown to enhance frontal dopaminergic activity in animal models. We predicted that substitution of risperidone for typical antipsychotic drugs in the treatment of schizophrenia would be associated with enhanced functional activation of frontal cortex. We measured cerebral blood oxygenation changes during periodic performance of a verbal working memory task, using functional MRI, on two occasions (baseline and 6 weeks later) in two cohorts of schizophrenic patients. One cohort (n = 10) was treated with typical antipsychotic drugs throughout the study. Risperidone was substituted for typical antipsychotics after baseline assessment in the second cohort (n = 10). A matched group of healthy volunteers (n = 10) was also studied on a single occasion. A network comprising bilateral dorsolateral prefrontal and lateral premotor cortex, the supplementary motor area, and posterior parietal cortex was activated by working memory task performance in both the patients and comparison subjects. A two-way analysis of covariance was used to estimate the effect of substituting risperidone for typical antipsychotics on power of functional response in the patient group. Substitution of risperidone increased functional activation in right prefrontal cortex, supplementary motor area, and posterior parietal cortex at both voxel and regional levels of analysis. This study provides direct evidence for significantly enhanced frontal function in schizophrenic patients after substitution of risperidone for typical antipsychotic drugs, and it indicates the potential value of functional MRI as a tool for longitudinal assessment of psychopharmacological effects on cerebral physiology. PMID:10557338

  1. Efficacy and safety of Trichosanthes kirilowii Maxim Injections in the treatment of coronary heart disease%瓜蒌皮注射液治疗心绞痛安全性和有效性的Meta分析

    Institute of Scientific and Technical Information of China (English)

    赵先; 宁泽琼; 王婧雯; 钱小亮; 胡冬梅; 封小娜; 爱东

    2016-01-01

    Objective To evaluate the efficacy and safety of Trichosanthes kirilowii Maxim Injections in the treatment of coronary heart disease .Methods Wanfang ,VIP ,CNKI ,PubMed and Medline database were searched and analyzed .The quality of includ-ed trials was evaluated by the criterion in Cochrane Handbook .Meta-analysis was conducted by using RevMan 5 .1 .The results of angina symptoms ,ECG ST-T period of change ,the change of hemorheology and adverse reactions were recorded .Results The study included 10 randomized controlled clinical trials ,a total of 1 345 cases of patients .In the respect of angina significant effi-ciency [OR=2 .03 ,95% CI (1 .60 ,2 .57) ,P <0 .01] ,ECG significant efficiency [OR=1 .64 ,95% CI (1 .10 ,2 .42) ,P=0 .01] , angina frequency [MD= -0 .59 ,95% CI (-0 .74 ,-0 .44) ,P <0 .01] ,and ST segment down [MD= -0 .68 ,95% CI (-1 .28 ,-0 .09) ,P=0 .02] ,the treatment group was better than the control group .The duration of angina was [MD=2 .56 ,95% CI (-0 .11 ,5 .22) ,P=0 .06] and the adverse reactions [OR=1 .06 ,95% CI (0 .56 ,2 .00) ,P=0 .85] showed no statistically signifi-cant .Conclusion Trichosanthes kirilowii Maxim Injections improves the symptoms of angina significantly and also has a certain effect on the improvement of electrocardiogram .%目的:评价瓜蒌皮注射液用于治疗心绞痛的安全性和有效性。方法计算机检索中国知网(CNKI)数据库,万方(Wanfang )数据库,维普(VIP)数据库,PubMed数据库和Medline数据库,采用Cochrane Handbook推荐的标准对纳入文献进行质量评价;使用RevMan 5.1进行Meta分析。选取心绞痛治疗显效率、心绞痛发作次数和持续时间、心电图疗效结果、心电图ST-T 段改变、不良反应作为观察指标。结果本研究纳入10项随机对照临床试验,共1345例。心绞痛治疗显效率[OR=2.03,95% CI (1.60,2.57),P<0.01],心电图显效率[OR=1.64,95% CI(1.10,2.42

  2. 不同剂量利培酮治疗首发精神分裂症的疗效观察%Clinical observation of various dosages of risperidone in treatment of first episode schizophrenia

    Institute of Scientific and Technical Information of China (English)

    隗春玲

    2015-01-01

    Objective To observe the effect of various dosages of Risperidone Tablets in treatment of first episode schizophrenia and safety evaluation.Methods Patients (127 cases) with first episode schizophrenia from Beijing Fangshan District Mental Health Care Hospital from April 2012 to April 2014 were randomly divided into high-dosage group ( 62 cases) and low-dosage group (65 cases). The patients in the high-dosage group werepo administered with Risperidone Tablets 0.5 — 1 mg/d at beginning, then gradually added to 6 mg/d according to patient's condition and adverse reactions in the second and third day, and maintained the dosage of 6 mg/d. The patients in the low-dosage group were same to those in the high-dosage group except added dosage and maintenance dosage of 3 mg/d. Two groups were treated for 8 weeks. After treatment, the efficacy was evaluated, and PANSS score, EPS occurrence and TESS scores in two groups were compared.Results The efficacies in the high-dosage and low-dosage groups were 93.85% and 82.26%, respectively, and there were differences between two groups (P < 0.05). After treatment, negative symptom scale scores, positive symptom scale score, the psychopathology scale scores, and PANSS total score in two groups were significantly lower, and the difference was statistically significant in the same group (P < 0.05). The observational indexes of the low-dosage group were significantly lower than those in the same period in the high-dosage group treated for 4 and 8 weeks, with significant difference between two groups (P < 0.05). The incidence of EPS and TESS scores at 4 and 8 week in the low-dosage group were obviously lower than those in the high-dosage group, and the difference was statistically significant between two groups (P < 0.05).Conclusion Low-dosage of Risperidone Tablets has curative effect in treatment of first episode schizophrenia with better clinical efficacy, less PANSS score, incidence of EPS, and TESS scores, which be superior to

  3. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study.

    Science.gov (United States)

    Bobes, J; Garc A-Portilla, M P; Rejas, J; Hern Ndez, G; Garcia-Garcia, M; Rico-Villademoros, F; Porras, A

    2003-01-01

    Atypical antipsychotics seem to differ mainly in their tolerability profile. The aim of this cross-sectional study, the Estudio de Investigaci n de Resultados en Esquizofrenia (Outcomes Research Study in Schizophrenia; EIRE study), was to assess in a clinical setting the frequency of several side-effects related to haloperidol, risperidone, olanzapine, and quetiapine. This article addresses sexual dysfunction and other reproductive side-effects (gynecomastia, menorrhage, amenorrhea, and galactorrhea). We recruited outpatients diagnosed with schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders (DSM-IV; American Psychiatric Association, 1994) criteria and who had received a single antipsychotic (risperidone, olanzapine, quetiapine, or haloperidol) for at least 4 weeks. During a single visit, we collected data, including demographic and clinical characteristics, current antipsychotic and concomitant treatment, and adverse effects listed in a modified version of the UKU Scale. We used a Chi-squared test to determine pairs comparisons of the frequency of adverse reactions between treatments. To estimate risk of a given adverse reaction with a given treatment, we used a logistic regression method. We assessed 636 evaluable patients out of 669 recruited. Frequency of sexual dysfunction was high with haloperidol (38.1%) and also with olanzapine (35.3%), quetiapine (18.2%), and risperidone (43.2%). We found the frequency of other reproductive side-effects to be relatively low with all four drugs: haloperidol (6.9%), olanzapine (6.4%), quetiapine (2.7%), and risperidone (11.7%). Sexual dysfunction appeared to be dose-related with haloperidol, risperidone, and olanzapine. Risperidone and olanzapine showed a higher risk of sexual dysfunction and other reproductive sideeffects than haloperidol. Quetiapine showed a lower risk of sexual dysfunction during short-term treatment ( 12 weeks) are lacking. Our results suggest that none of the atypical

  4. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study.

    Science.gov (United States)

    Bobes, J; Garc A-Portilla, M P; Rejas, J; Hern Ndez, G; Garcia-Garcia, M; Rico-Villademoros, F; Porras, A

    2003-01-01

    Atypical antipsychotics seem to differ mainly in their tolerability profile. The aim of this cross-sectional study, the Estudio de Investigaci n de Resultados en Esquizofrenia (Outcomes Research Study in Schizophrenia; EIRE study), was to assess in a clinical setting the frequency of several side-effects related to haloperidol, risperidone, olanzapine, and quetiapine. This article addresses sexual dysfunction and other reproductive side-effects (gynecomastia, menorrhage, amenorrhea, and galactorrhea). We recruited outpatients diagnosed with schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders (DSM-IV; American Psychiatric Association, 1994) criteria and who had received a single antipsychotic (risperidone, olanzapine, quetiapine, or haloperidol) for at least 4 weeks. During a single visit, we collected data, including demographic and clinical characteristics, current antipsychotic and concomitant treatment, and adverse effects listed in a modified version of the UKU Scale. We used a Chi-squared test to determine pairs comparisons of the frequency of adverse reactions between treatments. To estimate risk of a given adverse reaction with a given treatment, we used a logistic regression method. We assessed 636 evaluable patients out of 669 recruited. Frequency of sexual dysfunction was high with haloperidol (38.1%) and also with olanzapine (35.3%), quetiapine (18.2%), and risperidone (43.2%). We found the frequency of other reproductive side-effects to be relatively low with all four drugs: haloperidol (6.9%), olanzapine (6.4%), quetiapine (2.7%), and risperidone (11.7%). Sexual dysfunction appeared to be dose-related with haloperidol, risperidone, and olanzapine. Risperidone and olanzapine showed a higher risk of sexual dysfunction and other reproductive sideeffects than haloperidol. Quetiapine showed a lower risk of sexual dysfunction during short-term treatment ( 12 weeks) are lacking. Our results suggest that none of the atypical

  5. Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism.

    Science.gov (United States)

    Hellings, J A; Zarcone, J R; Crandall, K; Wallace, D; Schroeder, S R

    2001-01-01

    As part of an ongoing, prospective, ABA design, double-blind crossover study of risperidone versus placebo for the treatment of aggressive, destructive and self-injurious behavior in persons aged 6-65 years with mental retardation (MR) and autism, we measured the weight of 19 subjects at each study visit. We compared mean weight gain during the 16-week acute phase and 24-week open maintenance phase with that during the initial and middle placebo phases statistically, using a linear mixed model procedure. Results of the linear mixed model analysis showed that relative weight gain observed during the acute and maintenance drug phases was significantly greater than that observed during the initial and middle placebo phases respectively (p = .0001 and p = .0001). Over approximately a year, children aged 8-12 (n = 5) gained a mean of 8.2 kg (range = 2.7-17.7 kg); adolescents (n = 6) aged 13-16 gained a mean of 8.4 kg (range 3.6-15.5 kg); adults aged 21-51 (n = 8) gained a mean of 5.4 kg (range 0-9.5 kg). Weight gain observed in this controlled study of risperidone treatment in children, adolescents, and adults with MR and autism was significant. It may be greater in this population than in others reported and in this study was not limited to an acute effect only. Rate of weight gain diminished rapidly on tapering and stopping the drug. Further studies are urgently needed, including those incorporating diet and exercise programming. PMID:11642473

  6. Costi ed effetti di Risperidone Long Acting (RLA rispetto ad antipsicotici atipici nel trattamento dei soggetti schizofrenici in Italia

    Directory of Open Access Journals (Sweden)

    Lorenzo G. Mantovani

    2004-03-01

    Full Text Available Objective: to estimate the costs and effects of long-acting risperidone (LAR in the treatment of schizophrenic patients in Italy, as compared to conventional and oral atypical antipsychotics. Methods: a discrete event model was used. The model simulates patients. history for every single therapeutic alternative and selects incident events, on the basis of pre-defined probability distribution-powered, randomized repetitions. The model operates on two types of parameters: patient characteristics and time-dependent variables. Patient characteristics (age, sex, illness profile and severity, probability of incurring in an adverse event and potential dangerousness remain fixed during the 5 simulated years. Time-dependent variables are subject to changes and include outpatient visits, severity of psychotic episodes, symptom-scores, compliance, incidence of adverse effects, site of treatment and dangerousness. Three treatments have been selected: scenario 1 begins with LAR, switches to olanzapine and then to clozapine; scenario 2 starts with olanzapine, switches to oral risperidone and ends with clozapine. Direct medical costs have been computed on the basis of psychiatric visits, drug costs and costs of the institution in which the patient is treated (hospital, rehabilitation clinic, etc. Outcome measures were number of psychotic episodes in 5 years, total time spent during these episodes and cumulative score of positive and negative symptoms at 5 years. Information on alternatives, transition probabilities, model structure and health resources utilization were derived from the literature and from a panel of experts. Results: it has been estimated that LAR is economically dominant (more effective at lower cost respect to oral atypical antipsychotics, being able to prevent 0.87 psychotic episodes per patient, with a net cost saving of 4,773 euro per patient. Sub-group analysis indicate that LAR is always more effective than the considered alternatives

  7. 穴位注射结合牵引治疗神经根型颈椎病的疗效观察%Observation on Efficacy of Acupoint Injection Combined with Traction for Cervical Radiculopathy

    Institute of Scientific and Technical Information of China (English)

    汪崇淼; 吴耀持; 张峻峰; 黄承飞

    2011-01-01

    Objective: To observe the therapeutic effect of acupoint injection combined with traction for cervical radiculopathy.Methods: A hundred and twenty-two patients with cervical radiculopathy were randomly divided into 3 groups,including an observation group (42 cases),an acupoint injection group (40 cases) and a traction group (40 cases).The patients in the first group received acupoint injection combined traction therapy,while the ones in the second and the third group received acupoint injection and traction respectively.The differences of therapeutic effect were evaluated after the treatments.Results: The total effective rate of the observation group was 92.9%,while it was 72.5% in the acupoint injection group and 75.0% in the traction group.There were significant differences between the observation group and the other two groups respectively (P<0.05),but there was no statistic difference between the acupoint injection group and the traction group.Conclusion: Acupoint injection combined with traction treatment was more effective for the cervical radiculopathy than either acupoint injection or traction.%目的:观察穴位注射结合牵引治疗神经根型颈椎病的临床疗效.方法:将122例神经根型颈椎病患者随机分为3组,观察组42例,进行穴位注射结合牵引治疗;穴位注射组40例进行穴位注射治疗;牵引组40例进行牵引治疗.治疗结束比较三组间疗效差异.结果:观察组总有效率为92.9%,穴位注射组总有效率为72.5%,牵引组总有效率为75.0%,观察组与穴位注射组、牵引组比较均有显著差异(P<O.05),穴位注射组与牵引组比较无显著差异.结论:穴位注射结合牵引治疗神经根型颈椎病的疗效优于单纯穴位注射及单纯牵引治疗.

  8. 氨磺必利与利培酮治疗首发精神分裂症的随机双盲双模拟平行对照试验%Parallel Control Method with Random Double-blind and Double-simulation in Treatment with Amisulpride and Risperidone of First-onset Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    韩刚亚; 严冬梅; 张新风

    2012-01-01

    [目的]:探讨氨磺必利与利培酮治疗精神分裂症的疗效及安全性.[方法]:采用随机、双盲、双模拟、平行对照试验方法,将34例符合诊断标准的首发精神分裂症患者随机分为氨磺必利组和利培酮组,每组17例.氨磺必利和利培酮的治疗剂量分别为800~1 200 mg·d-1和2 ~6 mg·d-1.疗程均为8周.于治疗前及治疗第1,2,4,8周末采用阳性和阴性症状评定量表(PANSS)评定疗效,采用治疗中出现的症状量表(TESS)及实验室检查来评价安全性.[结果]:治疗后第2,4,8周末,两组PANSS总分较治疗前均显著降低(P<0.05);氨磺必利组和利培酮组总有效率分别为88.2%和82.4%,差异无统计学意义(P>0.05).两组不良反应发生率比较差异亦无统计学意义(P>0.05).[结论]:氨磺必利和利培酮对治疗精神分裂症的疗效相当,不良反应轻,值得临床应用.%Objective:To explore the efficacy and safety of amisulpride and risperidone in treatment of schizophrenia. Methods: A randomized, double blind, double-dummy, parallel controlled clinical trial was conducted. The 34 rases of first episode schizophrenia patients met the diagnostic criteria were randomly divided into amisulpride group and risperidone group, 17 cases in each group. The doses range of amisulpride and risperidone were 800-1200 mg and 2-6 mg per day, respectively. The treatment was 8 weeks. The efficacy and adverse events were assessed with the Positive and Negative Symptom Scale (PANSS), Treatment Emergent Symptom Scale(TESS) and the laboratory tests before and at 1st, 2nd, 4th, 8th weekend after treatment. Results :The scores of PANSS in the two groups decreased significantly compared with ihe baseline at 2nd, 4th, 8th weekend after treatment( P 0.05). Conclusion: Amisulpride is as effective as risperidone for the treatment of schizophrenia with fewer side effects and worth clinical application.

  9. 奥氮平与利培酮治疗老年痴呆伴精神行为症状对照观察%A control study of olanzapine vs .risperidone in senile demen-tia with behavioral and psychological symptoms

    Institute of Scientific and Technical Information of China (English)

    韩曙林; 孟红凤

    2015-01-01

    目的:比较奥氮平与利培酮治疗老年痴呆伴精神行为症状患者的疗效及安全性。方法将52例老年痴呆伴精神行为症状患者随机分为奥氮平组与利培酮组,分别予以奥氮平与利培酮治疗,观察8周。治疗前后采用痴呆病理行为评定量表、副反应量表评定临床疗效及不良反应。结果奥氮平组治疗第2周末起,利培酮组治疗第4周末起痴呆病理行为评定量表评分较治疗前显著降低(P<0.01),治疗第2周末奥氮平组显著低于利培酮组(P<0.05或0.01);奥氮平组有效率为92.3%,利培酮组为88.5%,两组比较差异无显著性( P>0.05);奥氮平组不良反应发生率显著低于利培酮组(P<0.05)。结论奥氮平与利培酮治疗老年痴呆伴精神行为症状患者疗效显著且相当,但奥氮平起效更快,安全性更高。%Objective To compare the efficacy and safety between olanzapine and risperidone in senile de‐mentia with behavioral and psychological symptoms (BPS) .Methods Fifty‐two senile dementia patients with BPS were randomly assigned to olanzapine and risperidone group treated with olanzapine or risperi‐done for 8 weeks .Efficacies were assessed with the Rating Scale of the Behavioral Pathology in Alzheime‐r′s Disease (BEHAVE‐AD) before and after treatment and adverse reactions with the Treatment Emergent Symptom Scale (TESS) .Results The BEHAVE‐AD score lowered more significantly since the end of the 2nd week in olanzapine group and since the 4th in risperidone group compared with pretreatment (P0 .05);the incidence of adverse reactions was significantly lower in olanzapine than in ris‐peridone group (P<0 .05) .Conclusion Both olanzapine and risperidone have an equivalent and evident effect in senile dementia with BPS ,but the former takes effect more rapidly and has higher safety .

  10. The exploration of clinical effectiveness of haloperidol and risperidone on improving behavioral and psycho-logical symptoms of dementia%氟哌啶醇与利培酮改善痴呆患者行为症状和精神状态的临床实效性探讨

    Institute of Scientific and Technical Information of China (English)

    穆军山; 叶建新; 林航; 林敏; 崔晓萍; 张敏

    2016-01-01

    Objective To observe and explore the effect of haloperidol and risperidone on improving behavioral and psy-chological symptoms of dementia (BPSD).Methods Eighty cases with dementia in the hospital from August 201 1 to October 2013 were selected,who were randomly divided into observation group treated by risperidone and control group treated with haloperidol,40 patients in each group.PANSS-EC and PANSS Rating Scale were used as the primary methods to effciently e-valuate the efficacy of two groups.Results After 6-week therapy,no significant difference was observed in two groups in terms of PANSS total score and PANSS-EC scores (P >0.05)between two groups,we found statistical difference when compared with before treatment in both groups (P 0.05)。而给药6周后与治疗前2组比较差异均具有统计学意义(P <0.05)。用药后观察组、对照组锥体外系不良反应发生率分别为42.5%、67.5%,差异有统计学意义(P <0.05)。观察组有效率为87.5%,对照组为65.0%,2组比较差异有统计学意义(P <0.05)。结论RPD 口服对改善 BPSD 与 HPL 疗效相当,但 RPD 的临床实效性更好,锥体外系不良反应发生率低,值得临床推广应用。

  11. 关节腔注射医用三氧和透明质酸钠治疗膝关节骨性关节炎的疗效%Efficacy of medical ozone combined with sodium hyaluronate intra-articular injection in the treatment of patients with knee osteoarthritis

    Institute of Scientific and Technical Information of China (English)

    姚发利; 佘淑华; 李海涛; 高华

    2015-01-01

    目的 探讨医用三氧结合透明质酸钠治疗膝关节骨性关节炎的临床疗效.方法 膝关节骨性关节炎患者84例,随机分为注射组和传统组,各组42例.注射组使用医用三氧结合透明质酸钠关节腔内注射方法治疗,传统组使用针灸、特定电磁波谱(TDP)、中频、微波、中药敷贴等传统治疗方法治疗,于治疗前及治疗后5周记录VAS评分及Lysholm膝关节评分,并于治疗后5周评定治疗效果,观察治疗后的临床疗效.结果 与治疗前比较,两组患者治疗后VAS评分均下降,且注射组较传统组下降更明显,差异均有统计学意义(P<0.05);与治疗前比较,治疗后两组患者Lysholm评分均升高,且注射组升高更明显,差异均有统计学意义(P<0.05).注射组的有效率(92.8%,39/42例)高于传统组(81.0%,34/42例),差异有统计学意义(P<0.05).结论 医用三氧结合透明质酸钠治疗膝关节骨性关节炎疗效较传统方法好.%Objective To explore the clinical efficacy of medical ozone combined with sodium hyaluronate intra-articular injection in the treatment of patients with knee osteoarthritis.Methods Eighty-four patients with knee osteoarthritis were divided into medical ozone combined with intra-articular sodium hyaluronate injection group (injection group) and traditional group, 42 cases in each group.Patients in the injection group were received medical ozone combined with sodium hyaluronate intra-articular injection, while the others in the traditional group were received acupuncture, TDP, midfrequency, microwave, traditional Chinese medicine.VAS and Lysholm score were recorded before and after the treatment, and the effective rates were evaluated after the treatment.Results Compared with pre-treatment, VAS was decreased significantly after the treatment in both two groups, and that in injection group was better than that in traditional group (P< 0.05).Lysholm score was significantly increased after the treatment

  12. 推拿、针灸、复位、水针四联疗法治疗腰椎间盘突出症45例疗效分析%Efficacy Analysis of Quadruple Therapy with Massage, Acupuncture, Manipulative Reduction and Acupoint Injection on Lumbar Disc Herniation in 45 Cases

    Institute of Scientific and Technical Information of China (English)

    张云会; 朱丽华

    2013-01-01

    Objective:To observe the curative effects of acupuncture, massage, manipulative reduction and acupoint injection on lumbar disc hernia-tion. Methods:45 patients were treated with quadruple therapy of massage, acupuncture, manipulative reduction and acupoint injection. Results:32 cases were cured, 10 cases improved, 3 cases ineffective, the total efficiency was 93.33%. Conclusion:Efficacy of quadruple therapy with massage, acupuncture, manipulative reduction and acupoint injection on lumbar disc herniation is significant, meanwhile avoiding pains of operation and easi-ly accepted by patients.%目的:观察推拿、针灸、复位、水针四联疗法治疗腰椎间盘突出症的疗效。方法:45例患者均采用推拿、针灸、复位、水针四联疗法治疗。结果:痊愈32例,好转10例,无效3例,总有效率93.33%。结论:推拿、针灸、复位、水针四联疗法治疗腰椎间盘突出症疗效显著,同时避免了手术痛苦,患者容易接受。

  13. A high-performance liquid chromatographic-atmospheric pressure chemical ionization-tandem mass spectrometric method for determination of risperidone and 9-hydroxyrisperidone in human plasma.

    Science.gov (United States)

    Moody, David E; Laycock, John D; Huang, Wei; Foltz, Rodger L

    2004-09-01

    Risperidone, a benzisoxazole derivative, is an antipsychotic agent used for the treatment of schizophrenia. We developed a liquid chromatographic-atmospheric pressure chemical ionization-tandem mass spectrometric (LC-APCI-MS-MS) method with improved sensitivity, selectivity, and dynamic range for determination of risperidone and 9-hydroxyrisperidone in human plasma. A structural analogue of risperidone, RO68808 (5 ng/mL), is added as the internal standard to 1 mL of human plasma. Plasma is made basic, extracted with pentane/methylene chloride (3:1), the organic phase evaporated to dryness, and the residue is reconstituted in water with 0.1% formic acid/acetonitrile (20:1). For LC-MS-MS analysis, a Metachem Inertsel HPLC column (2.1 x 150 mm, 5-microm particle size) is connected to a Finnigan TSQ7000 tandem MS via the Finnigan API interface. Both electrospray (ESI) and APCI produced predominantly MH(+) ions for the two analytes and the internal standard. Ions detected by selected reaction monitoring correspond to the following transitions: m/z 411 to 191 for risperidone, m/z 427 to 207 for 9-hydroxyrisperidone, and m/z 421 to 201 for the internal standard. APCI provided a larger dynamic range (0.1 to 25 ng/mL) and better precision and accuracy than ESI. Intrarun accuracy and precision determined at 0.1, 0.25, 2.5, and 15 ng/mL were within 12% of target with %CVs not exceeding 10.9%. Interrun accuracy and precision determined at the same concentrations were within 9.6% of target with %CVs not exceeding 6.7%. Analytes were stable in plasma after 24 h at room temperature, 2 freeze-thaw cycles, and 490 days at -20 degrees C. PMID:15516302

  14. C型臂引导下等离子髓核低温消融术联合臭氧治疗包容性腰椎间盘突出症的对比观察%CLINICAL OBSERVATION OF THE EFFICACY OF CONTAINED LUMBAR DISC HERNIATION TREATMENT USING PLASMA-MEDIATED COBLATION COMBINED WITH OZONE INJECTION THERAPY UNDER C-ARM GUIDANCE

    Institute of Scientific and Technical Information of China (English)

    王君; 夏庆来; 杨连海; 郑宝森

    2011-01-01

    Objective: To observe the efficacy of contained lumbar disc herniation using the technique of plasma-mediated coblation combined with ozone injection therapy under C-arm guidance.Methods: 90 patients diagnosed as contained lumbar disc herniation by MRI were randomly dividied into A, B, C group, with 30 patients each.The technique of plasma-mediated coblation combined with ozone injection therapy was applied in group A.Plasma-mediated coblation technique alone was applied in group B and ozone injection therapy alone in group C.Visual analogue score(VAS) was used to evaluate the degree of pain and improved MacNab criteria were used to evaluate the clinical efficacy during the time point 9 days, 18 days and 1 month after surgery.Results: The efficacy rate of group A 1 month after surgery was 96.6%, which was significantly higher than the other two groups of 76.6% in group B and 70% in group C ( P < 0.05 ).Conclusion: The efficacy of the technique of plasma-mediated coblation combined with ozone injection therapy to treat lumbar disc herniation have more advantage than the technique of PlasmaMediated Coblation or Ozone injection therapy alone.%目的:观察在C型臂引导下,应用等离子髓核低温消融术联合注射臭氧治疗包容性腰椎间盘突出症的临床疗效.方法:回顾性分析90例包容性腰椎间盘突出症,随机分为A、B、C三组,每组30例.A组采用等离子髓核低温消融术联合臭氧治疗,B组采用等离子髓核低温消融术治疗,C组采用腰椎间盘注射臭氧治疗.采用VAS视觉模拟疼痛评分作为疼痛水平评价指标,改良Mac-Nab标准评估治疗效果.观察三组患者术后9天、18天、1个月的临床疗效.结果:术后1个月A组治疗优良率为96.6%(29/30例),B组治疗的优良率为76.6%(23/30例),C组治疗后优良率为70%(21/30例).A组优良率高于B组和C组(P<0.05).结论:等离子髓核低温消融术联合臭氧治疗包容性腰椎间盘突出症疗效优于单独应

  15. 血栓通联合参芪扶正注射液治疗真性红细胞增多症的疗效观察%The clinic efficacy of Xueshuantong Capsule and Shengqi Fuzheng Injection in the treatment of polycythemia vera

    Institute of Scientific and Technical Information of China (English)

    余丹; 程辉; 张婷; 易雪

    2012-01-01

    Objective To observe the clinical efficacy of Shenqifuzheng Injection combined with Xueshuantong Capsule in the treatment of polycythemia vera. Methods Forty- six patients with polycythemia vera were randomly divided into two groups. Both groups were treated by exsangninate and recombinant human interferon α - 2A. The treatment group was, given Shengqi Fuzheng Injection and Xueshuantong Capsule. The changes of hemoglobin (HGB) value, the patient's status, the hemorheology and the incidence of cerebral infarction of the two groups were compared in the course of the treatment. Result In clinical observation, we found that various laboratory parameters and the clinical efficacy of the treatment group were much better than those of the control group. Conclusion Adding Shengqi Fuzheng Injection and Xueshuantong Capsule in the treatment of polycythemia vera can significantly improve clinical efficacy, reduce hemoglobin, improve life quality of patients and reduce embolism and other accidents.%目的 观察血栓通胶囊联合参芪扶正注射液治疗真性红细胞增多症(PV)的临床疗效.方法 将PV患者46例,随机分为两组,均给予红细胞单采及重组人干扰素α-2A治疗,治疗组加用血栓通胶囊及参芪扶正注射液,观察两组患者治疗前后血红蛋白(HGB)值变化情况,治疗中脑梗死发生率,患者健康状况及血液流变学变化.结果 通过临床观察发现治疗组患者各项实验室指标及疗效果明显优于对照患者.结论 加用血栓通胶囊及参芪扶正注射液治疗真性红细胞增多症,可明显改善疗效,降低血红蛋白,提高患者生活质量,减少栓塞等意外.

  16. Results and analysis of the 2008-2009 Insulin Injection Technique Questionnaire survey

    NARCIS (Netherlands)

    De Coninck, Carina; Frid, Anders; Gaspar, Ruth; Hicks, Debbie; Hirsch, Larry; Kreugel, Gillian; Liersch, Jutta; Letondeur, Corinne; Sauvanet, Jean-Pierre; Tubiana, Nadia; Strauss, Kenneth

    2010-01-01

    Background: The efficacy of injection therapy in diabetes depends on correct injection technique and, to provide patients with guidance in this area, we must understand how they currently inject. Methods: From September 2008 to June 2009, 4352 insulin-injecting Type 1 and Type 2 diabetic patients fr

  17. 阿立哌唑与利培酮治疗痴呆精神行为症状的疗效及安全性比较%Comparison of Efifcacy and Safety of Aripiprazole and Risperidone Treating Behavioral and Psychological Symptoms of Dementia

    Institute of Scientific and Technical Information of China (English)

    李洪涛

    2015-01-01

    目的:通过临床试验对阿立哌唑和利培酮对于痴呆精神行为的疗效和安全性进行观察和探讨。方法将本科室近来收治的有痴呆精神行为症状的患者72人进行随机分组,每组36人,并分别用阿立哌唑(A组)和利培酮来(B组)对患者进行为期8 w的治疗,在治疗之前以及治疗的第2、4以及第8周的最后一天对72名患者采用BEHAV-AD对患者的病理行为进行评定,以此来对两种药物的有效性进行对比;同时采用TESS(不良反应检测表)来对药物的安全性进行分析和比较。结果通过阿立哌唑和利培酮进行治疗的两组患者在治疗后BEHAV-AD评分较治疗之前有了明显的降低,A、B两组患者的治疗之前与治疗之后的BEHAV-AD评分相比较具有较为明显的统计学差异(P<0.05)。另外服用阿立哌唑的A组患者的不良反应发生率明显比服用利培酮的B组患者的不良反应发生率低,通过对差异进行分析发现,此差异同样具有统计学意义(P<0.01)。结论阿立哌唑和利培酮对于痴呆精神行为都具有较为明显的疗效,但是利培酮的安全性相比阿立哌唑较差。%Objective Observe and investigate the efficacy and safety of aripiprazole and risperidone for spirit behavior of dementia. Methods 72 patients with behavioral and psychological symptoms of dementia were randomly assigned into two groups, 36 people in each group , they were treated with aripiprazole (A group) and risperidone to (group B) respectively for a period of 8 w, assessed the behavior of the patients by BEHAV-AD at the points of prior to treatment, treatment of 2, 4 and 8 weeks , and the last day, compared the effectiveness of the two drugs, at the same time using the TESS (adverse reaction detection table) to assess the safety of the drugs. Results After the treatment of aripiprazole and risperidone, BEHAV-AD score signiifcantly reduced in two groups, there were

  18. The efficacy of preventive parasternal single injection of bupivacaine on intubation time, blood gas parameters, narcotic requirement, and pain relief after open heart surgery: A randomized clinical trial study

    Directory of Open Access Journals (Sweden)

    Mahmoud Saeidi

    2011-01-01

    Full Text Available Background: Postsurgical pain usually results in some complications in the patients. This study has tried to investigate the effects of parasternal single injection of bupivacaine on postoperative pulmonary and pain consequences in patients after open heart surgery. Methods: : In a prospective double blind clinical study, 100 consenting patients undergoing elective open heart surgery were randomized into two groups. In case group, bupivacaine was injected at both sides of sternum, immediately before sternal closure. In the control group, no intervention was performed. Then, the patients were investigated regarding intubation period, length of ICU stay, arterial blood gas (ABG parameters, morphine requirement, and their severity of postoperative pain using a visual analogue scale (VAS device. Results: No differences were found between the two groups regarding to age, sex, pump time, operation time, and body mass index and preoperative cardiac ejection fraction. Mean intubation length in case group was much shorter than that in control group. Mean PaO 2 in case group was lower in different checking times in postoperative period. The patients in the case group needed less morphine compared to those in the control group during the 24-hour observation period in the ICU. Finally, mean VAS scores of pain in case group were significantly lower than those in control group at 6, 12, and 24 hours postoperatively. Conclusions: Patients′ pain relief by parasternal single injection of bupivacaine in early postoperative period can facilitate earlier ventilator weaning and tracheal extubation after open heart surgery as well as achieving lower pain scores and narcotic requirements.

  19. Efficacy and tolerance of an injectable medical device containing stable hybrid cooperative complexes of high- and low-molecular-weight hyaluronic acid: a monocentric 16 weeks open-label evaluation

    Science.gov (United States)

    Sparavigna, Adele; Tenconi, Beatrice

    2016-01-01

    Background An injectable medical device containing stable hybrid cooperative complexes of high- and low-molecular-weight hyaluronic acid (HA) has been developed with characteristics suited for a global improvement of facial esthetics. Objective To evaluate the HA product performance in improving some key facial esthetic features. The study employed clinical scales, subjective evaluations, and facial skin objective measurements. Methods A single Italian site treated 64 female subjects aged 38–60 years, with injections at five predetermined points, on each side of the face, with a 4-week time lapse between the first and the second product administration. Subjects were evaluated after 4, 8, 12, and 16 weeks, using validated clinical scales, subjective evaluation, and objective quantitative outcome measures. Assessment of esthetic results included photographic documentation. Results Both the clinical and subjective assessments, and the majority of objective instrumental parameters indicated an improvement throughout the study and were already significant at week 4 or 8 and were still significant at week 16 (3 months after the second treatment). Minor and temporary local skin reactions were observed in 23% of subjects at the site of the injections, and the global judgment on tolerability was good or excellent, both in the investigators’ opinion and volunteers’ self-evaluation. Conclusion Both subjective and objective improvement of the facial parameters was consistent with the bio-remodeling purpose, and persistent and still statistically significant at the end of the study. The tolerability and safety profile of the product were judged good or excellent both by investigators and volunteers. This study supports the claim for bio-remodeling of these stable hybrid cooperative complexes of low- and high-molecular-weight HA. PMID:27713647

  20. A Control Study of Risperidone in Combination with Clozapine in Treating Refractory Schizophrenia%利培酮合并氯氮平治疗难治性精神分裂症的对照研究

    Institute of Scientific and Technical Information of China (English)

    彭红军; 邝如意; 黄雄; 王玲芝; 朱福坚

    2001-01-01

    目的探讨利培酮合并氯氮平治疗难治性精神分裂症的疗效及副作用.方法将101例难治患者用配对半随机法分成利培酮组(A)、氯氮平组(B)及二药联用组(AB),疗期8周,用PANSS、CGI、TESS评定疗效及副作用.结果三组8周疗效相似(p>0.05),有效率A组60.0%、B组61.8%、AB组62.5%;AB组与A组均于第一周起效,治疗2周时AB 组疗效较单用组佳(p0.05) among group AB(62.5%), group A(60.0%) and group B(61.8%) after 8 weeks treatment. Both group AB and group A responded at the first week, and the efficacy of group AB was superior to that of the other two groups (p<0.05) after 2 weeks, especially for positive symptoms(p<0.05). There were fewer side effects in group AB than the other two groups.Conclusions Risperidone was a effective treatment for refractory schizophrenia as well as Clozapine, and it could be a more safe and effective treatment if two drugs were used in combination.

  1. Medication Treatment Efficacy and Chronic Orofacial Pain.

    Science.gov (United States)

    Clark, Glenn T; Padilla, Mariela; Dionne, Raymond

    2016-08-01

    Chronic pain in the orofacial region has always been a vexing problem for dentists to diagnose and treat effectively. For trigeminal neuropathic pain, there are 3 medications (gabapentinoids, tricyclic antidepressants, and serotonin-norepinephrine reuptake inhibitors) to use plus topical anesthetics that have therapeutic efficacy. For chronic daily headaches (often migraine in origin), 3 prophylactic medications have reasonable therapeutic efficacy (β-blockers, tricyclic antidepressants, and antiepileptic drugs). The 3 Food and Drug Administration-approved drugs for fibromyalgia (pregabalin, duloxetine, and milnacipran) are not robust, with poor efficacy. For osteroarthritis, nonsteroidal anti-inflammatory drugs have therapeutic efficacy and when gastritis contraindicates them, corticosteriod injections are helpful. PMID:27475515

  2. Efficacy observation on treating old ankle sprain by manual therapy combined with acupoint injection%手法配合穴位注射治疗陈旧性踝关节扭伤疗效观察

    Institute of Scientific and Technical Information of China (English)

    张茂亮

    2013-01-01

    Ankle sprain is one of common clinicaltraumatology diseases, with a high incidence in joint damage in the human body. Old ankle sprain is mainly in acute ankle sprain. After treatment, the patient has been unhealed or has no timely break after cured and lead to recurrent. The author uses manual therapy combined with acupoint injection (Canggui Tanxue needling and liquid injection) method for the treatment of old ankle sprain, obtains satisfactory results, reported below.%踝关节扭伤是临床上常见的伤科疾病之一,在人体的关节损伤中发病率较高。陈旧性的踝关节扭伤多指踝关节在急性扭伤后,经治疗而一直未愈的或愈后未得到及时休息且又反复发作的。笔者采用手法治疗配合穴位注射(行苍龟探穴刺法并注射药液)的方法,针对陈旧性踝关节扭伤治疗取得较满意疗效,报道如下。

  3. Penicillin G Procaine Injection

    Science.gov (United States)

    Penicillin G procaine injection is used to treat certain infections caused by bacteria. Penicillin G procaine injection should not be used to treat ... in the treatment of certain serious infections. Penicillin G procaine injection is in a class of medications ...

  4. Corticosteroid injection for de Quervain's tenosynovitis

    NARCIS (Netherlands)

    Peters-Veluthamaningal, Cyriac; van der Windt, Danielle A. W. M.; Winters, Jan C.; Jong, Betty Meyboom-de

    2009-01-01

    Back ground De Quervain's tenosynovitis is a disorder characterised by pain on the radial (thumb) side of the wrist and functional disability of the hand. It can be treated by corticosteroid injection, splinting and surgery. Objectives To summarise evidence on the efficacy and safety of corticostero

  5. Eficácia do resfriamento da pele no alívio da dor desencadeada pela injeção de toxina botulínica tipo A nas distonias faciais Skin cooling efficacy on pain relief in periocular injections with botulinum toxin A in facial dystonias

    Directory of Open Access Journals (Sweden)

    Paula Barros Bandeira de Mello Monteiro

    2012-12-01

    Full Text Available OBJETIVO: Avaliar a eficácia do resfriamento da pele com gelo no alívio da dor desencadeada pela injeção de toxina botulínica tipo A na região periocular em pacientes portadores de distonia facial. MÉTODOS: Neste estudo prospectivo, 13 pacientes receberam injeção de toxina botulínica tipo A em região glabelar (m. prócero e periocular (m. orbicular para tratamento de distonia facial. Antes das aplicações, um lado da região glabelar foi resfriado com gelo durante 5 minutos, enquanto no outro lado foi aplicada pomada Epitezan®, funcionando como placebo. A aplicação foi feita primeiramente no lado resfriado. Após a aplicação em cada um dos lados os pacientes foram instruídos a dar uma nota para a dor desencadeada pela injeção, em uma escala de 0 a 10 onde 0 era ausência de dor e 10 a dor mais intensa. RESULTADOS: A média das notas dadas pelos pacientes à dor desencadeada pela injeção no lado onde foi aplicado placebo foi 3,92 ± 3,28. No local onde foi aplicado gelo a média das notas foi de 2,92 ± 2,18 (p PURPOSE: To evaluate the efficacy of skin cooling with ice on pain relief in periocular injection with botulinum toxin type A in patients with facial dystonias. METHODS: In this prospective study, 13 patients received botulinum toxin type A injection in glabela (procerus m. and periocular region (orbicular m. for facial dystonias treatment. Before the injections, one side of the glabela was submitted to a 5-minute cooling period, while the opposite side had Epitezan® cream applied, as a placebo. The application was done at the cooled side first. After the application on each side the patients were instructed to rate the pain associated with the injection on a scale from 0 to 10, with 0 indicating no pain and 10 the worst pain. RESULTS: The average pain score on the side where cold was applied was 3,92 ± 3,28, while on the control side the average pain score was 2,92 ± 2,18 (p < 0,0166. CONCLUSION: In this study

  6. Intraurethral Injection of Autologous Minced Skeletal Muscle

    DEFF Research Database (Denmark)

    Gräs, Søren; Klarskov, Niels; Lose, Gunnar

    2014-01-01

    PURPOSE: Intraurethral injection of in vitro expanded autologous skeletal muscle derived cells is a new regenerative therapy for stress urinary incontinence. We examined the efficacy and safety of a simpler alternative strategy using freshly harvested, minced autologous skeletal muscle tissue with...... its inherent content of regenerative cells. MATERIALS AND METHODS: A total of 20 and 15 women with uncomplicated and complicated stress urinary incontinence, respectively, received intraurethral injections of minced autologous skeletal muscle tissue and were followed for 1 year. Efficacy was assessed...... events were noted. CONCLUSIONS: Intraurethral injection of minced autologous muscle tissue is a simple surgical procedure that appears safe and moderately effective in women with uncomplicated stress urinary incontinence. It compares well to a more complicated regenerative strategy using in vitro...

  7. Efficacy Observation of Pethidine, Fentanyl Intravenous Injection for Shivering during Anesthesia%哌替啶、芬太尼静注用于麻醉期间寒战的疗效观察

    Institute of Scientific and Technical Information of China (English)

    蒋晓华

    2013-01-01

    Objective To explore meperidine, fentanyl intravenous anesthesia ef icacy on shivering during. Methods 81 cases of continuous epidural anesthesia for cesarean anesthesia shivering during operation were divided into observation group (48 cases) and control group (33 cases), chil s were observed after 1mg/kg pethidine group by intravenous injection, the control group appeared chil to fentanyl 2ug/kg injection, observe the patient shiver 15 points after the bel . Results in the observation group than the control group treatment ef ect (P<0.05). Conclusion it is ef ective of pethidine and Fentainijun on shivering during anesthesia, but pethidine has bet er ef icacy.%目的:探讨哌替啶、芬太尼静脉注射对于麻醉期间寒战的疗效。方法将81例连续硬膜外麻醉下剖宫产手术麻醉期间出现寒战的患者分为观察组(48例)和对照组(33例),观察组出现寒战后予以哌替啶1 mg/Kg静注,对照组出现寒战后予以芬太尼2 ug/Kg静注,15 min后观察患者寒战情况。结果观察组治疗效果优于对照组(P<0.05)。结论哌替啶和芬太尼均对麻醉期间寒战有效,而哌替啶疗效更佳。

  8. 氟哌啶醇与利培酮对精神分裂症患者生活质量的影响%Effect of Haloperidol and Risperidone on the Life Quality of the Patients with Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    任清涛; 闫加民; 李广

    2002-01-01

    Objective: To compare the effects between ha loperidol and rieperidon e on quality of life in patients with schizophrenia. Methods: The patients with schizophrenia treated respectively by haloperidol and risperidone were compared by double blind method. The General Quality of Life Inventory (GQOLI) was used to evaluate the life quality, while the Positive and Negative Symptoms Scale (PA NSS) and the Treatment Emergent Symptom Scale (TESS) were used to assess the eff icacy and side effects. Results: The risperidone group sho wed better effects tha n the haloperidol group in the domains of physical function ,mental health and s ocial function The difference was significant (P<0.01). Conclusion:[ WT5"BZ The quality of life of Schizophrenic patients treated by haloperidol were poorer than that o f risperidone.

  9. Analysis on Characteristics and Regularities of Efficacies of Acupoint Injection by Using Data Mining Technique%基于数据挖掘技术的穴位注射疗法效应特点研究

    Institute of Scientific and Technical Information of China (English)

    许晓康; 贾春生; 王建岭; 石晶; 覃亮; 张莘; 张选平

    2012-01-01

    Objective To analyze the potential learning and regularity characters of clinical application of acupoint injection In modern literature of Chinese medicine by using data mining technique, so as to provide a reference for clinical application of this therapy- Methods A database was established first by computer recording of the standardized information data after collection of papers about acupoint injection therapy published in modern medical journals, collections of theses of medical academic conferences, dissertations for medical master's and doctor's degrees. Then, the data mining technique was employed to conduct cross link design about the types or categories of illnesses or clinical conditions, categories of departments, selection of Chinese materia medica, acupoint recipes, and clinical outcomes, etc. At last, the rules and characteristics of the acupoint injection were summarized and analyzed. Results The acupoint injection therapy enjoys the first rank of therapies for the treatment of diseases or clinical conditions of the internal medicine, and the second rank in the treatment of surgical problems. With respect to the types of illnesses or clinical conditions, it is used most frequently for hiccup and backleg pain. Generally, about 4 acupoints and 2 categories of medicines (Chinese herbal medicine or western medicine preparations) are selected in one session of treatment by using the acupoint injection therapy. The acupoints used are those close to and remote to the loci. The drugs predominately employed are single or compound western medicine preparations. The total effective rate is up to more than 93%. Conclusion The acupoint injection therapy has some obvious advantages in the treatment of clinical conditions or illness of the internal medicine and surgical problems, especially for hiccup and backleg pain. It is simple in clinical application and has a higher therapeutic effect.%目的:应用数据挖掘技术,发现穴位注射临床运用中潜

  10. The therapeutic efficacy of Lipo PGE combined with Shuxuetong injection in treatment of diabetic peripheral neuropathy%前列地尔联合疏血通治疗糖尿病周围神经病变的疗效观察

    Institute of Scientific and Technical Information of China (English)

    张小东; 陈岚

    2010-01-01

    目的 观察前列地尔(凯时)联合疏血通静脉滴注对糖尿病周围神经病变(DPN)的疗效.方法 将68名DPN患者分为两组,治疗组凯时+疏血通静脉滴注;对照组为疏血通静脉滴注,疗程均为14 d.结果 治疗组患者四肢疼痛、麻木、感觉异常等症状较对照组明显减轻(P<0.01),同时正中神经、腓肠神经的传导速度较治疗前明显加快(P<0.05),对照组治疗前后变化差异无统计学意义(P<0.05).结论 凯时联合疏血通治疗DPN是安全有效的方法.%Objective To observe the efficacy of Lipo PGE combined with Shuxuetong injection in treatment of diabetic peripheral neuropathy (DPN). Methods The 68 DPN patients were randomly divided into treatment group with Lipo PGE plus Shuxuetong injection and comparison group with Shuxuetong alone. The treatment period was 14 days. Results The pain, numbness,paresthesia and other symptoms in the limbs of patients were significantly reduced in treatment group than in comparison group (P<0. 01). At the same time, the conduction velocity of median nerve and sural nerve was significantly increased in treatment group after treatment (P<0.05), there were no significant differences in comparison group before and after the treatment. Conclusions The treatment of DPN with Lipo PGE combined with Shuxuetong injection is safe and effective.

  11. 喜炎平联合β-内酰胺类抗生素治疗儿童化脓性扁桃体炎观察%Clinical Efficacy of Xiyanping Injection Combined withβ-lactam Antibiotics inTreatment of Children with Acute Suppurative Tonsillitis

    Institute of Scientific and Technical Information of China (English)

    乔勇; 余霞辉; 邓骥; 邱有波; 舒红文; 罗扬

    2015-01-01

    目的:探讨喜炎平联合β-内酰胺类抗生素治疗儿童急性化脓性扁桃体炎的临床疗效。方法:将126例儿童急性化脓性扁桃体炎患者随机分为观察组65例与对照组61例。对照组采用β-内酰胺类抗生素治疗,观察组在此基础上加用喜炎平治疗,疗程7~10 d,比较2组的临床疗效。结果:观察组临床症状、体征改善时间明显短于对照组( P<0.05),观察组总有效率高于对照组(P<0.05);2组患者不良反应发生率无显著性差异(P>0.05)。结论:喜炎平联合β-内酰胺类抗生素治疗儿童急性化脓性扁桃体炎,可显著缩短病程,提高治疗有效率,使用安全,值得临床推广。%Objective:To explore clinical efficacy of Xiyanping Injection combined with beta -lactam antibiotics in the treatment of children with acute suppurative tonsillitis.Methods:126 cases of children with acute suppurative tonsillitis were divided randomly into 65 cases of the treatment group and 61 cases of control group.β-lactam antibiotics therapy were used in two groups of children,but in treatment group added Xiyanping Injection.Therapy time lasted 7~10 d in two groups.The clinical efficacy was compared in the two groups.Results:Time of clinical symptoms and signs improved in the treatment group was significantly shorter than that in the control group,the difference was statistically significant(P0.05 ).Conclusion:Xiyanping Injection combined with β-lactam antibiotic in treatment of children with acute suppurative tonsillitis can significantly shorten the course of treatment,improve the treatment efficiency.This method can be used safely,worthy of clinical application.

  12. Dopamine D2/D3 receptor binding of [123I]epidepride in risperidone-treatment chronic MK-801-induced rat schizophrenia model using nanoSPECT/CT neuroimaging

    International Nuclear Information System (INIS)

    Introduction: Epidepride is a compound with an affinity in picomolar range for D2/D3 receptors. The aim of this work was designed to investigate the diagnostic possibility of [123I]epidepride imaging platform for risperidone-treatment chronic MK-801-induced rat schizophrenia model. Methods: Rats received repeated administration of MK-801 (dissolved in saline, i.p., 0.3 mg/kg/day) or saline for 4 weeks. After 1-week administration of MK-801, rats in MK-801 + risperidone group received risperidone (0.5 mg/kg/day) intraperitoneally 15 min prior to MK-801 administration for the rest of 3-week treatment. We obtained serial [123I]epidepride neuroimages from nanoSPECT/CT and evaluated the alteration of specific binding in striatum and midbrain. Results: Risperidone reversed chronic MK-801-induced decrease in social interaction duration. IHC and ELISA analysis showed consistent results that chronic MK-801 treatment significantly decreased striatal and midbrain D2R expression but repeated risperidone administration reversed the effect of MK-801 treatment. In addition, [123I]epidepride nanoSPECT/CT neuroimaging revealed that low specific [123I]epidepride binding ratios caused by MK-801 in striatum and midbrain were statistically alleviated after 1- and 2-week risperidone administration, respectively. Conclusions: We established a rat schizophrenia model by chronic MK-801 administration for 4 weeks. [123I]Epidepride nanoSPECT neuroimaging can trace the progressive alteration of D2R expression in striatum and midbrain caused by long-lasting MK-801 treatment. Besides diagnosing illness stage of disease, [123I]epidepride can be a useful tool to evaluate therapeutic effects of antipsychotic drug in chronic MK-801-induced rat schizophrenia model

  13. 齐拉西酮治疗甲基苯丙胺所致精神障碍临床疗效观察%Efficacy of Ziprasidone for methamphetamine-induced psychotic disorder

    Institute of Scientific and Technical Information of China (English)

    姚刚

    2011-01-01

    Objective To observe the efficacy and adverse drug effect of Ziprasidone, an antipsychotics for methamphetamine-induced psychotic disorder. Methods Eighty patients with methamphetamine-induced psychiatric disorder were randomly divided into Ziprasidone group (n = 40, MD≤160 mg/d) and Risperidone group (n = 40, MD≤6 mg/d). Both groups were treated with Ziprasidone or Risperidone for 3 weeks. The efficacy was assessed with Brief Psychiatric Rating Scale ( BPRS) , and adverse drug effect with Treatment Emergent Symptoms Scale (TESS). Results The effective rates of ziprasidone group and Risperidone group were 92. 30% and 90. 00% respectively { NS, P > 0.05). Compared with Risperidone, Ziprasidone caused less weight gain and endocrine change (P < 0. 05). Conclusions Both Ziprasidone and Risperidone are effective in the treatment of methamphetamine-induced psychiatric disorder. The adverse effect of Ziprasidone is slighter.%目的 观察抗精神病药物齐拉西酮治疗甲基苯丙胺所致精神障碍的疗效及不良反应.方法 80例甲基苯丙胺所致精神障碍患者按随机数字表法分为齐拉西酮组和利培酮组各40例,分别用齐拉西酮(最大剂量≤160 mg/d)和利培酮(最大剂量≤6 mg/d)治疗21天.采用简明精神病量表(BPRS)和副反应量表(TESS)评定患者的精神病性症状、疗效和不良反应.结果 总有效率齐拉西酮组为92.50%,利培酮组为90.00%,两组比较差异无统计学意义(P>0.05);齐拉西酮组与利培酮组比较,体重增加较少,内分泌改变较少,差异有统计学意义(P<0.05);其他不良反应,两组差异无统计学意义(P>0.05).结论 齐拉西酮与利培酮疗效相当,不良反应较轻.

  14. THE EFFICACY OF PLASMA-MEDIATED COBLATION COMBINED WITH OZONE INJECTION ON CONTAINED CERVICAL DISC HERNIATION AIMING BY C-ARM MACHINE%C型臂引导下等离子髓核低温消融术联合臭氧治疗包容型颈椎间盘突出症的对比观察

    Institute of Scientific and Technical Information of China (English)

    王君; 杨艳梅; 韩悦; 杨连海; 夏庆来; 郑宝森

    2012-01-01

    目的:观察在C型臂引导下采用等离子髓核低温消融术联合髓核内臭氧注射治疗包容型颈椎间盘突出症的临床疗效.方法:回顾性分析60例包容型颈椎间盘突出症,30例患者采用等离子髓核低温消融术治疗(A组),同期30例患者采用等离子髓核低温消融术+髓核内臭氧注射(B组).采用视觉模拟疼痛评分(visual analogue scale,VAS)作为疼痛水平评价指标,改良Macnab标准评估治疗效果.观察两组患者术后1周、2周、1个月、2个月的临床疗效.结果:A组治疗后的优良率为80% (24/30例),B组治疗后的优良率为96.6% (29/30例).B组术后2个月优良率高于A组(P<0.05).结论:等离子髓核低温消融术联合髓核内臭氧注射治疗包容型颈椎间盘突出症的疗效优于单独应用等离子髓核低温消融术.%Objective: To observe the efficacy of plasma-mediated coblation combined with ozone injection therapy on contained cervical disc herniation aiming by C-arm machine. Methods: Respectively analysis was used to analyse sixty patients who were diognosised as contained cervical disc herniation by MRI. These patients were into A, B groups in which thirty patients were enrolled respectively. The technique of plasma-mediated coblation alone were used in A group (n = 30). Plasmamediated coblation combined with ozone injection therapy were used in B group (n = 30). Visual analogue scale (VAS) was used to evaluate the degree of pain and improved Macnab criteria were used to evaluate the clinical efficacy which were observed during the time point one week, two weeks, one month, two months after surgery. Result: The efficacy rate of B group two month after surgery is 96.6%, which was significantly higher than the A group which was 80% (P < 0.05). Conclusion: The efficacy of technique of plasma-mediated coblation combined with ozone injection on cervical disc herniation have advantage than the technique of plasma-mediated coblation therapy alone.

  15. Efficacy Observation of Diabetic Peripheral Neuropathy Treated with Kudiezi Injection and Mecobalamin%苦碟子注射液联合甲钴胺治疗糖尿病周围神经病变疗效观察

    Institute of Scientific and Technical Information of China (English)

    万继峰; 陆尤; 郝丽梅; 任歆; 徐云燕; 常素杰; 周卫东

    2011-01-01

    Objective To explore the efficacy on diabelic peripheral neuropalhy( DPN) trealed with kudiezi injeclion and mecobalamin and judge objectively the efficacy assessment. Methods 152 cases of DNP were selecled and randomized inlo a trealmenl group and a conlrol group. In conlrol group, mecobalamin was administered for down - regulaling glucose. In trealmenl group,on the basis of the trealmenl as conlrol group, kudiezi injeclion was supplemented. The duralion of Irealmenl was 4 weeks. Before and afler trealmenl in Iwo groups, the nerve conduction velocity ( NCV) was delecled separately. Results Afler 4 - week treatment , the lalent period of median nerve and tibial nerve was shortened, the wave amplitude increased and con-duction velocity was accelerated, which was different statistically as compared wilh those before trealmenl in the same group ( P < 0. 05 ). In intra - group comparison afler trealment, the latenl period of each nerve in trealmenl group was much obviously shorlened, the wave amplitude much increased and the conduction velocity was greally accelerated,which was different statistically as compared wilh conlrol group(P <0. 05). Conclusion The combined therapy wilh kudiezi injeclion and mecobalamin achieves a definile efficacy on DPN and obviously improves NCV.%目的 探讨苦碟子联合甲钴胺治疗糖尿病周围神经病变(DPN)的疗效和客观判断疗效的方法.方法 选择糖尿病周围神经病变患者152例,随机分成治疗组和对照组,对照组给予降糖及甲钴胺治疗,治疗组在对照组治疗基础上加用苦碟子注射液,疗程均为4周;在治疗前后分别测定神经传导速度(NCV).结果 经过4周治疗后,两组正中神经和胫神经的潜伏期均缩短,波幅均增高,传导速度均增快,与本组治疗前比较,差异均有统计学意义(P<0.05);治疗后两组间比较,治疗组各神经的潜伏期缩短更明显,波幅增加更增高,传导速度更快,与对照组比较,

  16. 银杏达莫联合肾康注射液治疗慢性肾衰竭的疗效观察%Efficacy of Yinxingdamo and Shenkang injection in treatment of chronic renal failure

    Institute of Scientific and Technical Information of China (English)

    董丽娜

    2013-01-01

    Objective To explone the effect of Yinxingdamo and Shenkang injection in treatment of chronic renal failure. Methods Form February 2010 to June 2012 the treatment of 400 patients with chronic renal failure patients as research subjects enrolled patients were randomly divided into treatment group and control group,each 200 cases. Control group undergoing hemodialysis (CHD) , the time (30. 47 ±21. 52) months, 2 times a week, each time 4h. Observation group on the basis of conventional dialysis Yinxingdamo Stock Shenkang of injection treatment. Results Two groups on serum creatinine (Cr) and blood urea nitrogen (BUN) clearance rate was no significant difference (P > 0. 05 ) , treatment group, serum PTH clearance less than the clearance of serum leptin (leptin) . Control group before and after dialysis serum leptin levels and serum iPTH levels were negatively correlated (P 0. 05). Conclusions Yinxingdamo Shenkang injection can reduce infection in patients with chronic renal failure, inflammation and the incidence of cardiovascular complications, improve the patients prognosis and quality of life, worthy of promotion.%目的 探讨银杏达莫联合肾康注射液治疗慢性肾衰竭的疗效.方法 选取2010年2月至2012年6月治疗的400例慢性肾衰竭患者作为研究对象,入选患者随机分为治疗组和对照组,每组200例.对照组接受血液透析(CHD),时间为(30.47±21.52)个月,每周2次,每次4h.观察组在常规透析基础上采用银杏达莫联合肾康注射液进行治疗.结果 两组对血清肌酐(Cr)与血清尿素氮(BUN)的清除率差异无统计学意义(P>0.05),治疗组对血清PTH的清除率小于对血清瘦素(Leptin)的清除率.HPD前、后血清leptin水平与血清全段甲状旁腺素(iPTH)、BUN和Cr指标的关系,对照组透析前后血清leptin水平与血清iPTH水平均呈负相关(P<0.05),与血清BUN、Cr水平无相关性(P>0.05).结论 银杏达莫联合肾康注射液可减少慢性肾衰竭患

  17. Management of Tennis Elbow with sodium hyaluronate periarticular injections

    OpenAIRE

    Petrella Robert J; Cogliano Anthony; Decaria Joseph; Mohamed Naem; Lee Robert

    2010-01-01

    Abstract Objectives To determine the efficacy and safety of peri-articular hyaluronic acid injections in chronic lateral epicondylosis (tennis elbow). Design Prospective randomized clinical trial in primary care sport medicine. Patients Three hundred and thirty one consecutive competitive racquette sport athletes with chronic (>3 months) lateral epicondylosis were administered 2 injections (first injection at baseline) into the subcutaneous tissue and muscle 1 cm. from the lateral epicondyle ...

  18. Efficacy of Trigger Point Biopsy Combined with Injection Therapy in the Upper Trapezius Muscle for Myofascial Pain Syndrome%斜方肌激痛点活检复合注射疗法治疗肌筋膜疼痛综合征的疗效

    Institute of Scientific and Technical Information of China (English)

    郭亚秋; 齐峰; 胡启雅; 王姿; 郭静旋; 黄海真; 丁超; 潘新; 张力

    2014-01-01

    The aim was to observe the efficacy of trigger point biopsy combined with injection therapy on the upper trapezius muscle for myofascial pain syndrome (MPS). Sixty patients of MPS were recruited and randomly divided equally into two groups. Group BI groupreceived myofascial trigger point (MTrP) biopsy plus injection therapy and group IT treated with MTrP injection therapy alone. The Visual Analogue Scale (VAS) was measured before the treatment, after the treatment immediately, and the day 7, 14, 21 and 28 after the treatment. The efficacy rate was evaluated up to three months after the treatment. Side effects were also observed during the treatment. The VAS in both groups decreased significantly after treatment (P<0. 05). The VAS in the group BI decreased significantly as compared to that in the group IT at day 14, 21, 28 after treatment (P< 0. 05). The effective rate was significantly higher than that in group IT three months after treatment (P<0. 05). Only one side effect appeared in group BI. Myofascial trigger point biopsy combined with analgesic injection therapy can provide an effective treatment for MPS than injection therapy alone.%观察斜方肌激痛点活检复合注射疗法治疗肌筋膜疼痛综合征(MPS)的疗效是否优于单纯注射治疗。选择MPS患者60例,随机分为激痛点活检复合镇痛液注射治疗组(BI组)和单纯镇痛液注射治疗组(IT组),每组30例。BI组患者行激痛点活检,并于活检处行镇痛液注射疗法;IT组患者仅于激痛点处行镇痛液注射治疗。评定患者治疗前和治疗后即刻、7天、14天、21天及28天疼痛视觉模拟评分(VAS),治疗后3个月的临床有效率以及和治疗有关的不良反应。结果两组治疗后VAS评分与治疗前相比均降低(P<0.05),从治疗后14天起BI组VAS评分低于IT组(P<0.05)。治疗3个月后BI组有效率高于IT组(P<0.05)。BI组出现1例不良反应患者。激痛点活

  19. Economic consequences of the adverse reactions related with antipsychotics: an economic model comparing tolerability of ziprasidone, olanzapine, risperidone, and haloperidol in Spain.

    Science.gov (United States)

    Bobes, Julio; Cañas, Fernando; Rejas, Javier; Mackell, Joan

    2004-12-01

    Frequency of adverse reactions (ARs) related with antipsychotics usage is high. Along with clinical implications, economic impact might be important. The purpose of this study was to model the economic consequences of ARs related with ziprasidone, olanzapine, risperidone, and haloperidol in Spain, by means of a cost-effectiveness model developed using a Markov modeling approach. The model simulated treatment of a cohort of 1000 schizophrenics for 12 months, initiating treatment with one of four antipsychotic drugs; haloperidol, risperidone, olanzapine and ziprasidone. Conditional probabilities of developing any of four adverse events were calculated. Treatment was modified (decrease dose, switch medication) according to incidence of ARs and physician judgments, obtained from a local cross-sectional study and clinical trials previously published. The analysis was conducted in year 2002 from a third party payer perspective. Results are shown as annual cost per month with psychotic symptoms controlled and included univariate sensitivity analysis. The therapeutic strategy starting with ziprasidone showed the lower costs and the greater number of months with symptoms controlled in most scenarios evaluated versus the other options considered, although the differences were weak: 9.6, 9.3, 9.5 and 9.5 controlled months per patient in base scenario, with annual cost per patient per month with symptoms controlled of 1035 Euros, 1084 Euros, 1087 Euros and 1090 Euros for ziprasidone, haloperidol, risperidone and olanzapine, respectively. Results were robust to one-way sensitivity analysis. Despite the unlike drug prices of antipsychotics, a considerable economic impact due to adverse reactions was seen in our setting. These results should be taken into account by health decision makers and clinicians in the management of patients with schizophrenia.

  20. 精蛋白锌胰岛素30R与精蛋白生物合成人胰岛素30R对口服降糖药控制不佳2型糖尿病的有效性及安全性%Efficacy and safety of isophane protamine insulin injection 30R to isophane protamine biosynthetic human insulin injection 30R in type 2 diabetics poorly controlled with oral hypoglycemic agents

    Institute of Scientific and Technical Information of China (English)

    廖欢; 单忠艳; 曹艳丽; 张鹏; 贺佳; 邹大进; 苏青; 金杰; 杨涛; 沈备; 王坚; 王扬天; 成兴波; 谢云

    2011-01-01

    Objective To compare the efficacy and safety of isophane insulin injection 30R and isophane protamine biosynthetic human insulin injection 30R in patients with type 2 diabetes mellitus poorly controlled with oral hypoglycemic agents.Methods One hundred and forty patients with type 2 diabetes mellitus poorly controlled with oral hypoglycemic agents from June,2009 to June,2010 were divided randomly in a ratio of 1:1 into group A and group B.There was no differences in age,gender,height,weight between the two groups.The group A and group B were given isophane protamine insulin injection 30R and isophane protamine biosynthetic human insulin injection 30R respectively.All the patients were injected insulin before breakfast and supper together with previous oral agents for 12 weeks.Insulin dosage was determined and adjusted according to blood glucose.At the end of the 12 week,the two groups exchanged the insulins and continued the therapy for another 12 weeks.The glycated hemoglobin Alc (HbAlc),fasting blood glucose(FBG),2 h postprandial blood glucose (PBG) and insulin autoantibody (IAA) were investigated at the end of the treatments.Paired t test and Wilcoxon test were used in the data analysis.Results After 12 weeks,there were no significant differences in HbAlc ((7.7 ± 1.3 )% vs (7.5 ±0.9)%,t=1.24,P>0.05),FBG((8.0±2.0) vs (7.4±1.6)mmol/L,t=1.05,P>0.05) and PBG ( ( 13 ± 4) vs ( 12 ± 4) mmol/L,t =0.90,P > 0.05 ) in group A and group B.After 24 weeks,no significant differences in the above-mentioned indexes was found between the two groups either:HbAlc ((8.3±1.5)% vs (7.5 ±1.0)%,x2 =0.01,P>0.05),FBG ((7.8±2.0) vs (7.9±2.1) mmol/L,x2=0.04,P>0.05) andPBG ((12±4) vs (12±4)mmoL/L,x2=0.82,P>0.05).The levels of IAA were comparable between the two groups at the end of the 12th week ( ( 19 ± 12) vs ( 19 ± 13) mU/L,t =0.11,P>0.05) and at the end of the 24th week ((19 ±11) vs (18 ±12) mU/L,x2 =1.26,P>0.05).The incidence of hypoglycemia in

  1. On Maximal Injectivity

    Institute of Scientific and Technical Information of China (English)

    Ming Yi WANG; Guo ZHAO

    2005-01-01

    A right R-module E over a ring R is said to be maximally injective in case for any maximal right ideal m of R, every R-homomorphism f : m → E can be extended to an R-homomorphism f' : R → E. In this paper, we first construct an example to show that maximal injectivity is a proper generalization of injectivity. Then we prove that any right R-module over a left perfect ring R is maximally injective if and only if it is injective. We also give a partial affirmative answer to Faith's conjecture by further investigating the property of maximally injective rings. Finally, we get an approximation to Faith's conjecture, which asserts that every injective right R-module over any left perfect right self-injective ring R is the injective hull of a projective submodule.

  2. A control study of risperidone combined with clonazepam in schizophrenia with acute agitated symptoms%利培酮联合氯硝西泮治疗精神分裂症急性激越症状对照研究

    Institute of Scientific and Technical Information of China (English)

    柴艳丽; 余学; 张慧芳; 王丽

    2015-01-01

    Objective To explore the efficacy and safety of risperidone combined with clonazepam vs .halo‐peridol in schizophrenia with acute agitated symptoms .Methods Sixty‐nine schizophrenics with acute agi‐tated symptoms were randomly divided into two groups ,research group was treated with risperidone plus clonazepam orally and control group with haloperidol for 4 weeks .Efficacies were assessed with the total and excitation score of the Positive and Negative Syndrome Scale (PANSS) before and after treatment and adverse reactions with the Treatment Emergent Symptom Scale (TESS) .Results After treatment the to‐tal and excitation scores of the PANSS of both groups lowered continuously compared with pretreatment (P0 .05) .The incidence of adverse reactions was 37 .1% and benzhexol use rate 8 .6% in re‐search and 64 .7% and 44 .1% in control group ,the former was significantly lower than the latter (χ2 =5 .24 ,11 .30 ;P<0 .05 or 0 .01) .Conclusion Risperidone combined with clonazepam could rapidly and ef‐fectively control schizophrenic acute agitated symptoms ,has an equivalent effect to haloperidol ,higher safety and a long‐term treatment advantage ,and is beneficial to patients’ continuous treatment .%目的:探讨利培酮联合氯硝西泮与氟哌啶醇治疗精神分裂症患者急性激越症状的疗效和安全性。方法将69例伴急性激越症状的精神分裂症患者随机分为两组,研究组口服利培酮联合氯硝西泮治疗,对照组予以氟哌啶醇治疗,观察4周。于治疗前后采用阳性与阴性症状量表总分及兴奋因子分评定临床疗效,副反应量表评定不良反应。结果治疗后两组阳性与阴性症状量表总分及兴奋因子评分较治疗前持续下降( P<0.01),治疗4周末研究组显效率57.1%、有效率97.1%,对照组分别为50.0%、100%,两组比较差异均无显著性(χ2=0.35、0.99,P>0.05)。研究组不良反应发生率为37

  3. Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): effects of body weight and injection sites on pharmacokinetics.

    Science.gov (United States)

    Rahimy, M H; Cromie, M A; Hopkins, N K; Tong, D M

    1999-10-01

    A new contraceptive option, medroxyprogesterone acetate (MPA) and estradiol cypionate (E2C) (MPA/E2C, Lunelle Monthly Contraceptive Injection), will soon be available for women in the US. This article reports the results of a US trial that assessed the effects of body weight and injection site on the pharmacokinetics of MPA, the progestin mediating contraceptive efficacy. This assessment was part of a nonrandomized, open-label, multicenter US study in healthy women receiving a monthly injection of MPA/E2C for 60 weeks. A total of 77 women (aged 18-47 years) at four centers participated in the pharmacokinetics assessment during the sixth or the seventh injection. For determination of serum MPA concentration-time profiles, blood samples were collected before the sixth and seventh injections (day 0) and on days 3, 7, 14, 21, and 28 after the sixth and seventh monthly administrations. For effects of injection site, MPA pharmacokinetics were compared at injection sites of the arm, hip, and leg. The pharmacokinetics of MPA, determined at the sixth and seventh injection, were not significantly affected by injection sites. The mean area under the curve (AUC0-28), however, was different between the arm and the leg injection sites; the difference was 38, n = 6). There were no significant differences in the pharmacokinetics of MPA among the three BMI categories. The only significant difference (p = 0.0387) was the AUC0-28 between BMI 18-28 and BMI 29-38. Because of the small sample size in the highly obese group, a reanalysis was performed by pooling subjects of the obese and highly obese groups. Results of the pooled statistical analysis remained the same. In summary, these results suggest that minor differences observed in the MPA pharmacokinetics--whether due to injection site or body weight or both--have no impact on the contraceptive efficacy of MPA/E2C, as trough concentrations (Cmin) are well above the threshold levels required to suppress ovulation. No dose adjustment

  4. Effect of in utero exposure to the atypical anti-psychotic risperidone on histopathological features of the rat placenta.

    Science.gov (United States)

    Singh, K P; Singh, Manoj K; Gautam, Shrikant

    2016-04-01

    For clinical management of different forms of psychosis, both classical and atypical anti-psychotic drugs (APDs) are available. These drugs are widely prescribed, even during pregnancy considering their minimal extra-pyramidal side effects and teratogenic potential compared to classical APDs. Among AAPDs, risperidone (RIS) is a first-line drug of choice by physicians. The molecular weight of RIS is 410.49 g/mol; hence, it can easily cross the placental barrier and enter the foetal bloodstream. It is not known whether or not AAPDs like RIS may affect the developing placenta and foetus adversely. Reports on this issue are limited and sketchy. Therefore, this study has evaluated the effects of maternal exposure to equivalent therapeutic doses of RIS on placental growth, histopathological and cytoarchitectural changes, and to establish a relationship between placental dysfunction and foetal outcomes. Pregnant rats (n = 24) were exposed to selected doses (0.8, 1.0 and 2.0 mg/kg) of RIS from gestation days 6-21. These dams were sacrificed; their placentas and foetuses were collected, morphometrically examined and further processed for histopathological examination. This study revealed that in utero exposure to equivalent therapeutic doses of RIS during organogenesis-induced placental dystrophy (size and weight), disturbed cytoarchitectural organization (thickness of different placental layers), histopathological lesions (necrosis in trophoblast with disruption of trophoblastic septa and rupturing of maternal-foetal interface) and intrauterine growth restriction of the foetuses. It may be concluded that multifactorial mechanisms might be involved in the dysregulation of structure and function of the placenta and of poor foetal growth and development. PMID:27256515

  5. Association studies of genomic variants with treatment response to risperidone, clozapine, quetiapine and chlorpromazine in the Chinese Han population.

    Science.gov (United States)

    Xu, Q; Wu, X; Li, M; Huang, H; Minica, C; Yi, Z; Wang, G; Shen, L; Xing, Q; Shi, Y; He, L; Qin, S

    2016-08-01

    Schizophrenia is a widespread mental disease with a prevalence of about 1% in the world population. Continuous long-term treatment is required to maintain social functioning and prevent symptom relapse of schizophrenia patients. However, there are considerable individual differences in response to the antipsychotic drugs. There is a pressing need to identify more drug-response-related markers. But most pharmacogenomics of schizophrenia have typically focused on a few candidate genes in small sample size. In this study, 995 subjects were selected for discovering the drug-response-related markers. A total of 77 single-nucleotide polymorphisms of 25 genes have been investigated for four commonly used antipsychotic drugs in China: risperidone, clozapine, quetiapine, and chlorpromazine. Significant associations with treatment response for several genes, such as CYP2D6, CYP2C19, COMT, ABCB1, DRD3 and HTR2C have been verified in our study. Also, we found several new candidate genes (TNIK, RELN, NOTCH4 and SLC6A2) and combinations (haplotype rs1544325-rs5993883-rs6269-rs4818 in COMT) that are associated with treatment response to the four drugs. Also, multivariate interactions analysis demonstrated the combination of rs6269 in COMT and rs3813929 in HTR2C may work as a predictor to improve the clinical antipsychotic response. So our study is of great significance to improve current knowledge on the pharmacogenomics of schizophrenia, thus promoting the implementation of personalized medicine in schizophrenia.The Pharmacogenomics Journal advance online publication, 18 August 2015; doi:10.1038/tpj.2015.61. PMID:26282453

  6. 斑蝥酸钠维生素B6注射液联合奈达铂治疗胸腔积液的疗效分析%Analysis of the efficacy of cantharidin sodium vitamin B6 injection combined with nedaplatin treatment of pleural effusion

    Institute of Scientific and Technical Information of China (English)

    王吉天; 付桂莲

    2013-01-01

    目的 观察斑蝥酸钠维生素B6注射液联合奈达铂胸腔注入治疗恶性胸腔积液的疗效和不良反应.方法 将73例肺癌并发恶性胸腔积液患者随机分为观察组(38例)和对照组(35例),观察组患者用一次性中心静脉引流专用导管胸腔置管闭式引流胸腔积液后,胸腔内注射斑蝥酸钠维生素B6注射液和奈达铂;对照组患者胸腔内仅注射奈达铂.观察组胸腔给药:斑蝥酸钠维生素B6注射液50 ml+生理盐水20ml+奈达铂100 mg;对照组胸腔给药:奈达铂100 mg+生理盐水70 ml.结果 观察组患者的临床总有效率和生活质量改善率均优于对照组(均P<0.05),两组患者不良反应差异无统计学意义(P>0.05).结论 胸腔灌注斑蝥酸钠维生素B6注射液联合奈达铂治疗恶性胸腔积液的疗效优于单用奈达铂,不良反应轻.%Objective To observe the efficacy and adverse reactions of cantharidin sodium vitamin B6 injection combined with nedaplatin pleural injection for the treatment of malignant pleural effusion.Methods 73 cases of lung cancer complicated by patients with malignant pleural effusions,central venous drainage catheter chest tube closed drainage of pleural effusion,given the intrathoracic drug injection,cantharidin sodium vitamin B6 injection combined with of nedaplatin(observation group 38 cases),with nedaplatin only(control group,35 cases).observation Group pleural administration:the cantharides sodium vitamin B6 injection 50ml + saline 20ml + nedaplatin 100mg; control group pleural administration:nedaplatin 100mg + saline 70ml.Results Observation group of patients with clinical total rate of efficiency and improved quality of life was better than in control group (P < 0.05),similar to the two sets of adverse reactions.Conclusions Pleural perfusion the sodium cantharidate vitamin B6 injection in conjunction with nedaplatin treatment of malignant pleural effusion effective than single nedaplatin,and the side effects

  7. Clinical efficacy of micro-pump injection of nitroglycerin and sodium nitroprusside in the treatment of hypertensive crisis%静脉微泵注射硝酸甘油与硝普钠治疗高血压危象的效果观察

    Institute of Scientific and Technical Information of China (English)

    朱海龙; 王军; 王英; 梁夷; 张毅

    2012-01-01

    Objective To observe the clinical efficacy of micro-pump injection of nitroglycerin and sodium nitroprusside in the treatment of hypertensive crisis. Methods Sixty-eight patients were randomly divided into two groups, and recieved micro-pump injection of nitroglycerin (group A) or sodium nitroprusside (group B). The clinical efficacy were observed. Results The total effective rate of lowering blood pressure 94.12% in group A and 94.12% in group B, with no statistically significant difference between the two groups (P>0.05). But the duration of the lowering blood pressure was significantly shorter in group B than group A (P<0.05). The effective rate within 30 minutes was 67.65% in group B, but only 26.47% in group A. Conclusion For patients with hypertensive crisis, the clinical effect of sodium nitroglycerin and sodium nitroprusside is similar in lowering blood pressure, but sodium nitroprusside needs significantly shorter duration.%目的 观察静脉微泵注射硝酸甘油与硝普钠在高血压危象患者治疗中的降压效果.方法 68例高血压危象患者随机分成两组,分别行静脉微泵注射硝酸甘油与硝普钠行降压治疗,观察疗效.结果 硝酸甘油组与硝普钠组的降压总有效率相似(94.12%与94.12%,P>0.05),但降压达标时间硝普钠组短于硝酸甘油组(30 min显效率分别为67.65%与26.47%,P<0.05).结论 对于高血压危象患者,两种药物降压效果相似,均可选择.如果需要更快速地控制血压则首选硝普钠.

  8. Efficacy of Percutaneous Radiofrequency Ablation with Low-temperature Plasma Intradiscal Ozone Injection for Lumbar Disc Herniation%低温等离子射频消融术与臭氧注射术治疗腰椎间盘突出症的疗效分析

    Institute of Scientific and Technical Information of China (English)

    于龙潭; 李鹏; 张力; 谭磊

    2015-01-01

    目的 探讨对于同一腰椎间盘突出分型的患者采用经皮射频低温等离子消融术与椎间盘内臭氧注射术的疗效对比. 方法 根据治疗方法的不同将212例患者分为低温等离子组和臭氧组,分别于术后3个月、9个月进行随访,通过JOA评分改善率评估手术治疗效果. 结果 所有患者术中、术后均无严重并发症. 对于中央型、旁中央型椎间盘突出的患者,上述两种术式术后及随访期间,优良率差异无统计学意义(P>0.05);对于外侧型的患者,低温等离子射频术优良率要高于臭氧注射术,差异有统计学意义(P0.05),and for patients with lateral type,the good rate was significantly higher than that of ozone injection(P<0.05).Conclusion For patients with central type and next to the central type of disc herniation ,the above two types of operations have good therapeutic effect .For patients with lateral and extreme lateral ,the clinical efficacy of low temperature plasma radiofrequency ablation is better than that of ozone injection .

  9. RimabotulinumtoxinB Injection

    Science.gov (United States)

    (rim a bott' you lye num bee)RimabotulinumtoxinB injection may spread from the area of injection and ... Event Reporting program online (http://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).

  10. Iron Sucrose Injection

    Science.gov (United States)

    Iron sucrose injection is used treat iron-deficiency anemia (a lower than normal number of red blood cells due ... may cause the kidneys to stop working). Iron sucrose injection is in a class of medications called ...

  11. Urinary incontinence - injectable implant

    Science.gov (United States)

    Injectable implants are injections of material into the urethra to help control urine leakage ( urinary incontinence ) caused by a ... into the tissue next to the sphincter. The implant procedure is usually done in the hospital. Or ...

  12. Corticotropin, Repository Injection

    Science.gov (United States)

    ... hard, or sensitive, or that has tattoos, warts, scars, or birthmarks. Do not inject the medication into ... you are injecting the medication. You can help decrease your child's pain by placing an ice cube ...

  13. MiRNA-365 and miRNA-520c-3p respond to risperidone treatment in first-episode schizophrenia after a 1 year remission

    Institute of Scientific and Technical Information of China (English)

    LIU Sha; YUAN Yan-bo; GUAN Li-li; WEI Hui; CHENG Zhang; HAN Xue; YANG Lei

    2013-01-01

    Background MicroRNAs (miRNAs) control gene expression by destabilizing target transcripts and inhibiting their translation.Aberrant expression of miRNAs has been described in many human diseases,including schizophrenia.However,the effects on miRNA expression in response to antipsychotic treatment in peripheral circulation have not been thoroughly examined.Methods Using quantitative real-time PCR (qRT-PCR),We quantified the expression of seven candidate miRNAs in plasma samples of 40 first-episode schizophrenics before and after antipsychotic treatment.The patients were all treated with risperidone and achieved remission in 1 year.Results Compared with the baseline,the expression levels of miR-365 and miR-520c-3p were significantly downregulated after 1 year of risperidone treatment (P <0.001).There were no significant correlations between the clinical symptoms and the expression levels of these two miRNAs (P >0.05).Conclusions This study analyzed possible circulating miRNAs in response to antipsychotic monotherapy for schizophrenia,the further mechanism need to be confirmed.

  14. [Preparation and evaluation of risperidone-loaded microsphere/sucrose acetate isobutyrate in situ forming complex depot with double diffusion barriers].

    Science.gov (United States)

    Lin, Xia; Tang, Xing; Xu, Yu-hong; Zhang, Yu; Zhang, Yan; He, Hai-bing

    2015-06-01

    In the present study, a risperidone loaded microsphere/sucrose acetate isobutyrate (SAIB) in situ forming complex depot was designed to reduce the burst release of SAIB in situ forming depot and to continuously release risperidone for a long-term period without lagime. The model drug risperidone (Ris) was first encapsulated into microspheres and then the Ris-microspheres were embedded into SAIB depot to reduce the amount of dissolved drug in the depot. The effects of different types of microsphere matrix, including chitosan and poly(lactide-coglycolide) (PLGA), matrix/Ris ratios in microspheres and morphology of microspheres on the drug release behavior of complex depot were investigated. In comparison with the Ris-loaded SAIB depot (Ris-SAIB), the complex depot containing chitosan microspheres (in which chitosan/Ris = 1 : 1, w/w) (Ris-Cm-SAIB) decreased the burst release from 12.16% to 5.80%. However, increased drug release rate after 4 days was observed in Ris-Cm-SAIB, which was caused by the high penetration of the medium to Ris-Cm-SAIB due to the hydrophilie of chitosan. By encapsulation of risperidone in PLGA microspheres, most drugs can be prevented from dissolving in the depot and meanwhile the hydrophobic PLGA can reduce the media penetration effect on the depot. The complex depot containing PLGA microspheres (in which PLGA/ drug=4 : 2, w/w) (Ris-Pm-SAIB) showed a significant effectiveness on reducing the burst release both in vitro and in vivo whereby only 0.64% drug was released on the first day in vitro and a low AUC0-4d value [(105.2± 24.4) ng.mL-1.d] was detected over the first 4 days in vivo. In addition, drug release from Ris-Pm-SAIB can be modified by varying the morphology of microspheres. The porous PLGA microspheres could be prepared by adding medium chain triglyceride (MCT) in the organic phase which served as pore agents during the preparation of PLGA microspheres. The complex depot containing porous PLGA microspheres (which were prepared by

  15. Therapeutic Efficacy of Tanreqing Injection as Adjuvant Therapy in Treatment of Chronic Obstructive Pulmonary Disease with Respiratory Failure: A Report of 42 Cases%痰热清佐治慢性阻塞性肺疾病并发呼吸衰竭42例

    Institute of Scientific and Technical Information of China (English)

    曹英俊; 查贵智; 纪小平

    2012-01-01

    To observe the therapeutic efficacy of Tanreqing Injection as an adjuvant therapy in the treatment of chronic obstructive pulmonary disease (COPD) with respiratory failure .Methods Eighty-two COPD patients were randomly divided into treatment group (re=42) and control group (re?0). The control group received respirator therapy and conventional treatment , while the treatment group was given Tanreqing Injection by intravenous drip in addition to respirator therapy and conventional treatment . The two groups were compared for response rate , symptom score , blood gas parameters , and mechanical ventilation duration after treatment .Results Compared with the control group , the treatment group showed a significantly higher overall response rate (90 .47% vs 70 .00% , P<0 .01), as well as lower symptom score , shorter duration of mechanical ventilation , and better blood gas parameters (P<0 .01) . Conclusion Tanreqing Injection combined with conventional Western medicine treatment can improve such symptoms as cough , expectoration , and dyspnea, increase arterial partial pressure of oxygen and oxygenation index , and shorten the duration of mechanical ventilation in COPD patients .Q%目的 观察痰热清注射液辅助治疗慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)并发呼吸衰竭的疗效.方法 将82例COPD患者随机分为两组,治疗组42例,对照组40例,对照组仅予呼吸机及常规方案治疗,治疗组加用痰热清注射液静脉滴注,治疗后比较两组临床疗效、症状体征评分、血气分析指标及机械通气时间.结果 治疗组总有效率显著高于对照组(90.47% vs 70.00%,P<0.01);治疗组在降低症状体征评分、使用呼吸机时间及改善血气分析指标方面优于对照组(P<0.01).结论 痰热清联合西医常规治疗在改善COPD患者咳嗽、咳痰、喘息症状,提高动脉氧分压,提高氧合指数,缩短上机时间方面具有较好疗效.

  16. Clinical efficacy observation of intravenous drip of tranexamic acid injection combined with glutathione and Vitamin C in patients with chloasma%氨甲环酸注射液联合谷胱甘肽及维生素C治疗黄褐斑的近期临床观察

    Institute of Scientific and Technical Information of China (English)

    陈姮如; 邓列华

    2014-01-01

    目的:对氨甲环酸注射液联合谷胱甘肽及维生素C静滴治疗黄褐斑的临床疗效进行评价。方法将100例面部黄褐斑的患者分为两组。治疗组使用氨甲环酸0.25g注射液+谷胱甘肽1.2g+维生素C 5g静脉滴注8周。对照组仅用谷胱甘肽1.2g+维生素C 5g静脉滴注8周。结果治疗组总有效率为92%,对照组总有效率62%。两组疗效比较,差异有统计学意义(P<0.05)。结论氨甲环酸注射液联合谷胱甘肽及维生素C静滴治疗黄褐斑比单用谷胱甘肽1.2g+维生素C的疗效更好。%Objective To evaluate the clinical efficacy of intravenous drip of tranexamic acid injection combined with glutathione and vitamin C in patients with chloasma. Methods 100 patients with facial melasma were divided into two groups. The treatment group was given intravenous drip of 0.25g tranexamic acid injection combined with 1.2g glutathione and 5 g vitamin C for 8 weeks, and the control group was given intravenous drip of 1.2 g glutathione and 5 g vitamin C for 8 weeks. Results The total effective rate of treatment group and control group was 92% and 62% respectively, and the difference was statistically significant (P < 0.05). Conclusion The intravenous drip of tranexamic acid injection combined with glutathione and vitamin C is more effective in treating chloasma than the application of glutathione and vitamin C.

  17. Efficacy Observation of Fentanyl Skin Patches Combined with Compound Sophora flavescens Injection in the Treatment of Cancer Pain%芬太尼贴联合复方苦参注射液治疗晚期癌痛的疗效观察

    Institute of Scientific and Technical Information of China (English)

    豆利华; 郭治

    2012-01-01

    目的:观察芬太尼贴联合复方苦参注射液治疗晚期癌痛的治疗效果.方法:选取我院收治的晚期癌痛患者62例,随机分为治疗组和对照组,对照组予以芬太尼贴,每贴8.4 mg,每72 h更换1次;治疗组在对照组用药基础上加用复方苦参注射液15mL加入0.9%氯化钠注射液250 mL中静脉滴注,qd,连用12d.观察2组患者的疼痛缓解情况和生存质量(Karnofsky)评分.结果:治疗组的疼痛缓解率和Karnofsky评分均明显优于对照组,2组比较差异有统计学意义(P<0.05).2组不良反应均较轻微,差异无统计学意义(P>0.05).结论:芬太尼贴联合复方苦参注射液能有效治疗癌痛,改善晚期癌症患者的生存质量.%OBJECTIVE: To study on the therapeutic efficacy of Fentanyl skin patches combined with Compound Sophora flavescens injection in the treatment of cancer pain. METHODS: 62 cases suffering from advanced cancer pain which were diagnosed in our hospital were randomly divided into treatment group and control group. Control group was given Fentanyl skin patches 8.4 mg per patch every 72 hours. Treatment group was additionally given Compound S. flavescens injection 15 mL added into normal saline 250 mL with intravenous dripping once a day for consecutive 12 days. RESULTS: The remission rate of treatment group was significantly better than that of control group, there was statistical difference (P0.05). CONCLUSIONS: Fentanyl skin patches combined with Compound S. flavescens injection is effective in the treatment of cancer pain, effectively improve the survival quality among the patients with advanced cancer.

  18. Effects of nasal administration or subcutaneous injection of testosterone/testosterone propionate on expression efficacy of c-Fos in rat brain%经鼻及皮下给予睾丸酮/丙酸睾丸酮对大鼠相关脑区c-Fos表达效能的影响

    Institute of Scientific and Technical Information of China (English)

    张国梁; 牛小龙; 康云霄; 薛岩; 方卉; 石葛明

    2013-01-01

    Objective:To explore the efficacy of intranasal administration or subcutaneous injection of testosterone (T) / testosterone propionate (TP) on different brain regions in rats. Methods:Radioimmunoassay was used to detect testosterone concentration in cerebrospinal fluid and in serum after intranasal administration of TP. Immunohistochemistry was used to detect the expression of c-Fos protein in different brain regions. Results:Testosterone in cerebrospinal fluid and in serum was decreased in gonadectomized (GDX) rats compared to the normal control rats. Subcutaneous injection of TP in GDX rats only increased testosterone in serum. Testosterone in cerebrospinal fluid and in serum was increased after intranasal administration of TP in GDX rats and in the normal control rats. Testosterone in cerebrospinal fluid of GDX rats after intranasal administration of TP was higher than that in GDX rats after subcutaneous injection of TP, however testosterone in serum of GDX rats after intranasal administration of TP was lower than that in GDX rats after subcutaneous injection of TP. After intranasal administration of TP or T, the number of c-Fos-immunoreactive cells and the c-Fos immunoreactive intensity were increased in more brain regions. However, after subcutaneous injection of TP, the number of c-Fos-immunoreactive cells and the c-Fos immunoreactive intensity were increased only in a few brain regions. Conclusion:Intranasal administration of TP or T could induce the expression of c-Fos and activate more brain regions. That can provide a new therapy method for some central nervous system diseases.%目的:探讨经鼻和皮下给予睾丸酮(T)或丙酸睾丸酮(TP)对大鼠中枢神经系统相关脑区激活的效能.方法:利用放射免疫分析法检测大鼠经鼻滴注给予TP后脑脊液和血清睾丸酮浓度的变化;以免疫组织化学观察大鼠各脑区cFos的表达.结果:放射免疫结果显示去势组大鼠脑脊液和血清中睾丸酮含量比正

  19. Comparative study on efficacy of gastroscopic drug spray and drug injection in treating non -variceal upper gastrointesti-nal massive hemorrhage%两种方式注射治疗非静脉曲张性上消化道大出血的疗效研究

    Institute of Scientific and Technical Information of China (English)

    左华

    2015-01-01

    目的:探讨胃镜下去甲肾上腺素药物喷洒与肾上腺素注射治疗非静脉曲张性上消化道大出血的疗效。方法160例符合纳入标准的非静脉曲张性上消化道大出血患者按治疗方案分为药物喷洒组(80例)和药物注射组(80例)。所有患者均给予上消化道大出血的常规治疗。药物喷洒组患者在胃镜下给予去甲肾上腺素喷洒治疗,而药物注射组在胃镜下给予肾上腺素注射治疗。观察两组患者治疗疗效、止血时间、再出血率及不良反应发生情况。结果药物注射组的治疗总有效率为95.0%,明显高于药物喷洒组的80.0%(P<0.05)。与药物喷洒组相比,药物注射组的止血时间明显缩短,再出血率明显降低(均 P<0.05)。治疗过程中,两组均未发生严重不良反应,其不良反应发生率在两组间比较差异无统计学意义(P>0.05)。结论胃镜下肾上腺素注射是非静脉曲张性上消化道大出血的有效治疗方案,可以提高治疗有效率,缩短止血时间,且不良反应轻,疗效优于去甲肾上腺素喷洒治疗,临床上值得进一步研究。%Objective To investigate the clinical effect of gastroscopic noradrenalin spray and adrenalin injec‐tion in the treatment of non‐variceal upper gastrointestinal massive hemorrhage .Methods 160 cases of non‐variceal upper gastrointestinal massive hemorrhage meeting the inclusion critera were equally divided into the drug spray group and the drug injection group according to therapeutic scheme .Besides the conventional treatments ,the drug spray group was given gastroscopic spraying of noradrenalin ,while the drug injection group was treated with gastro‐scopic injection of adrenalin .Then ,the curative efficacy ,hemostatic time ,rebleeding rate and adverse reactions were observed and compared between the two groups .Results The total effective rate in the drug injection group was 95

  20. A Logic of Injectivity

    CERN Document Server

    Adamek, J; Souza, L

    2007-01-01

    Injectivity of objects with respect to a set $\\ch$ of morphisms is an important concept of algebra, model theory and homotopy theory. Here we study the logic of injectivity consequences of $\\ch$, by which we understand morphisms $h$ such that injectivity with respect to $\\ch$ implies injectivity with respect to $h$. We formulate three simple deduction rules for the injectivity logic and for its finitary version where \\mor s between finitely ranked objects are considered only, and prove that they are sound in all categories, and complete in all "reasonable" categories.

  1. Comparative Study on Effects of Clozapine and Risperidone on Psychological Theory of Schizophrenia Patients%氯氮平与利培酮对精神分裂症患者心理理论疗效的比较研究

    Institute of Scientific and Technical Information of China (English)

    赵彩荣; 卫玲; 汪凯

    2012-01-01

    目的 比较氯氮平与利培酮对精神分裂症患者心理理论的疗效.方法 入组的130例被试者中精神分裂症患者家属32例(亲属组)、正常者32例(正常对照组)、精神分裂症患者66例,再将 66例精神分裂症患者随机分为两组:服用氯氮平组(34例)和服用利培酮组(32例).四组患者分别予以失言识别测试,并进行对照研究.结果 四组被试者在对照问题上差异无统计学意义(P>0.05);四组失言1、失言2、失言3以及失言4比较差异有统计学意义(P<0.05).结论 精神分裂症存在前额叶认知功能障碍,两种药物对精神分裂症患者心理理论影响无明显差别.%Objective To compare the efficacy of clozapine and risperidone on the psychological theory of schizophrenia patients. Methods 130 cases were included in the study, including 32 cases of family member of schizophrenia( kin group ),32 normal cases( normal control group ),66 cases of patients with schizophrenia; then the 66 cases of schizophrenia were randomly divided into two group:clozapine group( n = 34 )and risperidone group( n = 32 ). The four groups of patients took the faux pas recognition test, and were comparatively studied. Results The differences of the control issue among the four groups were not statistically significant(P >0.05 );faux pas test differences of the four groups were statistically significant P < 0.05 ). Conclusion Schizophrenia has prefrontal cognitive dysfunction, no significant difference between the two drugs in influence on the psychological theory of patients with schizophrenia.

  2. 复方苦参注射液联合吉西他滨和顺铂治疗非小细胞肺癌的疗效观察%Efficacy of compound matrine injection in combination with gemcitabine and cisplatin chemotherapy in the treatment of patients with advanced non-small-cell lung cancer

    Institute of Scientific and Technical Information of China (English)

    刘国辉; 李婷

    2012-01-01

    Objective: To observe and compare the efficacy and toxicity of compound matrine injection in combination with CP regimen ( gemcitabine plus cisplatin) and CP regimen in the treatment of patients with advanced non-small-cell lung cancer (NSCLC). Methods: One hundred and twenty patients with advanced NSCLC diagnosed by pathology or cytology were assigned to receive either compound matrine injection in combination with CP regimen (matrine group,60 cases) or CP regimen alone (control group,60 cases). After treatment for at least 2 cycles,the curative efficacy was evaluated. Results; The total response rate in matrine group was 40. 00% ; 24 had partial remission, and 24 had stable disease. The total response rate in the control group was 36. 67% ; 22 had partial remission, and 24 had stable disease. The difference of the overall response rate between the two groups was insignificant. The pain remission rate in matrine group (37 patients with cancer pain) was 86.49% and that in the control group (38 patients with cancer pain) was 52.63% .showing significant difference between the two groups (P<0.05).The incidence rates of leucopenia, II ~ IV gastrointestinal reaction,and hepatorenal toxicity in matrine group were significantly less than control group (P<0.05). Conclusion; Compound matrine injection can alleviate the side effects of CP chemotherapy, thus enhance patients'tolerance to chemotherapy.%目的:观察和比较复方苦参注射液联合吉西他滨和顺铂(GP)的方案与单纯GP方案治疗非小细胞肺癌(NSCLC)的疗效及不良反应.方法:将经病理组织学或细胞学确诊为晚期非小细胞肺癌患者120例作为研究对象,按所接受的方案分为复方苦参注射液联合GP方案组(苦参组)60例及单纯GP方案组(对照组)60例.每例患者至少治疗2周期以上进行疗效评价.结果:苦参组60例:部分缓解( PR)24例,稳定(SD)24例,总有效率为40.00%;对照组60例:部分缓解(PR) 22例,稳定(SD) 24

  3. Comparison of Clinical Efficacy of Intradermal Injection of Peplomycin and Heparin Sodium in the Treatment of Eyelid Xanthoma%平阳霉素与肝素钠皮内注射治疗睑黄瘤临床疗效比较

    Institute of Scientific and Technical Information of China (English)

    孔晓路

    2015-01-01

    Objective To compare the clinical efficacy of intradermal injection of peplomycin and heparin sodi-um in the treatment of eyelid xanthoma. Methods The 101 patients with eyelid xanthoma were randomly divided into two groups,53 patients(105 eyes)of the treatment group were treated with intradermal injection of peplomycin and heparin sodium,and 48 patients(96 eyes)of the control group were treated with intradermal injection of hepa-rin sodium. The clinical efficacy was compared between the two groups. Results In the treatment group,99 eyes (94. 3% )were cured,6 eyes(5. 7% )were improved,and 3 eyes(3. 0% )were relapsed. In the control group,91 eyes(94. 8% )were cured,5 eyes(5. 2% )were improved and 2 eyes(2. 2% )were relapsed. There was no statisti-cal difference in the cure rate,improvement rate and relapse rate between the two groups. The treatment number of times and treatment time of the treatment group were higher than those of the control group. Conclusion Peplomy-cin and heparin therapy safe and effective for eyelid xanthoma,have a low recurrence rate. However,peplomycin has an advantage in the treatment number of times and treatment time.%目的:比较分析平阳霉素与肝素钠皮内注射治疗睑黄瘤的疗效。方法101例病理学确诊的睑黄瘤患者随机分为治疗组和对照组,其中治疗组53例患者105眼行皮内注射盐酸平阳霉素,对照组48例96眼行皮内注射肝素钠,比较2组的疗效。结果治疗组99眼(94.3%)治愈,6眼(5.7%)好转,其中治愈者中有3眼(3.0%)复发;对照组91眼(94.8%)治愈,5眼(5.2%)好转,其中治愈者中有2眼(2.2%)复发,2组的治愈率、好转率、复发率比较差异均无统计学意义(P ﹥0.05)。与对照组比较,治疗组的治疗次数少,治愈时间短(P ﹤0.05)。结论皮内注射平阳霉素与肝素钠治疗睑黄瘤均安全有效,具有高治愈率和低复发率,但皮内注射盐酸平阳霉素在治疗

  4. Analysis of the efficacy of Xuebijing injection in the treatment on lung cancer patients with radiation-induced pneumonia%肺癌并发早期放射性肺炎患者采用血必净注射液治疗的疗效分析

    Institute of Scientific and Technical Information of China (English)

    羊祝奇

    2015-01-01

    目的:探讨肺癌并发早期放射性肺炎后应用血必净注射液治疗的效果。方法:2013年2月-2014年2月收治肺癌并发放射性肺炎患者52例,运用抽签法则将其平均分成对照组和研究组,各26例,对照组给予营养支持、吸氧以及激素等常规治疗;研究组在常规治疗的同时加用血必净注射液进行治疗。结果:研究组总有效率84.62%(22/26)明显大于对照组57.69%(15/26),差异有统计学意义(P<0.05)。治疗后,两组患者的IL-10、CRP、IL-6、TNF-α等指标水平均有所改善,但研究组患者改善得更加显著,差异有统计学意义(P<0.05)。结论:早期使用血必净注射液可以显著增强放射性肺炎患者的免疫功能,对炎性递质的合成产生抑制,提高机体应激能力,缓解临床症状,临床疗效值得肯定。%Objective:To investigate the efficacy of Xuebijing injection in the treatment on lung cancer patients with radiation-induced pneumonia.Methods:52 lung cancer patients with radiation-induced pneumonia were selected from February 2013 to February 2014.They were average divided into the control group and the study group using the drawing method,and there were 26 cases in each group.Patients in the control group received nutritional support,oxygen,hormones and other conventional treatment;while the patients in the observation group with conventional therapy plus Xuebijing injection treatment.Results:The total efficiency of the study group was 84.62%(22/26),which was obviously higher than that of the control group 57.69%(15/26), and the difference was statistically significant(P<0.05).After treatment,the indexes of IL-10,CRP,IL-6 and TNF-a in two groups were improved,but improvement of the study group were more significantly than the control group,and the difference was statistically significant(P<0.05).Conclusion:Early use of Xuebijing injection can significantly enhance the immune function of patients with

  5. Acupoint Injection of Onabotulinumtoxin A for Migraines

    Directory of Open Access Journals (Sweden)

    Min Hou

    2015-10-01

    Full Text Available Onabotulinumtoxin A (BoNTA has been reported to be effective in the therapy for migraines. Acupuncture has been used worldwide for the treatment of migraine attacks. Injection of a small amount of drug at acupuncture points is an innovation as compared to traditional acupuncture. The purpose of this study was to evaluate and compare the effectiveness of fixed (muscle-site and acupoint-site injections of BoNTA for migraine therapy in a randomized, double-blinded, placebo-controlled clinical trial extending over four months. Subjects with both episodic and chronic migraines respectively received a placebo (n = 19 or BoNTA (2.5 U each site, 25 U per subject injection at fixed-sites (n = 41 including occipitofrontalis, corrugator supercilii, temporalis and trapeziue, or at acupoint-sites (n = 42 including Yintang (EX-HN3, Taiyang (EX-HN5, Baihui (GV20, Shuaigu (GB8, Fengchi (GB20 and Tianzhu (BL10. The variations between baseline and BoNTA post-injection for four months were calculated monthly as outcome measures. BoNTA injections at fixed-sites and acupoint-sites significantly reduced the migraine attack frequency, intensity, duration and associated symptoms for four months compared with placebo (p < 0.01. The efficacy of BoNTA for migraines in the acupoint-site group (93% improvement was more significant than that in the fixed-site group (85% improvement (p < 0.01. BoNTA administration for migraines is effective, and at acupoint-sites shows more efficacy than at fixed-sites. Further blinded studies are necessary to establish the efficacy of a low dose toxin (25 U introduced with this methodology in chronic and episodic migraines.

  6. The staying safe intervention: training people who inject drugs in strategies to avoid injection-related HCV and HIV infection.

    Science.gov (United States)

    Mateu-Gelabert, Pedro; Gwadz, Marya Viorst; Guarino, Honoria; Sandoval, Milagros; Cleland, Charles M; Jordan, Ashly; Hagan, Holly; Lune, Howard; Friedman, Samuel R

    2014-04-01

    This pilot study explores the feasibility and preliminary efficacy of the Staying Safe Intervention, an innovative, strengths-based program to facilitate prevention of infection with the human immunodeficiency virus and with the hepatitis C virus among people who inject drugs (PWID). The authors explored changes in the intervention's two primary endpoints: (a) frequency and amount of drug intake, and (b) frequency of risky injection practices. We also explored changes in hypothesized mediators of intervention efficacy: planning skills, motivation/self-efficacy to inject safely, skills to avoid PWID-associated stigma, social support, drug-related withdrawal symptoms, and injection network size and risk norms. A 1-week, five-session intervention (10 hours total) was evaluated using a pre- versus 3-month posttest design. Fifty-one participants completed pre- and posttest assessments. Participants reported significant reductions in drug intake and injection-related risk behavior. Participants also reported significant increases in planning skills, motivation/self-efficacy, and stigma management strategies, while reducing their exposure to drug withdrawal episodes and risky injection networks. PMID:24694328

  7. Effects of adjunctive celecoxib treatment with risperidone on the cognitive function in first-episode schizophrenia patients%利培酮合并赛来昔布治疗对精神分裂症首次发病患者认知功能的影响

    Institute of Scientific and Technical Information of China (English)

    陈大春; 张向阳; 李艳丽; 杨可冰; 王宁; 聂鹰; 谭云龙; 周东丰

    2008-01-01

    目的 探讨利培酮合并赛来昔布对精神分裂症首发患者认知功能的影响.方法 符合美国精神障碍诊断与统计手册第4版诊断标准的精神分裂症首次发病(以下简称首发)住院患者90例,随机分到利培酮+赛来昔布组(研究组,46例)或利培酮+空白剂组(对照组,44例),观察治疗时间均为12周.认知功能评定使用阳性和阴性症状量表、汉密尔顿抑郁量表、威斯康星卡片分类(WCST)、重复性神经心理测查系统(RBANS).结果 治疗第12周末,研究组PANSS总分及分量表分低于对照组(P均<0.05);研究组HAMD评分低于对照组;两组患者RBANS测验总分及部分分量表评分均较基线明显提高,差异均有统计学意义(P均<0.05);WCST部分因子分均较基线有明显改善,差异均有统计学意义(P均<0.05);两组间各量表评分的差异均无统计学意义(P均>0.05).研究组男性患者的延时记忆量表分明显高于女性患者,差异有统计学意义(F=4.8;υ=1.0,38;P=0.03),且临床症状的改善与认知功能的提高存在显著相关性(P<0.05).结论 利培酮具有改善首发精神分裂症患者认知功能的作用;赛来昔布对男性患者的延时记忆有改善作用.%Objective To evaluate the effects of celecoxib added to risperidone on the cognitive function in the first-episode patients with schizophrenia.Methods Ninety inpatients with first-episode schizophrenia (DSM-IV criteria) were enrolled and assigned randomly into risperidone plus celecoxib group (46 cases) and risperidone plus placebo group (44 cases).The dosage of risperidone,starting from 2 mg/ d was adjusted according to the clinical efficacy and side-effects.The dosage of celecoxib was 200 mg/d for the first week,and maintained at 400 mg/d until the end of 12-week study.The cognitive function was rated with the Wisconsin Cards Sort Test (WCST) and Repeatable Battery for the Assessmental of Neurepsychological Status(RBANS) both at baseline

  8. Changes of serum prolactin concentration and their influencing factors before and after Risperidone treatment in acute and chronic schizophrenia%精神分裂症急性期与慢性期利培酮治疗前后血清泌乳素的变化及影响因素

    Institute of Scientific and Technical Information of China (English)

    陈若虹; 徐勇; 王勇; 方华

    2012-01-01

    Objective To investigate the changes of serum prolactin concentration and their influencing factors before and after Risperidone treatment in acute and chronic schizophrenia. Methods The serum prolactin concentration before and after Risperidone treatment in 82 acute schizophrenia and 80 chronic schizophrenia were tested, and correlation analysis was done between the serum prolactin concentration and Risperidone concentration, age, course of disease, scores of PANSS. Results ①Compared with baseline, significant decreases were showed on scores of PANSS after 8 weeks treatment in acute and chronic schizophrenia (P 0.05). ③Significant positive correlation was found between Risperidone concentration and prolactin concentration (P < 0.01); before treatment, significant negative correlation was found between prolactin concentration and total scores and positive scale scores of PANSS (P < 0.05); after 8 weeks treatment, significant positive correlation was found between difference of prolactin concentration and difference of total scores and positive scale scores of PANSS between pretherapy and post-treatment (P < 0.05 or P < 0.01). Conclusion Acute schizophrenia patients show significant higher prolactin concentration than chronic schizophrenia patients after Risperidone treatment; the changes of serum prolactin concentration in schizophrenia patients are closely related with improvement of positive symptoms, which may be used as an objective laboratory means to evaluate the clinical efficacy.%目的 探讨精神分裂症急性期与慢性期患者利培酮治疗前后血清泌乳素的变化情况及其相关影响因素.方法 分别检测82例急性精神分裂症和80例慢性精神分裂症患者利培酮治疗前后的血清泌乳素浓度,并与利培酮血浓度、年龄、病程、PANSS量表评分进行相关分析.结果 ①与治疗前比较,精神分裂症急性期组和慢性期组治疗8周末的PANSS量表评分均显著降低(P < 0.05或P < 0

  9. MUD and Self Efficacy.

    Science.gov (United States)

    Lee, Kwan Min

    2000-01-01

    Proposes a theoretical framework for analyzing the effect of MUD (Multi-User Dungeons) playing on users' self-efficacy by applying Bandura's social learning theory, and introduces three types of self-efficacy: computer self-efficacy; social self-efficacy; and generalized self-efficacy. Considers successful performance, vicarious experience,…

  10. Comparison of plasma concentration of risperidone and serum prolactin level after risperidone treatment between male and female adolescents with schizophrenia%青少年男女精神分裂症患者利培酮治疗后血药浓度与血清催乳素的比较

    Institute of Scientific and Technical Information of China (English)

    韩晓虎; 郑毅; 王红星

    2012-01-01

    目的 比较男女青少年精神分裂症患者服用利培酮后利培酮、9-羟利培酮血药浓度和血清催乳素,并探讨血药浓度与血清催乳素的关系. 方法 符合DSM-V诊断标准的精神分裂症青少年患者41例(男20例,女21例),给予利培酮治疗8周.在治疗基线和第4,8周末测定血清催乳素水平,在治疗第4,8周末监测利培酮和9-羟利培酮的血药浓度. 结果 ①血清催乳素在时间上存在主效应(P<0.001),其中第4周末、第8周末男、女患者血清催乳素水平分别与基线进行自身比较,差异有统计学意义(P<0.001);②男、女患者间血药浓度和血清催乳素水平在第4周末、第8周末进行比较,无统计学差异(P>0.05).③男、女患者利培酮(Ris)、9-羟利培酮(9oh)血药浓度与血清催乳素存在正相关(男:4周末PRis<0.01、P9oh<0.01;8周末PRis<0.01、P9oh <0.05;女:4周末PRis>0.05、P9oh <0.01,8周末PRis<0.05、P9oh<0.01). 结论 ①利培酮能明显升高青少年患者血清催乳素水平;其血药浓度越高,催乳素水平也越高;②性别对血药浓度和血清催乳素水平无影响.%Objective To compare the plasma concentrations of risperidone,9-hydroxyrisperidone and serum prolactin levels after risperidone treatment between the male and female adolescents with schizophrenia, and to explore their relations. Methods A total of 41 patients(20 male and 21 female) met the DSM-IV criteria for schizophrenia. The patients were given risperidone for 8 weeks. Serum prolactin, plasma concentrations of risperidone and 9-hydroxyrisperidone were obtained at the baseline,at the end of 4th and 8th week. Results ?Serum prolactin had a significant main effect on the time of taking medicine ( P 0. 05). (5)In the male and female, serum prolactin was positively correlated with plasma concentration of risperidone( Ris) and 9-hydroxyrisperidone(9oh) ( male; at the end of 4th week PRis 0.05 and P9oh < 0.01; at the end of

  11. Epidural steroid injection for lumbosacral radiculopathy

    Energy Technology Data Exchange (ETDEWEB)

    Sung, Mi Sook [The Catholic University of Korea, Pucheon (Korea, Republic of)

    2006-06-15

    Low back pain combined with radicular pain remains as one of the most challenging musculoskeletal problems for its therapeutic management. This malady results from nerve root impingement and/or inflammation that causes neurologic symptoms in the distribution of the affected nerve root(s) Conservative treatment, percutaneous spine interventions and surgery have all been used as treatment; and the particular treatment that's chosen depends on the severity of the clinical and neurologic presentation. In 1930, Evans reported that sciatica could treated by epidural injection. The use of epidural corticosteroid injections for the treatment of axial and radicular back pain was first reported in 1953. Epidural steroid injections are currently used by many medical professionals for the treatment of lumbosacral radiculopathy. Performing 'blind' epidural steroid injection lacks target specificity that often results in incorrect delivery of medication to the lesion. Imaging-guided steroid injections are now becoming more popular despite the controversy regarding their efficacy. Many reports, including a few randomized controlled trials, have documented the clinical utility of epidural steroid injections.

  12. Epidural injections for back pain

    Science.gov (United States)

    ESI; Spinal injection for back pain; Back pain injection; Steroid injection - epidural; Steroid injection - back ... pillow under your stomach. If this position causes pain, you either sit up or lie on your ...

  13. Treatment of lipoma by injection lipolysis.

    Science.gov (United States)

    Nanda, Soni

    2011-05-01

    Injection lipolysis or lipodissolve is the practice of injecting phosphatidyl choline/ sodium deoxycholate (PDC/DC) compounds in the subcutaneous fat. Though this practice is being used extensively for nonsurgical contouring of body and dissolving localized collections of excess fat, it's use as a treatment modality for lipomas needs further evaluation. We present a case where this technique was used for treating a lipoma, with no recurrence after 9 months of follow up. Injection lipolysis as a treatment modality for lipomas needs to be evaluated for safety and efficacy in trials on larger population. This could prove to be a very valuable adjunct to the current practice of excision, if done by a trained person in a properly selected patient. Also the side effects and the controversies regarding this procedure have been discussed in detail in the present paper.

  14. The efficacy of hyperbaric oxygen combined with Xingnaojing injection in the treatment of viral meningitis in children%高压氧联合醒脑静注射液对小儿病毒性脑膜炎的疗效

    Institute of Scientific and Technical Information of China (English)

    林传琼

    2015-01-01

    目的:探讨高压氧联合醒脑静注射液对小儿病毒性脑膜炎运动功能及智力发育的影响。方法:选取我院收治的小儿病毒性脑膜炎患儿68例,随机分为观察组和对照组各34例,观察组给予高压氧联合醒脑静注射液治疗,对照组仅给予醒脑静注射液治疗。比较两组患儿运动功能及智力发育的改善情况。结果:两组患者治疗后上肢、下肢 FMA评分较治疗前均有明显改善,且观察组优于对照组;两组患者5个功能区发育商均有改善,观察组精细动作、适应能力、语言和社交能力发育商明显高于对照组。差异均有统计学意义。结论:高压氧联合醒脑静注射液治疗小儿病毒性脑膜炎,可明显提高患儿的运动功能及智力发育,提高生活质量。%Objective: To investigate the efficacy of hyperbaric oxygen combined with Xingnaojing injection on the motor function and intelligence development of children with viral meningitis. Methods: Sixty-eight cases of children with viral meningitis in our hospital were randomly divided into an observation group and a control group with 34 cases each. Hyperbaric oxygen combined with Xingnaojing injection was given in the observation group while only Xingnaojing injection in the control group. The improvement of motor function and intelligence development were compared between two groups. Results: The FMA scores for upper and lower limbs in two groups were significantly improved after the treatment, and were much higher in the observation group than in the control group. The developmental quotient (DQ) of 5 function areas was all improved, however, DQ of fine motor, adaptive capacity, language and social skills was significantly higher in the observation group than in the control group. All the differences were statistically significant. Conclusion: Hyperbaric oxygen combined with Xingnaojing injection in the treatment of children with viral meningitis can

  15. Efficacy of medical ozone injection combined with silver needle therapy in the treatment of patients with lumbar intervertebral disc herniation%医用三氧联合银质针治疗腰椎间盘突出症的疗效

    Institute of Scientific and Technical Information of China (English)

    杨义忠; 武志宏; 崔红艳; 刘天宝; 武君麟

    2015-01-01

    目的 评价医用三氧联合银质针治疗腰椎间盘突出症的疗效.方法 选择腰椎间盘突出症(L3 ~S1)患者150例,采用C型臂引导下医用三氧盘内、外注射联合银质针松解术治疗腰椎间盘突出症.医用三氧盘内、外注射治疗后,次日用银质针松解术治疗,两种治疗每周各做1次,3次为1个疗程.分别于治疗前及治疗后l周采用视觉模拟评分法(VAS)进行疼痛评估,并按改良MacNab法评估疗效,比较病程在3个月以内与3个月以上患者的疗效.结果 治疗1个疗程后1周,所有患者VAS值显著低于治疗前(P<0.05).病程3个月以内患者优良率为98.3%(113/115例),显著优于病程3个月以上组优良率77.1%(27/35例)(P<0.05).结论 三氧联合银质针治疗早期的、病程较短的腰椎间盘突出症疗效显著.%Objective To evaluate the efficacy of medical ozone injection combined with silver needle therapy in the treatment of patients with lumbar intervertebral disc herniation.Methods One hundred and fifty patients with lumbar intervertebral disc herniation (L3~S1) were received medical ozone intra-and out-discal injection guided by C-arm, combined with silver needle release.Medical ozone injection was followed by silver needle release in the next day, once in a week, 3 times in a course.Visual analogue scale (VAS) was used to evaluate the pain degree before and at one week after treatment.The treatment results were evaluated by modified MacNab method and the effect of disease course between 3 months and more than 3 months was compared.Results One week after the treatment, VAS of all patients was significantly lower than that before treatment (P< 0.05).The excellent and good rate in patients with disease course of less than three months 98.3% (113/115) was significantly better than that in the patients with course of more than 3 months 77.1% (27/35 cases) (P< 0.05).Conclusion Medical ozone injection combined with silver needle therapy

  16. THE CLINICAL EFFICACY OF INTRADISCAL OZONE INJECTION COMBINED WITH RADIOFREQUENCY THERMOCOAGULATION TECHNOLOGY IN THE TREATMENT OF CERVICAL DISC HERNIATION%CT引导下臭氧联合经皮射频热凝注射治疗颈椎间盘突出症

    Institute of Scientific and Technical Information of China (English)

    周伶; 李荣春

    2012-01-01

    目的:观察经皮穿刺盘内臭氧髓核化学溶解联合射频热凝治疗颈椎间盘突出症的临床效果.方法:颈椎间盘突出症患者528例,分为臭氧组264例,臭氧+射频组264例.均在CT引导下经颈前血管鞘和气管鞘之间穿刺入椎间盘髓核或突出物靶点.臭氧组每个盘内注射浓度为50 μg/ml的臭氧4ml.臭氧+射频组盘内注射浓度为50 μg/ml的臭氧后再行髓核或/和突出物射频热凝,设定最高温度为90℃,时间为4个周期.观察治疗后各个时期的疼痛视觉模拟评分(visual analoguescale,VAS)以及临床效果.记录治疗过程中及治疗后的并发症.结果:治疗后不同时期(24小时、1周、1个月、3个月及6个月)疼痛VAS评分与术前相比显著改善.且臭氧+射频组在治疗后3个月及6个月的VAS评分较臭氧组明显降低.治疗后6个月,臭氧组优良率为80.3%,臭氧+射频组优良率为86.5%.无一例发生严重并发症.结论:CT引导下经皮穿刺臭氧髓核化学溶解联合射频热凝是治疗颈椎间盘突出症有效的方法之一.%Objective: To observe the clinical efficacy of intradiscal ozone (O3) injection combined with radiofrequency (RF) thermocoagulation for the treatment of cervical disc hemiation. Methods: 528 patients with cervical disc herniation were randomly and evenly divided into two groups: O3 group (264 cases) and O3+RF group (264 cases). Under CT guiding, the needles were inserted into the nucleus pulposus and/or targets of cervical intervetebral disc through the path between anterior jugular tracheal sheath and vagina vasorum. In the O3 group, each disc was injected with ozone 50μg/ml (4 ml). In the O3+RF group, after injection of ozone 50μg/ml (4 ml), RF thermocoagulation was performed within nucleus pulposus and/or targets with the highest temperature of 90°C for 4 cycles. The VAS scores and complications were recorded at 24 h, 1 w, 1 month, 3 months and 6 months after treatment. Results: Compared with

  17. Efficacy and Safety of Sofren Injection Plus Fondaparinux Sodium for Lower Extremity Deep Venous Thrombosis in Elderly Bedridden Patients After Fractures%大株红景天注射液联合磺达肝葵钠防治老年骨折卧床患者下肢深静脉血栓的疗效观察

    Institute of Scientific and Technical Information of China (English)

    梁莉萍; 艾江平

    2015-01-01

    【目的】探讨大株红景天注射液联合磺达肝葵钠预防老年骨折卧床患者下肢深静脉血栓形成(DVT )的临床疗效。【方法】选择本院100例长期卧床的老年骨折患者(≥60岁),将其随机分为观察组( n =50)和对照组( n =50)。每组均皮下常规注射抗凝剂磺达肝葵钠,每日一次,治疗10 d ,观察组则在常规治疗的基础上,静脉滴注大株红景天注射液,每日一次,治疗10 d 。【结果】治疗10 d 后,观察组双下肢轻度肿胀发生率较对照组高,重度肿胀发生率低于对照组,双下肢重度疼痛发生率较对照组低,差异均有统计学意义(均 P <0.05)。对照组 DVT 发生率为10%,死亡率为4%,而观察组患者均未发生下肢 DVT ,差异具有统计学意义( P <0.05)。【结论】大株红景天注射液联合磺达肝葵钠可安全、有效的防治老年因骨折卧床患者 DVT 。%Objective]To explore the efficacy and safety of treating lower extremity deep venous thrombo‐sis (DVT ) with Sofren Injection plus fondaparinux sodium in elderly bedridden patients after fractures .[Methods] A total of 100 elderly bedridden patients after fractures were randomized into observation ( n = 50) and control ( n = 50) groups .A daily subcutaneous injection of conventional anticoagulant fondaparinux sodi‐um was administered for a 10‐day course in both groups while the observation group received additionally an in‐travenous drip of Sofren Injection for another 10‐day course .[Results] After treatment ,the incidence of mild swelling of lower extremity was higher while that of severe swelling lower in observation group than control group .And the differences were statistically significant (both P < 0 .05) .The incidence of DVT was 10% and the mortality rate 4% in control group .And no DVT occurred in observation group .There were statistically significant differences .[Conclusion] Sofren

  18. 利培酮片合用舒肝解郁胶囊对阴性症状为主精神分裂症患者认知功能的影响%The Effect of Risperidone Combined with Shuganjieyu Capsule on Cognitive Function of Schizophrenics with Negative Symptoms

    Institute of Scientific and Technical Information of China (English)

    成军; 李红; 石玉中; 宁夔; 张美霞; 杨淑珍; 王丽娜; 华婷婷; 李静

    2013-01-01

    目的 比较单用利培酮片以及利培酮片合用舒肝解郁胶囊对阴性症状为主的精神分裂症患者认知及社会功能的影响及差异.方法 采用阳性与阴性症状量表(PANSS)评定精神症状,威斯康星卡片分类测验(WCST)、连线测验(TMT)、大体功能评定量表(GAF)评定患者的认知及大体功能.结果 入组8周合用组正确应答数、错误应答数、持续错误数、完成分类数、TMT-A及TMT-B完成时间、GAF分数(t=-3.117,2.851,2.870,-3.344,12.377,8.988,-18.308;P均<0.01),单用组TMT-A及TMT-B完成时间、GAF评分(t=8.930,7.170,-18.976;P均<0.001),与入组时比较差异有统计学意义;入组8周3组间正确应答数、错误应答数、持续错误数、完成分类数、TMT-A及TMT-B完成时间差异均有统计学意义(F=6.425,5.456,3.066,6.006,3.285,136.141,P均<0.05),合用组正确应答数、GAF分数高于单用组,持续错误数、TMT-B完成时间低于单用组,差异均有统计学意义(P<0.05).结论 利培酮片合用舒肝解郁胶囊对阴性症状为主的精神分裂症患者认知功能的改善优于单用利培酮片治疗.%Objective To compare the efficacy produced by risperidone alone and risperidone combined with shuganjieyu capsule on cognitive and social function of schizophrenics with negative symptoms. Methods Positive and Negative Syndrome Scale for schizophrenia was adopted to evaluate the efficacy of schizophrenics. Wisconsin Card Sorting Test,Trail Making Test,Global Assessment Function were adopted to analyze the influence on cognitive and social function of schizophrenics after treatment. Results Patients in combination group at eight weekends had lower scores of number of error response,sustained error response,time of link,and higher scores of global assessment function and true response,accomplish classes than those at pre —treatment(t=2. 851, 2. 870,12. 377,8. 988,-3. 117,-3. 344;P<0. 01). Patients in alone group at eight weekends

  19. Injection moulding antireflective nanostructures

    DEFF Research Database (Denmark)

    Christiansen, Alexander Bruun; Clausen, Jeppe Sandvik; Mortensen, N. Asger;

    We present a method for injection moulding antireflective nanostructures on large areas, for high volume production. Nanostructured black silicon masters were fabricated by mask-less reactive ion etching, and electroplated with nickel. The nickel shim was antistiction coated and used in an...... injection moulding process, to fabricate the antireflective surfaces. The cycle-time was 35 s. The injection moulded structures had a height of 125 nm, and the visible spectrum reflectance of injection moulded black polypropylene surfaces was reduced from 4.5±0.5% to 2.5±0.5%. The gradient of the refractive...

  20. Urinary incontinence - injectable implant

    Science.gov (United States)

    ... repair; ISD repair; Injectable bulking agents for stress urinary incontinence ... Blaivas JM, Gormley EA, et al. Female Stress Urinary Incontinence Update Panel of the American Urological Association Education ...

  1. Clinical efficacy observation of nitroglycerin,dopamine and dobutamine pumped by micro-Injection pump in the treatment of refractory heart failure%微量注射泵泵入硝酸甘油、多巴胺、多巴酚丁胺治疗难治性心力衰竭的临床效果观察

    Institute of Scientific and Technical Information of China (English)

    夏清德; 王军香; 陈育山; 毛润芝; 蒋均仕

    2015-01-01

    目的:观察应用微量注射泵泵入硝酸甘油、多巴胺、多巴酚丁胺治疗难治性心力衰竭的临床疗效。方法选择2011年1月~2014年1月本院102例心功能Ⅲ~Ⅳ级(NYHA分级法)的住院患者,在卧床休息、控制饮食、吸氧、强心剂及利尿剂治疗的基础上,应用微量注射泵泵入硝酸甘油、多巴胺、多巴酚丁胺,疗程3~5d,观察患者临床症状、体征、心功能改善情况。结果102例患者用药后临床症状和心功能各项参数均明显改善,与治疗前比较,差异有统计学意义(P<0.05)。结论应用微量泵泵入硝酸甘油、多巴胺、多巴酚丁胺治疗难治性心力衰竭患者疗效明显,安全可靠。%Objective To observe the clinical efficacy of nitroglycerin,dopamine and dobutamine pumped by micro-in-jection pump for the treatment of refractory heart failure. Methods 102 hospitalized patients with Grade Ⅲ to Ⅳ(NY-HA grading method) heart function in our hospital from January 2011 to January 2014 were selected and given nitro-glycerin, dopamine and dobutamine pumped by micro-injection pump on the basis of bed rest,diet control,oxygen up-take,cardiotonic and diuretic therapy.The course of treatment was 3 to 5 days.The patients’ clinical symptoms,body signs and cardiac function improvement situation were observed. Results All 102 patients’ clinical symptoms and car-diac function parameters improved significantly after medication.Compared with before treatment,the difference was sta-tistically significant (P<0.05). Conclusion Nitroglycerin,dopamine and dobutamine pumped by micro-injection pump is significantly effective,safe and reliable for the treatment of refractory heart failure.

  2. Effect of caudal epidural steroid or saline injection in chronic lumbar radiculopathy: multicentre, blinded, randomised controlled trial

    DEFF Research Database (Denmark)

    Iversen, Trond; Solberg, Tore K; Romner, Bertil;

    2011-01-01

    To assess the efficacy of caudal epidural steroid or saline injection in chronic lumbar radiculopathy in the short (6 weeks), intermediate (12 weeks), and long term (52 weeks).......To assess the efficacy of caudal epidural steroid or saline injection in chronic lumbar radiculopathy in the short (6 weeks), intermediate (12 weeks), and long term (52 weeks)....

  3. Treatment of posttraumatic stress disorder - related nightmares and other sleep disturbances with risperidone in combat veterans and victims of domestic and childhood abuse

    Directory of Open Access Journals (Sweden)

    Nina Khachiyants

    2010-09-01

    Full Text Available Sleep disturbances including nightmares are often reported as hallmark of posttraumatic stress disorder (PTSD. The literature related to the pharmacological treatment of PTSD-related nightmares is sparse and inconclusive. After reviewing the literature it was obvious that currently a limited data on studies supporting the use of antipsychotic medications for the treatment of PTSD are published. Moreover, even more limited scientific evidence is now available to formulate evidence-based guidelines for the treatment of PTSD-related nightmares which are often reported as the most intrusive and disruptive symptom. Objective for this study is to review comprehensively the current research literature which reflects use of antipsychotic medication risperidone for the treatment of PTSD-related nightmares of different etiology.

  4. Bone marrow injection: A novel treatment for tennis elbow

    OpenAIRE

    Singh, Ajit; Gangwar, Devendra Singh; Singh, Shekhar

    2014-01-01

    Objective: The objective of this prospective study was assessment of efficacy of bone marrow aspirate (BMA) (containing plasma rich in growth factors and mesenchymal stem cells) injection in treatment of tennis elbow. Materials and Methods: A total of 30 adult patients of previously untreated tennis elbow were administered single injection of BMA. This concentrate was made by centrifugation of iliac BMA at 2000 rpm for 20-30 min and only upper layer containing platelet rich plasma and mononuc...

  5. Separably injective Banach spaces

    CERN Document Server

    Avilés, Antonio; Castillo, Jesús M F; González, Manuel; Moreno, Yolanda

    2016-01-01

    This monograph contains a detailed exposition of the up-to-date theory of separably injective spaces: new and old results are put into perspective with concrete examples (such as l∞/c0 and C(K) spaces, where K is a finite height compact space or an F-space, ultrapowers of L∞ spaces and spaces of universal disposition). It is no exaggeration to say that the theory of separably injective Banach spaces is strikingly different from that of injective spaces. For instance, separably injective Banach spaces are not necessarily isometric to, or complemented subspaces of, spaces of continuous functions on a compact space. Moreover, in contrast to the scarcity of examples and general results concerning injective spaces, we know of many different types of separably injective spaces and there is a rich theory around them. The monograph is completed with a preparatory chapter on injective spaces, a chapter on higher cardinal versions of separable injectivity and a lively discussion of open problems and further lines o...

  6. Perceptions of injections

    International Nuclear Information System (INIS)

    Based on interviews with experts in the petroleum and natural gas exploration industry and results of a workshop insight is given into the attitudes, opinions and perceptions on the possibility to store wastes from the exploration activities in the deep underground, e.g. by means of injection. In a separate report a comparison is made on injection and other waste processing options

  7. Spin injection into semiconductors

    Science.gov (United States)

    Oestreich, M.; Hübner, J.; Hägele, D.; Klar, P. J.; Heimbrodt, W.; Rühle, W. W.; Ashenford, D. E.; Lunn, B.

    1999-03-01

    The injection of spin-polarized electrons is presently one of the major challenges in semiconductor spin electronics. We propose and demonstrate a most efficient spin injection using diluted magnetic semiconductors as spin aligners. Time-resolved photoluminescence with a Cd0.98Mn0.02Te/CdTe structure proves the feasibility of the spin-alignment mechanism.

  8. [Intra-articular injections].

    Science.gov (United States)

    Chapelle, Ch

    2015-09-01

    It is not unusual for a specialist or general practitioner to be presented with a pathology which necessitates the use of an intra-articular injection of corticosteroids, hyaluronic acid or a local anaesthetic. It would seem to be interesting to update and to precise the techniques and methods of intraarticular injections which have appeared in recent international publications, when we know that 30 % of the injections given into the knee and so called "dry" are incorrect and, therefore, inefficient. The indication of an articular injection depends, firstly, on the diagnosis which should be done with great care; after which should be an objective analysis complete with secondary effects linked to both the injection and the product used. The conditions of asepsis, the choice of needles and quantities of the injection and even the ways of the injections should be reviewed in detail. The last studies clearly question the secondary effects of the cartilage degradations of the cortisone given as an intra-articular injection and shows its efficiency on the pain and inflammatory phenomonen in osteoarthritis. Studies on hyaluronic acid are often contradictory going from a modest result to an important pain relief but it is necessary to be aware that the objective criteria are difficult to interpret. The use of local anaesthetics in intra-articular is limited by the few indications in view of the major risk of aggravating the pre-existing lesions by the disappearing signs of pain.

  9. 参附注射液治疗乳腺癌术后化疗致白细胞减少的临床疗效及安全性评价%Clinical efficacy and safety of Shenfu injection in the treatment of leukopenia induced by chemotherapy after surgery of breast cancer

    Institute of Scientific and Technical Information of China (English)

    刘丽娜; 邱阚; 种宝贵; 杨书山; 支振东; 尹长恒

    2015-01-01

    Objective To evaluate the clinical efficacy and safety of Shenfu injection in the treatment of leukopenia induced by chemotherapy docetaxel, epirubicin and cyclophosphamide adjuvant chemotherapy ( TEC chemotherapy) after surgery of breast cancer.Methods A total of 106 patients with breast cancer were randomly divided into control group ( n=53 ) and treatment group ( n =53 ) .Control group was re-ceived 75 mg・ m-2 docetaxel, intravenous infusion on day 1 +50 mg・ m-2 epirubicin, intravenous infusion on day 1 +500 mg・ m-2 cy-clophosphamide, intravenous infusion on day 1, 3 weeks for a course. Treatment group was given 50 mL Shenfu injection added 500 mL of 5%glucose intravenous infusion and plus the treatment of control group, 1 to 10 days for a course.Patients of two groups were received 2 courses of treatment.The clinical efficacy, the incidence of leukopenia, white blood cell count to improve the rate and quality of life before and after treatment, and adverse drug reactions in two groups were compared.Results After treatment, total effective rate in treatment group was significantly higher than that in control group (84.91%vs 69.81%, P<0.05).After treatment 7,10 d, leukopenia rates in treatment group were 9.43%and 11.32%, significantly lower than 37.74%and 30.19%in control group (P<0.05).After treatment, the white blood cell count in the two groups all decreased than those before treatment, and the degree of decline in treatment group was higher than that in control group (P<0.05).After treatment, the rate of improvement of quality of life in treatment group was significantly higher than that in control group (88.68%vs 54.72%, P<0.05).The incidence of adverse drug reactions in treatment group was significantly lower than that in control group ( P<0.05).Conclusion Shenfu injection has a definitive clinical efficacy for the treatment of chemotherapy-induced leukopenia, which may improve immune function and the quality of life, worthy of further promotion in

  10. Efficacies of cerebrospinal fluid replacement combined with intrathecal injection of different drugs in treatment of craniotomy patients with postoperative intracranial infections%开颅手术后颅内感染患者脑脊液置换联合不同药物鞘内注射治疗的疗效研究

    Institute of Scientific and Technical Information of China (English)

    单小松; 丁亚楠; 王冀伟; 杜磊; 刘海鹏

    2015-01-01

    OBJECTIVE To compare the efficacies of the cerebrospinal fluid replacement combined with intrathecal injection of difference drugs in the treatment of the patients with postoperative intracranial infections undergoing craniotomy so as to provide guidance for effective treatment .METHODS A total of 86 patients with postoperative intracranial infections who underwent the craniotomy from Mar 2010 to Sep 2014 were recruited as the study objects and randomly divided into the observation group and the control group , with 43 cases in each . The observation group was treated with the cerebrospinal fluid replacement combined with intrathecal injection of vancomycin and dexamethasone ,while the control group was given the cerebrospinal fluid replacement combined with intravenous drip of ceftriaxone ;the clinical efficacies ,incidence of adverse reactions ,and changes of cerebro‐spinal fluid test indicators were observed and compared between the two groups of patients .RESULTS The total ef‐fective rate of treatment was 90 .70% in the observation group ,76 .74% in the control group ,and there was sta‐tistically significant difference between the two groups (P<0 .05) .The incidence of adverse reactions was 4 .64%in the observation group ,6 .96% in the control group ,with statistical significance (P<0 .05) .All the indicators for the cerebrospinal fluid routine examination of the two groups of patients were improved except for the chlo‐rides ,and the difference was statistically significant (P< 0 .05) .There was statistically significant difference in the test indicators of the cerebrospinal fluid between the two groups of patients (P<0 .05) .CONCLUSION The ce‐rebrospinal fluid replacement combined with intrathecal injection of vancomycin and examethasone may improve the clinical efficacy and reduce the incidence of adverse reactions ,and it is worthy to be promoted in the hospital .%目的:对比开颅手术后颅内感染患者脑脊液置换联合不同药物鞘

  11. Study on the clnical efficacy of epidural injection of methylene blue compound solution used for remission of cancer pain and neuropathic cancer pain%亚甲蓝硬膜外镇痛对癌痛及伴发神经病理性疼痛的疗效观察

    Institute of Scientific and Technical Information of China (English)

    李春香; 乔三福

    2016-01-01

    )in comparison with that of neuropathic cancer pain group(20 patients). In comparison to the dosage used before methylene blue compound solution was injected, the dosage of analgesic was decreased respectively,more than 60% vs. 25% ~ 50% in cancer pain group and neuropathic cancer pain group. The dosage interval was significantly longer,and it was effective by using general oral administration of analgesic when dull pain occured in cancer pain group. The duration of analgesic was more than 1 month vs 12 ~ 18 days in cancer pain group and neuropathic pain group respectively. Nausea, vomiting,hypotension,respiratory depression,change in heart rate and other symptoms did not appear in all 40 cases. Urine,diet and activity of lower limbs were normal. Conclusion The application of methylene blue compound solution by epidural injection had evident clinical efficacy and safety in treatment of patients with advanced cancer pain,since no significant complication had been observed. It would be better analgesic efficacy if methylene blue compound solution used before the cancer pain complicated by neuropathic cancer pain.

  12. 替吉奥联合康艾注射液治疗晚期非小细胞肺癌的疗效与安全性%Efficacy and safety of S-1 combined with Kang'ai injection in the treatment of advanced non-small cell lungcancer

    Institute of Scientific and Technical Information of China (English)

    杨君; 郭晓辉; 汪力慧

    2016-01-01

    Objective To investigate the efficacy and safety of S-1 combined with Kang'ai injection in the treatment of advanced non-small cell lung cancer (NSCLC). Methods This retrospective study included 118 patients from January 2009 to March 2015 with the failure of one or more regimens of systemic chemotherapy. The control group included 22 patients given the necessary supportive treatment. The chemotherapy groups were divided into S-1 group and combined treatment group, with 48 cases in each group. Patients in S-1 group received oral S-1 (80 mg/m2) in two divided doses daily. Based on chemotherapy, the combined treatment group applied Kang'ai injection 60 mL in 5%glu-cose or 0.9%sodium chloride injection 250 mL, intravenous drip once daily. S-1 was administered orally for 28 consecu-tive days, followed by a 14-day rest period. The overall survival (OS), progression free survival (PFS), objective re-sponse rate (ORR) and disease control rate (DCR) were observed and compared. The adverse reactions were analyzed and quality of life was assessed. Results The median OS of the control group and the chemotherapy groups were 6.0 months and 11.0 months, and the median PFS were 11.0 months and 3.5 months, respectively (P<0.001). The ORR of che-motherapy groups were 8.3%(4/48) and 10.4%(5/48) (P=0.728), and the DCR were 37.5%(18/48) and 47.9%(23/48) (P=0.305), respectively. The adverse reactions were generallyⅠ~Ⅱdegree. The degree of leukopenia, anemia, anorex-ia, diarrhea and fatigue in S-1 group was more significant than those in the combined treatment group, with statistically significant difference (P<0.05). The improvement of quality of life in chemotherapy groups was significantly higher than that in control group (P<0.001). And the improvement of quality of life in the combined treatment group was higher than that in S-1 group, and the difference was statistically significant (P=0.042). Conclusion S-1 monotherapy is effica-cious with acceptable toxicity in the treatment

  13. 丹红注射液对急性脑梗死患者sCD40L及超敏C-反应蛋白的影响%Efficacy of Danhong injection for patients with acute stage of cerebral infarction and its effects on serum sCD40L and hs-CRP levels

    Institute of Scientific and Technical Information of China (English)

    沈壮虹; 宋水江

    2013-01-01

    Objective To evaluate efficacy of Danhong injection for patients with acute stage of cerebral infarction and its effects on serum levels of soluble CD40 ligand (sCD40L) and high-sensitivity C-reactive protein(hs-CRP). Methods Ninety two patients with acute ischemic cerebral infarction were randomly assigned to receive Danhong injection (30ml/d, i.v drip, for 14d) in addition to routine treatment (Danhong group) or routine treatment only(control group).Serum sCD40L and hs-CRP were mea-sured, and Barthel index (BI) and Chinese stroke Scale (CSS) were assessed before and after treatment in both groups. Results The levels of sCD40L and hs-CRP were deceased after treatment in both groups, however, the levels in Danhong group were significantly lower than those in control group (P<0.05). The scores of CSS and BI of two groups were improved after treatment, while scores in Danhong group were better than those in control group (P<0.05). Conclusion Danhong injection can decrease serum levels of sCD40L and hs-CRP and improve the recovery of neural function for patients with acute cerebral infarction.%  目的探讨步长丹红注射液对急性脑梗死患者血清可溶性白细胞分化抗原40配体(sCD40L)及超敏 C-反应蛋白(hs-CRP)的影响及临床疗效。方法92例急性脑梗死患者分为两组,即常规治疗组和丹红治疗组,丹红治疗组在常规治疗基础上给予步长丹红注射液30ml 溶于0.9%氯化钠注射液250ml,1次/d,静脉滴注,共14d。治疗前后测定血 sCD40L 及 hs-CRP 的变化,并用中国卒中量表(CSS)及巴氏指数(BI)评定。结果两组患者 sCD40L 及 hs-CRP 均下降,丹红治疗组均明显低于常规治疗组(均 P<0.05)。治疗后两组 CSS 及 BI 评分较治疗前均明显增加,丹红治疗组均高于常规治疗组(均 P<0.05)。结论步长丹红注射液可降低急性脑梗死患者 sCD40L 及 hs-CRP 的水平,有益于患者神经功能的恢复。

  14. Autologus Blood Injection for Recurrent Lateral Epicondylitis

    Directory of Open Access Journals (Sweden)

    M. Dehghani, M.D.

    2007-09-01

    Full Text Available Background and purpose: Tennis elbow is a common complaint. Several treatment strategies, such as corticosteroid injections and physical terapy and braces have been described with no predictable efficacy. The purpose of this study was to evaluate prospectively the result of refractory lateral epicondylitis with autologus blood injections.Materials and Methods: Twenty two patients with lateral epicondylitis were injected with 2 mL of autologous blood under the extensor carpi radialis brevis. All patients had failed the two previous non surgical treatments including all or combination of physical therapy, splintinge, non steroidal anti-inflammatory medication and prior steroid injection. The patients were evaluated with patient-rated Tennis Elbow Evaluation (PRTEE.Results: The average fallow-up period was 7.3 months (range, 4-10mo. After autologus blood injection, the average pain score decreased from 43.7 to 9.1 (P-value < 0.001. The average functional score decreased from 42.4 to 10.1 (P-value <0.001.Conclusion: On the basis of this study, this minimally invasive treatment advocates refractory Tennis elbow.

  15. Summary data of potency and parameter information from semi-mechanistic PKPD modeling of prolactin release following administration of the dopamine D2 receptor antagonists risperidone, paliperidone and remoxipride in rats.

    Science.gov (United States)

    Taneja, Amit; Vermeulen, An; Huntjens, Dymphy R H; Danhof, Meindert; De Lange, Elizabeth C M; Proost, Johannes H

    2016-09-01

    We provide the reader with relevant data related to our recently published paper, comparing two mathematical models to describe prolactin turnover in rats following one or two doses of the dopamine D2 receptor antagonists risperidone, paliperidone and remoxipride, "A comparison of two semi-mechanistic models for prolactin release and prediction of receptor occupancy following administration of dopamine D2 receptor antagonists in rats" (Taneja et al., 2016) [1]. All information is tabulated. Summary level data on the in vitro potencies and the physicochemical properties is presented in Table 1. Model parameters required to explore the precursor pool model are presented in Table 2. In Table 3, estimated parameter comparisons for both models are presented, when separate potencies are estimated for risperidone and paliperidone, as compared to a common potency for both drugs. In Table 4, parameter estimates are compared when the drug effect is parameterized in terms of drug concentration or receptor occupancy. PMID:27617278

  16. 氯氮平与维思通对精神分裂患者血糖影响的比较%Different effects of clozapine and risperidone on levels of blood glucose in patients with schizophrenia

    Institute of Scientific and Technical Information of China (English)

    曹栋; 谢世平

    2001-01-01

    Objective To investigate the different effects of clozapine and risperidone on levels of blood glucose in patients with schizophrenia. Method 200 qualified cases selected from psychiatric department were divided into two groups randomly, of which 100 cases accepted the treatment with clozapine and the other 100 cases with risperidone. Blood glucose tests were used before treatment ,4 weeks after treatment and 8 weeks after treatment Results There was significantly higher blood glucose level in clozapine- treated group than in risperidone- treated group after 4 or 8 weeks treatment. The number of cases who had elevated blood glucose level (>6.1 mmol/L) in clozapine- treated group was significantly more than in risperidone- treated group. Conclusion The glucoregulatory abnormality which leads to glucose elevation in clozapine- treated patients is greater than in risperidone- treated patients. Additional motivation to clinical monitor for antipsychotic treatment- related hyperglycemia is indicated.

  17. A Novel Injective Approach For Osgood-schlatter Disease

    Science.gov (United States)

    Nakase, Junsuke; Numata, Hitoaki; Oshima, Takeshi; Takata, Yasushi; Tsuchiya, Hiroyuki

    2016-01-01

    Objectives: Despite first being reported more than 100 years ago, Osgood-Schlatter disease(OSD) currently has no effective treatment. The recent use of ultrasonography in the orthopedic surgery and sports medicine fields revealed that patellar tendinopathy and deep infrapatellar bursitis contributes to the pain experienced by patients with OSD. Considering the reported effectiveness and safety of hyperosmolar dextrose injection for patellar tendinopathy, here we investigated the efficacy and safety of hyperosmolar dextrose injection as a novel treatment for OSD. Our hypothesis was that hyperosmolar dextrose injection would be safe and well tolerated by patients with OSD. Methods: We performed this prospective randomized double-blind clinical trial between April 2012 and June 2015. A total of 44 knees in 36 boys (average age, 12.3 ± 1.1 years) for whom conventional conservative therapy for >1 month was ineffective were randomly assigned to the double-blind injection of 1% lidocaine (1 mL) with saline (1 mL) (Saline group) or 1% lidocaine (1 mL) with 20% dextrose (1 mL) (Dextrose group). Half of the solution was injected into the distal attachment of the patellar tendon, while the remaining half was injected into the deep infrapatellar bursa or infrapatellar fat pad under ultrasound guidance. Injections were administered monthly for 3 months by a single investigator. The Victorian Institute of Sport Assessment (VISA) score was used to evaluate pain. Results: A total of 40 knees in 33 boys were included in this clinical trial. The mean pre-injection VISA scores of the Dextrose and Saline groups were 59.6 ± 19.1 and 62.5 ± 16.6, while those at the final follow-up were 83.6 ± 19.3 and 84.1 ± 19.1, respectively. There were no significant differences in the two group pre-injection versus at the final follow-up (P = 0.61 and 0.93, respectively). In contrast, the mean VISA score significantly increased in both group between pre-injection and final follow-up (P < 0

  18. Differential long-term effects of haloperidol and risperidone on the acquisition and performance of tasks of spatial working and short-term memory and sustained attention in rats.

    Science.gov (United States)

    Hutchings, Elizabeth J; Waller, Jennifer L; Terry, Alvin V

    2013-12-01

    A common feature of the neuropsychiatric disorders for which antipsychotic drugs are prescribed is cognitive dysfunction, yet the effects of long-term antipsychotic treatment on cognition are largely unknown. In the current study, we evaluated the effects of long-term oral treatment with the first-generation antipsychotic haloperidol (1.0 and 2.0 mg/kg daily) and the second-generation antipsychotic risperidone (1.25 and 2.5 mg/kg daily) on the acquisition and performance of two radial-arm maze (RAM) tasks and a five-choice serial reaction-time task (5C-SRTT) in rats during days 15-60 and 84-320 days of treatment, respectively. In the RAM, neither antipsychotic significantly affected the acquisition or performance of a spatial win shift or a delayed non-match-to-position task. Conversely, in the rats administered 5C-SRTT, haloperidol was associated with profound deficits in performance, and the subjects were not able to progress through all stages of task acquisition. Depending on the dose, risperidone was associated with a greater number of trials to meet specific performance criteria during task acquisition compared with vehicle-treated controls; however, most subjects were eventually able to achieve all levels of task acquisition. Both haloperidol and risperidone also increased the number of perseverative and time-out responses during certain stages of task acquisition, and the response and reward latencies were slightly higher than controls during several stages of the study. These results in rats suggest that while long-term treatment with haloperidol or risperidone may not significantly affect spatial working or short-term memory, both antipsychotics can (depending on dose) impair sustained attention, decrease psychomotor speed, increase compulsive-type behaviors, and impair cognitive flexibility. PMID:24042161

  19. 丹红注射液联合西药常规治疗不稳定型心绞痛疗效和安全性系统评价%Efficacy and Safety of Danhong Injection Plus Conventional Western Medicine for Unstable Angina: A Systematic Review

    Institute of Scientific and Technical Information of China (English)

    崔然; 夏昆; 时萍; 聂小曼

    2012-01-01

    目的 系统评价丹红注射液联合西药常规治疗不稳定型心绞痛的有效性与安全性.方法 检索PubMed、Medline、中国期刊全文数据库、万方数据知识服务平台中丹红注射液联合西药常规治疗不稳定型心绞痛的临床随机对照试验文献,按照Cochrane协作网推荐的方法评价纳入研究文献的质量后,采用RevMan 4.2软件进行Meta分析.结果 经筛选纳入23篇文献,共2 675例,其中治疗组(丹红注射液联合西药常规治疗)1 382例,对照组(单纯西药治疗)1 293例.各研究基线情况具有可比性.Meta分析结果显示:丹红注射液加西药常规治疗在提高心电图疗效[RR=2.84,95% CI(2.28,3.55)]、心绞痛疗效[RR=4.13,95% CI(3.12,5.47)],升高高密度脂蛋白-胆固醇[high density lipoprotein-cholesterol,HDL-C)(WMD=0.29,95% CI(0.05,0.52)],降低低密度脂蛋白-胆固醇(low density lipoprotein-cholesterol,LDL-C)[WMD=-0.98,95% CI(-1.33,-0.63)]和高敏C反应蛋白(high sensitive C-reactive protein,hs-CRP)[WMD=-1.42,95% CI(-2.18,-0.65)]方面均优于西药常规治疗组.结论 丹红注射液联合西药常规治疗在改善不稳定型心绞痛患者的心电图疗效,升高HDL-C,降低LDL-C和hs-CRP水平方面优于对照组.受纳入文献质量的限制,本研究结论尚需更多高质量大样本的临床随机双盲对照研究加以验证.%Objective To systematically evaluate the efficacy and safety of Danhong Injection, a patent traditional Chinese Medicine (TCM) mainly composed of Salvia miltiorrhiza and safflower for activating blood stasis, combined with conventional western medicine in the treatment of unstable angina. Methods The literatures, which involve with randomized controlled trials (RCTs ) of Danhong Injection combined with conventional western medicine in the treatment of unstable angina, were retrieved in the databases such as PubMed, Medline, Chinese Journal Full-text Database, and Wanfang Data Knowledge Service Platform. The

  20. CONTRAST ANALYSIS OF RISPERIDONE AND CLOZAPINE ON EEG OF PATIENTS WITH SCHIZOPHRENIA%利培酮与氯氮平对精神分裂症患者脑电图的影响

    Institute of Scientific and Technical Information of China (English)

    郑育喜; 陆丽珍; 卢建国; 龙俊荣; 侯英; 梁容梅

    2014-01-01

    Objective To analyze the effects of risperidone and clozapine on EEG of patients with schizophrenia. Methods The two groups of patientstaking clozapine and risperidone respectively were given EEG examination before and af-ter 2nd and 4th week of treatment, the abnormal rate of EEG of two groups of patients were analyzed to compare the effects of the two drugs on electrical activity of the brain.Results The abnormal rate of EEG induced by clozapine was significantly higher than that induced by resperidone (p<0.05).Conclusion The influence of risperidone on EEG is lower than that of clozapine.%目的:分析利培酮与氯氮平对精神分裂症患者脑电图的影响。方法通过对两组分别服用氯氮平、利培酮的患者,在服药前、服药后第2周、第4周分别检查脑电图一次,分析两组病人脑电图的异常率,对比两种药物对脑电活动的影响。结果氯氮平引起脑电图异常率明显高于利培酮( p<0.05)。结论利培酮对脑电图的影响较氯氮平轻。

  1. Comparative Study on Tiapride and Risperidone in Treatment of Behavioral and Psychological Symptoms of Dementia%硫必利与利培酮治疗老年痴呆精神行为症状的对比研究

    Institute of Scientific and Technical Information of China (English)

    袁成勇

    2015-01-01

    Objective To study the clinical application of risperidone in the treatment of behavioral and psychological symptoms of dementia and tiapride therapy differences behavioral and psychological symptoms of dementia and related side effects. Methods Experimental group were treated with tiapride (50~400 mg / qd), the control group received risperidone (0.5~4.0 mg) /qd).6 weeks Differences between the two groups and the PANSS scale Results TESS data. Results Efifciency difference was not statistically significant (P>0.05) tiapride treatment group the number of cases of side effects than risperidone group, the Results were statistically significant (P 0.05).硫必利治疗组发生副反应的病例数少于利培酮治疗组,结果具有统计学意义(P<0.05).结论 硫必利治疗老年期痴呆精神及行为症状效果确切.

  2. 腰大池引流联合鞘内注射治疗开颅术后颅内感染患者的疗效研究%Clinical efficacy of lumbar cisterna drainage combined with intrathecal injection in treatment of craniotomy patients with postoperative intracranial infections

    Institute of Scientific and Technical Information of China (English)

    高剑峰; 路辉; 戴刚; 曹东彪; 李晓辉

    2015-01-01

    OBJECTIVE To observe the clinical efficacy of lumbar cisterna drainage combined with intrathecal injec‐tion in treatment of the craniotomy patients with postoperative intracranial infections so as to provide guidance for effective clinical treatment .METHODS A total of 62 patients with intracranial infections who were treated in the hospital from Jan 2010 to Dec 2013 were randomly divided into two groups .The observation group with 31 cases was treated with the lumbar cisterna drainage combined with intrathecal injection ,while the control group with 31 cases was given the intravenous therapy .The species of pathogens causing the infections ,change of white blood cells ,and clinical efficacies were observed and compared between the two groups of patients .RESULTS The isola‐ted Staphylococcus aureus strains accounted for 45 .2% in the observation group ,41 .9% in the control group;the isolated Staphylococcus epidermidis strains accounted for 25 .8% in the observation group ,22 .6% in the control group;the isolated Pseudomonas aeruginosa strains accounted for 9 .7% in the observation group ,16 .1% in the control group ;the isolated Escherichia coli strains accounted for 3 .2% in the observation group ,12 .9% in the control group;the isolated Proteus sp p strains accounted for 3 .2% in the observation group ,6 .5% in the control group;there was no significant difference between the two groups .The white blood cells counts in the cerebrospi‐nal fluid were gradually decreased in the observation group before the treatment or 1 ,5 days after the treatment (P0 .05);the white blood cells counts of the observation group were significantly lower than those of the control group after the treatment for 1 or 5 days (P<0 .05) .The cure rate was 61 .3% in the observation group ,significantly higher than 12 .9% in the control group ;the total effective rate was 90 .3% in the observation group ,significantly higher than 58 .1% in the control group (χ2 = 15 .552 ,5 .905 ,P< 0

  3. Botulinum toxin injection - larynx

    Science.gov (United States)

    Injection laryngoplasty; Botox-larynx: spasmodic dysphonia-BTX; Essential voice tremor (EVT)-btx; Glottic insufficiency; Percutaneous electromyography-guided botulinum toxin treatment; Percutaneous indirect laryngoscopy-guided botulinum toxin Treatment; ...

  4. Mouse bladder wall injection.

    Science.gov (United States)

    Fu, Chi-Ling; Apelo, Charity A; Torres, Baldemar; Thai, Kim H; Hsieh, Michael H

    2011-07-12

    Mouse bladder wall injection is a useful technique to orthotopically study bladder phenomena, including stem cell, smooth muscle, and cancer biology. Before starting injections, the surgical area must be cleaned with soap and water and antiseptic solution. Surgical equipment must be sterilized before use and between each animal. Each mouse is placed under inhaled isoflurane anesthesia (2-5% for induction, 1-3% for maintenance) and its bladder exposed by making a midline abdominal incision with scissors. If the bladder is full, it is partially decompressed by gentle squeezing between two fingers. The cell suspension of interest is intramurally injected into the wall of the bladder dome using a 29 or 30 gauge needle and 1 cc or smaller syringe. The wound is then closed using wound clips and the mouse allowed to recover on a warming pad. Bladder wall injection is a delicate microsurgical technique that can be mastered with practice.

  5. Epoetin Alfa Injection

    Science.gov (United States)

    ... a medication used to treat human immunodeficiency virus (HIV). Epoetin alfa injection is also used before and ... record book.If you are being treated with dialysis (treatment to remove waste from the blood when ...

  6. Giving an insulin injection

    Science.gov (United States)

    ... medlineplus.gov/ency/patientinstructions/000660.htm Giving an insulin injection To use the sharing features on this ... and syringes. Filling the Syringe - One Type of Insulin Wash your hands with soap and water. Dry ...

  7. Iron Dextran Injection

    Science.gov (United States)

    ... dextran injection is used to treat iron-deficiency anemia (a lower than normal number of red blood ... pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or ...

  8. Sodium Ferric Gluconate Injection

    Science.gov (United States)

    ... gluconate injection is used to treat iron-deficiency anemia (a lower than normal number of red blood ... pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or ...

  9. Injection and Dump Systems

    CERN Document Server

    Bracco, C; Barnes, M J; Carlier, E; Drosdal, L N; Goddard, B; Kain, V; Meddahi, M; Mertens, V; Uythoven, J

    2012-01-01

    Performance and failures of the LHC injection and ex- traction systems are presented. In particular, a comparison with the 2010 run, lessons learnt during operation with high intensity beams and foreseen upgrades are described. UFOs, vacuum and impedance problems related to the injection and extraction equipment are analysed together with possible improvements and solutions. New implemented features, diagnostics, critical issues of XPOC and IQC applications are addressed.

  10. EZVI Injection Field Test Leads to Pilot-Scale Application

    Science.gov (United States)

    Testing and monitoring of emulsified zero-valent ironTM (EZVI) injections was conducted at Cape Canaveral Air Force Station’s Launch Complex 34, FL, in 2002 to 2005 to evaluate the technology’s efficacy in enhancing in situ dehalogenation of dense nonaqueous-phase liquid (DNAPL) ...

  11. 短期应用胰岛素泵与多次皮下注射胰岛素治疗2型糖尿病疗效比较%Comparison of the efficacy between short term intensive therapy by insulin pump and multiple subcutaneous insulin injections

    Institute of Scientific and Technical Information of China (English)

    王计艳; 邢学农; 叶山东

    2012-01-01

    目的 比较多次皮下注射胰岛素与胰岛素泵强化治疗血糖控制欠佳的2型糖尿病(T2DM)患者的疗效.方法 观察对象分为胰岛素泵治疗组(CSⅡ组)40例和多次皮下胰岛素注射组(MSⅡ组)40例,CSⅡ组采用胰岛素泵持续皮下注射短效胰岛素,MSⅡ组采用三餐前皮下注射短效,夜间10点注射甘精胰岛素,应用剂量根据监测血糖来调整.比较两种治疗方法在控制血糖有效率、血糖达标时间、胰岛素均日用量及低血糖发生率等的不同.结果 两组降糖方案均有效,空腹血糖、餐后血糖均较治疗前明显下降,但CSⅡ组血糖达标时间、血糖的稳定性均优于MSⅡ组(P<0.01),平均日胰岛素使用量低于MSⅡ组(P<0.05),低血糖发生率无明显差别(P>0.05).结论 胰岛素泵治疗的患者血糖可更快地较稳地达到预期目标,且安全性较好.%Objective To compare the efficacy of short term intensive therapy by insulin pump( CSⅡ) with multiple subcutaneous insulin injections (MSⅡ) in patients with poorly-controlled type 2 diabetes. Methods 100 pa-tients with poorly-controlled type 2 diabetes were divided into CSⅡ group and MSH group. CSⅡ group applied continuous subcutaneous Humulin R,MSⅡ group were injected Humulin R before three meals,and insulin glargine at 22:00. The dose of insulin were adjusted according to blood sugar. Results The treatment in two groups were all effective. Fasting blood glucose, postprandial blood sugar all were significantly lowered after treatment in both groups. CSⅡ group' s time needed for the same glycemia and the stability of the glucose were all better than MSⅡ group (P 0.05). Conclusions Intensive therapy by insulin pump can control the hyperglycemia more effective and stable for patients with poorly-controlled type 2 diabetes.

  12. A Comparison of the Analgesic Efficacy of Femoral Nerve Block vs Intra-articular Injection for Anterior Cruciate Ligament Reconstruction-a Meta-analysis of Randomized Controlled Trials%股神经阻滞和关节内浸润控制前交叉韧带重建术后疼痛疗效比较的Meta分析

    Institute of Scientific and Technical Information of China (English)

    孙羽; 白希壮

    2012-01-01

    Objective To compare the efficacy of femoral nerve block and intraarticukr injection on relieving pain after anterior cruciate ligament reconstruction. Methods We searched electronic databases to identify randomized control trials,assessed methodological qualities and identified parameters for comparison. Mela-analysis was performed using Review Manager. Weighted mean difference was calculated for numerical data with 93% confidence interval. Heterogeneity was analyzed. Results 5 studies including 437 patients were identified. Meta-analysis of VAS with sensitivity analysis favored nerve block,WMD -5.50 (-9.897,-1.14). However,the effect may not be clinically significant. Conclusion Femoral nerve block might provide better pain relief, but the effect might not be clinically significant.%目的 比较股神经阻滞(FNB)和关节内浸润(IA)治疗前交叉韧带重建术后疼痛的疗效.方法 计算机检索MEDLINE(1966至2011.6)、EMBASE(1980至2011.6)、Cochrane图书馆以及ClinicalTrials.gov网站,检索相关随机对照研究,利用Detsky分级对纳入文献作方法学评估,对可合并结果行Meta分析,无法合并结果作描述分析.试构建倒漏斗图分析发表偏倚.结果 共纳入5项随机对照试验,计437例患者.术后疼痛视觉模拟量表(VAS)评分Meta分析显示FNB镇痛优于IA,WMD-5.50(-9.897,-1.14).未能构建有意义的倒漏斗图.结论 现有证据表明FNB镇痛优于IA,但优势程度难以体现出实际临床意义.本分析仅纳入5项研究,病例较少,尚需多中心、大样本随机对照研究验证.

  13. lntravitreal injection of triamcinolone acetonide combined photodynamic therapy for choroidal neovascularization in high myopia efficacy%玻璃体腔注射曲安奈德联合光动力疗法治疗高度近视脉络膜新生血管疗效观察

    Institute of Scientific and Technical Information of China (English)

    葛建杰; 高夕宁; 王沫学

    2011-01-01

    Objective To observe the clinical efficacy of intravitreal injection of triamcinolone acetonide (TA) combined photodynamic therapy (PDT) of choroidal revascularization (CNV) in high myopia.Methods Based on history,age,symptoms and by visual acuity,fundus examination,fundus photography,fundus fluorescein angiography (FFA),optical coherence tomography (OCT),high myopia diagnosed with choroidal neovascularization (CNV) of 153 patients (165 eyes) were randomly divided into group A,B and C.group A consisted of 51 cases (58 eyes),group B 51 cases (54 eyes),group C of 51 cases (53 eyes).Group A treated with intravitreal injection of TA combined with photodynamic therapy,group B with photodynamic therapy alone (PDT),group C with intravitreal injection of TA alone.All cases were follow-up 3,6 months after treatment.Results At the final follow up,corrected visual acuity was 0.01-1.2.In group A,58 eyes of 51 patients accounted for 43.10% cured in 25 eyes,improved 27 for 47.37%,invalid 6 for 9.53%,the total effective rate 90.47%,5.17% recurrence in 3 eyes.In group B,51 patients were cured 9 out of 54 eyes for 16.67%,27.78% improvement in 15 eyes,55.55% invalid in 30 eyes,total effective rate of 44.45%,recurrence 13 24.07%.In group C,53 eyes of 51 patients were cured in 10 eyes 18.88%,improved 14 eyes 26.41%,invalid 29eyes 54.71%,total effective rate of 45.29%,recurrence 14 26.41%.The total efficiency of the three groups had statistically significant difference (u =2.05693,P <0.05).Conclusions Intravitreous injection of TA combined photodynamic therapy for choroidal neovascularization in high myopia is effective and safe.It solves the problems that a single treatment exist many complications and high recurrence rate.%目的 观察玻璃体腔注射曲安奈德(triamcinolone acetonide TA)联合光动力疗法治疗高度近视脉络膜新生血管的临床疗效.方法 依据病史、年龄、症状及经视力、眼底检查、眼底彩色照相

  14. Effect of risperidone on S100B levels and relationship with treatment response in first-episode schizophrenic patients%利培酮对首发精神分裂症S1OOB蛋白含量影响与疗效关系

    Institute of Scientific and Technical Information of China (English)

    刘林晶; 修梅红; 张向阳; 陈大春

    2012-01-01

    AIM: To study if S100B levels is abnormity, to study the effect of risperidone on S100B levels and relationship between S100B levels and treatment response in first-episode schizophrenic patients. METHODS- Fifty-three first-episode schizophrenia inpatients according to DSM-IV were treated only with risperidone for 12 weeks, the Positive and Negative Syndrome Scale (PANSS), Clinical General Impression (CGI) and Hamiton Depression Rating Scale (HAMD) were estimated at the baseline and the endpoint to evaluate the clinical efficacy. The serum S100B levels of the patients at the baseline and the endpoint and the 58 healthy controls were assayed using Enzyme Linked Im-munosorbent Assay (ELISA). RESULTS: The serum S100B levels of the patients groups were significantly higher than the controls (P<0. 01) at the baseline, were significantly decreased after 12 weeks treatment with risperidone but remained significantly higher than controls (F< 0. 05). The serum S100B levels was negative correlated with the age of onset and score of HAMD(r= —0.28, -0.31, P all <0.05)at baseline, The serum S100B levels were significantly lower in the treatment responders comparing no-responders, were negative correlated with reduction of PANSS total score and negative subscore from baseline to 12 weeks O= — 0.28, -0.31, P all <0. 05). CONCLUSION: The serum S100B levels of the schizophrenic patients are significantly higher than the healthy controls, Risperidone treatment reduced the S-100B levels that were associated with treatment response, indicating that patients with schizophrenia may suffer structural damage in central nervous system.%目的:探讨首发精神分裂症S100B蛋白是否异常;利培酮对S100B影响与疗效之间关系.方法:收集符合美国精神障碍诊断与统计手册第4版诊断标准首发精神分裂症住院患者53例,正常对照58例.患者组单一利培酮治疗12周,阳性和阴性综合症量表(positive and negative syndrome scale,PANSS)

  15. Clinical Comparison Analysis on Risperidone and Clozapine in The Treatment of Schizophrenia%利培酮与氯氮平治疗精神分裂症临床对比分析

    Institute of Scientific and Technical Information of China (English)

    赵仁香

    2015-01-01

    目的:分析利培酮和氯氮平治疗精神分裂症的临床效果。方法选取我院2013~2014年的91例患者来进行研究分析,分组为利培酮和氯氮平组,前组有42例患者,后组有49例患者,分析两组的精神病量表(BPRS)、阳性症状量表(SAPS)、副反应量表(TESS)。结果利培酮组患者的显效时间为一至两周,平均(10.56±4.23)天,氯氮平为一周左右,平均(7.23±3.57)天,差异无统计学意义,P>0.05。利培酮组有36例显效,氯氮平组有38例显效,两组的治疗效果差异无统计学意义。量表结果显示,两种药物均对精神分裂症阳性症状改善明显,氯氮平组的BPRS和SAPS评分比利培酮组高,差异有统计学意义,P0.05. There were 36 excel ent cases in risperidone group,38 excel ent cases in clozapine group, and the difference of clinical effects were not significant. The clinical effects of two drugs to the positive symptoms of schizophrenia were obvious ,the BPRS and SAPS scores in clozapine group was higher than risperidone group significantly,P<0.05. The clinical effect of risperidone to the activation and bizarre behavior symptoms was worse,and was similar for other symptoms. Conclusion The clinical effect of risperidone and clozapine in the treatment of schizophrenia are excel ent,and the advantages of risperidone are greater.

  16. Efficacy and electrocardiogram abnormality of olanzapine in the treatment of old schizophrenic patients%奥氮平治疗老年精神分裂症患者的疗效观察及对心电图的影响

    Institute of Scientific and Technical Information of China (English)

    袁国锋; 俞玉礼

    2011-01-01

    AIM: To explore the efficacy and the electrocardiogram abnormality of olanzapine or risperidon in the treatment of old schizophrenic patients.METHODS: 120 patients with old schizophrenia were randomly divided into olanzapine group (60 cases) and risperidon group(60 cases) treated for 8 weeks.The efficacy was measured with the positive and negative symptoms scale (PANSS) and PANSS and the electrocardiogram test was used to evaluate the efficacy and adverse effects respectively before and at the ends of 2,4,6,8 weeks of treatment.The amount and information of electrocardiogram abnormality were analyzed.RESULTS:The efficacy rate of olanzapine was 78.3%, in which 56.7% was improved markedly.The efficacy rate of risperidon was 75.0%, in which 51.7% were improved markedly.There were no difference between two groups (P> 0.05 ).There were significant differences on extrapyramidal side effect and liver function between them.At the 2nd week, the efficacy of olanzapine was more than that of the risperidon (P < 0.05 ).There were significant difference in electrocardiogram abnormality between olanzapine group and risperidon group ( P < 0.05).CONCLUSION: There are no significant differences in the efficacy and the electrocardiogram abnormality between two groups.Olanzapine has less sideeffect especially.The two drugs adapt to old schizophrenic.%目的:比较奥氮平与利培酮治疗老年精神分裂症患者的疗效及对心电图的影响.方法:选取120例老年精神分裂症患者,随机分为奥氮平组(研究组)和利培酮组(对照组),各60例,分别于治疗前及治疗后第2、4、6、8周末采用阳性与阴性症状量表(PANSS)评定疗效,并进行心电图检查,统计异常心电图的数目和相关信息.结果:两组PANSS评分治疗后均较治疗前明显下降(P0.05).奥氮平组以嗜睡为主,利培酮组以锥体外系副反应和转氨酶升高为主,两组在锥体外系副反应和转氨酶升高两方面有统计学差异(P<0

  17. Syringe-injectable electronics.

    Science.gov (United States)

    Liu, Jia; Fu, Tian-Ming; Cheng, Zengguang; Hong, Guosong; Zhou, Tao; Jin, Lihua; Duvvuri, Madhavi; Jiang, Zhe; Kruskal, Peter; Xie, Chong; Suo, Zhigang; Fang, Ying; Lieber, Charles M

    2015-07-01

    Seamless and minimally invasive three-dimensional interpenetration of electronics within artificial or natural structures could allow for continuous monitoring and manipulation of their properties. Flexible electronics provide a means for conforming electronics to non-planar surfaces, yet targeted delivery of flexible electronics to internal regions remains difficult. Here, we overcome this challenge by demonstrating the syringe injection (and subsequent unfolding) of sub-micrometre-thick, centimetre-scale macroporous mesh electronics through needles with a diameter as small as 100 μm. Our results show that electronic components can be injected into man-made and biological cavities, as well as dense gels and tissue, with >90% device yield. We demonstrate several applications of syringe-injectable electronics as a general approach for interpenetrating flexible electronics with three-dimensional structures, including (1) monitoring internal mechanical strains in polymer cavities, (2) tight integration and low chronic immunoreactivity with several distinct regions of the brain, and (3) in vivo multiplexed neural recording. Moreover, syringe injection enables the delivery of flexible electronics through a rigid shell, the delivery of large-volume flexible electronics that can fill internal cavities, and co-injection of electronics with other materials into host structures, opening up unique applications for flexible electronics.

  18. 射频热凝术联合臭氧盘外注射治疗腰椎间盘突出症的疗效分析%The efficacy analysis of radiofrequency therapy combined with ozone injection in the treatment of lumbar disc protrusion

    Institute of Scientific and Technical Information of China (English)

    刘涛; 申才良; 唐开军; 林玉春; 孙勇

    2015-01-01

    Objective To assess the efficacy of radiofrequency therapy combined with ozone injection in the treatment of lumbar disc protrusion. Methods A total of 202 patients with lumbar disk protrusion were included and divided into three groups:radiofrequency (RF) group, ozone (Oz) group, and combination (Co) group. The efficacy was evaluated by visual analogue scale (VAS), Macnab curative effect evaluation, and oswestry disability index (ODI) at 1d, 1m and 6m after treat⁃ment. Results There were no significant differences in gender, age, the course of disease, preoperative VAS scores and ODI scores (P>0.05). All patients were operated successfully. There were no infection of the intervertebral disc, no compli⁃cations of spinal cord, nerve and no blood vessel injury. There were no significant differences in preoperative VAS and ODI scores between three groups. The VAS and ODI scores were significantly lower at 6 month and 12 month after operation in Co group combined with those of RF group and Oz group. There were no significant differences in these two scores between RF group and Oz group (P>0.05). There were no significant differences in effective rates at 1d, 6 month and 12 month after operation between three groups (P>0.05). But the excellent and good effective rates were higher in Co group than those of RF and Oz groups. There were no significant differences in excellent and good effective rates between RF group and Oz group. Conclusion The therapy of radiofrequency combined with ozone injection is an efficient and mini-invasive tech⁃nique for the treatment of lumbar disc protrusion and worth promoting.%目的:观察射频热凝术联合臭氧盘外注射治疗腰椎间盘突出症的临床疗效。方法分析202例腰椎间盘突出症患者,依据手术方式不同分为射频组、臭氧组、射频联合臭氧组(联合组)。通过视觉模拟(VAS)评分、Macnab疗效评价(观察指标包括有效率及优良率)和Oswestry功能

  19. Flow Injection Analysis

    DEFF Research Database (Denmark)

    Hansen, Elo Harald

    2004-01-01

    This chapter provides an introduction to automated chemical analysis, which essentially can be divided into two groups: batch assays, where the solution is stationary while the container is moved through a number of stations where various unit operations performed; and continuous-flow procedures......, where the system is stationary while the solution moves through a set of conduits in which all required manipulations are performed. Emphasis is placed on flow injection analysis (FIA) and its further developments, that is, sequential injection analysis (SIA) and the Lab-on-Valve (LOV) approach. Since...

  20. The effect of local corticosteroid injection on F-wave conduction velocity and sympathetic skin response in carpal tunnel syndrome

    OpenAIRE

    Deniz, Orhan; Aygül, Recep; Kotan, Dilcan; Özdemir, Gökhan; Odabaş, Faruk Ömer; Kaya, M. Dursun; Ulvi, Hızır

    2011-01-01

    The aim of this study was to evaluate the efficacy of steroid injection for the treatment of the carpal tunnel syndrome (CTS), with F-wave parameters and sympathetic skin response (SSR). Seventeen hands of 10 women patients were treated with local steroid injection with 2-month follow-up. All patients underwent single injection into the carpal tunnel. Response to injection was measured nerve conduction studies (NCSs), median nerve F waves, and SSR before and after treatment. To determine the ...

  1. 茵栀黄注射液联合间歇蓝光治疗新生儿高胆红素血症疗效观察%Clinical efficacy of Yinzhihuang injection combined with intermittent blu-ray on neonatal hyperbilirubinemia

    Institute of Scientific and Technical Information of China (English)

    李玲; 蔡冠虎

    2012-01-01

    Objective: To investigate clinical efficacy of Yinzhihuang injectin combined with intermittent blu-ray in treatment for neonatal hyperbilirubinemia. Methods: A total of 240 cases with neonatal hyperbilirubinemia were divided randomly into experimental group and control group by half. The experimental group was treated with Yinzhihuang injectin combined with intermittent blu-ray, while the control group was treated with intermittent blu-ray. The clinical efficacy,regression time of jaundice, the serum total bilirubin level (TBiL) and unconjugated bilirubin level (IBiL) were observed and compared between experimental group and control group. Results: The cure rate of the experimental group (92. 5%) was significantly higher than that of the control group (80. 73%) (X2= 7. 07, P<0. 05). The average regression time of jaundice of experimental group [(5. 23 + 2. 14) days] was significantly shorter than [(7. 18 + 2. 57)days] of the control group (t=6. 37, P<0. 05). After treatment, the serum TBiL and IBiL of experimental group and the control group were significantly reduced (P<0. 05); and the serum TBiL and IBiL of experimental group were significantly lower(P<0. 05). Conclusions: Yinzhihuang injection combined with intermittent blu-ray in the treatment of neonatal hyperbilirubinemia can decrease the serum TBiL and IBiL fastly, reduce regression time of jaundice, and improve the clinical efficacy.%目的:观察茵栀黄注射液联合间歇蓝光治疗新生儿高胆红素血症的临床疗效.方法:240例确诊为为高胆红素血症的新生儿随机分为实验组和对照组,每组患儿120例.实验组采用茵栀黄注射液联合间歇蓝光治疗,对照组仅采用间歇蓝光治疗.观察实验组和对照组的临床疗效、皮肤黄疸消退时间以及血清总胆红素浓度(total bilirubin level,TBiL)、未结合胆红素浓度(Unconjugated bilirubin level,IBiL).结果:实验组治疗有效率为92.5%,对照组治疗有效率为80.73%,实验组治

  2. 红景天注射液联合化疗治疗非小细胞肺癌的疗效评价%Evaluation of efficacy of rhodiola injection combined with chemotherapy in treatment of non-small cell lung cancer

    Institute of Scientific and Technical Information of China (English)

    李金水

    2016-01-01

    目的:探讨红景天注射液联合化疗治疗非小细胞肺癌(NSCLC)的临床效果。方法选取2012年3月至2015年1月于我院诊治的晚期 NSCLC 患者共117例进行研究,随机原则分为研究组(n =59)和对照组(n =58)。对照组实施长春瑞滨联合顺铂常规化疗,研究组采用常规化疗联合红景天注射液治疗。比较2组患者治疗前后细胞免疫功能、生活质量评分、药物毒性反应,并评定临床疗效。结果对照组患者在化疗1个周期后的细胞免疫功能指标(自然杀伤细胞、CD4+、CD8+、CD4+/CD8+)均明显下降(P <0.05),研究组的细胞免疫功能明显优于对照组(t 值分别为4.265、3.052、2.816、2.017,P 值均<0.05);研究组和对照组的生活质量评分总稳定率分别为89.83%和75.86%,近期总有效率分别为67.80%和46.55%,研究组均高于对照组(χ2值分别为4.034、5.398, P 值均<0.05);研究组的骨髓抑制发生情况低于对照组(χ2=5.341,P <0.05)。结论对晚期NSCLC 患者行红景天注射液联合化疗治疗,患者细胞免疫功能、生活质量明显改善,药物毒性反应低,效果显著,值得推广。%Objective To evaluate the clinical effect of rhodiola injection combined with chemotherapy in the treatment of non-small cell lung cancer (NSCLC).Methods 1 1 7 patients with advanced NSCLC in our hospital from March 2012 to January 201 5 were chosen,they were randomly divided into study group (n = 59) and control group (n = 58).The control group was treated with vinorelbine combined with cisplatin chemotherapy,while the study group was treated by conventional chemotherapy and rhodiola injection.The changes of cellular immune function,quality of life score,drug toxicity in two groups were compared,the clinical efficacy was evaluated.Results The cellular immune function (natural killer cell,CD4 + ,CD8 + ,CD4 +/CD8 +) of the control group after one cycle of chemotherapy was significantly decreased(P < 0.05),the cellular

  3. Evaluation of 2-Stage Injection Technique in Children.

    Science.gov (United States)

    Sandeep, Valasingam; Kumar, Manikya; Jyostna, P; Duggi, Vijay

    2016-01-01

    Effective pain control during local anesthetic injection is the cornerstone of behavior guidance in pediatric dentistry. The aim of this study was to evaluate the practical efficacy of a 2-stage injection technique in reducing injection pain in children. This was a split-mouth, randomized controlled crossover trial. One hundred cooperative children aged 7 to 13 years in need of bilateral local anesthetic injections (inferior alveolar nerve block, posterior superior alveolar nerve block, or maxillary and mandibular buccal infiltrations) for restorative, endodontic, and extraction treatments were recruited for the study. Children were randomly allocated to receive either the 2-stage injection technique or conventional technique at the first appointment. The other technique was used at the successive visit after 1 week. Subjective and objective evaluation of pain was done using the Wong-Baker FACES Pain Rating Scale (FPS) and Sound Eye Motor (SEM) scale, respectively. The comparison of pain scores was done by Wilcoxon sign-rank test. Both FPS and SEM scores were significantly lower when the 2-stage injection technique of local anesthetic nerve block/infiltration was used compared with the conventional technique. The 2-stage injection technique is a simple and effective means of reducing injection pain in children. PMID:26866405

  4. Survey of intravitreal injection techniques among retina specialists in Israel

    Science.gov (United States)

    Segal, Ori; Segal-Trivitz, Yael; Nemet, Arie Y; Geffen, Noa; Nesher, Ronit; Mimouni, Michael

    2016-01-01

    Purpose The purpose of this study was to describe antivascular endothelial growth factor intravitreal injection techniques of retinal specialists in order to establish a cornerstone for future practice guidelines. Methods All members of the Israeli Retina Society were contacted by email to complete an anonymous, 19-question, Internet-based survey regarding their intravitreal injection techniques. Results Overall, 66% (52/79) completed the survey. Most (98